USRE49735E1 - Oxazolidinones as modulators of MGLUR5 - Google Patents
Oxazolidinones as modulators of MGLUR5 Download PDFInfo
- Publication number
- USRE49735E1 USRE49735E1 US17/481,947 US202117481947A USRE49735E US RE49735 E1 USRE49735 E1 US RE49735E1 US 202117481947 A US202117481947 A US 202117481947A US RE49735 E USRE49735 E US RE49735E
- Authority
- US
- United States
- Prior art keywords
- pyridinyl
- oxazolidin
- phenyl
- fluorophenyl
- phenylethynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title description 57
- 101150087728 Grm5 gene Proteins 0.000 title 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 246
- 150000001875 compounds Chemical class 0.000 claims abstract description 98
- 239000000203 mixture Substances 0.000 claims abstract description 82
- 150000003839 salts Chemical class 0.000 claims abstract description 38
- -1 pyrrolopyridinyl Chemical group 0.000 claims description 205
- 229910052739 hydrogen Inorganic materials 0.000 claims description 169
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 118
- 125000004076 pyridyl group Chemical group 0.000 claims description 65
- 125000000217 alkyl group Chemical group 0.000 claims description 59
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 48
- 125000001424 substituent group Chemical group 0.000 claims description 48
- 125000001188 haloalkyl group Chemical group 0.000 claims description 43
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 40
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 36
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 35
- 125000003545 alkoxy group Chemical group 0.000 claims description 33
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- 125000002971 oxazolyl group Chemical group 0.000 claims description 24
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 23
- 125000001544 thienyl group Chemical group 0.000 claims description 23
- 125000000335 thiazolyl group Chemical group 0.000 claims description 22
- 125000002883 imidazolyl group Chemical group 0.000 claims description 21
- 125000004802 cyanophenyl group Chemical group 0.000 claims description 20
- 125000004414 alkyl thio group Chemical group 0.000 claims description 19
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 18
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 14
- 125000003282 alkyl amino group Chemical group 0.000 claims description 14
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 14
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 13
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims description 10
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 10
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 10
- 125000004188 dichlorophenyl group Chemical group 0.000 claims description 10
- 125000004212 difluorophenyl group Chemical group 0.000 claims description 10
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 10
- 125000005059 halophenyl group Chemical group 0.000 claims description 10
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000003944 tolyl group Chemical group 0.000 claims description 10
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 7
- HIRXVQATYCZQHB-NHCUHLMSSA-N (4r,5r)-5-(2,5-difluorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=C(F)C([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=C1 HIRXVQATYCZQHB-NHCUHLMSSA-N 0.000 claims description 6
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 6
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 5
- MNEWPFGQLYQEHL-NHCUHLMSSA-N (4r,5r)-4-[3-(2-phenylethynyl)phenyl]-5-pyridin-3-yl-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=CC=CN=C1 MNEWPFGQLYQEHL-NHCUHLMSSA-N 0.000 claims description 4
- WNOORNNENVRQKM-FGZHOGPDSA-N (4r,5r)-5-phenyl-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=CC=CC=C1 WNOORNNENVRQKM-FGZHOGPDSA-N 0.000 claims description 4
- WJJSLTYQVVPINQ-RTBURBONSA-N (4r,5r)-4-[2-fluoro-5-[2-(2-fluoropyridin-4-yl)ethynyl]pyridin-3-yl]-5-(3-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C(=NC=C(C=2)C#CC=2C=C(F)N=CC=2)F)=C1 WJJSLTYQVVPINQ-RTBURBONSA-N 0.000 claims description 3
- NHCBPBWBEPFVBV-RTBURBONSA-N (4r,5r)-4-[2-fluoro-5-[2-(5-fluoropyridin-3-yl)ethynyl]pyridin-3-yl]-5-(3-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C(=NC=C(C=2)C#CC=2C=C(F)C=NC=2)F)=C1 NHCBPBWBEPFVBV-RTBURBONSA-N 0.000 claims description 3
- JUHOYIXYMLNOAU-RTBURBONSA-N (4r,5r)-5-(3-fluorophenyl)-4-[2-fluoro-5-(2-pyridin-3-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C(=NC=C(C=2)C#CC=2C=NC=CC=2)F)=C1 JUHOYIXYMLNOAU-RTBURBONSA-N 0.000 claims description 3
- VRUYDDMLOZSUHK-RTBURBONSA-N (4r,5r)-5-(4-fluorophenyl)-4-[2-fluoro-5-(2-pyridin-3-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C(=NC=C(C=2)C#CC=2C=NC=CC=2)F)NC(=O)O1 VRUYDDMLOZSUHK-RTBURBONSA-N 0.000 claims description 3
- ZFHNIQBAVYINJA-RTBURBONSA-N (4r,5r)-4-[2-fluoro-5-[2-(5-fluoropyridin-3-yl)ethynyl]pyridin-3-yl]-5-(4-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C(=NC=C(C=2)C#CC=2C=C(F)C=NC=2)F)NC(=O)O1 ZFHNIQBAVYINJA-RTBURBONSA-N 0.000 claims description 2
- PWCGQAHNBNQALX-RTBURBONSA-N (4r,5r)-4-[2-fluoro-5-[2-(6-fluoropyridin-2-yl)ethynyl]pyridin-3-yl]-5-(4-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C(=NC=C(C=2)C#CC=2N=C(F)C=CC=2)F)NC(=O)O1 PWCGQAHNBNQALX-RTBURBONSA-N 0.000 claims description 2
- FMMBQFSNRFZSIK-FGZHOGPDSA-N (4r,5r)-4-[3-[2-(2-fluoropyridin-4-yl)ethynyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=C(F)N=CC=2)=C1 FMMBQFSNRFZSIK-FGZHOGPDSA-N 0.000 claims description 2
- YOLJSMSDALQNIT-FGZHOGPDSA-N (4r,5r)-4-[3-[2-(5-fluoropyridin-3-yl)ethynyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=C(F)C=NC=2)=C1 YOLJSMSDALQNIT-FGZHOGPDSA-N 0.000 claims description 2
- OMWPBHOOZRRHAV-WOJBJXKFSA-N (4r,5r)-4-[5-fluoro-2-[2-(5-fluoropyridin-3-yl)ethynyl]pyridin-4-yl]-5-(4-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C(=CN=C(C=2)C#CC=2C=C(F)C=NC=2)F)NC(=O)O1 OMWPBHOOZRRHAV-WOJBJXKFSA-N 0.000 claims description 2
- BJQIGFSSCLXKSZ-FYYLOGMGSA-N (4r,5r)-4-methyl-5-phenyl-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@H]2OC(=O)N[C@]2(C)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=CC=CC=C1 BJQIGFSSCLXKSZ-FYYLOGMGSA-N 0.000 claims description 2
- DGXWZILKWMLHJZ-NHCUHLMSSA-N (4r,5r)-5-(3-fluorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=C1 DGXWZILKWMLHJZ-NHCUHLMSSA-N 0.000 claims description 2
- YIAMLZJGLFXSLN-WOJBJXKFSA-N (4r,5r)-5-(3-fluorophenyl)-4-[5-(2-pyridin-3-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C=NC=CC=2)=C1 YIAMLZJGLFXSLN-WOJBJXKFSA-N 0.000 claims description 2
- BAXUIBRFQDYUTB-FGZHOGPDSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[2-(2-phenylethynyl)pyridin-4-yl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(N=CC=2)C#CC=2C=CC=CC=2)=C1 BAXUIBRFQDYUTB-FGZHOGPDSA-N 0.000 claims description 2
- LXFOOMJLPLAPPM-FGZHOGPDSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-(2-pyridin-2-ylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2N=CC=CC=2)=C1 LXFOOMJLPLAPPM-FGZHOGPDSA-N 0.000 claims description 2
- FTWQDGPACTYAKP-FGZHOGPDSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=C1 FTWQDGPACTYAKP-FGZHOGPDSA-N 0.000 claims description 2
- RMDPVWVGICECJK-RTBURBONSA-N (4r,5r)-5-(4-chlorophenyl)-4-[2-fluoro-5-(2-pyridin-3-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@H]2OC(=O)N[C@@H]2C2=CC(=CN=C2F)C#CC=2C=NC=CC=2)=CC=C(Cl)C=C1 RMDPVWVGICECJK-RTBURBONSA-N 0.000 claims description 2
- VGSFZUMJEUHHRV-NHCUHLMSSA-N (4r,5r)-5-(4-fluorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)NC(=O)O1 VGSFZUMJEUHHRV-NHCUHLMSSA-N 0.000 claims description 2
- AVGFRDZHGXFJLY-WOJBJXKFSA-N (4r,5r)-5-(4-fluorophenyl)-4-[5-(2-pyridin-3-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=NC=CC=2)NC(=O)O1 AVGFRDZHGXFJLY-WOJBJXKFSA-N 0.000 claims description 2
- OBOYWTBAOJHNNO-WOJBJXKFSA-N (4r,5r)-5-(4-fluorophenyl)-4-[5-[2-(5-fluoropyridin-3-yl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=C(F)C=NC=2)NC(=O)O1 OBOYWTBAOJHNNO-WOJBJXKFSA-N 0.000 claims description 2
- RXAIMRQTCSBPGM-NHCUHLMSSA-N (4r,5r)-5-(4-fluorophenyl)-4-[6-(2-phenylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2N=C(C=CC=2)C#CC=2C=CC=CC=2)NC(=O)O1 RXAIMRQTCSBPGM-NHCUHLMSSA-N 0.000 claims description 2
- UCKNUQDRESEENB-NHCUHLMSSA-N (4r,5r)-5-phenyl-4-[2-(2-phenylethynyl)pyridin-4-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(N=CC=2)C#CC=2C=CC=CC=2)=CC=CC=C1 UCKNUQDRESEENB-NHCUHLMSSA-N 0.000 claims description 2
- VUQQYHWXAUHXSA-WOJBJXKFSA-N (4r,5r)-5-phenyl-4-[2-(2-pyridin-3-ylethynyl)pyridin-4-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(N=CC=2)C#CC=2C=NC=CC=2)=CC=CC=C1 VUQQYHWXAUHXSA-WOJBJXKFSA-N 0.000 claims description 2
- AFTXLGIZWWXYTD-NHCUHLMSSA-N (4r,5r)-5-phenyl-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=CC=CC=C1 AFTXLGIZWWXYTD-NHCUHLMSSA-N 0.000 claims description 2
- RMPCVUXFUQSOII-NHCUHLMSSA-N (4r,5r)-5-phenyl-4-[6-(2-phenylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2N=C(C=CC=2)C#CC=2C=CC=CC=2)=CC=CC=C1 RMPCVUXFUQSOII-NHCUHLMSSA-N 0.000 claims description 2
- GZYNJQXRFJNGPF-DHIUTWEWSA-N 5-[2-[3-[(4r,5r)-5-(3-methoxyphenyl)-2-oxo-1,3-oxazolidin-4-yl]phenyl]ethynyl]pyridine-3-carbonitrile Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=C(C=NC=2)C#N)=C1 GZYNJQXRFJNGPF-DHIUTWEWSA-N 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- AYNODYNLLGQWRK-NHCUHLMSSA-N (4r,5r)-4-[3-(2-phenylethynyl)phenyl]-5-pyridin-4-yl-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=CC=NC=C1 AYNODYNLLGQWRK-NHCUHLMSSA-N 0.000 claims 1
- JFXHNDKUSILQEP-DHIUTWEWSA-N (4r,5r)-4-[3-[2-(2-fluorophenyl)ethynyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C(=CC=CC=2)F)=C1 JFXHNDKUSILQEP-DHIUTWEWSA-N 0.000 claims 1
- KKQAPIXNUKECIQ-DHIUTWEWSA-N (4r,5r)-4-[3-[2-(3-fluorophenyl)ethynyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=C(F)C=CC=2)=C1 KKQAPIXNUKECIQ-DHIUTWEWSA-N 0.000 claims 1
- IHNJLNXROBJAFV-FGZHOGPDSA-N (4r,5r)-4-[3-[2-(3-fluoropyridin-2-yl)ethynyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C(=CC=CN=2)F)=C1 IHNJLNXROBJAFV-FGZHOGPDSA-N 0.000 claims 1
- WJIKTQJADAWZQD-FGZHOGPDSA-N (4r,5r)-4-[3-[2-(4-fluoropyridin-2-yl)ethynyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2N=CC=C(F)C=2)=C1 WJIKTQJADAWZQD-FGZHOGPDSA-N 0.000 claims 1
- UFBCWFXHUADFRB-FGZHOGPDSA-N (4r,5r)-4-[3-[2-(6-fluoropyridin-3-yl)ethynyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=NC(F)=CC=2)=C1 UFBCWFXHUADFRB-FGZHOGPDSA-N 0.000 claims 1
- SRFIPCAWNZLEJD-NHCUHLMSSA-N (4r,5r)-4-[5-(2-phenylethynyl)pyridin-3-yl]-5-(2,3,4-trifluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=C(F)C(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)NC(=O)O1 SRFIPCAWNZLEJD-NHCUHLMSSA-N 0.000 claims 1
- YKRSAZWQLLCMOS-NHCUHLMSSA-N (4r,5r)-4-[5-(2-phenylethynyl)pyridin-3-yl]-5-(2,4,6-trifluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC(F)=CC(F)=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)NC(=O)O1 YKRSAZWQLLCMOS-NHCUHLMSSA-N 0.000 claims 1
- SEJGNOIJDJGVDT-WOJBJXKFSA-N (4r,5r)-4-[5-(2-phenylethynyl)pyridin-3-yl]-5-pyridin-3-yl-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=CC=CN=C1 SEJGNOIJDJGVDT-WOJBJXKFSA-N 0.000 claims 1
- IESNTRWXLZTBQL-MOPGFXCFSA-N (4r,5r)-4-[5-(2-phenylethynyl)pyridin-3-yl]-5-pyrimidin-4-yl-1,3-oxazolidin-2-one Chemical compound C1([C@H]2[C@H](NC(O2)=O)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=CC=NC=N1 IESNTRWXLZTBQL-MOPGFXCFSA-N 0.000 claims 1
- AGOZLCLQXCJRQA-NHCUHLMSSA-N (4r,5r)-4-[5-[2-(2-chlorophenyl)ethynyl]pyridin-3-yl]-5-(3-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C(=CC=CC=2)Cl)=C1 AGOZLCLQXCJRQA-NHCUHLMSSA-N 0.000 claims 1
- XJHVLJCGBLREHZ-NHCUHLMSSA-N (4r,5r)-4-[5-[2-(3-chlorophenyl)ethynyl]pyridin-3-yl]-5-(3-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C=C(Cl)C=CC=2)=C1 XJHVLJCGBLREHZ-NHCUHLMSSA-N 0.000 claims 1
- TVFQEGCLNCKVIQ-IFMALSPDSA-N (4r,5r)-4-[5-[2-(3-fluoropyridin-2-yl)ethynyl]pyridin-3-yl]-4-methyl-5-phenyl-1,3-oxazolidin-2-one Chemical compound C1([C@H]2OC(=O)N[C@]2(C)C=2C=C(C=NC=2)C#CC=2C(=CC=CN=2)F)=CC=CC=C1 TVFQEGCLNCKVIQ-IFMALSPDSA-N 0.000 claims 1
- PJDGHZWMLQHSDX-NHCUHLMSSA-N (4r,5r)-5-(2,3-dichlorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound ClC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=C1Cl PJDGHZWMLQHSDX-NHCUHLMSSA-N 0.000 claims 1
- YEASXMGLJOAINW-NHCUHLMSSA-N (4r,5r)-5-(2,3-difluorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=C1F YEASXMGLJOAINW-NHCUHLMSSA-N 0.000 claims 1
- RUAKLNBLYDTGCN-NHCUHLMSSA-N (4r,5r)-5-(2,3-difluorophenyl)-4-[5-[2-(2-fluorophenyl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C(=CC=CC=2)F)=C1F RUAKLNBLYDTGCN-NHCUHLMSSA-N 0.000 claims 1
- OVHIIBSEFQKYJD-NHCUHLMSSA-N (4r,5r)-5-(2,3-difluorophenyl)-4-[5-[2-(4-fluorophenyl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1C#CC1=CN=CC([C@@H]2[C@H](OC(=O)N2)C=2C(=C(F)C=CC=2)F)=C1 OVHIIBSEFQKYJD-NHCUHLMSSA-N 0.000 claims 1
- WWQYIMOINCSWFV-NHCUHLMSSA-N (4r,5r)-5-(2,4-difluorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)NC(=O)O1 WWQYIMOINCSWFV-NHCUHLMSSA-N 0.000 claims 1
- KPWVJDZSIKERJJ-WOJBJXKFSA-N (4r,5r)-5-(2,4-difluorophenyl)-4-[5-[2-(5-fluoropyridin-3-yl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=C(F)C=NC=2)NC(=O)O1 KPWVJDZSIKERJJ-WOJBJXKFSA-N 0.000 claims 1
- UVIKFRPRZMLHQZ-NHCUHLMSSA-N (4r,5r)-5-(2,4-difluorophenyl)-4-[6-[2-(3-fluorophenyl)ethynyl]pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC(C#CC=2N=C(C=CC=2)[C@@H]2[C@H](OC(=O)N2)C=2C(=CC(F)=CC=2)F)=C1 UVIKFRPRZMLHQZ-NHCUHLMSSA-N 0.000 claims 1
- MIXRHMIVIFYXNJ-WOJBJXKFSA-N (4r,5r)-5-(2,5-difluorophenyl)-4-[2-fluoro-5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=C(F)C([C@@H]2[C@H](NC(=O)O2)C=2C(=NC=C(C=2)C#CC=2C=CC=CC=2)F)=C1 MIXRHMIVIFYXNJ-WOJBJXKFSA-N 0.000 claims 1
- XUBBYXPXONBLAO-RTBURBONSA-N (4r,5r)-5-(2,5-difluorophenyl)-4-[5-(2-pyrazin-2-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=C(F)C([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2N=CC=NC=2)=C1 XUBBYXPXONBLAO-RTBURBONSA-N 0.000 claims 1
- NMFSSMZLWHPSCR-NHCUHLMSSA-N (4r,5r)-5-(2,5-difluorophenyl)-4-[5-[2-(2-fluorophenyl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=C(F)C([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C(=CC=CC=2)F)=C1 NMFSSMZLWHPSCR-NHCUHLMSSA-N 0.000 claims 1
- KURXTFQLDCSJNE-NHCUHLMSSA-N (4r,5r)-5-(2,5-difluorophenyl)-4-[5-[2-(4-fluorophenyl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1C#CC1=CN=CC([C@@H]2[C@H](OC(=O)N2)C=2C(=CC=C(F)C=2)F)=C1 KURXTFQLDCSJNE-NHCUHLMSSA-N 0.000 claims 1
- NHBJRBIVAMDVLA-WOJBJXKFSA-N (4r,5r)-5-(2,5-difluorophenyl)-4-[5-[2-(5-fluoropyridin-3-yl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=C(F)C([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C=C(F)C=NC=2)=C1 NHBJRBIVAMDVLA-WOJBJXKFSA-N 0.000 claims 1
- IBHZUYVLOXRKLQ-NHCUHLMSSA-N (4r,5r)-5-(2,5-difluorophenyl)-4-[5-fluoro-2-(2-phenylethynyl)pyridin-4-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=C(F)C([C@@H]2[C@H](NC(=O)O2)C=2C(=CN=C(C=2)C#CC=2C=CC=CC=2)F)=C1 IBHZUYVLOXRKLQ-NHCUHLMSSA-N 0.000 claims 1
- IAYVUQJOKDFLAL-NHCUHLMSSA-N (4r,5r)-5-(2-chlorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound ClC1=CC=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)NC(=O)O1 IAYVUQJOKDFLAL-NHCUHLMSSA-N 0.000 claims 1
- SXFDJGHRMZNXGF-WOJBJXKFSA-N (4r,5r)-5-(2-fluorophenyl)-4-[2-fluoro-5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC=C1[C@@H]1[C@@H](C=2C(=NC=C(C=2)C#CC=2C=CC=CC=2)F)NC(=O)O1 SXFDJGHRMZNXGF-WOJBJXKFSA-N 0.000 claims 1
- WFRDFDRVMDEEHL-FGZHOGPDSA-N (4r,5r)-5-(2-fluorophenyl)-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC=C1[C@@H]1[C@@H](C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)NC(=O)O1 WFRDFDRVMDEEHL-FGZHOGPDSA-N 0.000 claims 1
- RETSDKVSYUCURH-NHCUHLMSSA-N (4r,5r)-5-(2-fluorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)NC(=O)O1 RETSDKVSYUCURH-NHCUHLMSSA-N 0.000 claims 1
- CUBHLWOGTXMAKH-NHCUHLMSSA-N (4r,5r)-5-(2-fluorophenyl)-4-[5-fluoro-2-(2-phenylethynyl)pyridin-4-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC=C1[C@@H]1[C@@H](C=2C(=CN=C(C=2)C#CC=2C=CC=CC=2)F)NC(=O)O1 CUBHLWOGTXMAKH-NHCUHLMSSA-N 0.000 claims 1
- LRCGADNIJIRZLQ-NHCUHLMSSA-N (4r,5r)-5-(3,4-difluorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=C(F)C(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)NC(=O)O1 LRCGADNIJIRZLQ-NHCUHLMSSA-N 0.000 claims 1
- DVBNAHPPZUKUOC-WOJBJXKFSA-N (4r,5r)-5-(3,4-difluorophenyl)-4-[5-(2-pyridin-3-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=C(F)C(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=NC=CC=2)NC(=O)O1 DVBNAHPPZUKUOC-WOJBJXKFSA-N 0.000 claims 1
- UBKDOFYLBQFHQT-WOJBJXKFSA-N (4r,5r)-5-(3,4-difluorophenyl)-4-[5-[2-(5-fluoropyridin-3-yl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CN=CC(C#CC=2C=C(C=NC=2)[C@@H]2[C@H](OC(=O)N2)C=2C=C(F)C(F)=CC=2)=C1 UBKDOFYLBQFHQT-WOJBJXKFSA-N 0.000 claims 1
- SODCPOYOEMBPAD-DNQXCXABSA-N (4r,5r)-5-(3,4-dimethylphenyl)-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound C1=C(C)C(C)=CC=C1[C@@H]1[C@@H](C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)NC(=O)O1 SODCPOYOEMBPAD-DNQXCXABSA-N 0.000 claims 1
- FBYAOTSHEWGKTG-NHCUHLMSSA-N (4r,5r)-5-(3,5-difluorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC(F)=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=C1 FBYAOTSHEWGKTG-NHCUHLMSSA-N 0.000 claims 1
- ZWNDXNLTDPSLJR-NHCUHLMSSA-N (4r,5r)-5-(3-fluorophenyl)-4-[2-(2-phenylethynyl)pyridin-4-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(N=CC=2)C#CC=2C=CC=CC=2)=C1 ZWNDXNLTDPSLJR-NHCUHLMSSA-N 0.000 claims 1
- SCJQKFPKCZZOGI-WOJBJXKFSA-N (4r,5r)-5-(3-fluorophenyl)-4-[2-(2-phenylethynyl)pyrimidin-4-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2N=C(N=CC=2)C#CC=2C=CC=CC=2)=C1 SCJQKFPKCZZOGI-WOJBJXKFSA-N 0.000 claims 1
- RLNBGHWTAOAFGV-WOJBJXKFSA-N (4r,5r)-5-(3-fluorophenyl)-4-[2-(2-pyridin-3-ylethynyl)pyridin-4-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(N=CC=2)C#CC=2C=NC=CC=2)=C1 RLNBGHWTAOAFGV-WOJBJXKFSA-N 0.000 claims 1
- KRQBQOAYFDUNLA-WOJBJXKFSA-N (4r,5r)-5-(3-fluorophenyl)-4-[2-fluoro-5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C(=NC=C(C=2)C#CC=2C=CC=CC=2)F)=C1 KRQBQOAYFDUNLA-WOJBJXKFSA-N 0.000 claims 1
- QBUZBCUIWRYEGY-NHCUHLMSSA-N (4r,5r)-5-(3-fluorophenyl)-4-[2-methoxy-5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@H]2OC(=O)N[C@@H]2C2=CC(=CN=C2OC)C#CC=2C=CC=CC=2)=CC=CC(F)=C1 QBUZBCUIWRYEGY-NHCUHLMSSA-N 0.000 claims 1
- ONZBAIHVFMEUIY-FGZHOGPDSA-N (4r,5r)-5-(3-fluorophenyl)-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=C1 ONZBAIHVFMEUIY-FGZHOGPDSA-N 0.000 claims 1
- QTJPHEJQUMORSP-NHCUHLMSSA-N (4r,5r)-5-(3-fluorophenyl)-4-[5-[2-(3-fluorophenyl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC(C#CC=2C=C(C=NC=2)[C@@H]2[C@H](OC(=O)N2)C=2C=C(F)C=CC=2)=C1 QTJPHEJQUMORSP-NHCUHLMSSA-N 0.000 claims 1
- IMRSMYSFYRQHPF-FGZHOGPDSA-N (4r,5r)-5-(3-fluorophenyl)-4-[5-[2-(3-methylphenyl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(C#CC=2C=C(C=NC=2)[C@@H]2[C@H](OC(=O)N2)C=2C=C(F)C=CC=2)=C1 IMRSMYSFYRQHPF-FGZHOGPDSA-N 0.000 claims 1
- NAHIAMGFDYUATO-WOJBJXKFSA-N (4r,5r)-5-(3-fluorophenyl)-4-[5-[2-(5-fluoropyridin-3-yl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C=C(F)C=NC=2)=C1 NAHIAMGFDYUATO-WOJBJXKFSA-N 0.000 claims 1
- OFQYNWAXKHBVQZ-NHCUHLMSSA-N (4r,5r)-5-(3-fluorophenyl)-4-[6-(2-phenylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2N=C(C=CC=2)C#CC=2C=CC=CC=2)=C1 OFQYNWAXKHBVQZ-NHCUHLMSSA-N 0.000 claims 1
- KZSXOZJFFMYXQH-FYYLOGMGSA-N (4r,5r)-5-(3-fluorophenyl)-5-methyl-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C=1C([C@H]2NC(=O)O[C@]2(C)C=2C=C(F)C=CC=2)=CN=CC=1C#CC1=CC=CC=C1 KZSXOZJFFMYXQH-FYYLOGMGSA-N 0.000 claims 1
- WEVNLAWWVPJRAD-FGZHOGPDSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-(2-pyridin-4-ylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=CN=CC=2)=C1 WEVNLAWWVPJRAD-FGZHOGPDSA-N 0.000 claims 1
- LVGFVQOXKPHWDN-WOJBJXKFSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-[2-(1,3-thiazol-4-yl)ethynyl]phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2N=CSC=2)=C1 LVGFVQOXKPHWDN-WOJBJXKFSA-N 0.000 claims 1
- OZHMFFJFJSYBKB-DHIUTWEWSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-[2-(6-methoxypyridin-2-yl)ethynyl]phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2N=C(OC)C=CC=2)=C1 OZHMFFJFJSYBKB-DHIUTWEWSA-N 0.000 claims 1
- WEJDTERQTZOYSY-NHCUHLMSSA-N (4r,5r)-5-(4-chlorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(Cl)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)NC(=O)O1 WEJDTERQTZOYSY-NHCUHLMSSA-N 0.000 claims 1
- IWIQNTULARRNOD-FGZHOGPDSA-N (4r,5r)-5-(4-fluorophenyl)-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)NC(=O)O1 IWIQNTULARRNOD-FGZHOGPDSA-N 0.000 claims 1
- KCGNNMNTEGFKSJ-NHCUHLMSSA-N (4r,5r)-5-(4-fluorophenyl)-4-[4-(2-phenylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2N=CC=C(C=2)C#CC=2C=CC=CC=2)NC(=O)O1 KCGNNMNTEGFKSJ-NHCUHLMSSA-N 0.000 claims 1
- ZGUQHHSIPAKMRS-NHCUHLMSSA-N (4r,5r)-5-(4-fluorophenyl)-4-[4-[2-(2-fluorophenyl)ethynyl]pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2N=CC=C(C=2)C#CC=2C(=CC=CC=2)F)NC(=O)O1 ZGUQHHSIPAKMRS-NHCUHLMSSA-N 0.000 claims 1
- KUTIORODXUPQHB-NHCUHLMSSA-N (4r,5r)-5-(4-fluorophenyl)-4-[4-[2-(3-fluorophenyl)ethynyl]pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2N=CC=C(C=2)C#CC=2C=C(F)C=CC=2)NC(=O)O1 KUTIORODXUPQHB-NHCUHLMSSA-N 0.000 claims 1
- BWTBGSZRQTYODP-NHCUHLMSSA-N (4r,5r)-5-(4-fluorophenyl)-4-[4-[2-(4-fluorophenyl)ethynyl]pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1C#CC1=CC=NC([C@@H]2[C@H](OC(=O)N2)C=2C=CC(F)=CC=2)=C1 BWTBGSZRQTYODP-NHCUHLMSSA-N 0.000 claims 1
- UHKFPSCFIZVQIN-RTBURBONSA-N (4r,5r)-5-(4-fluorophenyl)-4-[5-(2-pyrazin-2-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2N=CC=NC=2)NC(=O)O1 UHKFPSCFIZVQIN-RTBURBONSA-N 0.000 claims 1
- OXKGAMRDQMRBHC-WOJBJXKFSA-N (4r,5r)-5-(4-fluorophenyl)-4-[5-(2-pyridin-4-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=CN=CC=2)NC(=O)O1 OXKGAMRDQMRBHC-WOJBJXKFSA-N 0.000 claims 1
- CDOCIDGSLALRDQ-WOJBJXKFSA-N (4r,5r)-5-(4-fluorophenyl)-4-[5-[2-(2-fluoropyridin-4-yl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=C(F)N=CC=2)NC(=O)O1 CDOCIDGSLALRDQ-WOJBJXKFSA-N 0.000 claims 1
- CZQVILLTDQTXSF-WOJBJXKFSA-N (4r,5r)-5-(4-fluorophenyl)-4-[5-[2-(3-fluoropyridin-2-yl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C(=CC=CN=2)F)NC(=O)O1 CZQVILLTDQTXSF-WOJBJXKFSA-N 0.000 claims 1
- RHVMDDGKHSUNKC-IFMALSPDSA-N (4r,5r)-5-(4-fluorophenyl)-4-[5-[2-(3-fluoropyridin-2-yl)ethynyl]pyridin-3-yl]-4-methyl-1,3-oxazolidin-2-one Chemical compound C1([C@H]2OC(=O)N[C@]2(C)C=2C=C(C=NC=2)C#CC=2C(=CC=CN=2)F)=CC=C(F)C=C1 RHVMDDGKHSUNKC-IFMALSPDSA-N 0.000 claims 1
- SFYSTMUSJGGUSS-IFMALSPDSA-N (4r,5r)-5-(4-fluorophenyl)-4-[5-[2-(5-fluoropyridin-3-yl)ethynyl]pyridin-3-yl]-5-methyl-1,3-oxazolidin-2-one Chemical compound C=1C([C@H]2NC(=O)O[C@]2(C)C=2C=CC(F)=CC=2)=CN=CC=1C#CC1=CN=CC(F)=C1 SFYSTMUSJGGUSS-IFMALSPDSA-N 0.000 claims 1
- CGRWNYOTHNFBDL-WOJBJXKFSA-N (4r,5r)-5-(4-fluorophenyl)-4-[5-[2-(6-fluoropyridin-2-yl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2N=C(F)C=CC=2)NC(=O)O1 CGRWNYOTHNFBDL-WOJBJXKFSA-N 0.000 claims 1
- YNYXCVHGSQKESH-WOJBJXKFSA-N (4r,5r)-5-(4-fluorophenyl)-4-[6-[2-(2-fluoropyridin-4-yl)ethynyl]pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2N=C(C=CC=2)C#CC=2C=C(F)N=CC=2)NC(=O)O1 YNYXCVHGSQKESH-WOJBJXKFSA-N 0.000 claims 1
- GVAFQQXDAQXKNU-WOJBJXKFSA-N (4r,5r)-5-(4-fluorophenyl)-4-[6-[2-(3-fluoropyridin-2-yl)ethynyl]pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2N=C(C=CC=2)C#CC=2C(=CC=CN=2)F)NC(=O)O1 GVAFQQXDAQXKNU-WOJBJXKFSA-N 0.000 claims 1
- IOPFIGZAZGJNLB-FYYLOGMGSA-N (4r,5r)-5-(4-fluorophenyl)-4-methyl-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@H]2OC(=O)N[C@]2(C)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=CC=C(F)C=C1 IOPFIGZAZGJNLB-FYYLOGMGSA-N 0.000 claims 1
- CZTXIPZHPOICGB-FYYLOGMGSA-N (4r,5r)-5-(4-fluorophenyl)-5-methyl-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C=1C([C@H]2NC(=O)O[C@]2(C)C=2C=CC(F)=CC=2)=CN=CC=1C#CC1=CC=CC=C1 CZTXIPZHPOICGB-FYYLOGMGSA-N 0.000 claims 1
- QJLGMEAEMSQUFE-DHIUTWEWSA-N (4r,5r)-5-(4-methylphenyl)-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(C)=CC=C1[C@@H]1[C@@H](C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)NC(=O)O1 QJLGMEAEMSQUFE-DHIUTWEWSA-N 0.000 claims 1
- HINJORDJCMFNPK-FYYLOGMGSA-N (4r,5r)-5-methyl-5-phenyl-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C=1C([C@H]2NC(=O)O[C@]2(C)C=2C=CC=CC=2)=CN=CC=1C#CC1=CC=CC=C1 HINJORDJCMFNPK-FYYLOGMGSA-N 0.000 claims 1
- UABUMMUQWBGOIU-WOJBJXKFSA-N (4r,5r)-5-pyridin-4-yl-4-[3-(2-pyridin-2-ylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(C=CC=2)C#CC=2N=CC=CC=2)=CC=NC=C1 UABUMMUQWBGOIU-WOJBJXKFSA-N 0.000 claims 1
- QHZIBVLKFALDTP-NHCUHLMSSA-N (4r,5s)-4-[3-(2-phenylethynyl)phenyl]-5-pyridin-2-yl-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=CC=CC=N1 QHZIBVLKFALDTP-NHCUHLMSSA-N 0.000 claims 1
- IOGXLEWJJSLTMC-WOJBJXKFSA-N (4r,5s)-4-[3-(2-phenylethynyl)phenyl]-5-pyrimidin-4-yl-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=CC=NC=N1 IOGXLEWJJSLTMC-WOJBJXKFSA-N 0.000 claims 1
- SZSWMKVFJLSTMA-WOJBJXKFSA-N (4r,5s)-4-[3-(2-phenylethynyl)phenyl]-5-thiophen-2-yl-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=CC=CS1 SZSWMKVFJLSTMA-WOJBJXKFSA-N 0.000 claims 1
- BJQIGFSSCLXKSZ-JTHBVZDNSA-N (4r,5s)-4-methyl-5-phenyl-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2OC(=O)N[C@]2(C)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=CC=CC=C1 BJQIGFSSCLXKSZ-JTHBVZDNSA-N 0.000 claims 1
- IAYVUQJOKDFLAL-RTWAWAEBSA-N (4r,5s)-5-(2-chlorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound ClC1=CC=CC=C1[C@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)NC(=O)O1 IAYVUQJOKDFLAL-RTWAWAEBSA-N 0.000 claims 1
- CZTXIPZHPOICGB-GGAORHGYSA-N (4r,5s)-5-(4-fluorophenyl)-5-methyl-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C=1C([C@H]2NC(=O)O[C@@]2(C)C=2C=CC(F)=CC=2)=CN=CC=1C#CC1=CC=CC=C1 CZTXIPZHPOICGB-GGAORHGYSA-N 0.000 claims 1
- MRBLTIKUQTUQQV-OALUTQOASA-N (4s,5r)-5-(2-methylpyrazol-3-yl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound CN1N=CC=C1[C@H]1[C@H](C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)NC(=O)O1 MRBLTIKUQTUQQV-OALUTQOASA-N 0.000 claims 1
- CVRQLCWWIXCZHD-FGZHOGPDSA-N 3-[2-[5-[(4r,5r)-5-(3,4-difluorophenyl)-2-oxo-1,3-oxazolidin-4-yl]pyridin-3-yl]ethynyl]benzonitrile Chemical compound C1=C(F)C(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=C(C=CC=2)C#N)NC(=O)O1 CVRQLCWWIXCZHD-FGZHOGPDSA-N 0.000 claims 1
- ISNLWLCYRBHPCS-FGZHOGPDSA-N 3-[2-[5-[(4r,5r)-5-(4-fluorophenyl)-2-oxo-1,3-oxazolidin-4-yl]pyridin-3-yl]ethynyl]benzonitrile Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#CC=2C=C(C=CC=2)C#N)NC(=O)O1 ISNLWLCYRBHPCS-FGZHOGPDSA-N 0.000 claims 1
- MCWBCUSPQANHQM-FGZHOGPDSA-N 4-[(4r,5r)-2-oxo-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-5-yl]benzonitrile Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=CC=C(C#N)C=C1 MCWBCUSPQANHQM-FGZHOGPDSA-N 0.000 claims 1
- 125000005289 uranyl group Chemical group 0.000 claims 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract description 11
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract description 11
- 210000003169 central nervous system Anatomy 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 239000000556 agonist Substances 0.000 abstract description 5
- 239000003446 ligand Substances 0.000 abstract description 4
- 239000004031 partial agonist Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 403
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 373
- 238000006243 chemical reaction Methods 0.000 description 262
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 246
- 238000005160 1H NMR spectroscopy Methods 0.000 description 244
- 238000004949 mass spectrometry Methods 0.000 description 231
- 229910001868 water Inorganic materials 0.000 description 206
- 235000019439 ethyl acetate Nutrition 0.000 description 164
- 239000000243 solution Substances 0.000 description 163
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 158
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 156
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 138
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 122
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 120
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 116
- 229910052796 boron Inorganic materials 0.000 description 110
- 239000007787 solid Substances 0.000 description 92
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 84
- 239000012267 brine Substances 0.000 description 84
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 84
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 82
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 78
- 238000003756 stirring Methods 0.000 description 78
- 229940093499 ethyl acetate Drugs 0.000 description 75
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 75
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 72
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 68
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 65
- 235000019341 magnesium sulphate Nutrition 0.000 description 63
- 238000002953 preparative HPLC Methods 0.000 description 61
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 57
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 56
- 239000011541 reaction mixture Substances 0.000 description 50
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 49
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 46
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 45
- 238000004440 column chromatography Methods 0.000 description 44
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 44
- 239000003921 oil Substances 0.000 description 41
- 229910052757 nitrogen Inorganic materials 0.000 description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- 239000003607 modifier Substances 0.000 description 35
- 239000000725 suspension Substances 0.000 description 35
- 238000000746 purification Methods 0.000 description 34
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical compound C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 32
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 30
- 229960004132 diethyl ether Drugs 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- 239000012044 organic layer Substances 0.000 description 26
- 229940086542 triethylamine Drugs 0.000 description 26
- 125000005843 halogen group Chemical group 0.000 description 25
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 229910021529 ammonia Inorganic materials 0.000 description 22
- 238000004808 supercritical fluid chromatography Methods 0.000 description 22
- UEOOCEWTSIQATM-DHIUTWEWSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=C1 UEOOCEWTSIQATM-DHIUTWEWSA-N 0.000 description 21
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 21
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 21
- 229910002027 silica gel Inorganic materials 0.000 description 21
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 19
- 239000010410 layer Substances 0.000 description 19
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 19
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 19
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 18
- DGODWNOPHMXOTR-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium;dihydrate Chemical compound O.O.[K+].[K+].[O-][Os]([O-])(=O)=O DGODWNOPHMXOTR-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- YUCBLVFHJWOYDN-HVLQGHBFSA-N 1,4-bis[(s)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]phthalazine Chemical compound C1=C(OC)C=C2C([C@H](OC=3C4=CC=CC=C4C(O[C@H]([C@@H]4N5CC[C@H]([C@H](C5)CC)C4)C=4C5=CC(OC)=CC=C5N=CC=4)=NN=3)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 YUCBLVFHJWOYDN-HVLQGHBFSA-N 0.000 description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 17
- 239000001301 oxygen Chemical group 0.000 description 17
- 229910052760 oxygen Inorganic materials 0.000 description 17
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- 230000014759 maintenance of location Effects 0.000 description 16
- 238000010992 reflux Methods 0.000 description 16
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 15
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 15
- 229940001474 sodium thiosulfate Drugs 0.000 description 15
- 235000019345 sodium thiosulphate Nutrition 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 14
- 235000011152 sodium sulphate Nutrition 0.000 description 14
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- PXAMPJOSYXIGKK-CHWSQXEVSA-N (4r,5r)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=C(F)C([C@@H]2[C@H](NC(=O)O2)C=2C=C(Br)C=NC=2)=C1 PXAMPJOSYXIGKK-CHWSQXEVSA-N 0.000 description 11
- CMOOEZNVLMCWGX-WOJBJXKFSA-N (4r,5r)-5-phenyl-4-[2-(2-pyridin-2-ylethynyl)pyridin-4-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(N=CC=2)C#CC=2N=CC=CC=2)=CC=CC=C1 CMOOEZNVLMCWGX-WOJBJXKFSA-N 0.000 description 11
- 239000005695 Ammonium acetate Substances 0.000 description 11
- 229910002651 NO3 Inorganic materials 0.000 description 11
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 11
- 235000019257 ammonium acetate Nutrition 0.000 description 11
- 229940043376 ammonium acetate Drugs 0.000 description 11
- 239000006260 foam Substances 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 10
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
- 238000004293 19F NMR spectroscopy Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000007810 chemical reaction solvent Substances 0.000 description 9
- 239000012230 colorless oil Substances 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- FXUIKFMSOBAWOJ-CHWSQXEVSA-N (4r,5r)-4-(6-bromopyridin-2-yl)-5-phenyl-1,3-oxazolidin-2-one Chemical compound BrC1=CC=CC([C@@H]2[C@H](OC(=O)N2)C=2C=CC=CC=2)=N1 FXUIKFMSOBAWOJ-CHWSQXEVSA-N 0.000 description 8
- WNOORNNENVRQKM-VXKWHMMOSA-N (4s,5s)-5-phenyl-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound C1([C@H]2[C@@H](NC(O2)=O)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=CC=CC=C1 WNOORNNENVRQKM-VXKWHMMOSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000010926 purge Methods 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- BMLOLVOAGKRWGA-HZPDHXFCSA-N tert-butyl n-[(1r,2r)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)-2-hydroxyethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2C=C(Br)C=NC=2)=CC(F)=CC=C1F BMLOLVOAGKRWGA-HZPDHXFCSA-N 0.000 description 8
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 8
- JUCXAOIVULBDAD-OWOJBTEDSA-N 3-bromo-5-[(e)-2-(2,5-difluorophenyl)ethenyl]pyridine Chemical compound FC1=CC=C(F)C(\C=C\C=2C=C(Br)C=NC=2)=C1 JUCXAOIVULBDAD-OWOJBTEDSA-N 0.000 description 7
- NGUVGKAEOFPLDT-UHFFFAOYSA-N 5-bromopyridine-3-carbaldehyde Chemical compound BrC1=CN=CC(C=O)=C1 NGUVGKAEOFPLDT-UHFFFAOYSA-N 0.000 description 7
- 208000012902 Nervous system disease Diseases 0.000 description 7
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 7
- 239000010779 crude oil Substances 0.000 description 7
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 7
- 238000012799 strong cation exchange Methods 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- BQCUIYXZOLCCFQ-CHWSQXEVSA-N (1r,2r)-2-amino-2-(5-bromopyridin-3-yl)-1-(2,5-difluorophenyl)ethanol Chemical compound C1([C@@H](O)[C@H](N)C=2C=C(Br)C=NC=2)=CC(F)=CC=C1F BQCUIYXZOLCCFQ-CHWSQXEVSA-N 0.000 description 6
- YKXZBLIOLDXHJS-ZIAGYGMSSA-N (4r,5r)-4-(6-bromopyridin-2-yl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2N=C(Br)C=CC=2)=C1 YKXZBLIOLDXHJS-ZIAGYGMSSA-N 0.000 description 6
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 6
- XOCUKRWGXXYSJL-UHFFFAOYSA-N 2-(diethoxyphosphorylmethyl)-1,4-difluorobenzene Chemical compound CCOP(=O)(OCC)CC1=CC(F)=CC=C1F XOCUKRWGXXYSJL-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 6
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- 208000018737 Parkinson disease Diseases 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 6
- 235000010265 sodium sulphite Nutrition 0.000 description 6
- QRRKSEFUMFXNDC-UHFFFAOYSA-N tert-butyl n-[2-hydroxy-1-[3-(2-phenylethynyl)phenyl]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(CO)C1=CC=CC(C#CC=2C=CC=CC=2)=C1 QRRKSEFUMFXNDC-UHFFFAOYSA-N 0.000 description 6
- YSCGVEFHCLALKC-CHWSQXEVSA-N (4r,5r)-4-(2-bromopyridin-4-yl)-5-phenyl-1,3-oxazolidin-2-one Chemical compound C1=NC(Br)=CC([C@@H]2[C@H](OC(=O)N2)C=2C=CC=CC=2)=C1 YSCGVEFHCLALKC-CHWSQXEVSA-N 0.000 description 5
- UYUWVTBTPICENL-HUUCEWRRSA-N (4r,5r)-4-(3-bromophenyl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(Br)C=CC=2)=C1 UYUWVTBTPICENL-HUUCEWRRSA-N 0.000 description 5
- LMMOEPNTVIEBGO-VXGBXAGGSA-N (4r,5r)-4-(5-bromo-2-fluoropyridin-3-yl)-5-(3-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C(=NC=C(Br)C=2)F)=C1 LMMOEPNTVIEBGO-VXGBXAGGSA-N 0.000 description 5
- SIAKILKLXLFMNW-ZIAGYGMSSA-N (4r,5r)-4-(5-bromopyridin-3-yl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(Br)C=NC=2)=C1 SIAKILKLXLFMNW-ZIAGYGMSSA-N 0.000 description 5
- MNEWPFGQLYQEHL-SFTDATJTSA-N (4s,5s)-4-[3-(2-phenylethynyl)phenyl]-5-pyridin-3-yl-1,3-oxazolidin-2-one Chemical compound C1([C@H]2[C@@H](NC(O2)=O)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=CC=CN=C1 MNEWPFGQLYQEHL-SFTDATJTSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- YNSHBNUIRMCLES-UHFFFAOYSA-N 2-bromo-4-(bromomethyl)pyrimidine Chemical compound BrCC1=CC=NC(Br)=N1 YNSHBNUIRMCLES-UHFFFAOYSA-N 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 5
- 208000025966 Neurological disease Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 229940043279 diisopropylamine Drugs 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- WOFPTESETJKCBH-UHFFFAOYSA-N trimethyl(2-pyridin-2-ylethynyl)silane Chemical compound C[Si](C)(C)C#CC1=CC=CC=N1 WOFPTESETJKCBH-UHFFFAOYSA-N 0.000 description 5
- MTMBLPOPETZZRX-UHFFFAOYSA-N trimethyl(2-pyridin-3-ylethynyl)silane Chemical compound C[Si](C)(C)C#CC1=CC=CN=C1 MTMBLPOPETZZRX-UHFFFAOYSA-N 0.000 description 5
- LWDMBSXQCIUATG-ZIAGYGMSSA-N (1r,2r)-1-azido-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propan-2-ol Chemical compound C1([C@@H](N=[N+]=[N-])[C@@](O)(C)C=2C(=CC=C(F)C=2)F)=CN=CC(Br)=C1 LWDMBSXQCIUATG-ZIAGYGMSSA-N 0.000 description 4
- OBRBKOTZNQGHRG-KGLIPLIRSA-N (1r,2s)-1-amino-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propan-2-ol Chemical compound C1([C@@H](N)[C@](O)(C)C=2C(=CC=C(F)C=2)F)=CN=CC(Br)=C1 OBRBKOTZNQGHRG-KGLIPLIRSA-N 0.000 description 4
- HFBMVYXBSQBANJ-UKRRQHHQSA-N (4r,5r)-4-(5-bromopyridin-3-yl)-4-methyl-5-phenyl-1,3-oxazolidin-2-one Chemical compound C1([C@H]2OC(=O)N[C@]2(C)C=2C=C(Br)C=NC=2)=CC=CC=C1 HFBMVYXBSQBANJ-UKRRQHHQSA-N 0.000 description 4
- AEDJVIWDXYJQMJ-CHWSQXEVSA-N (4r,5r)-4-(5-bromopyridin-3-yl)-5-(3-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(Br)C=NC=2)=C1 AEDJVIWDXYJQMJ-CHWSQXEVSA-N 0.000 description 4
- JDFGTRYOJYBDGX-CHWSQXEVSA-N (4r,5r)-4-(5-bromopyridin-3-yl)-5-(4-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(Br)C=NC=2)NC(=O)O1 JDFGTRYOJYBDGX-CHWSQXEVSA-N 0.000 description 4
- WNOORNNENVRQKM-FCHUYYIVSA-N (4s,5r)-5-phenyl-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@@H](NC(O2)=O)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=CC=CC=C1 WNOORNNENVRQKM-FCHUYYIVSA-N 0.000 description 4
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- AIPRAPZUGUTQKX-UHFFFAOYSA-N diethoxyphosphorylmethylbenzene Chemical compound CCOP(=O)(OCC)CC1=CC=CC=C1 AIPRAPZUGUTQKX-UHFFFAOYSA-N 0.000 description 4
- 238000007876 drug discovery Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
- DPGOEJBXMSLWHR-IAGOWNOFSA-N tert-butyl n-[(1r,2r)-1-(6-bromopyridin-2-yl)-2-hydroxy-2-(3-methoxyphenyl)ethyl]carbamate Chemical compound COC1=CC=CC([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2N=C(Br)C=CC=2)=C1 DPGOEJBXMSLWHR-IAGOWNOFSA-N 0.000 description 4
- HCPZJJFCNLMNKJ-HZPDHXFCSA-N tert-butyl n-[(1r,2r)-1-(6-bromopyridin-2-yl)-2-hydroxy-2-phenylethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2N=C(Br)C=CC=2)=CC=CC=C1 HCPZJJFCNLMNKJ-HZPDHXFCSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 4
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- WRLPFYWQMMNMSL-ZIAGYGMSSA-N (1r,2r)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propane-1,2-diol Chemical compound C1([C@@H](O)[C@@](O)(C)C=2C(=CC=C(F)C=2)F)=CN=CC(Br)=C1 WRLPFYWQMMNMSL-ZIAGYGMSSA-N 0.000 description 3
- WRLPFYWQMMNMSL-KGLIPLIRSA-N (1r,2s)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propane-1,2-diol Chemical compound C1([C@@H](O)[C@](O)(C)C=2C(=CC=C(F)C=2)F)=CN=CC(Br)=C1 WRLPFYWQMMNMSL-KGLIPLIRSA-N 0.000 description 3
- XBVJBJWTESLFCN-CHWSQXEVSA-N (4r,5r)-4-(2-bromo-5-fluoropyridin-4-yl)-5-(4-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C(=CN=C(Br)C=2)F)NC(=O)O1 XBVJBJWTESLFCN-CHWSQXEVSA-N 0.000 description 3
- JEIUDCRALHVJRB-VXGBXAGGSA-N (4r,5r)-4-(5-bromo-2-fluoropyridin-3-yl)-5-(4-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C(=NC=C(Br)C=2)F)NC(=O)O1 JEIUDCRALHVJRB-VXGBXAGGSA-N 0.000 description 3
- DDMUOLQKKTWWRB-VXGBXAGGSA-N (4r,5r)-4-(5-bromo-2-fluoropyridin-3-yl)-5-[4-(trifluoromethyl)phenyl]-1,3-oxazolidin-2-one Chemical compound FC1=NC=C(Br)C=C1[C@@H]1[C@@H](C=2C=CC(=CC=2)C(F)(F)F)OC(=O)N1 DDMUOLQKKTWWRB-VXGBXAGGSA-N 0.000 description 3
- BCOVSIKFYLBKCD-ZIAGYGMSSA-N (4r,5r)-4-(5-ethynyl-2-fluoropyridin-3-yl)-5-(3-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C(=NC=C(C=2)C#C)F)=C1 BCOVSIKFYLBKCD-ZIAGYGMSSA-N 0.000 description 3
- KJXCLTQTWBUUQO-IAGOWNOFSA-N (4r,5r)-5-(3-fluorophenyl)-4-[2-fluoro-5-(2-trimethylsilylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C[Si](C)(C)C#CC1=CN=C(F)C([C@@H]2[C@H](OC(=O)N2)C=2C=C(F)C=CC=2)=C1 KJXCLTQTWBUUQO-IAGOWNOFSA-N 0.000 description 3
- AZNZHVJANLCQAI-IAGOWNOFSA-N (4r,5s)-2-oxo-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidine-5-carbonitrile Chemical compound N#C[C@H]1OC(=O)N[C@@H]1C1=CC=CC(C#CC=2C=CC=CC=2)=C1 AZNZHVJANLCQAI-IAGOWNOFSA-N 0.000 description 3
- GMNRFXMLOFPFRM-CVEARBPZSA-N (4r,5s)-2-oxo-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidine-5-carbonyl chloride Chemical compound ClC(=O)[C@H]1OC(=O)N[C@@H]1C1=CC=CC(C#CC=2C=CC=CC=2)=C1 GMNRFXMLOFPFRM-CVEARBPZSA-N 0.000 description 3
- ZECQEHLAHIWMCA-CVEARBPZSA-N (4r,5s)-2-oxo-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidine-5-carboxamide Chemical compound NC(=O)[C@H]1OC(=O)N[C@@H]1C1=CC=CC(C#CC=2C=CC=CC=2)=C1 ZECQEHLAHIWMCA-CVEARBPZSA-N 0.000 description 3
- MIESTFIXHWAOTC-SFYZADRCSA-N (4r,5s)-4-(3-bromophenyl)-2-oxo-1,3-oxazolidine-5-carboxylic acid Chemical compound OC(=O)[C@H]1OC(=O)N[C@@H]1C1=CC=CC(Br)=C1 MIESTFIXHWAOTC-SFYZADRCSA-N 0.000 description 3
- UYUWVTBTPICENL-CABCVRRESA-N (4r,5s)-4-(3-bromophenyl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@H]2[C@H](NC(=O)O2)C=2C=C(Br)C=CC=2)=C1 UYUWVTBTPICENL-CABCVRRESA-N 0.000 description 3
- HFBMVYXBSQBANJ-DZGCQCFKSA-N (4r,5s)-4-(5-bromopyridin-3-yl)-4-methyl-5-phenyl-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2OC(=O)N[C@]2(C)C=2C=C(Br)C=NC=2)=CC=CC=C1 HFBMVYXBSQBANJ-DZGCQCFKSA-N 0.000 description 3
- SGBLXAOVSZCXKO-CVEARBPZSA-N (4r,5s)-4-[3-(2-phenylethynyl)phenyl]-5-(2h-tetrazol-5-yl)-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=NN=NN1 SGBLXAOVSZCXKO-CVEARBPZSA-N 0.000 description 3
- UYUWVTBTPICENL-GJZGRUSLSA-N (4s,5s)-4-(3-bromophenyl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@H]2[C@@H](NC(=O)O2)C=2C=C(Br)C=CC=2)=C1 UYUWVTBTPICENL-GJZGRUSLSA-N 0.000 description 3
- QXFLCHBRHZEILK-STQMWFEESA-N (4s,5s)-4-(3-bromophenyl)-5-pyridin-3-yl-1,3-oxazolidin-2-one Chemical compound BrC1=CC=CC([C@H]2[C@@H](OC(=O)N2)C=2C=NC=CC=2)=C1 QXFLCHBRHZEILK-STQMWFEESA-N 0.000 description 3
- YAXKWQSQZIVTFC-UHFFFAOYSA-N (5-bromo-2-fluoropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC(Br)=CN=C1F YAXKWQSQZIVTFC-UHFFFAOYSA-N 0.000 description 3
- WDVDHJLKXYCOFS-UHFFFAOYSA-N (5-bromopyridin-3-yl)methanol Chemical compound OCC1=CN=CC(Br)=C1 WDVDHJLKXYCOFS-UHFFFAOYSA-N 0.000 description 3
- JYFYRNCOOXHPGY-UHFFFAOYSA-N 1-(diethoxyphosphorylmethyl)-3-fluorobenzene Chemical compound CCOP(=O)(OCC)CC1=CC=CC(F)=C1 JYFYRNCOOXHPGY-UHFFFAOYSA-N 0.000 description 3
- IGGMUQNGGBRXFB-UHFFFAOYSA-N 1-(diethoxyphosphorylmethyl)-3-methoxybenzene Chemical compound CCOP(=O)(OCC)CC1=CC=CC(OC)=C1 IGGMUQNGGBRXFB-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- ZSVRPAOEXJYLHF-UHFFFAOYSA-N 2-(5-bromopyridin-3-yl)propanoic acid Chemical compound OC(=O)C(C)C1=CN=CC(Br)=C1 ZSVRPAOEXJYLHF-UHFFFAOYSA-N 0.000 description 3
- LQPDKWJXCIVCJV-DAFODLJHSA-N 2-bromo-5-fluoro-4-[(e)-2-(4-fluorophenyl)ethenyl]pyridine Chemical compound C1=CC(F)=CC=C1\C=C\C1=CC(Br)=NC=C1F LQPDKWJXCIVCJV-DAFODLJHSA-N 0.000 description 3
- HSZNWZZPSFVZJF-UHFFFAOYSA-N 2-bromo-6-(diethoxyphosphorylmethyl)pyridine Chemical compound CCOP(=O)(OCC)CC1=CC=CC(Br)=N1 HSZNWZZPSFVZJF-UHFFFAOYSA-N 0.000 description 3
- HAFZOOSURLLLAK-CMDGGOBGSA-N 2-bromo-6-[(e)-2-(3-methoxyphenyl)ethenyl]pyridine Chemical compound COC1=CC=CC(\C=C\C=2N=C(Br)C=CC=2)=C1 HAFZOOSURLLLAK-CMDGGOBGSA-N 0.000 description 3
- DSIWLDCXHHMNQL-UHFFFAOYSA-N 2-ethenyl-1,4-difluorobenzene Chemical compound FC1=CC=C(F)C(C=C)=C1 DSIWLDCXHHMNQL-UHFFFAOYSA-N 0.000 description 3
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 3
- BYWQPRFQFAVVEY-ZIAGYGMSSA-N 3-bromo-5-[(2r,3r)-3-(2,5-difluorophenyl)-3-methyloxiran-2-yl]pyridine Chemical compound C1([C@H]2O[C@]2(C)C=2C(=CC=C(F)C=2)F)=CN=CC(Br)=C1 BYWQPRFQFAVVEY-ZIAGYGMSSA-N 0.000 description 3
- BYWQPRFQFAVVEY-KGLIPLIRSA-N 3-bromo-5-[(2r,3s)-3-(2,5-difluorophenyl)-3-methyloxiran-2-yl]pyridine Chemical compound C1([C@H]2O[C@@]2(C)C=2C(=CC=C(F)C=2)F)=CN=CC(Br)=C1 BYWQPRFQFAVVEY-KGLIPLIRSA-N 0.000 description 3
- RPUBESCAMISNPE-WTKPLQERSA-N 3-bromo-5-[(z)-2-(2,5-difluorophenyl)prop-1-enyl]pyridine Chemical compound C=1C(F)=CC=C(F)C=1C(/C)=C\C1=CN=CC(Br)=C1 RPUBESCAMISNPE-WTKPLQERSA-N 0.000 description 3
- CLRPXACRDTXENY-UHFFFAOYSA-N 3-ethynylpyridine Chemical compound C#CC1=CC=CN=C1 CLRPXACRDTXENY-UHFFFAOYSA-N 0.000 description 3
- YUCBLVFHJWOYDN-PPIALRKJSA-N 4-[(r)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]-1-[(r)-[(2r,4r,5s)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]phthalazine Chemical compound C1=C(OC)C=C2C([C@@H](OC=3C4=CC=CC=C4C(O[C@@H]([C@@H]4N5CC[C@@H]([C@@H](C5)CC)C4)C=4C5=CC(OC)=CC=C5N=CC=4)=NN=3)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 YUCBLVFHJWOYDN-PPIALRKJSA-N 0.000 description 3
- FTWRRIIGLDNVBW-DAFODLJHSA-N 5-bromo-2-fluoro-3-[(e)-2-(4-fluorophenyl)ethenyl]pyridine Chemical compound C1=CC(F)=CC=C1\C=C\C1=CC(Br)=CN=C1F FTWRRIIGLDNVBW-DAFODLJHSA-N 0.000 description 3
- QNQUUMUCZDBOJI-DAFODLJHSA-N 5-bromo-2-fluoro-3-[(e)-2-[4-(trifluoromethyl)phenyl]ethenyl]pyridine Chemical compound FC1=NC=C(Br)C=C1\C=C\C1=CC=C(C(F)(F)F)C=C1 QNQUUMUCZDBOJI-DAFODLJHSA-N 0.000 description 3
- QWFHFNGMCPMOCD-UHFFFAOYSA-N 6-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=CC(C=O)=N1 QWFHFNGMCPMOCD-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- NCKJPOAHZSDZBM-UHFFFAOYSA-N BrC1=CN=CC(CP(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)=C1.Br Chemical compound BrC1=CN=CC(CP(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)=C1.Br NCKJPOAHZSDZBM-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 208000012661 Dyskinesia Diseases 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- TUMFZHOWQQUCFA-UHFFFAOYSA-N benzyl n-[2-(5-bromopyridin-3-yl)-1-[tert-butyl(dimethyl)silyl]oxy-1-(2,5-difluorophenyl)propan-2-yl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(C)(C=1C=C(Br)C=NC=1)C(O[Si](C)(C)C(C)(C)C)C1=CC(F)=CC=C1F TUMFZHOWQQUCFA-UHFFFAOYSA-N 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- OQZQWLRFNSXBTL-VOTSOKGWSA-N propan-2-yl (e)-3-(3-bromophenyl)prop-2-enoate Chemical compound CC(C)OC(=O)\C=C\C1=CC=CC(Br)=C1 OQZQWLRFNSXBTL-VOTSOKGWSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- SZWLKHDRWHKLAG-HZPDHXFCSA-N tert-butyl n-[(1r,2r)-1-(2-bromo-5-fluoropyridin-4-yl)-2-(4-fluorophenyl)-2-hydroxyethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2C(=CN=C(Br)C=2)F)=CC=C(F)C=C1 SZWLKHDRWHKLAG-HZPDHXFCSA-N 0.000 description 3
- BNHVZSYPKQXWLY-HUUCEWRRSA-N tert-butyl n-[(1r,2r)-1-(5-bromo-2-fluoropyridin-3-yl)-2-(3-fluorophenyl)-2-hydroxyethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2C(=NC=C(Br)C=2)F)=CC=CC(F)=C1 BNHVZSYPKQXWLY-HUUCEWRRSA-N 0.000 description 3
- AQPICUXGUAKRIH-HUUCEWRRSA-N tert-butyl n-[(1r,2r)-1-(5-bromo-2-fluoropyridin-3-yl)-2-(4-fluorophenyl)-2-hydroxyethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2C(=NC=C(Br)C=2)F)=CC=C(F)C=C1 AQPICUXGUAKRIH-HUUCEWRRSA-N 0.000 description 3
- MVDSGTNIWVULBH-HUUCEWRRSA-N tert-butyl n-[(1r,2r)-1-(5-bromo-2-fluoropyridin-3-yl)-2-hydroxy-2-[4-(trifluoromethyl)phenyl]ethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2C(=NC=C(Br)C=2)F)=CC=C(C(F)(F)F)C=C1 MVDSGTNIWVULBH-HUUCEWRRSA-N 0.000 description 3
- DLWVRTGLKFNKGP-HUUCEWRRSA-N tert-butyl n-[(1r,2r)-1-(6-chloropyrimidin-4-yl)-2-(3-fluorophenyl)-2-hydroxyethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2N=CN=C(Cl)C=2)=CC=CC(F)=C1 DLWVRTGLKFNKGP-HUUCEWRRSA-N 0.000 description 3
- SQBQLNYEBXEWKD-HZPDHXFCSA-N tert-butyl n-[(1r,2r)-2-(5-bromopyridin-3-yl)-1-(2,5-difluorophenyl)-2-hydroxyethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2C(=CC=C(F)C=2)F)=CN=CC(Br)=C1 SQBQLNYEBXEWKD-HZPDHXFCSA-N 0.000 description 3
- QRRKSEFUMFXNDC-LJQANCHMSA-N tert-butyl n-[(1s)-2-hydroxy-1-[3-(2-phenylethynyl)phenyl]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](CO)C1=CC=CC(C#CC=2C=CC=CC=2)=C1 QRRKSEFUMFXNDC-LJQANCHMSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- OBRBKOTZNQGHRG-ZIAGYGMSSA-N (1r,2r)-1-amino-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propan-2-ol Chemical compound C1([C@@H](N)[C@@](O)(C)C=2C(=CC=C(F)C=2)F)=CN=CC(Br)=C1 OBRBKOTZNQGHRG-ZIAGYGMSSA-N 0.000 description 2
- KRWSTBRDJZCVOU-GHMZBOCLSA-N (1r,2r)-2-amino-2-(2-chloropyrimidin-4-yl)-1-(2,5-difluorophenyl)ethanol Chemical compound C1([C@@H](O)[C@H](N)C=2N=C(Cl)N=CC=2)=CC(F)=CC=C1F KRWSTBRDJZCVOU-GHMZBOCLSA-N 0.000 description 2
- UQXRZWPIKNJQTP-WDEREUQCSA-N (1r,2r)-2-amino-2-(4-chloropyrimidin-2-yl)-1-(3-fluorophenyl)ethanol Chemical compound C1([C@@H](O)[C@H](N)C=2N=C(Cl)C=CN=2)=CC=CC(F)=C1 UQXRZWPIKNJQTP-WDEREUQCSA-N 0.000 description 2
- ZQRFBWNXCIVMOI-VXGBXAGGSA-N (1r,2r)-2-amino-2-(6-chloropyrimidin-4-yl)-1-(3-fluorophenyl)ethanol Chemical compound C1([C@@H](O)[C@H](N)C=2N=CN=C(Cl)C=2)=CC=CC(F)=C1 ZQRFBWNXCIVMOI-VXGBXAGGSA-N 0.000 description 2
- LWDMBSXQCIUATG-KGLIPLIRSA-N (1r,2s)-1-azido-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propan-2-ol Chemical compound C1([C@@H](N=[N+]=[N-])[C@](O)(C)C=2C(=CC=C(F)C=2)F)=CN=CC(Br)=C1 LWDMBSXQCIUATG-KGLIPLIRSA-N 0.000 description 2
- AXQCYFLMAUPOLN-UHFFFAOYSA-N (2-bromo-5-fluoropyridin-4-yl)boronic acid Chemical compound OB(O)C1=CC(Br)=NC=C1F AXQCYFLMAUPOLN-UHFFFAOYSA-N 0.000 description 2
- BEMXJAOLWPDGAK-CABCVRRESA-N (2r,3r)-2-(3-bromophenyl)-3-hydroxy-3-(3-methoxyphenyl)propanoic acid Chemical compound COC1=CC=CC([C@H](O)[C@H](C(O)=O)C=2C=C(Br)C=CC=2)=C1 BEMXJAOLWPDGAK-CABCVRRESA-N 0.000 description 2
- TVMZOJSNCBRUFJ-UKRRQHHQSA-N (2r,3r)-2-(5-bromopyridin-3-yl)-3-hydroxy-2-methyl-3-phenylpropanoic acid Chemical compound C1([C@@H](O)[C@](C)(C(O)=O)C=2C=C(Br)C=NC=2)=CC=CC=C1 TVMZOJSNCBRUFJ-UKRRQHHQSA-N 0.000 description 2
- BEMXJAOLWPDGAK-HUUCEWRRSA-N (2r,3s)-2-(3-bromophenyl)-3-hydroxy-3-(3-methoxyphenyl)propanoic acid Chemical compound COC1=CC=CC([C@@H](O)[C@H](C(O)=O)C=2C=C(Br)C=CC=2)=C1 BEMXJAOLWPDGAK-HUUCEWRRSA-N 0.000 description 2
- SZYKGMZAVLLKHL-CHWSQXEVSA-N (2r,3s)-2-(5-bromopyridin-3-yl)-3-(4-fluorophenyl)-3-hydroxypropanoic acid Chemical compound C1([C@@H](C(O)=O)[C@H](O)C=2C=CC(F)=CC=2)=CN=CC(Br)=C1 SZYKGMZAVLLKHL-CHWSQXEVSA-N 0.000 description 2
- TVMZOJSNCBRUFJ-DZGCQCFKSA-N (2r,3s)-2-(5-bromopyridin-3-yl)-3-hydroxy-2-methyl-3-phenylpropanoic acid Chemical compound C1([C@H](O)[C@](C)(C(O)=O)C=2C=C(Br)C=NC=2)=CC=CC=C1 TVMZOJSNCBRUFJ-DZGCQCFKSA-N 0.000 description 2
- RIFWVHPDNZQJTN-SFYZADRCSA-N (2s,3r)-3-amino-3-(3-bromophenyl)-2-hydroxypropanoic acid Chemical compound OC(=O)[C@@H](O)[C@H](N)C1=CC=CC(Br)=C1 RIFWVHPDNZQJTN-SFYZADRCSA-N 0.000 description 2
- QDIJFXOLQKXMCK-VXKWHMMOSA-N (2s,3r)-3-hydroxy-3-phenyl-2-[3-(2-phenylethynyl)phenyl]propanoic acid Chemical compound C=1C([C@H](C(O)=O)[C@@H](O)C=2C=CC=CC=2)=CC=CC=1C#CC1=CC=CC=C1 QDIJFXOLQKXMCK-VXKWHMMOSA-N 0.000 description 2
- LIUMNVOUTVCRMZ-ZIAGYGMSSA-N (4r,5r)-4-(2-bromopyridin-4-yl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(Br)N=CC=2)=C1 LIUMNVOUTVCRMZ-ZIAGYGMSSA-N 0.000 description 2
- BZOFSYBUYUUOOW-CHWSQXEVSA-N (4r,5r)-4-(4-bromopyridin-2-yl)-5-phenyl-1,3-oxazolidin-2-one Chemical compound BrC1=CC=NC([C@@H]2[C@H](OC(=O)N2)C=2C=CC=CC=2)=C1 BZOFSYBUYUUOOW-CHWSQXEVSA-N 0.000 description 2
- ZXZFSCOSNOYKTG-CHWSQXEVSA-N (4r,5r)-4-(5-bromopyridin-3-yl)-5-phenyl-1,3-oxazolidin-2-one Chemical compound BrC1=CN=CC([C@@H]2[C@H](OC(=O)N2)C=2C=CC=CC=2)=C1 ZXZFSCOSNOYKTG-CHWSQXEVSA-N 0.000 description 2
- RZOYXWLEPBEYSM-RTBURBONSA-N (4r,5r)-4-[2-fluoro-5-(2-pyridin-3-ylethynyl)pyridin-3-yl]-5-[4-(trifluoromethyl)phenyl]-1,3-oxazolidin-2-one Chemical compound C1([C@H]2OC(=O)N[C@@H]2C2=CC(=CN=C2F)C#CC=2C=NC=CC=2)=CC=C(C(F)(F)F)C=C1 RZOYXWLEPBEYSM-RTBURBONSA-N 0.000 description 2
- MPPHLDGJYXESIQ-HUUCEWRRSA-N (4r,5r)-5-(2,5-difluorophenyl)-4-(5-ethynylpyridin-3-yl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=C(F)C([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#C)=C1 MPPHLDGJYXESIQ-HUUCEWRRSA-N 0.000 description 2
- WHXDJWBHGSCJTG-CVEARBPZSA-N (4r,5s)-2-oxo-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidine-5-carboxylic acid Chemical compound OC(=O)[C@H]1OC(=O)N[C@@H]1C1=CC=CC(C#CC=2C=CC=CC=2)=C1 WHXDJWBHGSCJTG-CVEARBPZSA-N 0.000 description 2
- DHUCBFCOKNLZSR-SJORKVTESA-N (4r,5s)-5-(2-methyltetrazol-5-yl)-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound CN1N=NC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=N1 DHUCBFCOKNLZSR-SJORKVTESA-N 0.000 description 2
- LWJZBGIOIZYWAX-UHFFFAOYSA-N (5-bromo-2-fluoropyridin-3-yl)methanol Chemical compound OCC1=CC(Br)=CN=C1F LWJZBGIOIZYWAX-UHFFFAOYSA-N 0.000 description 2
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- VLIMXNFVVHBLMJ-UHFFFAOYSA-N 1-(diethoxyphosphorylmethyl)-2-fluorobenzene Chemical compound CCOP(=O)(OCC)CC1=CC=CC=C1F VLIMXNFVVHBLMJ-UHFFFAOYSA-N 0.000 description 2
- JWVTWJNGILGLAT-UHFFFAOYSA-N 1-ethenyl-4-fluorobenzene Chemical compound FC1=CC=C(C=C)C=C1 JWVTWJNGILGLAT-UHFFFAOYSA-N 0.000 description 2
- YFPQIXUNBPQKQR-UHFFFAOYSA-N 1-ethynyl-2-fluorobenzene Chemical compound FC1=CC=CC=C1C#C YFPQIXUNBPQKQR-UHFFFAOYSA-N 0.000 description 2
- PTRUTZFCVFUTMW-UHFFFAOYSA-N 1-ethynyl-3-fluorobenzene Chemical compound FC1=CC=CC(C#C)=C1 PTRUTZFCVFUTMW-UHFFFAOYSA-N 0.000 description 2
- QXSWHQGIEKUBAS-UHFFFAOYSA-N 1-ethynyl-4-fluorobenzene Chemical compound FC1=CC=C(C#C)C=C1 QXSWHQGIEKUBAS-UHFFFAOYSA-N 0.000 description 2
- VVVOJODFBWBNBI-UHFFFAOYSA-N 2,5-difluorobenzaldehyde Chemical compound FC1=CC=C(F)C(C=O)=C1 VVVOJODFBWBNBI-UHFFFAOYSA-N 0.000 description 2
- UETIDNDXXGCJCE-UHFFFAOYSA-N 2-(5-bromopyridin-3-yl)acetic acid Chemical compound OC(=O)CC1=CN=CC(Br)=C1 UETIDNDXXGCJCE-UHFFFAOYSA-N 0.000 description 2
- HCJMUULXNLWIJC-UHFFFAOYSA-N 2-(bromomethyl)-4-chloropyrimidine Chemical compound ClC1=CC=NC(CBr)=N1 HCJMUULXNLWIJC-UHFFFAOYSA-N 0.000 description 2
- ZLRAITVSGOWJEZ-UHFFFAOYSA-N 2-[3-(2-phenylethynyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C#CC=2C=CC=CC=2)=C1 ZLRAITVSGOWJEZ-UHFFFAOYSA-N 0.000 description 2
- FTTXNZAYCBRYDW-UHFFFAOYSA-N 2-amino-2-(6-bromopyridin-2-yl)propanenitrile Chemical compound N#CC(N)(C)C1=CC=CC(Br)=N1 FTTXNZAYCBRYDW-UHFFFAOYSA-N 0.000 description 2
- NHTTWYVUVXDWHB-UHFFFAOYSA-N 2-bromo-4-(diethoxyphosphorylmethyl)pyrimidine Chemical compound CCOP(=O)(OCC)CC1=CC=NC(Br)=N1 NHTTWYVUVXDWHB-UHFFFAOYSA-N 0.000 description 2
- BHRDVPJTITZSSE-OWOJBTEDSA-N 2-bromo-4-[(e)-2-(2,5-difluorophenyl)ethenyl]-5-fluoropyridine Chemical compound FC1=CC=C(F)C(\C=C\C=2C(=CN=C(Br)C=2)F)=C1 BHRDVPJTITZSSE-OWOJBTEDSA-N 0.000 description 2
- WJIIDGPQSXCOLL-HNQUOIGGSA-N 2-bromo-4-[(e)-2-(2,5-difluorophenyl)ethenyl]pyrimidine Chemical compound FC1=CC=C(F)C(\C=C\C=2N=C(Br)N=CC=2)=C1 WJIIDGPQSXCOLL-HNQUOIGGSA-N 0.000 description 2
- CEXBJGPNQCYQRN-VOTSOKGWSA-N 2-bromo-4-[(e)-2-phenylethenyl]pyridine Chemical compound C1=NC(Br)=CC(\C=C\C=2C=CC=CC=2)=C1 CEXBJGPNQCYQRN-VOTSOKGWSA-N 0.000 description 2
- KPOUVOAHLFFJLH-AATRIKPKSA-N 2-bromo-5-fluoro-4-[(e)-2-(2-fluorophenyl)ethenyl]pyridine Chemical compound FC1=CC=CC=C1\C=C\C1=CC(Br)=NC=C1F KPOUVOAHLFFJLH-AATRIKPKSA-N 0.000 description 2
- BHJMCLFEUAAESZ-CMDGGOBGSA-N 2-bromo-6-[(e)-2-(2-fluorophenyl)ethenyl]pyridine Chemical compound FC1=CC=CC=C1\C=C\C1=CC=CC(Br)=N1 BHJMCLFEUAAESZ-CMDGGOBGSA-N 0.000 description 2
- DNGDVTSIBMCOBJ-MDZDMXLPSA-N 2-bromo-6-[(e)-2-phenylethenyl]pyridine Chemical compound BrC1=CC=CC(\C=C\C=2C=CC=CC=2)=N1 DNGDVTSIBMCOBJ-MDZDMXLPSA-N 0.000 description 2
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 2
- RTWLIQFKXMWEJY-UHFFFAOYSA-N 2-bromopyridine-4-carbaldehyde Chemical compound BrC1=CC(C=O)=CC=N1 RTWLIQFKXMWEJY-UHFFFAOYSA-N 0.000 description 2
- LHKZOTGMMHMJEX-UHFFFAOYSA-N 3-(azidomethyl)-5-(2-phenylethynyl)pyridine Chemical compound [N-]=[N+]=NCC1=CN=CC(C#CC=2C=CC=CC=2)=C1 LHKZOTGMMHMJEX-UHFFFAOYSA-N 0.000 description 2
- OCKHJDIXPNBNAU-VOTSOKGWSA-N 3-[(e)-2-(3-bromophenyl)ethenyl]pyridine Chemical compound BrC1=CC=CC(\C=C\C=2C=NC=CC=2)=C1 OCKHJDIXPNBNAU-VOTSOKGWSA-N 0.000 description 2
- RPUBESCAMISNPE-RUDMXATFSA-N 3-bromo-5-[(e)-2-(2,5-difluorophenyl)prop-1-enyl]pyridine Chemical compound C=1C(F)=CC=C(F)C=1C(/C)=C/C1=CN=CC(Br)=C1 RPUBESCAMISNPE-RUDMXATFSA-N 0.000 description 2
- GNQRGLMYUWRBKF-AATRIKPKSA-N 3-bromo-5-[(e)-2-(3-methoxyphenyl)ethenyl]pyridine Chemical compound COC1=CC=CC(\C=C\C=2C=C(Br)C=NC=2)=C1 GNQRGLMYUWRBKF-AATRIKPKSA-N 0.000 description 2
- ZDZZIDZFZUBFPX-YRNVUSSQSA-N 3-bromo-5-[(e)-2-phenylprop-1-enyl]pyridine Chemical compound C=1C=CC=CC=1C(/C)=C/C1=CN=CC(Br)=C1 ZDZZIDZFZUBFPX-YRNVUSSQSA-N 0.000 description 2
- ZDZZIDZFZUBFPX-XFFZJAGNSA-N 3-bromo-5-[(z)-2-phenylprop-1-enyl]pyridine Chemical compound C=1C=CC=CC=1C(/C)=C\C1=CN=CC(Br)=C1 ZDZZIDZFZUBFPX-XFFZJAGNSA-N 0.000 description 2
- HNNNBQRRIHKFLI-UHFFFAOYSA-N 3-bromo-5-fluoropyridine Chemical compound FC1=CN=CC(Br)=C1 HNNNBQRRIHKFLI-UHFFFAOYSA-N 0.000 description 2
- ADCLTLQMVAEBLB-UHFFFAOYSA-N 3-bromo-5-methylpyridine Chemical compound CC1=CN=CC(Br)=C1 ADCLTLQMVAEBLB-UHFFFAOYSA-N 0.000 description 2
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 2
- HICJXFHZGYLFJQ-UHFFFAOYSA-N 3-ethynyl-5-fluoropyridine Chemical compound FC1=CN=CC(C#C)=C1 HICJXFHZGYLFJQ-UHFFFAOYSA-N 0.000 description 2
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 2
- BREBLOQLDAMOQJ-UHFFFAOYSA-N 4-(bromomethyl)-6-chloropyrimidine Chemical compound ClC1=CC(CBr)=NC=N1 BREBLOQLDAMOQJ-UHFFFAOYSA-N 0.000 description 2
- PTPTZLXZHPPVKG-UHFFFAOYSA-N 4-bromo-2-fluoropyridine Chemical compound FC1=CC(Br)=CC=N1 PTPTZLXZHPPVKG-UHFFFAOYSA-N 0.000 description 2
- LYRXILTUZBBMNS-UHFFFAOYSA-N 4-bromo-2-methyl-1,3-thiazole Chemical compound CC1=NC(Br)=CS1 LYRXILTUZBBMNS-UHFFFAOYSA-N 0.000 description 2
- JFBMFWHEXBLFCR-UHFFFAOYSA-N 4-bromo-2-methylpyridine Chemical compound CC1=CC(Br)=CC=N1 JFBMFWHEXBLFCR-UHFFFAOYSA-N 0.000 description 2
- MPZMVUQGXAOJIK-UHFFFAOYSA-N 4-bromopyridine;hydron;chloride Chemical compound Cl.BrC1=CC=NC=C1 MPZMVUQGXAOJIK-UHFFFAOYSA-N 0.000 description 2
- MRXCZMUFGLKFGU-SNAWJCMRSA-N 4-chloro-2-[(e)-2-(3-fluorophenyl)ethenyl]pyrimidine Chemical compound FC1=CC=CC(\C=C\C=2N=C(Cl)C=CN=2)=C1 MRXCZMUFGLKFGU-SNAWJCMRSA-N 0.000 description 2
- FAVWVTLQLCXZJK-SNAWJCMRSA-N 4-chloro-6-[(e)-2-(3-fluorophenyl)ethenyl]pyrimidine Chemical compound FC1=CC=CC(\C=C\C=2N=CN=C(Cl)C=2)=C1 FAVWVTLQLCXZJK-SNAWJCMRSA-N 0.000 description 2
- QCBAVDLKOJVDNF-UHFFFAOYSA-N 5-(2-phenylethynyl)pyridine-3-carbaldehyde Chemical compound O=CC1=CN=CC(C#CC=2C=CC=CC=2)=C1 QCBAVDLKOJVDNF-UHFFFAOYSA-N 0.000 description 2
- OIAMQYNCHDKZSK-SNAWJCMRSA-N 5-bromo-2-fluoro-3-[(e)-2-(3-fluorophenyl)ethenyl]pyridine Chemical compound FC1=CC=CC(\C=C\C=2C(=NC=C(Br)C=2)F)=C1 OIAMQYNCHDKZSK-SNAWJCMRSA-N 0.000 description 2
- KRRJKENJDYPWKA-OWOJBTEDSA-N 5-bromo-3-[(e)-2-(2,5-difluorophenyl)ethenyl]-2-fluoropyridine Chemical compound FC1=CC=C(F)C(\C=C\C=2C(=NC=C(Br)C=2)F)=C1 KRRJKENJDYPWKA-OWOJBTEDSA-N 0.000 description 2
- QJKZADDATGTHCN-SOFGYWHQSA-N 6-bromo-3-fluoro-2-[(e)-2-phenylethenyl]pyridine Chemical compound FC1=CC=C(Br)N=C1\C=C\C1=CC=CC=C1 QJKZADDATGTHCN-SOFGYWHQSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- WYLZHZHOTNNMMF-UHFFFAOYSA-N [5-(2-phenylethynyl)pyridin-3-yl]methanamine Chemical compound NCC1=CN=CC(C#CC=2C=CC=CC=2)=C1 WYLZHZHOTNNMMF-UHFFFAOYSA-N 0.000 description 2
- AIUVGYBFWOSPBB-UHFFFAOYSA-N [5-(2-phenylethynyl)pyridin-3-yl]methanol Chemical compound OCC1=CN=CC(C#CC=2C=CC=CC=2)=C1 AIUVGYBFWOSPBB-UHFFFAOYSA-N 0.000 description 2
- NFSMTXPGEBBLLV-UHFFFAOYSA-M [Br-].CC1=CC=CC([Mg+])=C1 Chemical compound [Br-].CC1=CC=CC([Mg+])=C1 NFSMTXPGEBBLLV-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 208000030963 borderline personality disease Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- MUROAULZKZRKEW-UHFFFAOYSA-N ethyl 2-(6-bromopyridin-2-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)NC(C)(C(=O)OCC)C1=CC=CC(Br)=N1 MUROAULZKZRKEW-UHFFFAOYSA-N 0.000 description 2
- CRLCMMLPHLFKHE-UHFFFAOYSA-N ethyl 2-(6-chloropyridin-2-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)NC(C)(C(=O)OCC)C1=CC=CC(Cl)=N1 CRLCMMLPHLFKHE-UHFFFAOYSA-N 0.000 description 2
- GLCQEAZHIIHEPK-UHFFFAOYSA-N ethyl 2-amino-2-(6-bromopyridin-2-yl)propanoate Chemical compound CCOC(=O)C(C)(N)C1=CC=CC(Br)=N1 GLCQEAZHIIHEPK-UHFFFAOYSA-N 0.000 description 2
- GICNCANUNUBJPH-UHFFFAOYSA-N ethyl 2-amino-2-(6-chloropyridin-2-yl)propanoate Chemical compound CCOC(=O)C(C)(N)C1=CC=CC(Cl)=N1 GICNCANUNUBJPH-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- HDWQQYPALOLHGW-BDAKNGLRSA-N methyl (4r,5s)-4-(3-bromophenyl)-2-oxo-1,3-oxazolidine-5-carboxylate Chemical compound COC(=O)[C@H]1OC(=O)N[C@@H]1C1=CC=CC(Br)=C1 HDWQQYPALOLHGW-BDAKNGLRSA-N 0.000 description 2
- GHJJIFVFBRAMEB-UHFFFAOYSA-N methyl 2-(5-bromopyridin-3-yl)acetate Chemical compound COC(=O)CC1=CN=CC(Br)=C1 GHJJIFVFBRAMEB-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- DXOKBYGKGLTZMX-UHFFFAOYSA-N oxoosmium;potassium Chemical compound [K].[Os]=O DXOKBYGKGLTZMX-UHFFFAOYSA-N 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000004262 preparative liquid chromatography Methods 0.000 description 2
- UHVGIPFRQNWLGY-OLZOCXBDSA-N propan-2-yl (2s,3r)-3-acetamido-3-(3-bromophenyl)-2-hydroxypropanoate Chemical compound CC(C)OC(=O)[C@@H](O)[C@H](NC(C)=O)C1=CC=CC(Br)=C1 UHVGIPFRQNWLGY-OLZOCXBDSA-N 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- QHORWDRKFHLNPN-HZPDHXFCSA-N tert-butyl n-[(1r,2r)-1-(2-bromo-5-fluoropyridin-4-yl)-2-(2,5-difluorophenyl)-2-hydroxyethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2C(=CN=C(Br)C=2)F)=CC(F)=CC=C1F QHORWDRKFHLNPN-HZPDHXFCSA-N 0.000 description 2
- OVPXFIJLLHVYBS-HZPDHXFCSA-N tert-butyl n-[(1r,2r)-1-(2-bromo-5-fluoropyridin-4-yl)-2-(2-fluorophenyl)-2-hydroxyethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2C(=CN=C(Br)C=2)F)=CC=CC=C1F OVPXFIJLLHVYBS-HZPDHXFCSA-N 0.000 description 2
- INCWPPSORXBTAK-HZPDHXFCSA-N tert-butyl n-[(1r,2r)-1-(2-bromopyridin-4-yl)-2-hydroxy-2-phenylethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2C=C(Br)N=CC=2)=CC=CC=C1 INCWPPSORXBTAK-HZPDHXFCSA-N 0.000 description 2
- YUIKJYVOWMXTFH-ZIAGYGMSSA-N tert-butyl n-[(1r,2r)-1-(2-bromopyrimidin-4-yl)-2-(2,5-difluorophenyl)-2-hydroxyethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2N=C(Br)N=CC=2)=CC(F)=CC=C1F YUIKJYVOWMXTFH-ZIAGYGMSSA-N 0.000 description 2
- ZGZWDCYGFKPELD-HZPDHXFCSA-N tert-butyl n-[(1r,2r)-1-(3-bromophenyl)-2-hydroxy-2-pyridin-3-ylethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2C=C(Br)C=CC=2)=CC=CN=C1 ZGZWDCYGFKPELD-HZPDHXFCSA-N 0.000 description 2
- YUOYYOXQLXULSQ-HUUCEWRRSA-N tert-butyl n-[(1r,2r)-1-(5-bromo-2-fluoropyridin-3-yl)-2-(2,5-difluorophenyl)-2-hydroxyethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2C(=NC=C(Br)C=2)F)=CC(F)=CC=C1F YUOYYOXQLXULSQ-HUUCEWRRSA-N 0.000 description 2
- HXKITGFWTAXUJO-IAGOWNOFSA-N tert-butyl n-[(1r,2r)-1-(5-bromopyridin-3-yl)-2-hydroxy-2-(3-methoxyphenyl)ethyl]carbamate Chemical compound COC1=CC=CC([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2C=C(Br)C=NC=2)=C1 HXKITGFWTAXUJO-IAGOWNOFSA-N 0.000 description 2
- RHXSFMJBQVNSNJ-HZPDHXFCSA-N tert-butyl n-[(1r,2r)-1-(6-bromo-3-fluoropyridin-2-yl)-2-hydroxy-2-phenylethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2C(=CC=C(Br)N=2)F)=CC=CC=C1 RHXSFMJBQVNSNJ-HZPDHXFCSA-N 0.000 description 2
- ITBJJFFFGWCMLU-HZPDHXFCSA-N tert-butyl n-[(1r,2r)-1-(6-bromopyridin-2-yl)-2-(2-fluorophenyl)-2-hydroxyethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2N=C(Br)C=CC=2)=CC=CC=C1F ITBJJFFFGWCMLU-HZPDHXFCSA-N 0.000 description 2
- PFNDINCZZUWVQO-LJQANCHMSA-N tert-butyl n-[(1s)-2-oxo-1-[3-(2-phenylethynyl)phenyl]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C=O)C1=CC=CC(C#CC=2C=CC=CC=2)=C1 PFNDINCZZUWVQO-LJQANCHMSA-N 0.000 description 2
- XYDDGQRYPCWYDV-UHFFFAOYSA-N tert-butyl n-[2-(6-bromopyridin-2-yl)-1-(2-fluorophenyl)-1-hydroxypropan-2-yl]carbamate Chemical compound C=1C=CC(Br)=NC=1C(C)(NC(=O)OC(C)(C)C)C(O)C1=CC=CC=C1F XYDDGQRYPCWYDV-UHFFFAOYSA-N 0.000 description 2
- BBEXKMYFBWKLPE-UHFFFAOYSA-N tert-butyl n-[2-(6-bromopyridin-2-yl)-1-hydroxypropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC(C)(CO)C1=CC=CC(Br)=N1 BBEXKMYFBWKLPE-UHFFFAOYSA-N 0.000 description 2
- XPGKYGZOWKWPKJ-UHFFFAOYSA-N tert-butyl n-[2-(6-chloropyridin-2-yl)-1-(2-fluorophenyl)-1-hydroxypropan-2-yl]carbamate Chemical compound C=1C=CC(Cl)=NC=1C(C)(NC(=O)OC(C)(C)C)C(O)C1=CC=CC=C1F XPGKYGZOWKWPKJ-UHFFFAOYSA-N 0.000 description 2
- DIMBWGXEQBFLJK-UHFFFAOYSA-N tert-butyl n-[2-(6-chloropyridin-2-yl)-1-hydroxypropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC(C)(CO)C1=CC=CC(Cl)=N1 DIMBWGXEQBFLJK-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- UKKNFAGXYOWTDR-UHFFFAOYSA-N trimethyl-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]silane Chemical compound CC1=NC(C#C[Si](C)(C)C)=CS1 UKKNFAGXYOWTDR-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- CHQXBPWXBRYSMD-WIYYLYMNSA-N (2r,3r)-2-(5-bromopyridin-3-yl)-3-[tert-butyl(dimethyl)silyl]oxy-2-methyl-3-phenylpropanoic acid Chemical compound C1([C@@H](O[Si](C)(C)C(C)(C)C)[C@](C)(C(O)=O)C=2C=C(Br)C=NC=2)=CC=CC=C1 CHQXBPWXBRYSMD-WIYYLYMNSA-N 0.000 description 1
- RIFWVHPDNZQJTN-HTQZYQBOSA-N (2r,3r)-3-amino-3-(3-bromophenyl)-2-hydroxypropanoic acid Chemical compound OC(=O)[C@H](O)[C@H](N)C1=CC=CC(Br)=C1 RIFWVHPDNZQJTN-HTQZYQBOSA-N 0.000 description 1
- CHQXBPWXBRYSMD-GHTZIAJQSA-N (2r,3s)-2-(5-bromopyridin-3-yl)-3-[tert-butyl(dimethyl)silyl]oxy-2-methyl-3-phenylpropanoic acid Chemical compound C1([C@H](O[Si](C)(C)C(C)(C)C)[C@](C)(C(O)=O)C=2C=C(Br)C=NC=2)=CC=CC=C1 CHQXBPWXBRYSMD-GHTZIAJQSA-N 0.000 description 1
- BSVHTRRLCAVQCZ-JDEXMCKMSA-N (2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrro Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 BSVHTRRLCAVQCZ-JDEXMCKMSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- KMSDRZANWSPZEM-CHWSQXEVSA-N (4r,5r)-4-(2-bromo-5-fluoropyridin-4-yl)-5-(2,5-difluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=C(F)C([C@@H]2[C@H](NC(=O)O2)C=2C(=CN=C(Br)C=2)F)=C1 KMSDRZANWSPZEM-CHWSQXEVSA-N 0.000 description 1
- JGCPHKVXUSHRFI-CHWSQXEVSA-N (4r,5r)-4-(2-bromo-5-fluoropyridin-4-yl)-5-(2-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC=C1[C@@H]1[C@@H](C=2C(=CN=C(Br)C=2)F)NC(=O)O1 JGCPHKVXUSHRFI-CHWSQXEVSA-N 0.000 description 1
- YWHOYCVZDUTTOK-GHMZBOCLSA-N (4r,5r)-4-(2-chloropyrimidin-4-yl)-5-(2,5-difluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=C(F)C([C@@H]2[C@H](NC(=O)O2)C=2N=C(Cl)N=CC=2)=C1 YWHOYCVZDUTTOK-GHMZBOCLSA-N 0.000 description 1
- PVTNGCIPKNUXIA-IAGOWNOFSA-N (4r,5r)-4-(3-ethynylphenyl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#C)=C1 PVTNGCIPKNUXIA-IAGOWNOFSA-N 0.000 description 1
- RRVLCOOIUIWROZ-WDEREUQCSA-N (4r,5r)-4-(4-chloropyrimidin-2-yl)-5-(3-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2N=C(Cl)C=CN=2)=C1 RRVLCOOIUIWROZ-WDEREUQCSA-N 0.000 description 1
- WZNQQUQHOMUNRL-VXGBXAGGSA-N (4r,5r)-4-(5-bromo-2-fluoropyridin-3-yl)-5-(2,5-difluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=C(F)C([C@@H]2[C@H](NC(=O)O2)C=2C(=NC=C(Br)C=2)F)=C1 WZNQQUQHOMUNRL-VXGBXAGGSA-N 0.000 description 1
- XOZBSOMDDNUGQW-UKRRQHHQSA-N (4r,5r)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)-5-methyl-1,3-oxazolidin-2-one Chemical compound C1([C@H]2NC(=O)O[C@]2(C)C=2C(=CC=C(F)C=2)F)=CN=CC(Br)=C1 XOZBSOMDDNUGQW-UKRRQHHQSA-N 0.000 description 1
- WZYXWUUYGGJKMX-HUUCEWRRSA-N (4r,5r)-4-(5-ethynylpyridin-3-yl)-5-(4-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C=C(C=NC=2)C#C)NC(=O)O1 WZYXWUUYGGJKMX-HUUCEWRRSA-N 0.000 description 1
- OXZBRTAAMKYYTM-CHWSQXEVSA-N (4r,5r)-4-(6-bromo-3-fluoropyridin-2-yl)-5-phenyl-1,3-oxazolidin-2-one Chemical compound FC1=CC=C(Br)N=C1[C@@H]1[C@@H](C=2C=CC=CC=2)OC(=O)N1 OXZBRTAAMKYYTM-CHWSQXEVSA-N 0.000 description 1
- FQJAEYRAJKBYKW-CHWSQXEVSA-N (4r,5r)-4-(6-bromopyridin-2-yl)-5-(2-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC=C1[C@@H]1[C@@H](C=2N=C(Br)C=CC=2)NC(=O)O1 FQJAEYRAJKBYKW-CHWSQXEVSA-N 0.000 description 1
- TVEOANUAHGACEQ-CHWSQXEVSA-N (4r,5r)-4-(6-bromopyridin-2-yl)-5-(4-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2N=C(Br)C=CC=2)NC(=O)O1 TVEOANUAHGACEQ-CHWSQXEVSA-N 0.000 description 1
- JWTNRKRDPLBZGM-CHWSQXEVSA-N (4r,5r)-4-(6-chloropyridin-3-yl)-5-(3-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=NC(Cl)=CC=2)=C1 JWTNRKRDPLBZGM-CHWSQXEVSA-N 0.000 description 1
- NFNBDHWKOXXVAU-VXGBXAGGSA-N (4r,5r)-4-(6-chloropyrimidin-4-yl)-5-(3-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2N=CN=C(Cl)C=2)=C1 NFNBDHWKOXXVAU-VXGBXAGGSA-N 0.000 description 1
- WSZOUPOTCZOWFO-RTBURBONSA-N (4r,5r)-4-[2-fluoro-5-[2-(3-fluoropyridin-2-yl)ethynyl]pyridin-3-yl]-5-(3-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C(=NC=C(C=2)C#CC=2C(=CC=CN=2)F)F)=C1 WSZOUPOTCZOWFO-RTBURBONSA-N 0.000 description 1
- GCKPRDCTVLRORA-CLJLJLNGSA-N (4r,5r)-4-[3-(2-isoquinolin-3-ylethynyl)phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2N=CC3=CC=CC=C3C=2)=C1 GCKPRDCTVLRORA-CLJLJLNGSA-N 0.000 description 1
- HEAHWEUSTPOVKO-NHCUHLMSSA-N (4r,5r)-4-[3-[2-(2-chloropyridin-3-yl)ethynyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C(=NC=CC=2)Cl)=C1 HEAHWEUSTPOVKO-NHCUHLMSSA-N 0.000 description 1
- UFGIPYQEBMSBQW-FGZHOGPDSA-N (4r,5r)-4-[3-[2-(2-chloropyridin-4-yl)ethynyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=C(Cl)N=CC=2)=C1 UFGIPYQEBMSBQW-FGZHOGPDSA-N 0.000 description 1
- KJCMDSHFZVWFQD-FGZHOGPDSA-N (4r,5r)-4-[3-[2-(2-ethoxypyrimidin-5-yl)ethynyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound C1=NC(OCC)=NC=C1C#CC1=CC=CC([C@@H]2[C@H](OC(=O)N2)C=2C=C(OC)C=CC=2)=C1 KJCMDSHFZVWFQD-FGZHOGPDSA-N 0.000 description 1
- YDPWYSJNCCHPIY-NHCUHLMSSA-N (4r,5r)-4-[3-[2-(2-fluoropyridin-3-yl)ethynyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C(=NC=CC=2)F)=C1 YDPWYSJNCCHPIY-NHCUHLMSSA-N 0.000 description 1
- NUWZCFQGTIGFFP-FGZHOGPDSA-N (4r,5r)-4-[3-[2-(4-chloropyridin-3-yl)ethynyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C(=CC=NC=2)Cl)=C1 NUWZCFQGTIGFFP-FGZHOGPDSA-N 0.000 description 1
- WIUITNRPRBGPFF-FGZHOGPDSA-N (4r,5r)-4-[3-[2-(6-chloropyridin-3-yl)ethynyl]phenyl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=NC(Cl)=CC=2)=C1 WIUITNRPRBGPFF-FGZHOGPDSA-N 0.000 description 1
- AQBUHWMRYFZLMD-FGZHOGPDSA-N (4r,5r)-4-[5-[2-(2-cyclopropylpyridin-4-yl)ethynyl]-2-fluoropyridin-3-yl]-5-(4-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C(=NC=C(C=2)C#CC=2C=C(N=CC=2)C2CC2)F)NC(=O)O1 AQBUHWMRYFZLMD-FGZHOGPDSA-N 0.000 description 1
- HMDFQLQLLQJSGS-FGZHOGPDSA-N (4r,5r)-4-[5-[2-(5-cyclopropylpyridin-3-yl)ethynyl]-2-fluoropyridin-3-yl]-5-(4-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C(=NC=C(C=2)C#CC=2C=C(C=NC=2)C2CC2)F)NC(=O)O1 HMDFQLQLLQJSGS-FGZHOGPDSA-N 0.000 description 1
- UEVFTZLKWRFCFB-FGZHOGPDSA-N (4r,5r)-4-[5-[2-(6-cyclopropylpyridin-2-yl)ethynyl]-2-fluoropyridin-3-yl]-5-(4-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C(=NC=C(C=2)C#CC=2N=C(C=CC=2)C2CC2)F)NC(=O)O1 UEVFTZLKWRFCFB-FGZHOGPDSA-N 0.000 description 1
- ISVOFGWBXYVVPT-FGZHOGPDSA-N (4r,5r)-4-[5-[2-(6-cyclopropylpyridin-3-yl)ethynyl]-2-fluoropyridin-3-yl]-5-(4-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C(=NC=C(C=2)C#CC=2C=NC(=CC=2)C2CC2)F)NC(=O)O1 ISVOFGWBXYVVPT-FGZHOGPDSA-N 0.000 description 1
- YEEIZLTYBCGZOJ-FGZHOGPDSA-N (4r,5r)-4-[6-[2-(2-fluorophenyl)ethynyl]pyridin-2-yl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2N=C(C=CC=2)C#CC=2C(=CC=CC=2)F)=C1 YEEIZLTYBCGZOJ-FGZHOGPDSA-N 0.000 description 1
- VAVHRAYJDKCISA-NHCUHLMSSA-N (4r,5r)-4-[6-[2-(2-fluorophenyl)ethynyl]pyridin-2-yl]-5-phenyl-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC=C1C#CC1=CC=CC([C@@H]2[C@H](OC(=O)N2)C=2C=CC=CC=2)=N1 VAVHRAYJDKCISA-NHCUHLMSSA-N 0.000 description 1
- JDDNDQKFTCCSRY-FGZHOGPDSA-N (4r,5r)-4-[6-[2-(3-fluorophenyl)ethynyl]pyridin-2-yl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2N=C(C=CC=2)C#CC=2C=C(F)C=CC=2)=C1 JDDNDQKFTCCSRY-FGZHOGPDSA-N 0.000 description 1
- RBDRZTKYLJLFPO-FGZHOGPDSA-N (4r,5r)-4-[6-[2-(4-fluorophenyl)ethynyl]pyridin-2-yl]-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2N=C(C=CC=2)C#CC=2C=CC(F)=CC=2)=C1 RBDRZTKYLJLFPO-FGZHOGPDSA-N 0.000 description 1
- NKDVUEYOSYICMR-NHCUHLMSSA-N (4r,5r)-4-[6-[2-(4-fluorophenyl)ethynyl]pyridin-2-yl]-5-phenyl-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1C#CC1=CC=CC([C@@H]2[C@H](OC(=O)N2)C=2C=CC=CC=2)=N1 NKDVUEYOSYICMR-NHCUHLMSSA-N 0.000 description 1
- VKAXGLPXHPELJW-RTBURBONSA-N (4r,5r)-5-(3-fluorophenyl)-4-[2-fluoro-5-(2-pyridin-2-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C(=NC=C(C=2)C#CC=2N=CC=CC=2)F)=C1 VKAXGLPXHPELJW-RTBURBONSA-N 0.000 description 1
- KUNLGKPNAVPRCJ-WOJBJXKFSA-N (4r,5r)-5-(3-fluorophenyl)-4-[5-(2-pyridin-2-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2N=CC=CC=2)=C1 KUNLGKPNAVPRCJ-WOJBJXKFSA-N 0.000 description 1
- SSTNQVPYFORREH-NHCUHLMSSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-(2-pyrazin-2-ylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2N=CC=NC=2)=C1 SSTNQVPYFORREH-NHCUHLMSSA-N 0.000 description 1
- SKQKQNHPWLBMAY-NHCUHLMSSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-(2-pyrimidin-2-ylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2N=CC=CN=2)=C1 SKQKQNHPWLBMAY-NHCUHLMSSA-N 0.000 description 1
- LTVCEWYCZXQRNV-NHCUHLMSSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-(2-pyrimidin-4-ylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2N=CN=CC=2)=C1 LTVCEWYCZXQRNV-NHCUHLMSSA-N 0.000 description 1
- UCAPHSFKBUUDIY-NHCUHLMSSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-(2-pyrimidin-5-ylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=NC=NC=2)=C1 UCAPHSFKBUUDIY-NHCUHLMSSA-N 0.000 description 1
- GKODCSLVPAXBGC-CLJLJLNGSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-(2-quinolin-2-ylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2N=C3C=CC=CC3=CC=2)=C1 GKODCSLVPAXBGC-CLJLJLNGSA-N 0.000 description 1
- DTNRMAUVVRIDBS-CLJLJLNGSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-(2-quinolin-3-ylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=C3C=CC=CC3=NC=2)=C1 DTNRMAUVVRIDBS-CLJLJLNGSA-N 0.000 description 1
- QDKJWSQYCUFZMK-DNQXCXABSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-[2-(2-methoxyphenyl)ethynyl]phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C(=CC=CC=2)OC)=C1 QDKJWSQYCUFZMK-DNQXCXABSA-N 0.000 description 1
- DJLBARSHQZONBY-FGZHOGPDSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-[2-(2-methoxypyridin-3-yl)ethynyl]phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C(=NC=CC=2)OC)=C1 DJLBARSHQZONBY-FGZHOGPDSA-N 0.000 description 1
- RRCUWAOZMFYTME-DHIUTWEWSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-[2-(2-methylpyridin-3-yl)ethynyl]phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C(=NC=CC=2)C)=C1 RRCUWAOZMFYTME-DHIUTWEWSA-N 0.000 description 1
- XFYILMRXLRQVLQ-DNQXCXABSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-[2-(3-methoxyphenyl)ethynyl]phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC(C#CC=2C=C(C=CC=2)[C@@H]2[C@H](OC(=O)N2)C=2C=C(OC)C=CC=2)=C1 XFYILMRXLRQVLQ-DNQXCXABSA-N 0.000 description 1
- MKOGNLBBFMYJQF-DHIUTWEWSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-[2-(4-methoxypyridin-3-yl)ethynyl]phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C(=CC=NC=2)OC)=C1 MKOGNLBBFMYJQF-DHIUTWEWSA-N 0.000 description 1
- IPUWCPFTCIGWNO-DHIUTWEWSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-[2-(4-methylpyridin-3-yl)ethynyl]phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C(=CC=NC=2)C)=C1 IPUWCPFTCIGWNO-DHIUTWEWSA-N 0.000 description 1
- AUPUVIDTYXJXHJ-DHIUTWEWSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-[2-(5-methylpyridin-3-yl)ethynyl]phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=C(C)C=NC=2)=C1 AUPUVIDTYXJXHJ-DHIUTWEWSA-N 0.000 description 1
- OOCWBEZBEDTAIS-DHIUTWEWSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-[2-(6-methoxypyridin-3-yl)ethynyl]phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=NC(OC)=CC=2)=C1 OOCWBEZBEDTAIS-DHIUTWEWSA-N 0.000 description 1
- MKWHXIWSWVCVFN-DHIUTWEWSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-[2-(6-methylpyridin-3-yl)ethynyl]phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=NC(C)=CC=2)=C1 MKWHXIWSWVCVFN-DHIUTWEWSA-N 0.000 description 1
- FRGYJMWTDHSAJT-DHIUTWEWSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[3-[2-[6-(methylamino)pyridin-3-yl]ethynyl]phenyl]-1,3-oxazolidin-2-one Chemical compound C1=NC(NC)=CC=C1C#CC1=CC=CC([C@@H]2[C@H](OC(=O)N2)C=2C=C(OC)C=CC=2)=C1 FRGYJMWTDHSAJT-DHIUTWEWSA-N 0.000 description 1
- TWHFWPBBOYZUFT-NHCUHLMSSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[5-(2-pyridin-2-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2N=CC=CC=2)=C1 TWHFWPBBOYZUFT-NHCUHLMSSA-N 0.000 description 1
- QFEADGSAPOYCRB-WOJBJXKFSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2N=C(C)SC=2)=C1 QFEADGSAPOYCRB-WOJBJXKFSA-N 0.000 description 1
- QLQVUCPWHZFFBK-FGZHOGPDSA-N (4r,5r)-5-(3-methoxyphenyl)-4-[6-(2-phenylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2N=C(C=CC=2)C#CC=2C=CC=CC=2)=C1 QLQVUCPWHZFFBK-FGZHOGPDSA-N 0.000 description 1
- ODMBOMMHDOXRNZ-FGZHOGPDSA-N (4r,5r)-5-(4-chlorophenyl)-4-[5-[2-(2-cyclopropylpyridin-4-yl)ethynyl]-2-fluoropyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@H]2OC(=O)N[C@@H]2C2=CC(=CN=C2F)C#CC=2C=C(N=CC=2)C2CC2)=CC=C(Cl)C=C1 ODMBOMMHDOXRNZ-FGZHOGPDSA-N 0.000 description 1
- VXTIYQPZHBILLN-RTBURBONSA-N (4r,5r)-5-(4-fluorophenyl)-4-[2-fluoro-5-(2-pyridin-2-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C(=NC=C(C=2)C#CC=2N=CC=CC=2)F)NC(=O)O1 VXTIYQPZHBILLN-RTBURBONSA-N 0.000 description 1
- HZLPXXJMRRQNNO-FGZHOGPDSA-N (4r,5r)-5-(4-fluorophenyl)-4-[2-fluoro-5-(2-quinoxalin-6-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C(=NC=C(C=2)C#CC=2C=C3N=CC=NC3=CC=2)F)NC(=O)O1 HZLPXXJMRRQNNO-FGZHOGPDSA-N 0.000 description 1
- DYPJCBJHLTVCIW-VXGBXAGGSA-N (4r,5r)-5-(5-bromo-2-fluoropyridin-3-yl)-4-(3-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC([C@@H]2[C@H](OC(=O)N2)C=2C(=NC=C(Br)C=2)F)=C1 DYPJCBJHLTVCIW-VXGBXAGGSA-N 0.000 description 1
- XBKXNLYGMWHODS-WOJBJXKFSA-N (4r,5r)-5-[5-fluoro-2-[2-(5-fluoropyridin-3-yl)ethynyl]pyridin-4-yl]-4-(4-fluorophenyl)-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@@H](C=2C(=CN=C(C=2)C#CC=2C=C(F)C=NC=2)F)OC(=O)N1 XBKXNLYGMWHODS-WOJBJXKFSA-N 0.000 description 1
- MLGSJJSDUUXPSV-NHCUHLMSSA-N (4r,5r)-5-phenyl-4-[4-(2-phenylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2N=CC=C(C=2)C#CC=2C=CC=CC=2)=CC=CC=C1 MLGSJJSDUUXPSV-NHCUHLMSSA-N 0.000 description 1
- JFGOHLBQFDMXFP-WOJBJXKFSA-N (4r,5r)-5-phenyl-4-[6-(2-pyridin-2-ylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2N=C(C=CC=2)C#CC=2N=CC=CC=2)=CC=CC=C1 JFGOHLBQFDMXFP-WOJBJXKFSA-N 0.000 description 1
- HNYGTQZMIUFJPK-WOJBJXKFSA-N (4r,5r)-5-phenyl-4-[6-(2-pyridin-3-ylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2[C@H](NC(O2)=O)C=2N=C(C=CC=2)C#CC=2C=NC=CC=2)=CC=CC=C1 HNYGTQZMIUFJPK-WOJBJXKFSA-N 0.000 description 1
- XOZBSOMDDNUGQW-HIFRSBDPSA-N (4r,5s)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)-5-methyl-1,3-oxazolidin-2-one Chemical compound C1([C@H]2NC(=O)O[C@@]2(C)C=2C(=CC=C(F)C=2)F)=CN=CC(Br)=C1 XOZBSOMDDNUGQW-HIFRSBDPSA-N 0.000 description 1
- UEOOCEWTSIQATM-PKTZIBPZSA-N (4r,5s)-5-(3-methoxyphenyl)-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=C1 UEOOCEWTSIQATM-PKTZIBPZSA-N 0.000 description 1
- SZSWMKVFJLSTMA-PMACEKPBSA-N (4s,5r)-4-[3-(2-phenylethynyl)phenyl]-5-thiophen-2-yl-1,3-oxazolidin-2-one Chemical compound C1([C@H]2[C@@H](NC(O2)=O)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=CC=CS1 SZSWMKVFJLSTMA-PMACEKPBSA-N 0.000 description 1
- UEOOCEWTSIQATM-XZOQPEGZSA-N (4s,5r)-5-(3-methoxyphenyl)-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@@H]2[C@@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=C1 UEOOCEWTSIQATM-XZOQPEGZSA-N 0.000 description 1
- VAVHRAYJDKCISA-SFTDATJTSA-N (4s,5s)-4-[6-[2-(2-fluorophenyl)ethynyl]pyridin-2-yl]-5-phenyl-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC=C1C#CC1=CC=CC([C@H]2[C@@H](OC(=O)N2)C=2C=CC=CC=2)=N1 VAVHRAYJDKCISA-SFTDATJTSA-N 0.000 description 1
- MLEUIINCWZBDQZ-SFTDATJTSA-N (4s,5s)-4-[6-[2-(3-fluorophenyl)ethynyl]pyridin-2-yl]-5-phenyl-1,3-oxazolidin-2-one Chemical compound FC1=CC=CC(C#CC=2N=C(C=CC=2)[C@H]2[C@@H](OC(=O)N2)C=2C=CC=CC=2)=C1 MLEUIINCWZBDQZ-SFTDATJTSA-N 0.000 description 1
- NKDVUEYOSYICMR-SFTDATJTSA-N (4s,5s)-4-[6-[2-(4-fluorophenyl)ethynyl]pyridin-2-yl]-5-phenyl-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1C#CC1=CC=CC([C@H]2[C@@H](OC(=O)N2)C=2C=CC=CC=2)=N1 NKDVUEYOSYICMR-SFTDATJTSA-N 0.000 description 1
- BJQIGFSSCLXKSZ-GMAHTHKFSA-N (4s,5s)-4-methyl-5-phenyl-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@@H]2OC(=O)N[C@@]2(C)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=CC=CC=C1 BJQIGFSSCLXKSZ-GMAHTHKFSA-N 0.000 description 1
- BAXUIBRFQDYUTB-VXKWHMMOSA-N (4s,5s)-5-(3-methoxyphenyl)-4-[2-(2-phenylethynyl)pyridin-4-yl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@H]2[C@@H](NC(=O)O2)C=2C=C(N=CC=2)C#CC=2C=CC=CC=2)=C1 BAXUIBRFQDYUTB-VXKWHMMOSA-N 0.000 description 1
- UEOOCEWTSIQATM-GOTSBHOMSA-N (4s,5s)-5-(3-methoxyphenyl)-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@H]2[C@@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=C1 UEOOCEWTSIQATM-GOTSBHOMSA-N 0.000 description 1
- FTWQDGPACTYAKP-VXKWHMMOSA-N (4s,5s)-5-(3-methoxyphenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@H]2[C@@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=C1 FTWQDGPACTYAKP-VXKWHMMOSA-N 0.000 description 1
- TWHFWPBBOYZUFT-SFTDATJTSA-N (4s,5s)-5-(3-methoxyphenyl)-4-[5-(2-pyridin-2-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@H]2[C@@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2N=CC=CC=2)=C1 TWHFWPBBOYZUFT-SFTDATJTSA-N 0.000 description 1
- QFEADGSAPOYCRB-PMACEKPBSA-N (4s,5s)-5-(3-methoxyphenyl)-4-[5-[2-(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@H]2[C@@H](NC(=O)O2)C=2C=C(C=NC=2)C#CC=2N=C(C)SC=2)=C1 QFEADGSAPOYCRB-PMACEKPBSA-N 0.000 description 1
- QLQVUCPWHZFFBK-VXKWHMMOSA-N (4s,5s)-5-(3-methoxyphenyl)-4-[6-(2-phenylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound COC1=CC=CC([C@H]2[C@@H](NC(=O)O2)C=2N=C(C=CC=2)C#CC=2C=CC=CC=2)=C1 QLQVUCPWHZFFBK-VXKWHMMOSA-N 0.000 description 1
- XZTXPNAWFPJQGS-GOTSBHOMSA-N (4s,5s)-5-(3-methylphenyl)-4-[3-(2-phenylethynyl)phenyl]-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC([C@H]2[C@@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=C1 XZTXPNAWFPJQGS-GOTSBHOMSA-N 0.000 description 1
- VGSFZUMJEUHHRV-SFTDATJTSA-N (4s,5s)-5-(4-fluorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)NC(=O)O1 VGSFZUMJEUHHRV-SFTDATJTSA-N 0.000 description 1
- AVGFRDZHGXFJLY-PMACEKPBSA-N (4s,5s)-5-(4-fluorophenyl)-4-[5-(2-pyridin-3-ylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](C=2C=C(C=NC=2)C#CC=2C=NC=CC=2)NC(=O)O1 AVGFRDZHGXFJLY-PMACEKPBSA-N 0.000 description 1
- OBOYWTBAOJHNNO-PMACEKPBSA-N (4s,5s)-5-(4-fluorophenyl)-4-[5-[2-(5-fluoropyridin-3-yl)ethynyl]pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](C=2C=C(C=NC=2)C#CC=2C=C(F)C=NC=2)NC(=O)O1 OBOYWTBAOJHNNO-PMACEKPBSA-N 0.000 description 1
- RXAIMRQTCSBPGM-SFTDATJTSA-N (4s,5s)-5-(4-fluorophenyl)-4-[6-(2-phenylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](C=2N=C(C=CC=2)C#CC=2C=CC=CC=2)NC(=O)O1 RXAIMRQTCSBPGM-SFTDATJTSA-N 0.000 description 1
- MLGSJJSDUUXPSV-SFTDATJTSA-N (4s,5s)-5-phenyl-4-[4-(2-phenylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@H]2[C@@H](NC(O2)=O)C=2N=CC=C(C=2)C#CC=2C=CC=CC=2)=CC=CC=C1 MLGSJJSDUUXPSV-SFTDATJTSA-N 0.000 description 1
- AFTXLGIZWWXYTD-SFTDATJTSA-N (4s,5s)-5-phenyl-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@H]2[C@@H](NC(O2)=O)C=2C=C(C=NC=2)C#CC=2C=CC=CC=2)=CC=CC=C1 AFTXLGIZWWXYTD-SFTDATJTSA-N 0.000 description 1
- RMPCVUXFUQSOII-SFTDATJTSA-N (4s,5s)-5-phenyl-4-[6-(2-phenylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@H]2[C@@H](NC(O2)=O)C=2N=C(C=CC=2)C#CC=2C=CC=CC=2)=CC=CC=C1 RMPCVUXFUQSOII-SFTDATJTSA-N 0.000 description 1
- JFGOHLBQFDMXFP-PMACEKPBSA-N (4s,5s)-5-phenyl-4-[6-(2-pyridin-2-ylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@H]2[C@@H](NC(O2)=O)C=2N=C(C=CC=2)C#CC=2N=CC=CC=2)=CC=CC=C1 JFGOHLBQFDMXFP-PMACEKPBSA-N 0.000 description 1
- HNYGTQZMIUFJPK-PMACEKPBSA-N (4s,5s)-5-phenyl-4-[6-(2-pyridin-3-ylethynyl)pyridin-2-yl]-1,3-oxazolidin-2-one Chemical compound C1([C@H]2[C@@H](NC(O2)=O)C=2N=C(C=CC=2)C#CC=2C=NC=CC=2)=CC=CC=C1 HNYGTQZMIUFJPK-PMACEKPBSA-N 0.000 description 1
- XDDGKNRSCDEWBR-UHFFFAOYSA-N (6-bromopyridin-2-yl)methanol Chemical compound OCC1=CC=CC(Br)=N1 XDDGKNRSCDEWBR-UHFFFAOYSA-N 0.000 description 1
- YEMUSDCFQUBPAL-SNAWJCMRSA-N (e)-3-(3-bromophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(Br)=C1 YEMUSDCFQUBPAL-SNAWJCMRSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- QLYCTVYKOMMVHC-UHFFFAOYSA-N 1,1-diphenyl-n-[[5-(2-phenylethynyl)pyridin-3-yl]methyl]methanimine Chemical compound C=1N=CC(C#CC=2C=CC=CC=2)=CC=1CN=C(C=1C=CC=CC=1)C1=CC=CC=C1 QLYCTVYKOMMVHC-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- HLAFIZUVVWJAKL-UHFFFAOYSA-N 1-(2,5-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC(F)=CC=C1F HLAFIZUVVWJAKL-UHFFFAOYSA-N 0.000 description 1
- RUJTWTUYVOEEFW-UHFFFAOYSA-N 1-(6-bromopyridin-2-yl)ethanone Chemical compound CC(=O)C1=CC=CC(Br)=N1 RUJTWTUYVOEEFW-UHFFFAOYSA-N 0.000 description 1
- FFWQLZFIMNTUCZ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC=CC=C1CBr FFWQLZFIMNTUCZ-UHFFFAOYSA-N 0.000 description 1
- SCBZBMXPJYMXRC-UHFFFAOYSA-N 1-(bromomethyl)-3-fluorobenzene Chemical compound FC1=CC=CC(CBr)=C1 SCBZBMXPJYMXRC-UHFFFAOYSA-N 0.000 description 1
- FIYRZOAUPPNGAO-UHFFFAOYSA-N 1-(diethoxyphosphorylmethyl)-4-fluorobenzene Chemical compound CCOP(=O)(OCC)CC1=CC=C(F)C=C1 FIYRZOAUPPNGAO-UHFFFAOYSA-N 0.000 description 1
- IPWBFGUBXWMIPR-UHFFFAOYSA-N 1-bromo-2-fluorobenzene Chemical compound FC1=CC=CC=C1Br IPWBFGUBXWMIPR-UHFFFAOYSA-N 0.000 description 1
- HTDQSWDEWGSAMN-UHFFFAOYSA-N 1-bromo-2-methoxybenzene Chemical compound COC1=CC=CC=C1Br HTDQSWDEWGSAMN-UHFFFAOYSA-N 0.000 description 1
- KVNNRCDDRDXWIW-UHFFFAOYSA-N 1-bromo-3-(diethoxyphosphorylmethyl)benzene Chemical compound CCOP(=O)(OCC)CC1=CC=CC(Br)=C1 KVNNRCDDRDXWIW-UHFFFAOYSA-N 0.000 description 1
- PLDWAJLZAAHOGG-UHFFFAOYSA-N 1-bromo-3-methoxybenzene Chemical compound COC1=CC=CC(Br)=C1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 1
- WJIFKOVZNJTSGO-UHFFFAOYSA-N 1-bromo-3-methylbenzene Chemical compound CC1=CC=CC(Br)=C1 WJIFKOVZNJTSGO-UHFFFAOYSA-N 0.000 description 1
- FODNNPZZKXOLLX-UHFFFAOYSA-N 1-diethoxyphosphorylethylbenzene Chemical compound CCOP(=O)(OCC)C(C)C1=CC=CC=C1 FODNNPZZKXOLLX-UHFFFAOYSA-N 0.000 description 1
- ZJSKEGAHBAHFON-UHFFFAOYSA-N 1-ethenyl-3-fluorobenzene Chemical compound FC1=CC=CC(C=C)=C1 ZJSKEGAHBAHFON-UHFFFAOYSA-N 0.000 description 1
- CEWDRCQPGANDRS-UHFFFAOYSA-N 1-ethenyl-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(C=C)C=C1 CEWDRCQPGANDRS-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- PCMMSLVJMKQWMQ-UHFFFAOYSA-N 2,4-dibromopyridine Chemical compound BrC1=CC=NC(Br)=C1 PCMMSLVJMKQWMQ-UHFFFAOYSA-N 0.000 description 1
- KYNNBXCGXUOREX-UHFFFAOYSA-N 2-(3-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1 KYNNBXCGXUOREX-UHFFFAOYSA-N 0.000 description 1
- KSNGXOIKHOUAAE-UHFFFAOYSA-N 2-(5-bromopyridin-3-yl)-3-(2,5-difluorophenyl)-3-hydroxy-2-methylpropanoic acid Chemical compound C=1N=CC(Br)=CC=1C(C)(C(O)=O)C(O)C1=CC(F)=CC=C1F KSNGXOIKHOUAAE-UHFFFAOYSA-N 0.000 description 1
- ZVCANPKKZIVLGQ-UHFFFAOYSA-N 2-(5-bromopyridin-3-yl)-3-[tert-butyl(dimethyl)silyl]oxy-3-(2,5-difluorophenyl)-2-methylpropanoic acid Chemical compound C=1N=CC(Br)=CC=1C(C)(C(O)=O)C(O[Si](C)(C)C(C)(C)C)C1=CC(F)=CC=C1F ZVCANPKKZIVLGQ-UHFFFAOYSA-N 0.000 description 1
- ONWGSWNHQZYCFK-UHFFFAOYSA-N 2-(bromomethyl)-1,4-difluorobenzene Chemical compound FC1=CC=C(F)C(CBr)=C1 ONWGSWNHQZYCFK-UHFFFAOYSA-N 0.000 description 1
- SFMBUYNHRYJLOJ-DNQXCXABSA-N 2-[2-[3-[(4r,5r)-5-(3-methoxyphenyl)-2-oxo-1,3-oxazolidin-4-yl]phenyl]ethynyl]benzonitrile Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C(=CC=CC=2)C#N)=C1 SFMBUYNHRYJLOJ-DNQXCXABSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AXHRGVJWDJDYPO-UHFFFAOYSA-N 2-bromo-1h-imidazole Chemical compound BrC1=NC=CN1 AXHRGVJWDJDYPO-UHFFFAOYSA-N 0.000 description 1
- UZIJEBOLOXOVFY-UHFFFAOYSA-N 2-bromo-4-methylpyrimidine Chemical compound CC1=CC=NC(Br)=N1 UZIJEBOLOXOVFY-UHFFFAOYSA-N 0.000 description 1
- DDLSIOQASXKYHW-UHFFFAOYSA-N 2-bromo-5-fluoropyridine-4-carbaldehyde Chemical compound FC1=CN=C(Br)C=C1C=O DDLSIOQASXKYHW-UHFFFAOYSA-N 0.000 description 1
- ZIDIKYIZXMYHAW-UHFFFAOYSA-N 2-bromo-6-fluoropyridine Chemical compound FC1=CC=CC(Br)=N1 ZIDIKYIZXMYHAW-UHFFFAOYSA-N 0.000 description 1
- KMODISUYWZPVGV-UHFFFAOYSA-N 2-bromo-6-methoxypyridine Chemical compound COC1=CC=CC(Br)=N1 KMODISUYWZPVGV-UHFFFAOYSA-N 0.000 description 1
- SOHDPICLICFSOP-UHFFFAOYSA-N 2-bromo-6-methylpyridine Chemical compound CC1=CC=CC(Br)=N1 SOHDPICLICFSOP-UHFFFAOYSA-N 0.000 description 1
- AFMPMSCZPVNPEM-UHFFFAOYSA-N 2-bromobenzonitrile Chemical compound BrC1=CC=CC=C1C#N AFMPMSCZPVNPEM-UHFFFAOYSA-N 0.000 description 1
- WGFCNCNTGOFBBF-UHFFFAOYSA-N 2-bromopyrazine Chemical compound BrC1=CN=CC=N1 WGFCNCNTGOFBBF-UHFFFAOYSA-N 0.000 description 1
- PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 1
- QKJAZPHKNWSXDF-UHFFFAOYSA-N 2-bromoquinoline Chemical compound C1=CC=CC2=NC(Br)=CC=C21 QKJAZPHKNWSXDF-UHFFFAOYSA-N 0.000 description 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- GMEYKTSUHQAEOI-DHIUTWEWSA-N 3-[2-[3-[(4r,5r)-5-(3-methoxyphenyl)-2-oxo-1,3-oxazolidin-4-yl]phenyl]ethynyl]pyridine-2-carbonitrile Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2C(=NC=CC=2)C#N)=C1 GMEYKTSUHQAEOI-DHIUTWEWSA-N 0.000 description 1
- HDYNIWBNWMFBDO-UHFFFAOYSA-N 3-bromo-2-chloropyridine Chemical compound ClC1=NC=CC=C1Br HDYNIWBNWMFBDO-UHFFFAOYSA-N 0.000 description 1
- KESUTBOSNOHAMK-UHFFFAOYSA-N 3-bromo-2-fluoropyridine Chemical compound FC1=NC=CC=C1Br KESUTBOSNOHAMK-UHFFFAOYSA-N 0.000 description 1
- PORGLLGXCAQORO-UHFFFAOYSA-N 3-bromo-2-methoxypyridine Chemical compound COC1=NC=CC=C1Br PORGLLGXCAQORO-UHFFFAOYSA-N 0.000 description 1
- AIPWPTPHMIYYOX-UHFFFAOYSA-N 3-bromo-2-methylpyridine Chemical compound CC1=NC=CC=C1Br AIPWPTPHMIYYOX-UHFFFAOYSA-N 0.000 description 1
- QADXKWUCCGPQNR-UHFFFAOYSA-N 3-bromo-4-chloropyridine Chemical compound ClC1=CC=NC=C1Br QADXKWUCCGPQNR-UHFFFAOYSA-N 0.000 description 1
- PKYADCLPLQPPKK-UHFFFAOYSA-N 3-bromo-4-fluoropyridine Chemical compound FC1=CC=NC=C1Br PKYADCLPLQPPKK-UHFFFAOYSA-N 0.000 description 1
- GSQZOLXWFQQJHJ-UHFFFAOYSA-N 3-bromo-4-methylpyridine Chemical compound CC1=CC=NC=C1Br GSQZOLXWFQQJHJ-UHFFFAOYSA-N 0.000 description 1
- AJQDEUJYFUHVHS-UHFFFAOYSA-N 3-bromo-5-(bromomethyl)pyridine Chemical compound BrCC1=CN=CC(Br)=C1 AJQDEUJYFUHVHS-UHFFFAOYSA-N 0.000 description 1
- BELDOPUBSLPBCQ-UHFFFAOYSA-N 3-bromo-5-chloropyridine Chemical compound ClC1=CN=CC(Br)=C1 BELDOPUBSLPBCQ-UHFFFAOYSA-N 0.000 description 1
- USEXQPWLCGBYNT-UHFFFAOYSA-N 3-bromo-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC(Br)=C1 USEXQPWLCGBYNT-UHFFFAOYSA-N 0.000 description 1
- STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
- ZWJYXJDEDLXUHU-UHFFFAOYSA-N 3-bromoisoquinoline Chemical compound C1=CC=C2C=NC(Br)=CC2=C1 ZWJYXJDEDLXUHU-UHFFFAOYSA-N 0.000 description 1
- HCOPIUVJCIZALB-UHFFFAOYSA-N 3-bromopyridine-2-carbonitrile Chemical compound BrC1=CC=CN=C1C#N HCOPIUVJCIZALB-UHFFFAOYSA-N 0.000 description 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
- CDKQUBAFMOFICJ-UHFFFAOYSA-N 4-(6-bromopyridin-2-yl)-5-(2-fluorophenyl)-4-methyl-1,3-oxazolidin-2-one Chemical compound C=1C=CC(Br)=NC=1C1(C)NC(=O)OC1C1=CC=CC=C1F CDKQUBAFMOFICJ-UHFFFAOYSA-N 0.000 description 1
- DJLUHMVDBZKWIZ-UHFFFAOYSA-N 4-(6-chloropyridin-2-yl)-5-(2-fluorophenyl)-4-methyl-1,3-oxazolidin-2-one Chemical compound C=1C=CC(Cl)=NC=1C1(C)NC(=O)OC1C1=CC=CC=C1F DJLUHMVDBZKWIZ-UHFFFAOYSA-N 0.000 description 1
- ILMCMPWDBLHKJA-WOJBJXKFSA-N 4-[(4r,5r)-4-[2-fluoro-5-(2-pyridin-2-ylethynyl)pyridin-3-yl]-2-oxo-1,3-oxazolidin-5-yl]benzonitrile Chemical compound C1([C@H]2OC(=O)N[C@@H]2C2=CC(=CN=C2F)C#CC=2N=CC=CC=2)=CC=C(C#N)C=C1 ILMCMPWDBLHKJA-WOJBJXKFSA-N 0.000 description 1
- KISAWPXPYQSTQQ-UHFFFAOYSA-N 4-[[4-[(4-cyanophenoxy)methyl]phenyl]methoxy]benzonitrile Chemical compound C1=CC(C#N)=CC=C1OCC(C=C1)=CC=C1COC1=CC=C(C#N)C=C1 KISAWPXPYQSTQQ-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- VDTIGYKLTROQAH-UHFFFAOYSA-N 4-bromo-1,3-thiazole Chemical compound BrC1=CSC=N1 VDTIGYKLTROQAH-UHFFFAOYSA-N 0.000 description 1
- RQQGHJAFINPLDP-ZZXKWVIFSA-N 4-bromo-2-[(e)-2-(4-fluorophenyl)ethenyl]pyridine Chemical compound C1=CC(F)=CC=C1\C=C\C1=CC(Br)=CC=N1 RQQGHJAFINPLDP-ZZXKWVIFSA-N 0.000 description 1
- ONHMWUXYIFULDO-UHFFFAOYSA-N 4-bromo-2-chloropyridine Chemical compound ClC1=CC(Br)=CC=N1 ONHMWUXYIFULDO-UHFFFAOYSA-N 0.000 description 1
- CKVQWOKUEZYWRQ-UHFFFAOYSA-N 4-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=NC(C=O)=C1 CKVQWOKUEZYWRQ-UHFFFAOYSA-N 0.000 description 1
- CZXDCTUSFIKLIJ-UHFFFAOYSA-N 4-bromopyridine-2-carbonitrile Chemical compound BrC1=CC=NC(C#N)=C1 CZXDCTUSFIKLIJ-UHFFFAOYSA-N 0.000 description 1
- XDADSGBUZWZQQQ-UHFFFAOYSA-N 4-bromopyrimidine Chemical compound BrC1=CC=NC=N1 XDADSGBUZWZQQQ-UHFFFAOYSA-N 0.000 description 1
- PRIOZKXZDNYFDP-UHFFFAOYSA-N 4-chloro-2-(diethoxyphosphorylmethyl)pyrimidine Chemical compound CCOP(=O)(OCC)CC1=NC=CC(Cl)=N1 PRIOZKXZDNYFDP-UHFFFAOYSA-N 0.000 description 1
- WDTVJRYCMIZPMX-UHFFFAOYSA-N 4-chloro-2-methylpyrimidine Chemical compound CC1=NC=CC(Cl)=N1 WDTVJRYCMIZPMX-UHFFFAOYSA-N 0.000 description 1
- CNSIINILNZYRHT-UHFFFAOYSA-N 4-chloro-6-(diethoxyphosphorylmethyl)pyrimidine Chemical compound CCOP(=O)(OCC)CC1=CC(Cl)=NC=N1 CNSIINILNZYRHT-UHFFFAOYSA-N 0.000 description 1
- MVAXKFAQKTWRAH-UHFFFAOYSA-N 4-chloro-6-methylpyrimidine Chemical compound CC1=CC(Cl)=NC=N1 MVAXKFAQKTWRAH-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- SJISCEAZUHNOMD-UHFFFAOYSA-N 4-phenylcyclohexan-1-amine Chemical compound C1CC(N)CCC1C1=CC=CC=C1 SJISCEAZUHNOMD-UHFFFAOYSA-N 0.000 description 1
- YJOULMMJZAADRY-UHFFFAOYSA-N 5-(bromomethyl)-2-chloropyridine Chemical compound ClC1=CC=C(CBr)C=N1 YJOULMMJZAADRY-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- PEAOEIWYQVXZMB-UHFFFAOYSA-N 5-bromo-2-chloropyridine Chemical compound ClC1=CC=C(Br)C=N1 PEAOEIWYQVXZMB-UHFFFAOYSA-N 0.000 description 1
- GNSREVHIXMTHFA-UHFFFAOYSA-N 5-bromo-2-ethoxypyrimidine Chemical compound CCOC1=NC=C(Br)C=N1 GNSREVHIXMTHFA-UHFFFAOYSA-N 0.000 description 1
- LSBZMTVRIRYRDL-UHFFFAOYSA-N 5-bromo-2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC(Br)=CN=C1F LSBZMTVRIRYRDL-UHFFFAOYSA-N 0.000 description 1
- MYUQKYGWKHTRPG-UHFFFAOYSA-N 5-bromo-2-fluoropyridine Chemical compound FC1=CC=C(Br)C=N1 MYUQKYGWKHTRPG-UHFFFAOYSA-N 0.000 description 1
- MUYVOGAJRCBWCY-UHFFFAOYSA-N 5-bromo-2-fluoropyridine-3-carbaldehyde Chemical compound FC1=NC=C(Br)C=C1C=O MUYVOGAJRCBWCY-UHFFFAOYSA-N 0.000 description 1
- XADICJHFELMBGX-UHFFFAOYSA-N 5-bromo-2-methoxypyridine Chemical compound COC1=CC=C(Br)C=N1 XADICJHFELMBGX-UHFFFAOYSA-N 0.000 description 1
- OFKWIQJLYCKDNY-UHFFFAOYSA-N 5-bromo-2-methylpyridine Chemical compound CC1=CC=C(Br)C=N1 OFKWIQJLYCKDNY-UHFFFAOYSA-N 0.000 description 1
- GBOYJZQMXVUIGC-UHFFFAOYSA-N 5-bromo-3-(diethoxyphosphorylmethyl)-2-fluoropyridine Chemical compound CCOP(=O)(OCC)CC1=CC(Br)=CN=C1F GBOYJZQMXVUIGC-UHFFFAOYSA-N 0.000 description 1
- UDQGIOYIJKRLFH-UHFFFAOYSA-N 5-bromo-n-methylpyrimidin-2-amine Chemical compound CNC1=NC=C(Br)C=N1 UDQGIOYIJKRLFH-UHFFFAOYSA-N 0.000 description 1
- DMSHUVBQFSNBBL-UHFFFAOYSA-N 5-bromopyridine-2-carbonitrile Chemical compound BrC1=CC=C(C#N)N=C1 DMSHUVBQFSNBBL-UHFFFAOYSA-N 0.000 description 1
- FTFFHWWIPOQCBC-UHFFFAOYSA-N 5-bromopyridine-3-carbonitrile Chemical compound BrC1=CN=CC(C#N)=C1 FTFFHWWIPOQCBC-UHFFFAOYSA-N 0.000 description 1
- GYCPLYCTMDTEPU-UHFFFAOYSA-N 5-bromopyrimidine Chemical compound BrC1=CN=CN=C1 GYCPLYCTMDTEPU-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- JMVVQAIRSSKLCP-DHIUTWEWSA-N 6-[2-[3-[(4r,5r)-5-(3-methoxyphenyl)-2-oxo-1,3-oxazolidin-4-yl]phenyl]ethynyl]pyridine-2-carbonitrile Chemical compound COC1=CC=CC([C@@H]2[C@H](NC(=O)O2)C=2C=C(C=CC=2)C#CC=2N=C(C=CC=2)C#N)=C1 JMVVQAIRSSKLCP-DHIUTWEWSA-N 0.000 description 1
- BFBRCFKSFRYJGE-UHFFFAOYSA-N 6-bromo-3-fluoropyridine-2-carbaldehyde Chemical compound FC1=CC=C(Br)N=C1C=O BFBRCFKSFRYJGE-UHFFFAOYSA-N 0.000 description 1
- HNEBPTAKURBYRM-UHFFFAOYSA-N 6-bromopyridine-2-carbonitrile Chemical compound BrC1=CC=CC(C#N)=N1 HNEBPTAKURBYRM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010008063 Amino Acid Transport System X-AG Proteins 0.000 description 1
- 102000006941 Amino Acid Transport System X-AG Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001480079 Corymbia calophylla Species 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 239000004398 Ethyl lauroyl arginate Substances 0.000 description 1
- 108010000722 Excitatory Amino Acid Transporter 1 Proteins 0.000 description 1
- 102100031563 Excitatory amino acid transporter 1 Human genes 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010077495 Peptide oostatic hormone Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- GBNJRIQSFJFDII-AATRIKPKSA-N [(e)-2-(4-fluorophenyl)ethenyl]boronic acid Chemical compound OB(O)\C=C\C1=CC=C(F)C=C1 GBNJRIQSFJFDII-AATRIKPKSA-N 0.000 description 1
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229950010850 acistrate Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000006399 aminohydroxylation reaction Methods 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- 239000004316 dimethyl dicarbonate Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 102000052256 human GRM5 Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- HTJPDOPKPWUNBX-UHFFFAOYSA-M magnesium;2h-thiophen-2-ide;bromide Chemical compound [Mg+2].[Br-].C=1C=[C-]SC=1 HTJPDOPKPWUNBX-UHFFFAOYSA-M 0.000 description 1
- BVUQKCCKUOSAEV-UHFFFAOYSA-M magnesium;methylbenzene;bromide Chemical compound [Mg+2].[Br-].CC1=CC=[C-]C=C1 BVUQKCCKUOSAEV-UHFFFAOYSA-M 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- OBIISMVXINILKY-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-4-methylfuro[3,2-b]pyrrole-5-carboxamide Chemical compound C=1C=2OC=CC=2N(C)C=1C(=O)NC1=CC=C(F)C(Cl)=C1 OBIISMVXINILKY-UHFFFAOYSA-N 0.000 description 1
- VBTQNRFWXBXZQR-UHFFFAOYSA-N n-bromoacetamide Chemical compound CC(=O)NBr VBTQNRFWXBXZQR-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 125000004316 oxathiadiazolyl group Chemical group O1SNN=C1* 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000006417 postsynaptic localization Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 239000004304 potassium nitrite Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- UHVGIPFRQNWLGY-CHWSQXEVSA-N propan-2-yl (2r,3r)-3-acetamido-3-(3-bromophenyl)-2-hydroxypropanoate Chemical compound CC(C)OC(=O)[C@H](O)[C@H](NC(C)=O)C1=CC=CC(Br)=C1 UHVGIPFRQNWLGY-CHWSQXEVSA-N 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- WAKHIKIPQUMRJN-KGLIPLIRSA-N tert-butyl N-[(1S,2S)-1-(4-chloropyrimidin-2-yl)-2-(3-fluorophenyl)-2-hydroxyethyl]carbamate Chemical compound C(C)(C)(C)OC(N[C@H]([C@@H](O)C1=CC(=CC=C1)F)C1=NC=CC(=N1)Cl)=O WAKHIKIPQUMRJN-KGLIPLIRSA-N 0.000 description 1
- WAKHIKIPQUMRJN-UONOGXRCSA-N tert-butyl n-[(1r,2r)-1-(4-chloropyrimidin-2-yl)-2-(3-fluorophenyl)-2-hydroxyethyl]carbamate Chemical compound C1([C@@H](O)[C@H](NC(=O)OC(C)(C)C)C=2N=C(Cl)C=CN=2)=CC=CC(F)=C1 WAKHIKIPQUMRJN-UONOGXRCSA-N 0.000 description 1
- IPCHTWZDELUYMH-CXAGYDPISA-N tert-butyl n-[(1r,2r)-1-(5-bromopyridin-3-yl)-2-phenylpropyl]carbamate Chemical compound C1([C@H](NC(=O)OC(C)(C)C)[C@H](C)C=2C=CC=CC=2)=CN=CC(Br)=C1 IPCHTWZDELUYMH-CXAGYDPISA-N 0.000 description 1
- QXHHXOUONXBLED-SKCDSABHSA-N tert-butyl n-[(1s)-2-hydroxy-2-phenyl-1-[3-(2-phenylethynyl)phenyl]ethyl]carbamate Chemical compound OC([C@@H](NC(=O)OC(C)(C)C)C=1C=C(C=CC=1)C#CC=1C=CC=CC=1)C1=CC=CC=C1 QXHHXOUONXBLED-SKCDSABHSA-N 0.000 description 1
- QXHHXOUONXBLED-DQEYMECFSA-N tert-butyl n-[(1s,2s)-2-hydroxy-2-phenyl-1-[3-(2-phenylethynyl)phenyl]ethyl]carbamate Chemical compound C1([C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=2C=C(C=CC=2)C#CC=2C=CC=CC=2)=CC=CC=C1 QXHHXOUONXBLED-DQEYMECFSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229910021516 thallium(I) hydroxide Inorganic materials 0.000 description 1
- QGYXCSSUHCHXHB-UHFFFAOYSA-M thallium(i) hydroxide Chemical compound [OH-].[Tl+] QGYXCSSUHCHXHB-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- UZIXCCMXZQWTPB-UHFFFAOYSA-N trimethyl(2-phenylethynyl)silane Chemical compound C[Si](C)(C)C#CC1=CC=CC=C1 UZIXCCMXZQWTPB-UHFFFAOYSA-N 0.000 description 1
- CWZAHASBSZJRDV-UHFFFAOYSA-N trimethyl(2-pyridin-4-ylethynyl)silane Chemical compound C[Si](C)(C)C#CC1=CC=NC=C1 CWZAHASBSZJRDV-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.
Description
This patent application claims the benefit of U.S. provisional patent application No. 61/412,541 filed Nov. 11, 2010.
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.
Glutamate is the major excitatory neurotransmitter in the mammalian brain, playing an important physiological role in a wide variety of processes. Glutamatergic neurotransmission is predominantly mediated through activation of cell surface receptors including ligand-gated ion channels (ionotropic receptors) and metabotropic glutamate G protein coupled receptors (mGluRs). The metabotropic glutamate receptor family is comprised of 8 family members that are part of the family 3 GPCR superfamily. These receptors are further subdivided into Group I (mGluR 1, 5), Group II (mGluR 2, 3) and Group III (mGluR 4, 6, 7, 8) based upon sequence homology, receptor signaling, and pharmacology.
The Group I receptor mGluR5 has emerged as a target of potential therapeutic utility in a number of disease states (see: Rodriguez, A. L., et al. Current Opinion in Drug Discovery & Development (2007), 10(6), 715-722. and Chen, Y., et al. Drugs of the Future (2008), 33(4), 355-360. and Lindsley, C. W., et al. Current Opinion in Drug Discovery & Development (2009), 12(4), 446-457). The receptor is expressed broadly throughout the CNS with predominant post-synaptic localization, although pre-synaptic expression is also present. mGluR5 is a Gαq-coupled receptor activating phospholipase C and elevating intracellular calcium levels, leading to activation of downstream signaling molecules. Many studies have demonstrated a role for the receptor in regulating NMDA receptor activity as well as synaptic plasticity, suggesting this receptor plays a key role in glutamatergic signal transduction.
Based on the expression pattern and functional role of mGluR5, this receptor has emerged as an important target for drug discovery in a number of therapeutic indications. Evaluation of genetically modified mice lacking mGluR5 as well as compounds that modulate receptor function suggest ligands that modulate mGluR5 receptor function have therapeutic utility in CNS and peripheral disease states including, but not limited to, schizophrenia (see: Conn, P. J., et al. Trends in Pharmacological Sciences (2009), 30(1), 25-31; and Kanuma, K., et al. Recent Patents on CNS Drug Discovery (2010), 5(1), 23-34), cognitive impairment (see: Simonyi, A., et al. European Journal of Pharmacology (2010), 639(1-3), 17-25), Alzheimer's disease, Parkinson's disease (see: Johnson, K. A., et al. CNS & Neurological Disorders Drug Targets (2009), 8(6), 475-491), Parkinson's disease levodopa-induced dyskinesia (see: Rylander, D., et al. Neurobiology of Disease (2010), 39(3), 352-361), addiction (see: Olive, M. F. Current Drug Abuse Reviews (2009), 2(1), 83-98), anxiety (see: Jacob, W., et al. Neuropharmacology (2009), 57(2), 97-108), depression (see: Witkin, J. M., et al. CNS & Neurological Disorders: Drug Targets (2007), 6(2), 87-100), psychosis, epilepsy, Fragile X (see: Dolen, G., et al. Journal of Physiology (Oxford, United Kingdom) (2008), 586(6), 1503-1508), gastroesophageal reflux disease (see: Boeckxstaens, G. E. Expert Opinion on Emerging Drugs (2009), 14(3), 481-491), migraine (see: Marin, J., et al. Expert Opinion on Investigational Drugs (2010), 19(4), 555-561), pain, and others.
The invention provides technical advantages, for example, the compounds are novel and are ligands for the mGluR receptor and may be useful for the treatment of various disorders of the central nervous system. Additionally, the compounds provide advantages for pharmaceutical uses, for example, with regard to one or more of their mechanism of action, binding, inhibition efficacy, target selectivity, solubility, safety profiles, or bioavailability.
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions, and their use in treating disorders related to levels of tachykinins or serotonin or both.
One aspect of the invention is a compound of formula I
Ar1 is phenyl or a 6 membered heteroaryl containing 1-3 heteroatoms in which Ar1 is substituted with 1 R3 substituent and with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;
Ar2 is aryl or heteroaryl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, and phenyl; and
Ar3 is aryl or heteroaryl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino;
or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where:
Ar1 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, or pyridazinyl, and is substituted with 1 R3 substituent and with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;
Ar2 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, or benzimidazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, and phenyl; and
Ar3 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, oxazolyl, thiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, or pyrrolopyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino;
or a pharmaceutically acceptable salt thereof.
Ar3 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, oxazolyl, thiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, or pyrrolopyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino;
or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where Ar1 is phenyl, pyridinyl, or pyrimidinyl and is substituted with 1 R3 substituent and with 0-1 halo or alkoxy substituents; Ar2 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, pyrazolyl, oxazolyl, oxadiazolyl, or tetrazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, hydroxy, alkoxy, and phenyl; and Ar3 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, thiazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, or pyrrolopyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where Ar1 is phenyl, pyridinyl, halopyridinyl, alkoxypyridinyl, or pyrimidinyl; Ar2 is phenyl, cyanophenyl, halophenyl, dihalophenyl, (haloalkyl)phenyl, alkylphenyl, dialkylphenyl, hydroxyphenyl, alkoxyphenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, (alkyl)pyrazolyl, oxazolyl, (alkyl)oxadiazolyl, (phenyl)oxadiazolyl, (pyridinyl)oxadiazolyl, or tetrazolyl; and Ar3 is phenyl, cyanophenyl, halophenyl, dihalophenyl, alkylphenyl, (haloalkyl)phenyl, alkoxyphenyl, (haloalkoxy)phenyl, (alkylthio)phenyl, (amino)phenyl, alkylaminophenyl, dialkylaminophenyl, alkoxycarbonylphenyl, alkylcarbonylphenyl, pyridinyl, cyanopyridinyl, halopyridinyl, alkylpyridinyl, cycloalkylpyridinyl, alkoxypyridinyl, pyrazinyl, pyrimidinyl, alkoxypyrimidinyl, aminopyrimidinyl, alkylaminopyrimidinyl, dialkylaminopyrimidinyl, pyridazinyl, pyrrolopyridinyl, isoquinolinyl, quinoxalinyl, imidazolyl, thiazolyl, or alkylthiazolyl; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I 4 where R1 is hydrogen or methyl; R2 is hydrogen or methyl; Ar1 is phenyl, pyridinyl, fluoropyridinyl, methoxypyridinyl, or pyrimidinyl and is substituted with 1 R3 substituent; Ar2 is phenyl, cyanophenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, trifluoromethylphenyl, methylphenyl, dimethylphenyl, trifluoromethylphenyl, hydroxyphenyl, methoxyphenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, (methyl)pyrazolyl, oxazolyl, (methyl)oxadiazolyl, (phenyl)oxadiazolyl, (pyridinyl)oxadiazolyl, or tetrazolyl; and Ar3 is phenyl, cyanophenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methylphenyl, t-butylphenyl, trifluoromethylphenyl, methoxyphenyl, trifluoromethoxyphenyl, methylthiophenyl, (amino)phenyl, dimethylaminophenyl, methoxycarbonylphenyl, methylcarbonylphenyl, pyridinyl, cyanopyridinyl, chloropyridinyl, fluoropyridinyl, methylpyridinyl, cyclopropylpyridinyl, methoxypyridinyl, pyrazinyl, pyrimidinyl, ethoxypyrimidinyl, methylaminopyrimidinyl, pyridazinyl, pyrrolopyridinyl, isoquinolinyl, quinoxalinyl, imidazolyl, thiazolyl, or methylthiazolyl; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where R1 is hydrogen; R2 is hydrogen; Ar1 is phenyl or pyridinyl substituted in the meta position with R3; Ar2 is aryl or heteroaryl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, and phenyl; Ar3 is phenyl or pyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where R1 is hydrogen; R2 is hydrogen; Ar1 is phenyl or pyridinyl substituted in the meta position with R3; Ar2 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, or benzimidazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, and phenyl; Ar3 is phenyl or pyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where R1 is hydrogen; R2 is hydrogen; Ar1 is phenyl or pyridinyl substituted in the meta position with R3; Ar2 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, pyrazolyl, oxazolyl, oxadiazolyl, or tetrazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, hydroxy, alkoxy, and phenyl; Ar3 is phenyl or pyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where R1 is hydrogen; R2 is hydrogen; Ar1 is phenyl or pyridinyl substituted in the meta position with R3; Ar2 is phenyl, cyanophenyl, halophenyl, dihalophenyl, (haloalkyl)phenyl, alkylphenyl, dialkylphenyl, hydroxyphenyl, alkoxyphenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, (alkyl)pyrazolyl, oxazolyl, (alkyl)oxadiazolyl, (phenyl)oxadiazolyl, (pyridinyl)oxadiazolyl, or tetrazolyl; Ar3 is phenyl, cyanophenyl, halophenyl, dihalophenyl, dihalophenyl, alkylphenyl, (haloalkyl)phenyl, alkoxyphenyl, (haloalkoxy)phenyl, (alkylthio)phenyl, (amino)phenyl, alkylaminophenyl, dialkylaminophenyl, alkoxycarbonylphenyl, alkylcarbonylphenyl, pyridinyl, cyanopyridinyl, halopyridinyl, alkylpyridinyl, cycloalkylpyridinyl, alkoxypyridinyl, pyrazinyl, pyrimidinyl, alkoxypyrimidinyl, aminopyrimidinyl, alkylaminopyrimidinyl, dialkylaminopyrimidinyl, pyridazinyl, pyrrolopyridinyl, isoquinolinyl, quinoxalinyl, imidazolyl, thiazolyl, or alkylthiazolyl; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where R1 is hydrogen; R2 is hydrogen; Ar1 is phenyl or pyridinyl substituted in the meta position with R3; Ar2 is phenyl, cyanophenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, trifluoromethylphenyl, methylphenyl, dimethylphenyl, trifluoromethylphenyl, hydroxyphenyl, methoxyphenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, (methyl)pyrazolyl, oxazolyl, (methyl)oxadiazolyl, (phenyl)oxadiazolyl, (pyridinyl)oxadiazolyl, or tetrazolyl; Ar3 is phenyl, cyanophenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methylphenyl, t-butylphenyl, trifluoromethylphenyl, methoxyphenyl, trifluoromethoxyphenyl, methylthiophenyl, (amino)phenyl, dimethylaminophenyl, methoxycarbonylphenyl, methylcarbonylphenyl, pyridinyl, cyanopyridinyl, chloropyridinyl, fluoropyridinyl, methylpyridinyl, cyclopropylpyridinyl, methoxypyridinyl, pyrazinyl, pyrimidinyl, ethoxypyrimidinyl, methylaminopyrimidinyl, pyridazinyl, pyrrolopyridinyl, isoquinolinyl, quinoxalinyl, imidazolyl, thiazolyl, or methylthiazolyl; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I with the indicated stereochemisty
Another aspect of the invention is a compound of formula I where:
R1 is hydrogen or alkyl;
R2 is hydrogen or alkyl;
R3 is
Ar1 phenyl or pyridinyl and is substituted with 1 R3 substituent and with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;
Ar2 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, oxathiadiazolyl, tetrazolyl, or benzimidazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, alkoxy, and haloalkoxy; and
Ar3 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, oxazolyl, thiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, or pyrrolopyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino;
or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where R1 is hydrogen or alkyl; R2 is hydrogen or alkyl; R3 is
Ar1 phenyl or pyridinyl and is substituted with 1 R3 substituent and with 0-1 halo substituents; Ar2 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, oxadiazolyl, or tetrazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, and alkoxy; and Ar3 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, thiazolyl, quinolinyl, quinoxalinyl, or pyrrolopyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where R1 is hydrogen or methyl; R2 is hydrogen or methyl; R3 is
Ar1 phenyl or pyridinyl and is substituted with 1 R3 substituent and with 0-1 fluoro substituents; Ar2 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, oxadiazolyl, or tetrazolyl, and is substituted with 0-2 substituents selected from fluoro, chloro, cyano, methyl, trifluoromethyl, and methoxy; and Ar3 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, thiazolyl, quinolinyl, quinoxalinyl, or pyrrolopyridinyl, and is substituted with 0-2 substituents selected from fluoro, chloro, cyano, methyl, trifluoromethyl, cyclopropyl, hydroxy, methoxy, ethoxy, trifluoromethoxy, acetyl, methoxycarbonyl, methylthio, amino, methylamino, and dimethylamino; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where R1 is hydrogen; R2 is hydrogen; Ar1 is phenyl, pyridinyl, halopyridinyl, alkoxypyridinyl, or pyrimidinyl substituted in the meta position with R3.
Another aspect of the invention is a compound of formula I where Ar2 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, or benzimidazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, and phenyl; Ar3 is phenyl or pyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where Ar2 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, pyrazolyl, oxazolyl, oxadiazolyl, or tetrazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, hydroxy, alkoxy, and phenyl; Ar3 is phenyl or pyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where Ar2 is phenyl, cyanophenyl, halophenyl, dihalophenyl, (haloalkyl)phenyl, alkylphenyl, dialkylphenyl, hydroxyphenyl, alkoxyphenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, (alkyl)pyrazolyl, oxazolyl, (alkyl)oxadiazolyl, (phenyl)oxadiazolyl, (pyridinyl)oxadiazolyl, or tetrazolyl; Ar3 is phenyl, cyanophenyl, halophenyl, dihalophenyl, dihalophenyl, alkylphenyl, (haloalkyl)phenyl, alkoxyphenyl, (haloalkoxy)phenyl, (alkylthio)phenyl, (amino)phenyl, alkylaminophenyl, dialkylaminophenyl, alkoxycarbonylphenyl, alkylcarbonylphenyl, pyridinyl, cyanopyridinyl, halopyridinyl, alkylpyridinyl, cycloalkylpyridinyl, alkoxypyridinyl, pyrazinyl, pyrimidinyl, alkoxypyrimidinyl, aminopyrimidinyl, alkylaminopyrimidinyl, dialkylaminopyrimidinyl, pyridazinyl, pyrrolopyridinyl, isoquinolinyl, quinoxalinyl, imidazolyl, thiazolyl, or alkylthiazolyl; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where Ar2 is phenyl, cyanophenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, trifluoromethylphenyl, methylphenyl, dimethylphenyl, trifluoromethylphenyl, hydroxyphenyl, methoxyphenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, (methyl)pyrazolyl, oxazolyl, (methyl)oxadiazolyl, (phenyl)oxadiazolyl, (pyridinyl)oxadiazolyl, or tetrazolyl; Ar3 is phenyl, cyanophenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methylphenyl, t-butylphenyl, trifluoromethylphenyl, methoxyphenyl, trifluoromethoxyphenyl, methylthiophenyl, (amino)phenyl, dimethylaminophenyl, methoxycarbonylphenyl, methylcarbonylphenyl, pyridinyl, cyanopyridinyl, chloropyridinyl, fluoropyridinyl, methylpyridinyl, cyclopropylpyridinyl, methoxypyridinyl, pyrazinyl, pyrimidinyl, ethoxypyrimidinyl, methylaminopyrimidinyl, pyridazinyl, pyrrolopyridinyl, isoquinolinyl, quinoxalinyl, imidazolyl, thiazolyl, or methylthiazolyl; or a pharmaceutically acceptable salt thereof.
Another aspect of the invention is a compound of formula I where R1 is hydrogen or methyl.
Another aspect of the invention is a compound of formula I where R2 is hydrogen or methyl.
Another aspect of the invention is a compound of formula I where R1 and R2 is hydrogen.
Another aspect of the invention is a compound of formula I where Ar1 has 3,5-pyridindiyl (meta) regiochemistry.
Another aspect of the invention is a compound of formula I where Ar1 has 2,6-pyridinyl (meta) regiochemistry.
Another aspect of the invention is a compound of formula I where Ar2 is dihalophenyl.
Another aspect of the invention is a compound of formula I where Ar2 is 2,5-difluorophenyl.
Another aspect of the invention is a compound of formula I where Ar3 is phenyl.
For a compound of formula I, the scope of any instance of a variable substituent, including R1, R2, R3, Ar1, Ar2, and Ar3 can be used independently with the scope of any other instance of a variable substituent. As such, the invention includes combinations of the different aspects.
Unless specified otherwise, these terms have the following meanings. “Halo” includes fluoro, chloro, bromo, and iodo. “Alkyl” means a straight or branched alkyl group composed of 1 to 6 carbons. “Alkenyl” means a straight or branched alkyl group composed of 2 to 6 carbons with at least one double bond. “Alkynyl” means a straight or branched alkyl group composed of 2 to 6 carbons with at least one triple bond. “Cycloalkyl” means a monocyclic ring system composed of 3 to 7 carbons. “Haloalkyl” and “haloalkoxy” include all halogenated isomers from monohalo to perhalo. Terms with a hydrocarbon moiety (e.g. alkoxy) include straight and branched isomers for the hydrocarbon portion. “Aryl” means a monocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbon atoms, or a bicyclic fused ring system wherein one or both of the rings is a phenyl group. Bicyclic fused ring systems consist of a phenyl group fused to a four- to six-membered aromatic or non-aromatic carbocyclic ring. Representative examples of aryl groups include, but are not limited to, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl. “Heteroaryl” means a 5 to 7 membered monocyclic or 8 to 11 membered bicyclic aromatic ring system with 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Parenthetic and multiparenthetic terms are intended to clarify bonding relationships to those skilled in the art. For example, a term such as ((R)alkyl) means an alkyl substituent further substituted with the substituent R.
The invention includes all pharmaceutically acceptable salt forms of the compounds. Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucouronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.
Some Formula I compounds contain at least one asymmetric carbon atom, an example of which is shown below. The invention includes all stereoisomeric forms of the compounds, both mixtures and separated isomers. Mixtures of stereoisomers can be separated into individual isomers by methods known in the art. The relative and absolute stereochemistry of formula I compounds depicted in the specific embodiments section (and the intermediates used to prepare them) represent the most likely stereoisomer based on the data collected for each compound.
The invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include 13C and 14C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds may have a variety of potential uses, for example as standards and reagents in determining biological activity. In the case of stable isotopes, such compounds may have the potential to favorably modify biological, pharmacological, or pharmacokinetic properties.
Compounds of Formula I may be made by methods known in the art including those described below and including variations within the skill of the art. Some reagents and intermediates are known in the art. Other reagents and intermediates can be made by methods known in the art using readily available materials. The variables (e.g. numbered “R” substituents) used to describe the synthesis of the compounds are intended only to illustrate how to make the compounds and are not to be confused with variables used in the claims or in other sections of the specification. The following methods are for illustrative purposes and are not intended to limit the scope of the invention. The schemes encompass reasonable variations known in the art.
mGluR5 FLIPR Assay.
HEK293 (ZF) cells stably transfected with human mGluR5A (pIRES neo) and the rat glutamate-aspartate transporter (GLAST; pIRES puro) are grown in a monolayer culture at 37° C. in 5% CO2 and fed with Minimum Essential Medium (MEM) supplemented with 10% dialysed fetal bovine serum. 24 hours prior to assay, cells are enzymatically dissociated from the culture flask (Trypsin, 0.25%), spun down (1000 rpm, 3 min), resuspended, and plated on Greiner black clear bottomed PDL-coated 384-well plates at a density of 30 thousand cells/well. On the day of the experiment, media is removed from the cell plates and replaced with Molecular Devices Calcium 4 microfluorometric Ca++ sensitive dye in assay buffer (HBSS; Gibco #14025+20 mM HEPES and 250 uM probenacid). Plates are incubated in dye at 37° C. in 5% CO2 for 60 minutes prior to delivery of test compounds in assay buffer. Test compounds are incubated with cells in the presence of dye for 10 minutes prior to being read on the FLIPR platform (Molecular Devices). A Ca++ signal is induced in the assay plates via the delivery of an ˜EC10 concentration of the endogenous agonist 1-glutamate; images are acquired at 1 Hz for 100 seconds post-delivery of agonist stimulus. Positive modulator activity (i.e. the ability of test compounds to increase the Ca++ response to a sub-maximal concentration of agonist) is normalized to a saturating concentration of a known mGluR5 PAM run in each assay plate. An EC50 concentration of test compounds is derived from 4-parameter logistic curve fits of transformed fluoresence data via proprietary software suite.
Example | mGluR5 EC50 | ||
1 | A | ||
2 | C | ||
3 | B | ||
4 | C | ||
5 | A | ||
6 | C | ||
7 | C | ||
8 | C | ||
9 | C | ||
10 | A | ||
11 | C | ||
12 | C | ||
13 | C | ||
14 | C | ||
15 | C | ||
16 | A | ||
17 | C | ||
18 | C | ||
19 | C | ||
20 | A | ||
21 | A | ||
22 | C | ||
23 | A | ||
24 | C | ||
25 | C | ||
26 | B | ||
27 | C | ||
28 | C | ||
29 | C | ||
30 | C | ||
31 | C | ||
32 | C | ||
33 | A | ||
34 | C | ||
35 | A | ||
36 | C | ||
37 | A | ||
38 | C | ||
39 | A | ||
40 | C | ||
41 | A | ||
42 | C | ||
43 | A | ||
44 | C | ||
45 | A | ||
46 | A | ||
47 | A | ||
48 | C | ||
49 | C | ||
50 | B | ||
51 | A | ||
52 | C | ||
53 | C | ||
54 | C | ||
55 | A | ||
56 | C | ||
57 | C | ||
58 | C | ||
59 | A | ||
60 | C | ||
61 | A | ||
62 | C | ||
63 | A | ||
64 | C | ||
65 | B | ||
66 | B | ||
67 | C | ||
68 | A | ||
69 | A | ||
70 | C | ||
71 | B | ||
72 | A | ||
73 | A | ||
74 | C | ||
75 | C | ||
76 | C | ||
77 | C | ||
78 | C | ||
79 | A | ||
80 | A | ||
81 | A | ||
82 | B | ||
83 | B | ||
84 | C | ||
85 | C | ||
86 | A | ||
87 | C | ||
88 | C | ||
89 | C | ||
90 | C | ||
91 | B | ||
92 | C | ||
93 | C | ||
94 | C | ||
95 | A | ||
96 | B | ||
97 | C | ||
98 | C | ||
99 | A | ||
100 | B | ||
101 | A | ||
102 | C | ||
103 | A | ||
104 | A | ||
105 | C | ||
106 | A | ||
107 | A | ||
108 | C | ||
109 | A | ||
110 | C | ||
111 | A | ||
112 | A | ||
113 | B | ||
114 | A | ||
115 | C | ||
116 | A | ||
117 | A | ||
118 | C | ||
119 | C | ||
120 | C | ||
121 | A | ||
122 | C | ||
123 | B | ||
124 | C | ||
125 | C | ||
126 | C | ||
127 | B | ||
128 | C | ||
129 | C | ||
130 | C | ||
131 | A | ||
132 | C | ||
133 | A | ||
134 | C | ||
135 | A | ||
136 | C | ||
137 | B | ||
138 | A | ||
139 | A | ||
140 | A | ||
141 | A | ||
142 | A | ||
143 | A | ||
144 | A | ||
145 | A | ||
146 | A | ||
147 | C | ||
148 | C | ||
149 | B | ||
150 | C | ||
151 | C | ||
152 | C | ||
153 | B | ||
154 | C | ||
155 | C | ||
156 | A | ||
157 | A | ||
158 | C | ||
159 | C | ||
160 | C | ||
161 | C | ||
162 | C | ||
163 | C | ||
164 | C | ||
165 | C | ||
166 | C | ||
167 | C | ||
168 | C | ||
169 | C | ||
170 | A | ||
171 | A | ||
172 | A | ||
173 | A | ||
174 | C | ||
175 | A | ||
176 | A | ||
177 | C | ||
178 | B | ||
179 | A | ||
180 | B | ||
181 | B | ||
182 | A | ||
183 | A | ||
184 | A | ||
185 | A | ||
186 | A | ||
187 | A | ||
188 | C | ||
189 | C | ||
190 | C | ||
191 | C | ||
192 | C | ||
193 | A | ||
194 | B | ||
195 | C | ||
196 | A | ||
197 | C | ||
198 | A | ||
199 | C | ||
200 | C | ||
201 | B | ||
202 | C | ||
203 | A | ||
204 | A | ||
205 | A | ||
206 | B | ||
207 | C | ||
208 | A | ||
209 | A | ||
210 | A | ||
211 | A | ||
212 | A | ||
213 | A | ||
214 | A | ||
215 | A | ||
216 | A | ||
217 | A | ||
218 | C | ||
219 | A | ||
220 | B | ||
221 | C | ||
222 | A | ||
223 | B | ||
224 | C | ||
225 | C | ||
226 | A | ||
227 | A | ||
228 | C | ||
229 | A | ||
230 | C | ||
231 | A | ||
232 | C | ||
233 | A | ||
234 | A | ||
235 | B | ||
236 | C | ||
237 | B | ||
238 | C | ||
239 | A | ||
240 | C | ||
241 | C | ||
242 | C | ||
243 | B | ||
244 | C | ||
245 | C | ||
246 | C | ||
247 | C | ||
248 | C | ||
249 | C | ||
250 | C | ||
251 | C | ||
252 | C | ||
253 | C | ||
254 | C | ||
255 | C | ||
256 | A | ||
257 | B | ||
258 | A | ||
259 | A | ||
260 | C | ||
261 | C | ||
262 | B | ||
263 | C | ||
264 | B | ||
265 | B | ||
266 | B | ||
267 | B | ||
268 | C | ||
269 | C | ||
270 | C | ||
271 | C | ||
272 | C | ||
273 | C | ||
274 | C | ||
275 | A | ||
276 | B | ||
277 | A | ||
278 | C | ||
279 | A | ||
280 | C | ||
281 | C | ||
282 | A | ||
283 | A | ||
284 | A | ||
285 | B | ||
286 | A | ||
287 | B | ||
288 | B | ||
289 | A | ||
290 | C | ||
291 | B | ||
292 | A | ||
293 | C | ||
294 | A | ||
295 | C | ||
296 | A | ||
297 | A | ||
298 | B | ||
299 | A | ||
300 | A | ||
301 | A | ||
302 | A | ||
303 | C | ||
304 | A | ||
305 | C | ||
306 | C | ||
307 | C | ||
308 | C | ||
309 | A | ||
310 | C | ||
311 | A | ||
312 | C | ||
313 | B | ||
314 | C | ||
315 | C | ||
316 | C | ||
317 | C | ||
318 | A | ||
319 | C | ||
320 | A | ||
321 | C | ||
322 | A | ||
323 | C | ||
324 | A | ||
325 | C | ||
326 | C | ||
327 | C | ||
328 | C | ||
329 | C | ||
330 | A | ||
331 | C | ||
332 | C | ||
333 | C | ||
334 | C | ||
335 | C | ||
336 | C | ||
337 | B | ||
338 | C | ||
339 | C | ||
340 | C | ||
341 | C | ||
342 | A | ||
343 | C | ||
344 | A | ||
345 | C | ||
346 | A | ||
347 | C | ||
348 | C | ||
349 | B | ||
350 | C | ||
351 | B | ||
352 | C | ||
353 | A | ||
354 | B | ||
355 | A | ||
356 | B | ||
357 | A | ||
358 | C | ||
359 | B | ||
360 | A | ||
361 | C | ||
362 | A | ||
363 | A | ||
364 | C | ||
365 | A | ||
366 | C | ||
367 | C | ||
368 | B | ||
369 | C | ||
370 | A | ||
371 | C | ||
372 | A | ||
373 | C | ||
374 | C | ||
375 | A | ||
376 | B | ||
377 | C | ||
378 | A | ||
379 | C | ||
380 | A | ||
381 | B | ||
382 | B | ||
383 | C | ||
384 | C | ||
385 | C | ||
386 | C | ||
387 | C | ||
388 | B | ||
389 | C | ||
390 | B | ||
391 | C | ||
392 | A | ||
393 | C | ||
394 | C | ||
395 | B | ||
396 | A | ||
397 | A | ||
398 | B | ||
399 | A | ||
400 | A | ||
401 | A | ||
402 | C | ||
403 | A | ||
404 | A | ||
405 | A | ||
406 | B | ||
407 | A | ||
408 | B | ||
409 | B | ||
410 | C | ||
A = less than 100 nM; B = between 100 nM and 1 uM; C = greater than 1 uM |
Example | mGluR5 EC50 (nM) | ||
1 | 39 | ||
2 | >30000 | ||
3 | 283 | ||
4 | >30000 | ||
18 | >30000 | ||
21 | 1.0 | ||
26 | 367 | ||
35 | 6.3 | ||
45 | 3.8 | ||
47 | 7.4 | ||
50 | 353 | ||
52 | >30000 | ||
57 | >30000 | ||
58 | >30000 | ||
64 | >30000 | ||
65 | 139 | ||
71 | 325 | ||
74 | >30000 | ||
75 | >30000 | ||
76 | >30000 | ||
105 | >30000 | ||
117 | 4.7 | ||
125 | >30000 | ||
126 | >30000 | ||
135 | 8.5 | ||
138 | 0.43 | ||
142 | 3.7 | ||
149 | 106 | ||
153 | 188 | ||
158 | >30000 | ||
176 | 5.2 | ||
178 | 117 | ||
180 | 259 | ||
181 | 279 | ||
185 | 17.4 | ||
194 | 281 | ||
203 | 2.5 | ||
205 | 2.2 | ||
234 | 2.7 | ||
235 | 211 | ||
243 | 272 | ||
257 | 164 | ||
259 | 1.9 | ||
273 | >3000 | ||
276 | 468 | ||
277 | 21.5 | ||
294 | 2.7 | ||
297 | 4.7 | ||
298 | 232 | ||
306 | >3000 | ||
312 | >3000 | ||
325 | >1500 | ||
326 | >3000 | ||
334 | >3000 | ||
337 | 688 | ||
346 | 13.3 | ||
349 | 305 | ||
354 | 392 | ||
360 | 2.0 | ||
370 | 31.8 | ||
382 | 537 | ||
398 | 141 | ||
402 | >3000 | ||
Compounds of formula I bind to mGluR 5 and can be useful in treating neurological or psychiatric disorders. Therefore, another aspect of the invention is a composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Another aspect of the invention is a method for the treatment of schizophrenia, cognitive impairment, Alzheimer's disease, Parkinson's disease, Parkinson's disease levodopa-induced dyskinesia, addiction, anxiety, depression, psychosis, epilepsy, Fragile X, gastroesophageal reflux disease, migraine, pain, borderline personality disorder, bipolar disorder, or other neurological and/or psychiatric disorder associated with glutamate dysfunction, which comprises administering to a patient a therapeutically affective amount of a compound of formula I.
Another aspect of the invention is a method for the treatment of schizophrenia which comprises administering to a patient a therapeutically affective amount of a compound of formula I.
Another aspect of the invention is a method for the treatment of Alzheimer's disease which comprises administering to a patient a therapeutically affective amount of a compound of formula I.
Another aspect of the invention is the use of a compound of formula I in the manufacture of a medicament for the treatment of neurological or psychiatric disorders.
Another aspect of the invention is the use of a compound of formula I in the manufacture of a medicament for the treatment of schizophrenia, cognitive impairment, Alzheimer's disease, Parkinson's disease, Parkinson's disease levodopa-induced dyskinesia, addiction, anxiety, depression, psychosis, epilepsy, Fragile X, gastroesophageal reflux disease, migraine, pain, borderline personality disorder, bipolar disorder, or other neurological and/or psychiatric disorder associated with glutamate dysfunction.
Another aspect of the invention is the use of a compound of formula I in the manufacture of a medicament for the treatment of Alzheimer's disease.
Another aspect of the invention is the use of a compound of formula I in the manufacture of a medicament for the treatment of schizophrenia.
“Patient” means a person suitable for therapy as understood by practitioners in the field of affective disorders and neurodegenerative disorders.
“Treatment,” “therapy,” and related terms are used as understood by practitioners in the field of neurological and psychiatric disorders.
The compounds of this invention are generally given as pharmaceutical compositions comprised of a therapeutically effective amount of a compound or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier and may contain conventional excipients. Pharmaceutically acceptable carriers are those conventionally known carriers having acceptable safety profiles. Compositions encompass all common solid and liquid forms including for example capsules, tablets, losenges, and powders as well as liquid suspensions, syrups, elixers, and solutions. Compositions are made using common formulation techniques, and conventional excipients (such as binding and wetting agents) and vehicles (such as water and alcohols) are generally used for compositions. See, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 17th edition, 1985.
Solid compositions are normally formulated in dosage units and compositions providing from about 1 to 1000 mg of the active ingredient per dose are preferred. Some examples of dosages are 1 mg, 10 mg, 100 mg, 250 mg, 500 mg, and 1000 mg. Generally, other agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 0.25-1000 mg/unit.
Liquid compositions are usually in dosage unit ranges. Generally, the liquid composition will be in a unit dosage range of 1-100 mg/mL. Some examples of dosages are 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL. Generally, other agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 1-100 mg/mL.
The invention encompasses all conventional modes of administration; oral and parenteral methods are preferred. Generally, the dosing regimen will be similar to other agents used clinically. Typically, the daily dose will be 1-100 mg/kg body weight daily. Generally, more compound is required orally and less parenterally. The specific dosing regime, however, will be determined by a physician using sound medical judgement.
The following experimental procedures describe the synthesis of some Formula I compounds. Standard chemistry conventions are used in the text unless otherwise noted. The experimental encompass reasonable variations known in the art. The following HPLC conditions may be used where indicated.
Preparative HPLC Method 1: Sunfire C18 19×100 mm, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=0% B, 10.0 min=100% B, 15.0 min=100% B, Flow rate=25 mL/min.
Preparative HPLC Method 2: Chiralpak AD 21×250 20 μM, A=Heptane, B=Ethanol, 0.00 min=30% B, 15.0 min=100% B, 250 min=100% B, Flow Rate=20 ml/min.
Preparative HPLC Method 3: Chiralpak AD 21×250 20 μM, A=Heptane, B=Ethanol, 0.00 min=20% B, 25.0 min=100% B, 300 min=100% B, Flow Rate=20 ml/min.
Preparative HPLC Method 4: Sunfire C18 19×100 mm, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=20% B, 15.0 min=100% B, 22.0 min=100% B, Flow rate=25 mL/min.
Preparative HPLC Method 5: Xbridge C18 19×100 mm 5 μOBD, A=95% H2O/5% Acetonitrile, B=95% Acetonitrile/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=20% B, 10.0 min=100% B, 15.0 min=100% B, Flow rate=20 mL/min.
Preparative HPLC Method 6: Sunfire C18 30×100 mm 5μ, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=30% B, 10.0 min=100% B, 15.0 min=100% B, Flow rate=35 mL/min.
Preparative HPLC Method 7: Sunfire C18 30×100 mm, A=90% H2O/10% ACN, B=90% ACN/10% H2O, Modifier 0.1% TFA, 0.00 min=30% B, 12.0 min=100% B, 26.0 min=100% B, Flow rate=35 mL/min.
Preparative HPLC Method 8: Sunfire C18 30×100 mm, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=30% B, 12.0 min=100% B, 18.0 min=100% B, Flow rate=35 mL/min.
Preparative HPLC Method 9: Waters Atlantis 30×100 mm, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=30% B, 12.0 min=100% B, 18.0 min=100% B, Flow rate=35 mL/min.
Preparative HPLC Method 10: Waters Atlantis 30×100 mm, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=30% B, 15.0 min=100% B, 20.0 min=100% B, Flow rate=35 mL/min.
Preparative HPLC Method 11: Waters Atlantis 30×100 mm, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=40% B, 15.0 min=100% B, 23.0 min=100% B, Flow rate=35 mL/min.
Preparative HPLC Method 12: Chiralpak AS 21×250 mm 10 μM, A=0.1% diethylamine/Heptane, B=Ethanol, 0.00 min=40% B, 400 min=40% B, Flow Rate=15 ml/min.
Preparative HPLC method 13: SunFire 30×150 mm OBD, A=95% H2O/5% ACN, B=95% ACN/5% H2O, Modifier 10 mM NH4OAc, 0.00 min=10% B, 20 min=100% B 25 min=100% B, Flow rate=40 mL/min.
Preparative HPLC Method 14: Chiralpak AS 21×250 mm 10 μM, A=0.1% diethylamine/Heptane, B=Ethanol, 0.00 min=10% B, 400 min=10% B, Flow Rate=15 ml/min.
Preparative HPLC Method 15: Sunfire C18 30×100 mm 5μ, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=30% B, 10.0 min=100% B, 15.0 min=100% B, Flow rate=35 mL/min.
Preparative HPLC Method 16: Sunfire C18 30×100 mm 5μ, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=25% B, 18.0 min=90% B, 25.0 min=100% B, Flow rate=35 mL/min.
Analytical HPLC method 1: Phenomenex Luna 3.0×50 mm S10, A=95% H2O/5% MeOH, B=95% MeOH/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=0% B, 2.0 min=100% B, 3.0 min=100% B, Flow rate=4 mL/min.
Analytical HPLC method 2: Phenomenex Luna 3.0×50 mm S10, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=0% B, 2.0 min=100% B, 3.0 min=100% B, Flow rate=4 mL/min.
Analytical HPLC method 3: YMC ODS-A 4.6×50 mm S5, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=0% B, 12.0 min=100% B, 15.0 min=100% B, Flow rate=5 mL/min.
Analytical HPLC method 4: Chiralpak AD-H analytical column, 4.6×250 mm, 5 μm, Mobile Phase: 15% MeOH in CO2 @ 150 Bar, Temp: 35° C., Flow rate: 2.0 mL/min. for 30 min, UV monitored @ 258 nm.
Analytical HPLC method 5: XTERRA 4.6×30 mm S5, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=0% B, 12.0 min=100% B, 15.0 min=100% B, Flow rate=5 mL/min.
Analytical HPLC method 6: Waters Sunfire 4.6×30 mm 5μ, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=0% B, 3.0 min=100% B, 4.0 min=100% B, Flow rate=4 mL/min.
Analytical HPLC method 7: Xbridge C18 4.6×50 mm 5μ, A=95% H2O/5% Methanol, B=95% Methanol/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=0% B, 4.0 min=100% B, 5.0 min=100% B, Flow rate=4 mL/min.
Analytical HPLC method 8: Xbridge C18 4.6×50 mm 5μ, A=95% H2O/5% MeOH, B=95% MeOH/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=0% B, 2.0 min=100% B, 3.0 min=100% B, Flow rate=4 mL/min.
Analytical HPLC method 9: Xbridge C18 4.6×100 mm 5μ, A=Water; B=ACN; Modifier=10 mM Ammonium Acetate, 0.00 min=30% B, 8.0 min=95% B, Flow rate=1 mL/min.
Analytical HPLC method 10: Phenomenex Luna 30×2.0 mm 3μ, A=95% H2O/5% MeOH, B=95% MeOH/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=0% B, 2.0 min=100% B, 3.0 min=100% B, Flow rate=1 mL/min.
Analytical HPLC method 11: Phenomenex Luna 2.0×50 mm 3μ, A=95% H2O/5% MeOH, B=95% MeOH/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=0% B, 4.0 min=100% B, 5.0 min=100% B, Flow rate=0.8 mL/min.
Analytical HPLC method 12: Xbridge C18 2.1×50 mm 3μ, A=95% H2O/5% MeOH, B=95% MeOH/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=0% B, 4.0 min=100% B, 5.0 min=100% B, Flow rate=0.8 mL/min.
Analytical HPLC method 13: Phenomenex Luna 3.0×50 mm S10, A=95% H2O/5% MeOH, B=95% MeOH/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=0% B, 3.0 min=100% B, 4.0 min=100% B, Flow rate=4 mL/min.
Analytical HPLC method 14: Phenomenex Luna 3.0×30 mm 3 um, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA, 0.00 min=0% B, 2.0 min=100% B, 3.0 min=100% B, Flow rate=1 mL/min.
Analytical HPLC method 15: Phenomenex LUNA C18, 50×2 3μ, A=90% H2O/10% CH3CN, B=90% CH3CN/10% H2O, Modifier 0.1% TFA, 0.00 min=0% B, 4.0 min=100% B, 4.0 min=100% B, Flow rate=0.8 mL/min.
Preparative SFC Method 1: Chiralcel OJ-H analytical column, 4.6×250 mm, 5 μm, Mobile Phase: 45% MeOH (0.1% DEA) in CO2; Temp: 35° C.; Flow rate: 70.0 mL/min. for 32 min; UV monitored @ 258 nm.
Preparative SFC Method 2: Chiralpak AD-H preparative column, 21×250 mm, 5 μm, Mobile Phase: 15% MeOH in CO2 @ 150 Bar, Temp: 35° C., Flow rate: 45.0 mL/min. for 35 min, UV monitored @ 258 nm.
Preparative SFC Method 3: ChiralPak AS-H (30×250 mm) 5 μm, Mobile Phase: 25% MeOH (w/0.1% DEA)/75% CO2, Pressure: 150 bar, Temperature: 35° C., Flow Rate: 70 mL/min, UV: 280 nm, Collection: Manual.
Preparative SFC Method 4: ChiralPak AD-H (30×250 mm) 5 μm, Mobile Phase: 17% MeOH (w/0.1% DEA)/83% CO2, Pressure: 150 bar, Temperature: 35° C., Flow Rate: 70 mL/min, UV: 280 nM, Collection: Manual.
Preparative SFC Method 5: ChiralPak AD-H (21×250 mm) 5 μm, Mobile Phase: 50% MeOH (w/0.1% DEA), Pressure: 150 bar, Temperature: 35° C., Flow Rate: 45 mL/min, UV: 283 nM, Collection: Manual.
Abbreviations used in the schemes generally follow conventions used in the art. Chemical abbreviations used in the specification and examples are defined as follows: “NaHMDS” for sodium bis(trimethylsilyl)amide; “DMF” for N,N-dimethylformamide; “MeOH” for methanol; “NBS” for N-bromosuccinimide; “Ar” for aryl; “TFA” for trifluoroacetic acid; “LAH” for lithium aluminum hydride; “BOC” for t-butoxycarbonyl, “DMSO” for dimethylsulfoxide; “h” for hours; “rt” for room temperature or retention time (context will dictate); “min” for minutes; “EtOAc” for ethyl acetate; “THF” for tetrahydrofuran; “EDTA” for ethylenediaminetetraacetic acid; “Et2O” for diethyl ether; “DMAP” for 4-dimethylaminopyridine; “DCE” for 1,2-dichloroethane; “ACN” for acetonitrile; “DME” for 1,2-dimethoxyethane; “HOBt” for 1-hydroxybenzotriazole hydrate; “DIEA” for diisopropylethylamine, “Nf” for CF3(CF2)3SO2—; and “TMOF” for trimethylorthoformate.
Abbreviations as used herein, are defined as follows: “1×” for once, “2×” for twice, “3×” for thrice, “° C.” for degrees Celsius, “eq” for equivalent or equivalents, “g” for gram or grams, “mg” for milligram or milligrams, “L” for liter or liters, “mL” for milliliter or milliliters, “μL” for microliter or microliters, “N” for normal, “M” for molar, “mmol” for millimole or millimoles, “min” for minute or minutes, “h” for hour or hours, “rt” for room temperature, “RT” for retention time, “atm” for atmosphere, “psi” for pounds per square inch, “conc.” for concentrate, “sat” or “sat'd” for saturated, “MW” for molecular weight, “mp” for melting point, “cc” for enantiomeric excess, “MS” or “Mass Spec” for mass spectrometry, “ESI” for electrospray ionization mass spectroscopy, “HR” for high resolution, “HRMS” for high resolution mass spectrometry, “LCMS” for liquid chromatography mass spectrometry, “HPLC” for high pressure liquid chromatography, “RP HPLC” for reverse phase HPLC, “TLC” or “tlc” for thin layer chromatography, “NMR” for nuclear magnetic resonance spectroscopy, “1H” for proton, “δ” for delta, “s” for singlet, “d” for doublet, “t” for triplet, “q” for quartet, “m” for multiplet, “br” for broad, “Hz” for hertz, and “α”, “β”, “R”, “S”, “E”, and “Z” are stereochemical designations familiar to one skilled in the art.
To a solution of diisopropylamine (19.7 mL, 138 mmol) in tetrahydrofuran (50 mL) at −78° C. was added nBuLi (2.5 M in hexane, 55.8 mL, 140 mmol) dropwise. The reaction was allowed to gradually warm in the bath to −30° C., held there for 5 min, and re-cooled to −78° C. The reaction was treated with 2-(3-bromophenyl)acetic acid (15 g, 70 mmol) in tetrahydrofuran (200 mL) over 10 minutes. The ice bath was removed and stirring continued for 1.5 h. The reaction was cooled to 0° C., and treated with a solution of 3-methoxybenzaldehyde (8.49 mL, 69.8 mmol) in tetrahydrofuran (50 mL). The reaction was allowed to gradually warm to room temperature overnight. The reaction was poured onto ice water and extracted with diethyl ether. The ethereal was discarded. The aqueous layer was acidified by addition of concentrated hydrochloric acid at 0° C. until it was very acidic. The product was extracted with diethyl ether (3×). The ethereal was washed with brine, dried over magnesium sulfate, and concentrated to give 24.8 g (83%) as a colorless viscous gum as a racemic mixture of diastereomers which was used without purification. Mass spec.: 374.03 (MNa)+.
A mixture of (±)-(2R,3S)-2-(3-bromophenyl)-3-hydroxy-3-(3-methoxyphenyl)propanoic acid and (±)-(2R,3R)-2-(3-bromophenyl)-3-hydroxy-3-(3-methoxyphenyl)propanoic acid (23.9 g, 68 mmol) was dissolved in toluene (500 mL) and treated with triethylamine (9.5 mL, 68.1 mmol), stirred briefly, and treated with diphenyl phosphorazidate (14.7 mL, 68.1 mmol) slowly over 15 min. The reaction was fitted with an internal thermometer and gradually warmed to 60° C. After reaching 60° C., the reaction was heated for 3 h at that temperature and then allowed to cool to room temperature and stirred overnight. The reaction was quenched by addition of sat'd ammonia in water. After stirring 10 min, the reaction was diluted with 500 mL diethyl ether and the layers separated. The organics were washed with brine, dried over magnesium sulfate, concentrated, and purified by column chromatography (silica gel, 25%-->75% EtOAc/Hex). The first product to elute was the trans product ((±)-(4R,5R)-4-(3-bromophenyl)-5-(3-methoxyphenyl)oxazolidin-2-one, 7.73 g). 1H-NMR (CDCl3, 500 MHz) δ 7.50-7.60 (m, 2H), 7.20-7.40 (m, 3H), 6.96 (m, 1H), 6.82-6.90 (m, 2H), 5.74 (bs, 1H), 5.27 (d, J=7.3, 1H), 4.74 (d, J=7.3, 1H), 3.84 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 160.0, 158.9, 140.8, 138.5, 132.0, 130.7, 130.1, 129.4, 125.1, 123.2, 118.0, 114.8, 111.1, 85.7, 64.2, 55.3. The enantiomers were separated by chiral SFC (chiralcel OJ-H, 20% MeOH/CO2). Enantiomer 1: (−)-(4S,5S)-4-(3-bromophenyl)-5-(3-methoxyphenyl)oxazolidin-2-one. Enantiomer 2: (+)-(4R,5R)-4-(3-bromophenyl)-5-(3-methoxyphenyl)oxazolidin-2-one. The second product to elute from the silica gel column was the cis product ((±)-(4R,5S)-4-(3-bromophenyl)-5-(3-methoxyphenyl)oxazolidin-2-one, 264 mg). 1H-NMR (CDCl3, 500 MHz) δ 7.27 (m, 1H), 7.16 (s, 1H), 7.08 (dd, J=8.2, 7.6, 1H), 6.99 (dd, J=7.9, 7.6, 1H), 6.89 (d, J=7.6, 1H), 6.69 (dd, J=8.2, 2.4, 1H), 6.61 (m, 2H), 6.47 (bs, 1H), 5.92 (d, J=8.2, 1H), 5.15 (d, J=8.2, 1H), 3.65 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 159.4, 159.3, 138.5, 135.4, 131.3, 130.0, 129.8, 129.1, 125.5, 122.4, 118.4, 114.7, 111.1, 82.0, 60.7, 55.3.
To a solution of diethyl 3-methoxybenzylphosphonate (0.5 g, 1.94 mmol) in dimethylformamide (5 mL) at room temperature was added sodium methoxide (0.209 g, 3.87 mmol) and 18-Crown-6 (0.205 g, 0.77 mmol). After stirring at room temperature for 5 min, the reaction was cooled to 0° C. and treated with a solution of 6-bromopicolinaldehyde (0.432 g, 2.32 mmol) in dimethylformamide (2 mL) dropwise. When addition was complete, the ice bath was removed and the reaction stirred at room temperature for 1 h. The reaction was heated to 120° C. and held there for 2 h. The reaction was cooled to room temperature and stirred overnight. The resulting suspension was poured into water (70 mL) with vigorous stirring. The resulting suspension was extracted with diethyl ether (2×), washed with brine, dried over magnesium sulfate, and concentrated. The resulting residue was suspended in ethanol (ca. 10 ml). The resulting solution was placed in the freezer and held there for 3 h. The resulting precipitate was collected by filtration to give 150 mg (27%) as a white powder. 1H-NMR (CDCl3, 500 MHz) δ 7.61 (d, J=15.9, 1H), 7.49 (dd, J=7.6, 7.6, 1H), 7.22-7.36 (m, 3H), 7.16 (d, J=7.6, 1H), 7.10 (m, 1H), 7.07 (d, J=15.9, 1H), 6.87 (dd, J=8.2, 2.1, 1H), 3.84 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 160.0, 157.1, 142.3, 138.9, 137.7, 134.4, 129.8, 126.7, 126.3, 120.7, 120.1, 114.8, 112.3, 55.4. Mass spec.: 290.01 (MH)+.
To a solution of tert-butyl carbamate (109 mg, 0.931 mmol) in acetonitrile (5 mL) at 0° C. was added tert-butyl hypochlorite (0.105 mL, 0.93 mmol). After stirring for 5 min, the reaction was treated with silver oxide (108 mg, 0.465 mmol). After stirring for 10 min, the resulting suspension was treated with (E)-2-bromo-6-(3-methoxystyryl)pyridine (180 mg, 0.620 mmol), osmium tetroxide (0.1 mL, 0.32 mmol), and water (0.025 mL, 1.37 mmol). The ice bath was removed and stirring continued for 8 h. The reaction was filtered and treated with a solution of sodium sulfite (5% in water, 1.5 mL). The resulting solution was heated to 50° C. and held there for 8 h. The reaction was cooled to room temperature and diluted with ethyl acetate. The organics were washed with water, then brine, dried over magnesium sulfate, concentrated, and purified by column chromatography (25% EtOAc/Hex). HNMR of the purified material suggested that it was ca. 1:1 mixture of regioisomers. The product (114 mg, 43%) was used as a mixture of regioisomers. Mass spec.: 423.09 (MH)+.
(±)-tert-Butyl (1R,2R)-1-(6-bromopyridin-2-yl)-2-hydroxy-2-(3-methoxyphenyl)ethylcarbamate (114 mg, 0.135 mmol) was dissolved in trifluoroacetic acid (10% in dichloromethane, 5 mL) and stirred at room temperature for 2 h. The reaction was concentrated under a stream of nitrogen, dissolved in methanol, and loaded onto a strong cation exchange cartridge. The cartridge was flushed with several volumes of methanol which were discarded. The product was eluted with 2M ammonia in methanol and concentrated. The resulting residue was suspended in tetrahydrofuran (2 mL), cooled to 0° C., and treated with carbonyldiimidazole (43.7 mg, 0.27 mmol) in a single portion. The resulting suspension was stirred at 0° C. for 5 min. The ice bath was removed and stirring continued for 1 h. The reaction was quenched by addition of 2M ammonia in methanol and concentrated. The resulting residue was dissolved in a minimum of ethyl acetate and poured into water. The organics were diluted with several volumes of diethyl ether. The ethereal was washed with water (2×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (25%-->50% EtOAc/Hex) gave 25 mg (53%). 1H-NMR (CDCl3, 500 MHz) δ 7.64 (dd, J=7.9, 7.6, 1H), 7.51 (d, J=7.9, 1H), 7.40 (d, J=7.6, 1H), 7.35 (dd, J=8.2, 8.2, 1H), 7.03 (m, 2H), 6.93 (m, 1H), 6.84 (bs, 1H), 5.60 (d, J=5.5, 1H), 4.91 (d, J=5.8, 1H), 3.85 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 160.2, 159.9, 159.1, 142.6, 139.8, 139.7, 130.2, 128.2, 119.7, 117.8, 114.8, 111.0, 83.4, 64.4, 55.5. Mass spec.: 349.04 (MH)+.
To tert-butyl carbamate (688 mg, 5.88 mmol) in propanol (10 mL) was added sodium hydroxide (231 mg, 5.78 mmol) in water (20 mL) followed by tert-butyl hypochlorite (0.652 mL, 5.78 mmol). The solution was cooled to 0° C. and (DHQD)2PHAL (89 mg, 0.114 mmol) was added in propanol (3 mL) followed by (E)-2-bromo-6-(3-methoxystyryl)pyridine (550 mg, 1.90 mmol) in propanol (10 mL). To this was added potassium osmate dihydrate (27.9 mg, 0.076 mmol) as a solid in one portion. The reaction was allowed to gradually warm to room temperature overnight. The reaction was placed in a cool bath (ca. 15° C.) and quenched by addition of sodiumthiosulfate (1.1 g) in water (8 mL). The reaction was stirred at room temperature for 30 min. The reaction was diluted with 1:1 diethylether/ethyl acetate, washed with water (2×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (20%-->50% EtOAc/Hex) gave 860 mg (107% yield) as a mixture of regioisomers. Mass spec.: 444.98 (MNa)+.
Optically-enriched tert-butyl (1R,2R)-1-(6-bromopyridin-2-yl)-2-hydroxy-2-(3-methoxyphenyl)ethylcarbamate (860 mg, 1.02 mmol) was dissolved in trifluoroacetic acid (15% in dichloromethane, 25 mL) and stirred at room temperature for 1 h. The reaction was concentrated, dissolved in methanol, and loaded onto a strong cation exchange cartridge. The cartridge was flushed with several volumes of methanol which were discarded. The product was eluted with 2M ammonia in methanol and concentrated. The resulting residue was suspended in tetrahydrofuran (20 mL), cooled to 0° C., and treated with carbonyldiimidazole (201 mg, 1.24 mmol) in a single portion. The resulting suspension was stirred at 0° C. for 5 min. The ice bath was removed and stirring continued for 1 h. Upon warming to room temperature, everything went into solution. The reaction was quenched by addition of 2M ammonia in methanol and concentrated. The resulting residue was dissolved in a minimum of ethyl acetate and poured into water. The organics were diluted with several volumes of diethyl ether. The ethereal was washed with water (2×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (25%-->50% EtOAc/Hex) gave 92 mg (26%). 1H-NMR (CDCl3, 500 MHz) δ 7.64 (dd, J=7.9, 7.6, 1H), 7.51 (d, J=7.9, 1H), 7.40 (d, J=7.6, 1H), 7.35 (dd, J=8.2, 8.2, 1H), 7.03 (m, 2H), 6.93 (m, 1H), 6.84 (bs, 1H), 5.60 (d, J=5.5, 1H), 4.91 (d, J=5.8, 1H), 3.85 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 160.2, 159.9, 159.1, 142.6, 139.8, 139.7, 130.2, 128.2, 119.7, 117.8, 114.8, 111.0, 83.4, 64.4, 55.5. Mass spec.: 349.04 (MH)+.
To a solution of diethyl benzylphosphonate (4.57 mL, 21.91 mmol) in dimethylformamide (50 mL) at room temperature was added sodium methoxide (2.367 g, 43.8 mmol) and 18-Crown-6 (2.316 g, 8.76 mmol). After stirring at room temperature for 5 min, the reaction was cooled to 0° C. and treated with 6-bromopicolinaldehyde (4.89 g, 26.3 mmol) as a solid in one portion. The ice bath was removed and the reaction stirred at room temperature for 1 h. The reaction was gradually warmed to 120° C. and held there for 2 h. The reaction was cooled to room temperature and poured into water (500 mL) with vigorous stirring. The resulting suspension was extracted with diethyl ether, washed with water (3×), then brine, dried over magnesium sulfate, and concentrated to an oil. The oil was dissolved in hexanes and reconcentrated to give something that appeared to be crashing out as a solid. The resulting residue (solid in oil) was suspended in ethanol, concentrated, and pumped under high vacuum to give a dark-colored, moist solid. The resulting residue was suspended in ethanol (total volume (solid+solution)=20 ml). The resulting suspension was placed in the freezer and held there overnight. The resulting precipitate was collected by filtration to give 2.46 g (43%) as a faint tan powder. 1H-NMR (CDCl3, 500 MHz) δ 7.69 (d, J=16.2, 1H), 7.60 (d, J=8.9, 2H), 7.53 (dd, J=7.9, 7.6, 1H), 7.41 (dd, J=7.6, 7.3, 2H), 7.31-7.38 (m, 3H), 7.11 (d, J=16.2, 1H). 13C-NMR (CDCl3, 126 MHz) δ 157.2, 142.3, 138.8, 136.3, 134.5, 128.9, 128.8, 127.4, 126.4, 126.2, 120.7.
To tert-butyl carbamate (2.094 g, 17.88 mmol) in propanol (24 mL) was added sodium hydroxide (0.703 g, 17.59 mmol) in water (45 mL) followed by tert-butyl hypochlorite (1.99 mL, 17.59 mmol). The solution was cooled to 0° C. and treated with a solution of (DHQD)2PHAL (0.112 g, 0.144 mmol) and (DHQ)2PHAL (0.112 g, 0.144 mmol) in propanol (21 mL). The reaction was diluted with propanol (30 ml), and treated with (E)-2-bromo-6-styrylpyridine (1.5 g, 5.77 mmol) as a solid in one portion. To this was added potassium osmate dihydrate (0.085 g, 0.231 mmol) as a solid in one portion. The ice bath was removed and stirring continued for 1.5 h at room temperature. The reaction was placed in a cool bath (ca. 15° C.) and quenched by addition of sodiumthiosulfate (2.1 g) in water (12 mL). The reaction was stirred at room temperature for 30 min. The reaction was diluted with 1:1 diethylether/ethyl acetate, washed with water (2×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (20%-->50% EtOAc/Hex) gave 1.1 g (49%) as a mixture of regioisomers. The reaction was azeotroped with toluene and pumped under high vacuum (2 cycles) to aid in the removal of an unknown impurity. The material was used without additional purification. Mass spec.: 393.1 (MH)+.
Prepared according to the same procedure as (±)-tert-Butyl (1R,2R)-1-(6-bromopyridin-2-yl)-2-hydroxy-2-phenylethylcarbamate, starting with 2-bromoisonicotinaldehyde and diethyl-3-methoxybenzylphosphonate. 1H-NMR (CDCl3, 500 MHz) δ 8.42 (d, J=5.2 Hz, 1H), 7.48 (s, 1H), 7.37 (t, J=8.2 Hz, 1H), 7.20 (d, J=5.2 Hz, 1H), 6.98 (m, 1H), 6.86 (s, 1H), 6.71 (s, 1H), 5.18 (d, J=7.3 Hz, 1H), 4.79 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.4, 158.6, 151.1, 150.6, 143.3, 138.0, 130.5, 125.6, 120.3, 118.2, 115.3, 111.6, 85.1, 63.3, 55.5. Mass spec.: 349.0 (MH)+.
Prepared according to the same procedure as (±)-tert-Butyl (1R,2R)-1-(6-bromopyridin-2-yl)-2-hydroxy-2-phenylethylcarbamate, starting with 5-bromonicotinaldehyde and diethylbenzylphosphonate. 1H-NMR (CDCl3, 500 MHz) δ 8.67 (d, J=2.1 Hz, 1H), 8.37 (d, J=1.5 Hz, 1H), 7.91 (t, J=2.1 Hz, 1H), 7.43 (m, 3H), 7.30 (m, 2H), 7.12 (bs, 1H), 5.25 (d, J=7.6 Hz, 1H), 4.84 (d, J=7.6 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ ppm 159.0, 151.6, 146.4, 136.7, 136.4, 136.1, 129.7, 129.3, 126.1, 125.5, 121.6, 85.7, 62.3, 60.5. Mass spec.: 320.95 (MH)+.
(±)-tert-Butyl (1R,2R)-1-(6-bromopyridin-2-yl)-2-hydroxy-2-phenylethylcarbamate (1.1 g, 1.40 mmol) was dissolved in trifluoroacetic acid (25% in dichloromethane, 25 mL) and stirred at room temperature for 1 h. The reaction was concentrated, dissolved in methanol, and loaded onto a strong cation exchange cartridge. The cartridge was flushed with several volumes of methanol which were discarded. The product was eluted with 2M ammonia in methanol and concentrated. The resulting residue was suspended in tetrahydrofuran (25 mL), cooled to 0° C., and treated with carbonyldiimidazole (580 mg, 3.58 mmol) in a single portion. The resulting suspension was stirred at 0° C. for 5 min. The ice bath was removed and stirring continued for 1 h. The reaction was treated with an additional portion of carbonyldiimidazole (90 mg) and stirred at room temperature for 2 h. The reaction was quenched by addition of 2M ammonia in methanol and concentrated. The resulting residue was purified by column chromatography (25%-->50% EtOAc/Hex) to give nearly pure product. The material was further purified by trituration of the solid with diethyl ether. 1H-NMR (CDCl3, 500 MHz) δ 7.65 (dd, J=7.6, 7.6, 1H), 7.52 (d, J=7.6, 1H), 7.37-7.50 (m, 6H), 6.83 (bs, 1H), 5.63 (d, J=5.5, 1H), 4.92 (d, J=5.5, 1H). 13C-NMR (CDCl3, 126 MHz) δ 159.9, 159.2, 142.6, 139.7, 138.2, 129.13, 129.08, 128.2, 125.8, 119.6, 83.6, 64.4. Mass spec.: 319.1 (MH)+.
Prepared according to the same procedure as (±)-(4R,5R)-4-(6-bromopyridin-2-yl)-5-phenyloxazolidin-2-one, starting with 4-bromopicolinaldehyde. 1H-NMR (CDCl3, 500 MHz) δ 8.49 (d, J=5.5, 1H), 7.63 (d, J=1.8, 1H), 7.50 (dd, J=5.2, 1.8, 1H), 7.36-7.48 (m, 5H), 6.77 (bs, 1H), 5.60 (d, J=5.5, 1H), 4.93 (d, J=5.5, 1H). 13C-NMR (CDCl3, 126 MHz) δ 160.2, 159.1, 151.0, 138.3, 134.3, 129.12, 129.09, 127.0, 125.7, 124.3, 83.7, 64.6. Mass spec.: 319.1 (MH)+.
To a solution of diethyl benzylphosphonate (4.57 mL, 21.91 mmol) in dimethylformamide (50 mL) at room temperature was added sodium methoxide (2.367 g, 43.8 mmol) and 18-Crown-6 (2.316 g, 8.76 mmol). After stirring at room temperature for 5 min, the reaction was cooled to 0° C. and treated with 2-bromoisonicotinaldehyde (4.89 g, 26.3 mmol) as a solid in one portion. The ice bath was removed and the reaction stirred at room temperature for 1 h. The reaction was gradually warmed to 120° C. and held there for 2 h. The reaction was cooled to room temperature and poured into water (500 mL) with vigorous stirring. The resulting suspension was extracted with diethyl ether (3×), washed with water, then brine, dried over magnesium sulfate, and concentrated to an oil. The resulting residue was purified by column chromatography (6% EtOAc/Hex-->12% EtOAc/Hex) to give 2.12 g (37%) as an oil. 1H-NMR (CDCl3, 500 MHz) δ 8.35 (d, J=5.2, 1H), 7.52-7.62 (m, 3H), 7.43 (m, 2H), 7.30-7.40 (m, 3H), 6.98 (d, J=16.2, 1H). 13C-NMR (CDCl3, 126 MHz) δ 150.4, 147.7, 143.1, 135.8, 134.8, 129.3, 129.0, 127.3, 125.0, 124.6, 120.1.
To a solution of tert-butyl carbamate (2.96 g, 25.3 mmol) in propanol (30 mL) was added sodium hydroxide (0.994 g, 24.86 mmol) in water (54 mL) followed by tert-butyl hypochlorite (2.81 mL, 24.86 mmol). After 5 min, the solution was cooled to 0° C. and treated with a solution of (DHQD)2PHAL (0.317 g, 0.407 mmol) in propanol (30 mL). To this was added a solution of (E)-2-bromo-4-styrylpyridine (2.12 g, 8.15 mmol) in propanol (51 mL). To this was added potassium osmate dihydrate (0.120 g, 0.326 mmol) as a solid in one portion. The reaction was allowed to gradually warm in the glass dewar overnight. In the morning, the bath was still cool (5° C.). The reaction was quenched by addition of sodiumthiosulfate (2.7 g) in water (30 mL). The cooling bath was removed and the reaction stirred for 30 min. The reaction was poured into water (ca. 400 mL) and extracted with diethyl ether (2×). The combined organics were washed with water (2×), then brine, dried over magnesium sulfate, and concentrated. The resulting residue was concentrated from toluene (3×) to help remove an unknown impurity. The resulting residue was purified by column chromatography (25%-->40% EtOAc/Hex) to give 1.85 g (58%) as a mixture of regioisomers which was used without further purification. Mass spec.: 393.15 (MH)+.
Optically-enriched tert-butyl (1R,2R)-1-(2-bromopyridin-4-yl)-2-hydroxy-2-phenylethylcarbamate (1.85 g, 2.35 mmol) was dissolved in trifluoroacetic acid (25% in dichloromethane, 40 mL) and stirred at room temperature for 1 h. LC/MS shows clean conversion to product. The reaction was concentrated, dissolved in methanol, and loaded onto a strong cation exchange cartridge. The cartridge was flushed with several volumes of methanol which were discarded. The product was eluted with 2M ammonia in methanol and concentrated. The resulting residue was suspended in tetrahydrofuran (50 mL), cooled to 0° C., and treated with carbonyldiimidazole (0.763 g, 4.70 mmol) in a single portion. The resulting suspension was stirred at 0° C. for 5 min. The ice bath was removed and stirring continued for 1 h. The reaction was re-cooled to 0° C., and treated with an additional portion of carbonyldiimidazole (160 mg) and stirred at room temperature for 2 h. The reaction was quenched by addition of 2M ammonia in methanol and concentrated. The resulting residue was purified by column chromatography (25%-->50% EtOAc/Hex) to give the optically-enriched product. The minor enantiomer was removed by SFC Prep HPLC (Chiralpak AS-H, 25% MeOH in CO2) to give 452 mg (30%). 1H-NMR (CDCl3, 500 MHz) δ 8.42 (d, J=5.2, 1H), 7.40-7.56 (m, 4H), 7.33 (m, 2H), 7.19 (dd, J=5.2, 1.2, 1H), 6.95 (bs, 1H), 5.21 (d, J=7.3, 1H), 4.81 (d, J=7.3, 1H). 13C-NMR (CDCl3, 126 MHz) δ 158.9, 151.1, 150.6, 143.3, 136.4, 129.9, 129.4, 126.2, 125.6, 120.3, 85.3, 63.4. Mass spec.: 319.04 (MH)+.
A flask was charged with 1-(bromomethyl)-3-fluorobenzene (7.5 mL, 61.1 mmol) and treated with triethylphosphite (21.39 mL, 122 mmol) dropwise with stirring. Upon completion of the addition, the reaction was fitted with a reflux condensor (no cooling) and a slow stream of nitrogen was passed over the reaction mixture. The reaction was slowly warmed to 150° C. and held there for 2 h. The reaction was cooled to room temperature and concentrated under high vacuum to remove most of the excess triethylphosphite. The resulting residue was purified by column chromatography (50%-->100% EtOAc/Hex) to give 15.13 g (quant.) as a colorless oil. 1H-NMR (CDCl3, 500 MHz) δ 7.29 (m, 1H), 7.10 (m, 1H), 7.05 (m, 1H), 6.97 (m, 1H), 4.06 (m, 4H), 3.16 (d, J=21.7, 2H), 1.28 (t, J=7.0, 6H). 13C-NMR (CDCl3, 126 MHz) δ 162.85 (dd, J=246, 3.8), 134.2 (t, J=8.6), 130.0 (dd, J=7.7, 2.9), 125.6 (dd, J=6.7, 2.9), 116.9 (dd, J=22, 6.7, 114.0 (dd, J=21, 2.9), 62.3 (d, J=6.7), 33.7 (dd, J=138, 1.9, 16.5 (d, J=5.8).
Prepared according to the same procedure as (4R,5R)-4-(2-bromopyridin-4-yl)-5-phenyloxazolidin-2-one, starting with diethyl 3-fluorobenzylphosphonate and 5-bromonicotinaldehyde. 1H-NMR (CDCl3, 500 MHz) δ 8.72 (d, J=2.1, 1H), 8.41 (d, J=1.8, 1H), 7.94 (dd, J=2.1, 1.8, 1H), 7.42 (ddd, J=7.9, 7.9, 5.8, 1H), 7.14 (ddd, J=8.6, 8.6, 2.4, 1H), 7.01-7.10 (m, 2H), 6.78 (bs, 1H), 5.27 (d, J=7.3, 1H), 4.81 (d, J=7.3, 1H). 13C-NMR (CDCl3, 126 MHz) δ 163.2 (d, J=249), 158.5, 152.0, 146.4, 138.5 (d, J=6.7), 136.7, 135.7, 131.1 (d, J=8.6), 121.6 (d, J=17), 116.8 (d, J=21), 113.0 (d, J=22), 84.8, 62.2. Mass spec.: 337.06 (MH)+.
To a solution of diethyl 3-methoxybenzylphosphonate (5 g, 19.36 mmol) in dimethylformamide (50 mL) at room temperature was added sodium methoxide (2.092 g, 38.7 mmol) and 18-Crown-6 (2.047 g, 7.74 mmol). After stirring at room temperature for 5 min, the reaction was cooled to 0° C. and treated with 5-bromonicotinaldehyde (4.32 g, 23.23 mmol) as a solid in one portion. The ice bath was removed and the reaction stirred at room temperature for 2 h. The reaction was poured into water (500 mL) with vigorous stirring. The resulting suspension was extracted with diethyl ether, washed with water (3×), then brine, dried over magnesium sulfate, and concentrated to an oil which crystallized upon standing. The solid was triturated with a minimum of ethanol (ca. 12 mL) and placed in the freezer for 72 h. The resulting solid was broken up with a spatula, collected by filtration, and rinsed with a minimum of cold ethanol to give 3.79 g (68%) as a white crystalline solid. 1H-NMR (CDCl3, 500 MHz) δ 8.64 (d, J=1.8, 1H), 8.57 (d, J=2.1, 1H), 8.00 (dd, J=2.1, 1.8, 1H), 7.33 (dd, J=7.9, 7.9, 1H), 7.10-7.20 (m, 2H), 7.07 (m, 1H), 7.01 (d, J=16.5, 1H), 6.91 (dd, J=7.6, 2.1, 1H), 3.88 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 160.1, 149.5, 146.7, 137.7, 135.1, 134.8, 132.4, 130.0, 123.7, 121.1, 119.6, 114.4, 112.2, 55.4. Mass spec.: 290.14 (MH)+.
To a solution of tert-butyl carbamate (4.63 g, 39.5 mmol) in propanol (45 mL) was added sodium hydroxide (1.556 g, 38.9 mmol) in water (81 mL) followed by tert-butyl hypochlorite (4.39 mL, 38.9 mmol). After 5 min, the solution was cooled to 0° C. and treated with a solution of (DHQD)2PHAL (0.497 g, 0.638 mmol) in propanol (45 mL). To this was added a solution of (E)-3-bromo-5-(3-methoxystyryl)pyridine (3.7 g, 12.75 mmol) in propanol (76 mL). To this was added potassium osmate dihydrate (0.188 g, 0.510 mmol) as a solid in one portion. The reaction was allowed to gradually warm in the glass dewar over 36 h. The reaction was quenched by addition of sodiumthiosulfate (4.2 g) in water (45 mL). After stirring for 30 min, the reaction was poured into water (ca. 600 mL) and extracted with diethyl ether (2×). The combined organics were washed with water (2×), then brine, dried over magnesium sulfate, and concentrated. The resulting residue was concentrated from toluene (3×) to help remove an unknown impurity. The resulting residue was purified by column chromatography (25%-->40% EtOAc/Hex) to give 3.76 g (70%) as a mixture of regioisomers which was used without further purification. Mass spec.: 423.15 (MH)+.
Optically-enriched tert-butyl (1R,2R)-1-(5-bromopyridin-3-yl)-2-hydroxy-2-(3-methoxyphenyl)ethylcarbamate (3.76 g, 4.44 mmol) was dissolved in trifluoroacetic acid (25% in dichloromethane, 40 mL) and stirred at room temperature for 1 h. The reaction was concentrated, dissolved in methanol, and loaded onto a strong cation exchange cartridge. The cartridge was flushed with several volumes of methanol which were discarded. The product was eluted with 2M ammonia in methanol and concentrated. The resulting residue was suspended in tetrahydrofuran (40 mL), cooled to 0° C., and treated with carbonyldiimidazole (1.46 g, 9.00 mmol) in a single portion. The resulting suspension was stirred at 0° C. for 5 min. The ice bath was removed and stirring continued for 1 h. The reaction was re-cooled to 0° C., and treated with an additional portion of carbonyldiimidazole (500 mg) and stirred at room temperature for 1 h. The reaction was quenched by addition of 2M ammonia in methanol and concentrated. The resulting residue was purified by column chromatography (25%-->50% EtOAc/Hex) to give 660 mg (21%). 1H-NMR (CDCl3, 500 MHz) δ 8.69 (d, J=2.1, 1H), 8.39 (d, J=2.1, 1H), 7.92 (dd, J=2.1, 1.8, 1H), 7.34 (dd, J=7.9, 7.9, 1H), 6.95 (dd, J=8.6, 1.8, 1H), 6.77-6.91 (m, 3H), 5.22 (d, J=7.6, 1H), 4.82 (d, J=7.6, 1H), 3.82 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 160.3, 158.9, 151.7, 146.4, 137.8, 136.7, 136.0, 130.5, 121.6, 118.1, 115.2, 111.4, 85.6, 62.2, 55.5. Mass spec.: 349.12 (MH)+.
A flask was charged with 2-bromopyridine (1.21 mL, 12.66 mmol) and triethylamine (40 mL) and sparged with nitrogen for 15 min. To this was added ethynyltrimethylsilane (1.97 mL, 13.92 mmol) and the reaction was purged 15 min longer. To this was added copper(I) iodide (0.121 g, 0.633 mmol), and Pd(PPh3)2Cl2 (0.444 g, 0.633 mmol). Reaction stirred at room temperature for 72 h. The reaction was diluted with ethyl acetate (60 mL) and poured into water. The black heterogeneous emulsion was filtered through a plug of celite and the layers separated. The organics were washed with brine, dried over magnesium sulfate, and concentrated. Column chromatography (5%-->15% EtOAc/Hex) gave 1.73 g (78%) as a dark oil. 1H-NMR (CDCl3, 500 MHz) δ 8.58 (m, 1H), 7.66 (ddd, J=7.9, 7.9, 1.8, 1H), 7.47 (m, 1H), 7.24 (ddd, J=7.6, 4.9, 1.2, 1H), 0.29 (s, 9H). 13C-NMR (CDCl3, 126 MHz) δ 150.1, 143.2, 136.1, 127.4, 123.1, 103.8, 94.9, −0.2. Mass spec.: 176.14 (MH)+.
A flask was charged with 3-bromopyridine (1.22 mL, 12.66 mmol) and triethylamine (40 mL) and sparged with nitrogen for 15 min. To this was added ethynyltrimethylsilane (1.97 mL, 13.92 mmol) and the reaction purged 15 min longer. To this was added copper(I) iodide (0.121 g, 0.633 mmol), and Pd(PPh3)2Cl2 (0.444 g, 0.633 mmol). The reaction was stirred at room temperature for 72 h. The reaction was diluted with ethyl acetate (60 mL) and poured into water. The black heterogeneous emulsion was filtered through a plug of celite and the layers separated. The organics were washed with brine, dried over magnesium sulfate, and concentrated. Column chromatography (5%-->15% EtOAc/Hex) gave 1.70 g (77%) as a dark oil. 1H-NMR (CDCl3, 500 MHz) δ 8.71 (m, 1H), 8.55 (dd, J=4.9, 1.5, 1H), 7.76 (ddd, J=7.9, 1.8, 1.8, 1H), 7.26 (ddd, J=7.9, 4.9, 0.6, 1H), 0.29 (s, 9H). 13C-NMR (CDCl3, 126 MHz) δ 152.8, 148.8, 138.9, 123.0, 120.4, 101.6, 98.3, −0.1. Mass spec.: 176.14 (MH)+.
A flask was charged with 4-bromopyridine.HCl (2.46 g, 12.65 mmol) and triethylamine (40 mL) and sparged with nitrogen for 15 min. To this was added ethynyltrimethylsilane (1.967 mL, 13.92 mmol) and purged 15 min longer. To this was added copper(I) iodide (0.120 g, 0.633 mmol), and Pd(PPh3)2Cl2 (0.444 g, 0.633 mmol). The reaction was stirred at room temperature for 72 h. The reaction was warmed to 50° C. and held at that temperature for 24 h. The reaction was diluted with ethyl acetate (60 mL) and poured into water. The black heterogeneous emulsion was filtered through a plug of celite and the layers separated. The organics were washed with brine, dried over magnesium sulfate, and concentrated. Column chromatography (5%-->25% EtOAc/Hex) gave 667 mg (30%) as a dark oil. 1H-NMR (CDCl3, 500 MHz) δ 8.58 (d, J=6.1, 2H), 7.33 (d, J=6.1, 2H), 0.29 (s, 9H). 13C-NMR (CDCl3, 126 MHz) δ 149.8, 131.3, 125.9, 102.1, 100.1, −0.2. Mass spec.: 176.14 (MH)+.
3-Bromo-5-fluoropyridine (2 g, 11.36 mmol) in triethylamine (35 mL) was purged with nitrogen for 15 minutes. Ethynyltrimethylsilane (1.77 mL, 12.50 mmol) was added and the reaction mixture purged with nitrogen for another 15 minutes. To this was added copper(I) iodide (0.108 g, 0.568 mmol) and Pd(PPh3)2Cl2 (0.399 g, 0.568 mmol). The reaction was stirred at room temperature over the weekend. The reaction was diluted with ethyl acetate and poured into water. The black heterogeneous emulsion was filtered through a plug of celite and the layers separated. The organics were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. Biotage purification eluting with 5% ethyl acetate/hexane gave 1.5 g (68%) as a yellow oil. 1H-NMR (CDCl3, 500 MHz) δ 8.59 (bs, 2H), 7.47 (d, J=8.6 Hz, 1H), 0.28 (s, 9H); 13C NMR (126 MHz, CDCl3) δ ppm 148.5, 137.5, 137.3, 125.4, 125.3, 100.1, 99.9, 0.20. Mass spec.: 194.0 (MH)+.
A flask was charged with 4-bromo-2-methylthiazole (400 mg, 2.247 mmol) and triethylamine (8 mL) and sparged with nitrogen for 15 min. To this was added ethynyltrimethylsilane (0.381 mL, 2.70 mmol) and purged 15 min longer. To this was added copper(I) iodide (21.39 mg, 0.112 mmol), and Pd(PPh3)2Cl2 (79 mg, 0.112 mmol). The reaction stirred at room temperature for 72 h. The reaction was diluted with ethyl acetate (16 mL) and poured into water. The black heterogeneous emulsion was filtered through a plug of celite and the layers separated. The organics were washed with brine, dried over magnesium sulfate, and concentrated. Column chromatography (5%-->6% EtOAc/Hex) gave 307 mg (70%) as a light amber oil. 1H-NMR (CDCl3, 500 MHz) δ 7.34 (s, 1H), 2.72 (s, 3H), 0.27 (s, 9H). 13C-NMR (CDCl3, 126 MHz) δ 165.6, 137.0, 123.0, 98.4, 94.6, 19.3, −0.1.
To a solution of diisopropylamine (8.98 mL, 63 mmol) in tetrahedrofuran (22.5 mL) in 1 L flask at −78° C. was added n-butyllithium (25.2 mL, 2.5M in hexane, 63.0 mmol) dropwise. The reaction was allowed to gradually warm in the bath to −30° C., and held there for 5 minutes. It was re-cooled to −78° C. and treated with solid 2-(5-bromopyridin-3-yl)acetic acid (6.80 g, 31.5 mmol) and tetahydrofuran (78 mL). The ice bath was removed and stirring continued for 1.5 h. The reaction was again cooled to 0° C., and treated with a solution of 4-fluorobenzaldehyde (3.38 mL, 31.5 mmol) in tetrahydrofuran (22.5 mL). The reaction was allowed to gradually warm to room temperature overnight. The reaction solution, after removal of the solid by filtration, was acidified with citric acid to pH ca. 4. It was extracted with diethyl ether and concentrated. The resulting residue was dried three times with toluene and the crude product (ca. 10.1 g) was used in the next reaction without further purification. Mass spec.: 340.9 (MH)+.
(±)-(2R,3S)-2-(5-Bromopyridin-3-yl)-3-(4-fluorophenyl)-3-hydroxypropanoic acid (10.10 g, 29.7 mmol) in toluene (120 mL) was treated with TEA (4.14 mL, 29.7 mmol), stirred briefly, and then treated with diphenyl phosphorazidate (8.17 g, 29.7 mmol) slowly. The reaction was heated under nitrogen at 60° C. overnight. The reaction was quenched by addition of saturated ammonia in water. After stirring 10 minutes, the reaction was diluted with diethyl ether. The organics were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. Biotage purification eluting with 50% ethyl acetate/hexane gave 320 mg (3%) as light yellow foam solid. 1H-NMR (CDCl3, 400 MHz) δ 8.75 (d, J=2.0 Hz, 1H), 8.40 (d, J=1.8 Hz, 1H), 7.93 (t, J=2.0 Hz, 1H), 7.32 (m, 2H), 7.16 (t, J=8.5 Hz, 2H), 5.91 (bs, 1H), 5.27 (d, J=7.8 Hz, 1H), 4.80 (d, J=8.3 Hz, 1H); 13C NMR (100.6 MHz, CDCl3) δ ppm 164.2, 161.7, 158.1, 151.4, 145.9, 136.2, 135.2, 131.6, 131.5, 127.7, 127.6, 121.2, 116.1, 115.9, 84.7, 61.9. Mass spec.: 338.8 (MH)+.
To tert-butyl carbamate (1396 mg, 11.91 mmol) in propanol (25 mL) was added sodium hydroxide (469 mg, 11.72 mmol) in water (40 mL) followed by tert-butyl hypochlorite (1.323 mL, 11.72 mmol). The solution was cooled to 0° C., (DHQ)2PHAL (180 mg, 0.231 mmol) was added in propanol (25 mL) followed by 1-(phenylethynyl)-3-vinylbenzene (785 mg, 3.84 mmol; Tsuda, Katsuyuki; Tsutsumi, Kenichi; Yaegashi, Manabu; Miyajima, Masahiro; Ishizone, Takashi; Hirao, Akira; Ishii, Fumiaki; Kakuchi, Toyoji. Polymer Bulletin (Berlin) (1998), 40(6), 651) in propanol (20 mL) and potassium osmate dihydrate (56.6 mg, 0.154 mmol). After 1 h, TLC (25% EtOAc/Hex; UV) of the yellow solution showed consumption of starting material with two new spots evident at Rf 0.15 (major) and Rf 0.30 (minor). Quenched with 50 mL saturated sodium sulfite. Extracted with 2×100 mL ethyl acetate, washed combined organics with 30 mL brine, dried over MgSO4, filtered and concentrated. The orange residue was dissolved in dichloromethane, applied to a 40 g silica gel cartridge prepacked with 5% ethyl acetate/hexanes and eluted with 5 to 30% ethyl acetate/hexanes over 800 mL resulting in partial separation of regioisomers. Repooled mixed fractions, concentrated and rechromatographed to give the title compound (664 mg, 51%). 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 7.53-7.60 (2H, m), 7.51 (1H, s), 7.48 (1H, d, J=7.63 Hz), 7.33-7.42 (4H, m), 7.30 (1H, d, J=8.85 Hz), 5.39 (1H, br. s.), 4.80 (1H, br. s.), 3.86 (2H, br. s.), 2.63 (1H, br. s.), 1.47 (9H, br. s.).
(±)-tert-Butyl 2-hydroxy-1-(3-(phenylethynyl)phenyl)ethylcarbamate was prepared identically to the procedure describing the preparation of (S)-tert-butyl 2-hydroxy-1-(3-(phenylethynyl)phenyl)ethylcarbamate except that an equimolar mixture of (DHQ)2PHAL and (DHQD)2PHAL was used.
To diethyl 3-bromobenzylphosphonate (Kennedy, G. Perboni, A. D. Tetrahedron Lett. 1996, 37, 7611-7614; 1.91 g, 6.22 mmol) in dimethylformamide (20 mL) was added sodium methanolate (0.672 g, 12.44 mmol) followed by 18-crown-6 (0.658 g, 2.488 mmol) and nicotinaldehyde (0.666 g, 6.22 mmol). The reaction mixture was heated to 120° C. for 2 h at which time the heating bath was turned off and the reaction mixture was allowed to reach ambient temperature over 18 h. The mixture was poured into water and extracted with 3×75 mL ethyl acetate. The combined organics were washed with brine, dried over MgSO4, filtered and concentrated in vacuo to 1.7 g amber liquid which was loaded onto a 90 g silica gel cartridge and eluted with 5 to 60% ethyl acetate/hexanes over 1300 mL. The major spot (Rf=0.45; 50% ethyl acetate/hexanes; UV) was collected and concentrated to 939 mg as a colorless oil. 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 8.72 (1H, d, J=1.83 Hz), 8.50 (1H, dd, J=4.73, 1.68 Hz), 7.81 (1H, dt, J=8.01, 1.95 Hz), 7.67 (1H, t, J=1.68 Hz), 7.37-7.46 (2H, m), 7.29 (1H, dd, J=7.93, 4.88 Hz), 7.20-7.25 (1H, m), 7.07 (2H, s).
To tert-butyl carbamate (1256 mg, 10.73 mmol) in propanol (25 mL) was added sodium hydroxide (422 mg, 10.55 mmol) in water (30 mL) followed by tert-butyl hypochlorite (1.191 mL, 10.55 mmol). The solution was cooled to 0° C. and (DHQD)2PHAL (67.4 mg, 0.086 mmol) and (DHQ)2PHAL (67.4 mg, 0.086 mmol) were added in propanol (20 mL) followed by (E)-3-(3-bromostyryl)pyridine (900 mg, 3.46 mmol) in propanol (25 mL) and finally potassium osmate dihydrate (51.0 mg, 0.138 mmol) in one portion. The mixture was allowed to stir overnight and come to ambient temperature in the process. The mixture was quenched with sodium sulfite (50 mL) and the mixture was extracted with 3×50 mL ethyl acetate and the combined organics were washed with sodium sulfite (25 mL) and brine (25 mL), dried over MgSO4, filtered and concentrated to an amber oil which was loaded with dichloromethane onto a 90 g silica gel cartridge pre-equilibrated with 5% ethyl acetate/hexanes. Elution with 5 to 100% ethyl acetate over 2.5 L provided 965 mg (71%) as a mixture of regioisomers. LC/MS (analytical HPLC method 1; 1.63 min): Anal. Calcd. for [M+H]+ C18H21BrN2O3: 393.07. found 392.97.
To a mixture of (±)-tert-butyl (1R,2R)-1-(3-bromophenyl)-2-hydroxy-2-(pyridin-3-yl)ethylcarbamate (1.1 g, 2.80 mmol), was added 50 mL 4N HCl/Dioxane. The reaction mixture was allowed to stir at ambient temperature overnight and which time the white slurry was concentrated in vacuo and placed on high vac for 18 h. The resulting colorless solid was dissolved in tetrahydrofuran (25 mL) and Hunig's Base (0.586 mL, 3.36 mmol). To this solution was added carbonyldiimidazole (0.544 g, 3.36 mmol) and after 1 h, the reaction mixture was concentrated in vacuo and loaded with dichloromethane onto a 90 g silica gel cartridge prepacked with 25% ethyl acetate/hexanes. Elution was performed with 25 to 100% ethyl acetate/hexanes over 1200 mL then 100% ethyl acetate for 500 mL. Fractions containing the top spot (Rf=0.45 in 75% ethyl acetate/hexanes; UV) were pooled and concentrated to give 266 mg of trans-4-(3-bromophenyl)-5-(pyridin-3-yl)oxazolidin-2-one as a colorless solid. Anal. Calcd. for [M+H]+ C14H11BrN2O2: 319.00. found 318.85. 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 8.66 (1H, dd, J=4.88, 1.53 Hz), 8.49 (1H, d, J=2.14 Hz), 7.72 (1H, dt, J=7.93, 1.98 Hz), 7.48-7.57 (2H, m), 7.40 (1H, dd, J=7.78, 4.73 Hz), 7.27-7.33 (1H, m), 7.22 (1H, d, J=7.63 Hz), 6.87 (1H, s), 5.30 (1H, d, J=7.63 Hz), 4.77 (1H, d, J=7.32 Hz). 13C NMR (126 MHz, CHLOROFORM-d) δ ppm 158.53, 150.80, 147.61, 140.18, 133.76, 132.84, 132.57, 131.09, 129.48, 125.23, 124.07, 123.64, 83.74, 64.20.
A solution of (4R,5R)-4-(3-bromophenyl)-5-(3-methoxyphenyl)oxazolidin-2-one (4.3 g, 12.35 mmol) in triethylamine (12 mL) was purged with nitrogen for one h. The reaction was treated with triphenylphosphine (91 mg, 0.346 mmol), ethynyltrimethylsilane (1.83 mL, 12.97 mmol), and purged 10 minutes longer. To this was added dichlorobis(triphenylphosphine)palladium(II) (20 mg, 0.028 mmol) and copper(I) iodide (4.48 mg, 0.0235 mmol). After purging 10 min longer, the reaction was heated at 95° C. overnight. The reaction was cooled to room temperature, diluted with diethyl ether, filtered to remove the solid, and concentrated. The resulting residue was dissolved in diethyl ether, washed with water, then brine, dried over anhydrous magnesium sulfate, and concentrated. Biotage purification eluting with 35% ethyl acetate/hexane gave 2.25 g (50%) as a white foam solid. 1H-NMR (CDCl3, 500 MHz) δ 7.49 (m, 2H), 7.38-7.31 (m, 2H), 7.25 (d, J=7.9 Hz, 1H), 6.93 (dd, J=8.4, 2.1 Hz, 1H), 6.85 (m, 2H), 6.19 (s, 1H), 5.25 (d, J=7.3 Hz, 1H), 4.73 (d, J=7.3 Hz, 1H), 3.82 (s, 3H), 0.28 (s, 9H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 158.8, 138.8, 132.6, 130.2, 129.2, 126.7, 124.4, 118.1, 115.0, 111.1, 104.2, 95.5, 85.9, 64.6, 55.5, 00.1. Mass spec.: 366.13 (MH)+.
To a solution of potassium hydroxide (0.691 g, 12.31 mmol) in 14.5 mL of methanol was added solution of (4R,5R)-5-(3-methoxyphenyl-4-(3-(trimethylsilyl)ethynyl)phenyl)oxazolidin-2-one (2.25 g, 6.16 mmol) in 1.5 mL of methanol, the resulting solution was stirred at room temperature for 1.5 h. The reaction was diluted with water. The reaction was extracted with diethyl ether (3×), washed with brine, dried over anhydrous magnesium sulfate, and concentrated. Biotage purification, eluting with 40% ethyl acetate/hexane, gave 1.68 g (87%) as a white solid. 1H-NMR (CDCl3, 400 MHz) δ 7.54 (m, 1H), 7.50 (s, 1H), 7.40 (t, J=7.5 Hz, 1H), 7.33 (m, 2H), 6.95 (m, 1H), 6.86 (m, 2H), 5.55 (s, 1H), 5.27 (d, J=7.3 Hz, 1H), 4.74 (d, J=7.3 Hz, 1H), 3.83 (s, 3H), 3.14 (s, 1H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 158.7, 139.0, 138.8, 132.8, 130.22, 130.18, 129.4, 127.0, 123.4, 118.1, 115.0, 111.2, 85.9, 82.9, 78.4, 64.6, 55.5. Mass spec.: 366.13 (MH)+.
Prepared according to the same procedure as optically-enriched (4R,5R)-4-(5-bromopyridin-3-yl)-5-(3-methoxyphenyl)oxazolidin-2-one, starting with 6-bromopicolinaldehyde and diethyl 4-fluorobenzylphosphonate. 1H-NMR (CDCl3, 500 MHz) δ 7.65 (dd, J=7.9, 7.6, 1H), 7.51 (d, J=7.6, 1H), 7.46 (dd, J=8.9, 5.2, 2H), 7.41 (d, J=7.6, 1H), 7.13 (m, 3H), 5.61 (d, J=7.5, 1H), 4.90 (d, J=5.8, 1H). 13C-NMR (CDCl3, 126 MHz) δ 163.1 (d, J=249), 159.4 (d, J=55), 142.6, 139.8, 134.0, 128.3, 127.8, 127.7, 119.6, 116.2, 116.0, 83.1, 64.4.
2-(5-bromopyridin-3-yl)acetic acid (5.00 g, 23.14 mmol) in methanol (55 mL) at 0° C. was added thionyl chloride (2.196 mL, 30.1 mmol) slowly, pyridine (2.434 mL, 30.1 mmol) was added slowly after and the reaction was stirred at room temperature overnight. Solvent was removed in vacuo and the residue was diluted with water and extracted with ethyl acetate, the organics was washed with brine, dried over magnesium sulfate, filtered and concentrated. Biotage purification (35% EtOAc/Hex) gave title compound (4.73 g, 20.6 mmol, 89% yield). 1H-NMR (CDCl3, 500 MHz) δ 8.63 (d, J=2.14 Hz, 1H), 8.47 (d, J=1.83 Hz, 1H), 7.84 (dd, J=2.14, 1.83 Hz, 1H), 3.76 (s, 3H), 3.65 (s, 2H). Mass spec.: 230.9 (MH)+.
To a solution of diidopropylamine (3.52 mL, 24.72 mmol) in tetrahydrofuran (3.5 mL) at −78° C. was added n-butyl lithium (2.5 M in hexane, 8.24 mL, 20.60 mmol) drop wise, it was allowed to gradually warm in the bath to −30° C., held at this temperature for 5 min, and re-cooled to −78° C. The reaction was then treated with methyl 2-(5-bromopyridin-3-yl)acetate (4.74 g, 20.60 mmol) in tetrahydrofuran (60 mL) slowly. The ice bath was removed and stirring continued for 1.5 hours. The reaction was cooled to 0° C., and treated with iodomethane (2.057 mL, 33.0 mmol), and it was allowed to gradually warm to room temperature overnight. The reaction was poured onto ice water and extracted with ethyl acetate. The organics were washed with brine, dried over magnesium sulfate, and concentrated. Biotage purification (30% EtOAc/Hex) gave title compound (3.4 g, 13.9 mmol, 67.6% yield). Mass spec.: 244.9 (MH)+.
Methyl 2-(5-bromopyridin-3-yl)propanote (3.33 g, 13.62 mmol) in Methanol (60 mL) at 0° C. was added lithium hydroxide (22.70 mL, 68.1 mmol), it was stirred at room temperature for an hour. Methanol was removed and water was added, the aqueous was acidified to pH˜6/7 with 1N hydrochloric acid, the solid was filtered out and dried to give 2.1 g of product. The aqueous was further extracted with ethyl acetate, the organics was washed with brine, dried over magnesium sulfate, filtered and concentrated to give another 1.03 g of product (total 3.13 g, 12.83 mmol, 94% yield). Mass spec.: 230.9 (MH)+.
To a solution of diisopropylamine (1.028 mL, 7.22 mmol) in tetrahydrofuran (2.6 mL) at −78° C. was added n-butyl lithium (2.5 M in hexane, 2.89 mL, 7.22 mmol) drop wise. The reaction was allowed to gradually warm in the bath to −30° C., it was held at this temperature for 5 minutes, and re-cooled to −78° C. It was treated with 2-(5-bromopyridin-3-yl)propanoic acid (0.830 g, 3.61 mmol) in tetrahydrofuran (10 mL) over 10 minutes. The ice bath was removed and stirring continued for 1.5 hours. It was then cooled to 0° C., and treated with a solution of benzaldehyde (0.367 mL, 3.61 mmol) in tetrahydrofuran (2.6 mL), and allowed to gradually warm to room temperature overnight. The reaction was poured onto ice water, acidified by addition of 1N hydrochloric acid till PH˜5/6, extracted with ether. The ethereal was washed with brine, dried over magnesium sulfate, and concentrated to give mixture of title compounds (0.82 g, 2.44 mmol, 67.6% yield) as yellow viscous foam. Mass spec.: 336.9 (MH)+.
(±)-(2R,3R)-2-(5-Bromopyridin-3-yl)-3-(tert-butyldimethylsdyloxy)-2-methyl-3-phenylpropanoate, and (±)-(2R,3S)-2-(5-bromopyridin-3-yl)-3-(tert-butyldimethylsdyloxy)-2-methyl-3-phenylpropanoate
(±)-(2R,3R)-2-(5-bromopyridin-3-yl)-3-hydroxy-2-methyl-3-phenylpropanoic acid, and (±)-(2R,3S)-2-(5-bromopyridin-3-yl)-3-hydroxy-2-methyl-3-phenylpropanoic acid (0.820 g, 2.439 mmol) in dichloromethane (3.5 mL) was added 2,6-lutidine (0.597 mL, 5.12 mmol), it was cooled to 0° C., tert-butyldimethylsilyl trifluoromethanesulfonate (1.120 mL, 4.88 mmol) was added slowly, and stirred at room temperature for 2 hours. The reaction was diluted with ether and washed with water, the organics were washed with brine, dried over magnesium sulfate, filtered and concentrated. It was again dissolved in methanol (17.5 mL), potassium carbonate (6.10 mL, 12.20 mmol) was added and stirred at room temperature for an hour, methanol was removed, acidified with 1N hydrochloric acid and extracted with ethyl acetate. The organics was washed with brine, dried over magnesium sulfate, filtered and concentrated to give mixture of title compounds (0.945 g, 2.1 mmol, 86% yield). Mass spec.: 451.2 (MH)+.
(±)-(2R,3R)-2-(5-bromopyridin-3-yl)-3-(tert-butyldimethylsilyloxy)-2-methyl-3-phenylpropanoate, and (±)-(2R,3S)-2-(5-bromopyridin-3-yl)-3-(tert-butyldimethylsilyloxy)-2-methyl-3-phenylpropanoate (945 mg, 2.098 mmol) in toluene (10.5 mL, 99 mmol) was treated with phenylmethanol (0.217 mL, 2.098 mmol), triethylamine (0.585 mL, 4.20 mmol), stirred briefly, and treated with diphenyl phosphorazidate (0.454 mL, 2.098 mmol) slowly. The reaction was heated under nitrogen at 60° C. overnight. Reaction was quenched by water and concentrated. Biotage purification (20% EtOAc/Hex) gave mixture of title compounds (0.44 g, 0.79 mmol, 37.7% yield) as clear oil. Mass spec.: 556.9 (MH)+.
(±)-benzyl (2R,3R)-2-(5-bromopyridin-3-yl)-1-(tert-butyldimethylsilyloxy)-1-phenylpropan-2-ylcarbamate and (±)-benzyl (2R,3S)-2-(5-bromopyridin-3-yl)-1-(tert-butyldimethylsilyloxy)-1-phenylpropan-2-ylcarbamate (440 mg, 0.792 mmol) in tetrahydrofuran (12 mL) was added tetra-butyl ammonium fluoride (1.584 mL, 1.584 mmol), it was stirred at 60° C. overnight. Water was added to the reaction and it was extracted with ethyl acetate, the organics was washed with brine, dried over magnesium sulfate, filtered and concentrated. Biotage purification (50% EtOAc/Hex) gave (±)-(4R,5R)-4-(5-bromopyridin-3-yl)-4-methyl-5-phenyloxazolidin-2-one (150 mg, 0.450 mmol, 56.8% yield), and (±)-(4R,5S)-4-(5-bromopyridin-3-yl)-4-methyl-5-phenyloxazolidin-2-one (22 mg, 0.066 mmol, 8.34% yield). (±)-(4R,5R)-4-(5-bromopyridin-3-yl)-4-methyl-5-phenyloxazolidin-2-one: 1H-NMR (CDCl3, 500 MHz) δ 8.69 (d, J=2.14 Hz, 1H), 8.57 (d, J=1.83 Hz, 1H), 8.02 (m, 1H), 7.42 (m, 3H), 7.19-7.21 (m, 3H), 5.42 (s, 1H), 1.32 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 158.8, 150.7, 145.7, 140.7, 136.4, 133.0, 129.5, 128.9, 126.3, 121.3, 88.0, 63.3, 23.0. (±)-(4R,5S)-4-(5-bromopyridin-3-yl)-4-methyl-5-phenyloxazolidin-2-one: 1H-NMR (CDCl3, 500 MHz) δ 8.41 (d, J=2.14 Hz, 1H), 8.11 (d, J=2.14 Hz, 1H), 7.43 (m, 1H), 7.21 (m, 3H), 6.96 (m, 3H), 5.56 (s, 1H), 1.96 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 158.7, 150.7, 149.8, 145.7, 137.8, 136.5, 133.7, 129.3, 128.6, 126.2, 120.4, 88.8, 63.7, 27.0. Mass spec.: 333.0 (MH)+.
To a solution of diethyl 1-phenylethylphosphonate (4.62 mL, 20.64 mmol) in N,N-dimethylformamide (47 mL, 607 mmol) at room temperature was added sodium methoxide (2.347 g, 41.3 mmol) and 18-Crown-6 (2.182 g, 8.26 mmol). After stirring at room temperature for 5 minutes, the reaction was cooled to 0° C. and treated with a solution of 5-bromonicotinaldehyde (4.61 g, 24.77 mmol) in N,N-dimethylformamide (18.6 mL) drop wise. When addition was complete, the ice bath was removed and the reaction stirred at room temperature for 1 hour, it was then heated at 120° C. for 2 hours, and slowly cooled down to room temperature overnight. The resulting suspension was poured into water with vigorous stirring, it was then extracted with ether, washed with brine, dried over magnesium sulfate, and concentrated. Biotage purification (7% EtOAc/Hex) gave mixture of title compounds (4 g, 5.25 mmol, 25.5% yield, 3:1 mixture of Z/E product). 1H-NMR (CDCl3, 40 MHz) δ 8.59 (d, J=2.26 Hz, 1H), 8.55 (d, J=1.76 Hz, 1H), 8.39 (d, J=2.26 Hz, 0.2H), 8.13 (d, J=1.76 Hz, 0.2H), 7.84 (m, 1H), 7.40-7.30 (m, 3H), 7.24-7.20 (m, 1H), 7.07 (m, 0.22H), 7.05 (m, 0.48H), 7.03 (m, 0.22H), 6.94-6.92 (m, 0.22H), 6.90-6.88 (m, 0.22), 6.74 (s, 1H), 6.41 (s, 1H), 2.29 (d, J=1.25 Hz, 3H), 2.26 (d, J=1.51 Hz, 0.67H). Mass spec.: 274.3 (MH)+.
To a solution of tert-butyl carbamate (1.907 g, 16.28 mmol) in propanol (4.6 mL) was added sodium hydroxide (0.641 g, 16.02 mmol) in water (8 mL) followed by tert-butyl hypochlorite (1.808 ml, 16.02 mmol). After 5 minutes, the solution was cooled to 0° C. and treated with a solution of (DHQD)2PHAL (0.245 g, 0.315 mmol) in propanol (4.6 mL). To this was added a solution of (Z)-3-bromo-5-(2-phenylprop-1-enyl)pyridine and (E)-3-bromo-5-(2-phenylprop-1-enyl)pyridine (1.440 g, 5.25 mmol) in propanol (7.8 mL), and potassium osmate dihydrate (0.077 g, 0.210 mmol) as a solid in one portion. The ice bath was removed and stirring continued overnight. The reaction was quenched by addition of a solution of sodium thiosulfate (1.84 g) in water (23 mL). After 30 minutes, the reaction was diluted with ether, washed with water, then brine, dried over MgSO4, and concentrated. Biotage purification (20%-50% EtOAc/Hex) gave title compound (1.18 g, 2.90 mmol, 55% yield) as colored semi-solid. Mass spec.: 407.0 (MH)+.
To a 100 mL round bottom flask was added 1-fluoro-3-vinylbenzene (1.2 g, 9.82 mmol), 5-bromo-2-fluoropyridin-3-ylboronic acid (3.24 g, 14.74 mmol), and Sodium carbonate (2.60 g, 24.56 mmol) in dimethylformamide (32.7 ml). The reaction vessel was sealed and purged with oxygen via a balloon for 5 min. After purging with oxygen, palladium (II) acetate (0.221 g, 0.982 mmol) added and immediately purged with oxygen for (15 min.). The reaction was kept under a blanket of oxygen and left to stir overnight at room temperature. The reaction was then quenched with water and extracted with ethylacetate (3×). The organic layer was separated, washed with brine, dried over sodium sulfate, and concentrated in vacuo. The crude oil was loaded onto 90 g silica gel cartridge and the product was eluted with 5% DCM/Hex. The product fractions were collected and concentrated to afford 0.712 g (22%) as an off white crystalline solid. 1H-NMR (CDCl3, 400 MHz) δ 8.16 (s, 1H), 8.09 (dd, J=8.5, 2.3, 1H), 7.42-7.29 (m, 2H), 7.27-7.17 (m, 2H), 7.11-7.01 (m, 2H), LC/Mass spec. (Analytical HPLC method 2): RT=2.88 min. Mass=296.01 (MH)+.
To a solution of tert-butyl carbamate (363 mg, 3.10 mmol) in propanol (10 mL) was added sodium hydroxide (122 mg, 3.05 mmol) in water (4 mL) followed by tert-butyl hypochlorite (331 mg, 3.05 mmol). After 5 min the solution was cooled to 0° C. and treated with a solution of (DHQD)2PHAL (38.9 mg, 0.050 mmol) in propanol (4 mL). To this solution was added a solution of (E)-5-bromo-2-fluoro-3-(3-fluorostyryl)pyridine (296 mg, 1.0 mmol) in propanol (10 mL). To this solution was added potassium osmate dihydrate (14.73 mg, 0.040 mmol) in one portion. The reaction turned light orange and was allowed to stir at 0° C. for 1 hr. The ice bath was then removed and the reaction was allowed to warm to room temperature and stirred overnight. The reaction was quenched with a 10% solution of sodium thiosulfate and stirred for 30 min. The reaction was then extracted with diethylether (3×). The combined organic extracts were combined washed with water, then brine. The organic layer was separated, dried over sodium sulfate and evaporated in vacuo. The crude residue was purified by silica gel chromatography 25% EtOAc/75% Hexanes to 50%/50% EtOAc/Hexanes to afford tert-butyl (1R,2R)-1-(5-bromo-2-fluoropyridin-3-yl)-2-(3-fluorophenyl)-2-hydroxyethylcarbamate (223 mg, 0.520 mmol, 52.0% yield) along with its regioisomer as an inseparable mixture. LC/Mass spec. (Analytical HPLC method 2): RT=2.11 min. Mass=453.14 (MNa)+.
To a 25 mL round bottom flask was added tert-butyl (1R,2R)-1-(5-bromo-2-fluoropyridin-3-yl)-2-(3-fluorophenyl)-2-hydroxyethylcarbamate (223 mg, 0.520 mmol) in dichloromethane (4 mL). To this solution was added trifluoroacetic acid (1.014 mL, 13.16 mmol) and the reaction was allowed to stir over night at room temperature. The reaction solvent was then evaporated in vacuo. The crude reaction mixture was then dissolved in 5 mL of 2N ammonia in methanol and stirred for 5 min. The solvent was then evaporated in vacuo and the crude residue was diluted with dry tetrahydrofuran (4 mL) and carbonyldiimidazole (168 mg, 1.039 mmol) was added and the reaction was stirred at room temperature for 1 hr. The reaction solvent was then evaporated in vacuo and the crude solid was purified by silica gel chromatography 10% EtOAc/90% Hexanes to 30% EtOAc/70% Hexanes affording (4R,5R)-4-(5-bromo-2-fluoropyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (25 mg, 0.070 mmol, 13.55% yield) and (4R,5R)-5-(5-bromo-2-fluoropyridin-3-yl)-4-(3-fluorophenyl)oxazolidin-2-one (17 mg, 0.048 mmol, 9.2% yield) as an inseparable mixture. 1H-NMR (CDCl3, 400 MHz) δ 8.33 (d, J=2.3, 1H), 7.47-7.41 (m, 1H), 7.19-7.11 (m, 3H), 5.64 (s, 1H), 5.36 (d, J=5.0, 1H), 5.00 (d, J=5.0, 1H), LC/Mass spec. (Analytical HPLC method 2): RT=2.09 min. Mass=355.09 (MH)+.
To a sealable microwave vial was added (4R,5R)-4-(5-bromo-2-fluoropyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (105 mg, 0.296 mmol), copper(I) iodide (1.689 mg, 8.87 μmol), triphenylphosphine (23.26 mg, 0.089 mmol) and triethylamine (4 mL). The solution was stirred and ethynyltrimethylsilane (43.6 mg, 0.443 mmol) was added and the reaction mixture was degassed with nitrogen for 10 min. To this mixture was added bis(triphenylphosphine)palladium(II) chloride (4.15 mg, 5.91 μmol) in one portion and the reaction vessel was sealed and heated to 90° C. overnight. The reaction was cooled to room temperature, the solvent was evaporated in vacuo and the crude solid was added to a silica gel column and eluted with 20% EtOAc/80% Hexanes affording (4R,5R)-4-(2-fluoro-5-((trimethylsilyl)ethynyl)pyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (77 mg, 0.207 mmol, 69.9% yield) as an off white solid. 1H-NMR (CDCl3, 400 MHz) δ 8.35 (s, 1H), 8.04 (dd, J=8.0, 4.0, 1H), 7.47-7.41 (m, 1H), 7.18-7.12 (m, 3H), 5.44 (brs, 1H), 5.36 (d, J=4.0, 1H) 5.00 (d, J=5.0, 1H), 0.30 (s, 9H), LC/Mass spec. (Analytical HPLC method 2): RT=2.23 min. Mass=373.19 (MH)+.
To a 25 mL round bottom flask was added (4R,5R)-4-(2-fluoro-5-((trimethylsilyl)ethynyl)pyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (77 mg, 0.207 mmol) in MeOH (4 mL). The solution was stirred and potassium carbonate (28.6 mg, 0.207 mmol) was added in one portion and the reaction was allowed to stir for 30 min. The reaction was complete by TLC and LC/MS. The reaction solvent was then evaporated in vacuo and the crude solid was dissolved in dichloromethane and washed with saturated ammonium chloride. The organic layer was separated, dried over sodium sulfate, and evaporated in vacuo to afford (4R,5R)-4-(5-ethynyl-2-fluoropyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (60 mg, 0.180 mmol, 87% yield) as an off white solid. This material was used as is without purification. 1H-NMR (CDCl3, 400 MHz) δ 8.39 (s, 1H), 8.07 (dd, J=8.0, 2.0, 1H), 7.47-7.42 (m, 1H), 7.19-7.12 (m, 3H), 5.86 (brs, 1H), 5.37 (d, J=4.0, 1H), 5.02 (s, J=4.0, 1H), 3.31 (s, 1H). LC/Mass spec. (Analytical HPLC method 2): RT=1.82 min. Mass=301.19 (MH)+.
To a 15 mL round bottom flask was added 5-bromo-2-fluoropyridin-3-ylboronic acid (895 mg, 4.07 mmol), sodium carbonate (863 mg, 8.14 mmol) and 1-fluoro-4-vinylbenzene (647 mg, 5.29 mmol) in dimethylformamide (8 mL). The solution was stirred at room temperature and the flask was purged with oxygen for 3 min. To the purged flask was quickly added palladium(II) acetate (91 mg, 0.407 mmol) and the reaction flask was again sealed and purged with oxygen for 15 min. The reaction mixture was then stirred at room temperature overnight. The next day the reaction was quenched with water and diluted with ethylacetate. The organic layer was separated, washed with brine, dried over sodium sulfate and evaporated in vacuo. The crude oil was purified by silica gel chromatography eluting with 0% EtOAc/100% hexanes to 15% EtOAc/85% hexanes affording (E)-5-bromo-2-fluoro-3-(4-fluorostyryl)pyridine (380 mg, 1.283 mmol, 31.5% yield) as a white solid. 1H-NMR (CDCl3, 400 MHz) δ 8.15 (s, 1H), 8.09 (dd, J=8.0, 2.0, 1H), 7.55-7.52 (m, 2H), 7.22 (d, J=16.0, 1H), 7.13-7.09 (m, 2H), 7.00 (d, J=16.0, 1H), LC/Mass spec. (Analytical HPLC method 2): RT=2.31 min. Mass=296.08 (MH)+.
To a solution of tert-butyl carbamate (1431 mg, 12.22 mmol) in propanol (10 mL) was added sodium hydroxide (481 mg, 12.02 mmol) in water (4 mL) followed by tert-butyl hypochlorite (1305 mg, 12.02 mmol). After 5 min the solution was cooled to 0° C. and treated with a solution of (DHQD)2PHAL (154 mg, 0.197 mmol) in propanol (4 mL). To this solution was added a solution of (E)-5-bromo-2-fluoro-3-(4-fluorostyryl)pyridine (1167 mg, 3.94 mmol) in propanol (10 mL). To this solution was added potassium osmate dihydrate (58.1 mg, 0.158 mmol) in one portion. The reaction turned light orange and was allowed to stir at 0° C. for 1 hr. The ice bath was then removed and the reaction was allowed to warm to room temperature and stirred over night. The reaction was quenched with a 10% solution of sodium thiosulfate and stirred for 30 min. The reaction was then extracted with diethylether (3×). The combined organic extracts were combined washed with water, then brine. The organic layer was separated, dried over sodium sulfate and evaporated in vacuo. The crude residue was purified by silica gel chromatography 5% acetone/95% Hexanes to 50%/50% Acetone/Hexanes to afford tert-butyl (1R,2R)-1-(5-bromo-2-fluoropyridin-3-yl)-2-(4-fluorophenyl)-2-hydroxyethylcarbamate (1450 mg, 3.38 mmol, 86% yield) along with its regioisomer as an inseparable mixture. LC/Mass spec. (Analytical HPLC method 2): RT=2.07 min. Mass=429.30 (MH)+.
To a 25 mL round bottom flask was added tert-butyl (1R,2R)-1-(5-bromo-2-fluoropyridin-3-yl)-2-(4-fluorophenyl)-2-hydroxyethylcarbamate (1450 mg, 3.38 mmol) in dichloromethane (12 mL). To this solution was added trifluoroacetic acid (2.60 mL, 33.8 mmol) and the reaction was allowed to stir over night at room temperature. The reaction solvent was evaporated in vacuo and the crude oil was diluted with diethylether and washed with saturated sodium bicarbonate. The organic layer was separated, dried over sodium sulfate and the solvent was then evaporated in vacuo and the crude residue was diluted with dry tetrahydrofuran. The solution was cooled to 0° C. and carbonyldiimidazole (282 mg, 1.74 mmol) was added and the reaction was allowed to stir overnight. The reaction solvent was then evaporated in vacuo and the crude residue was diluted with 2N ammonia in methanol and stirred for 15 min. The solvent was then evaporated in vacuo and the crude solid was purified by silica gel chromatography 15% EtOAc/85% Hexanes to 50% EtOAc/50% Hexanes affording the desired product and its regioisomer as an inseparable mixture. The inseparable mixture was further purified by reverse phase chromatography using a sunfire col 30×100 45%-55% MeOH/H2O 0.1% TFA over a 20 minute run time affording (4R,5R)-4-(5-bromo-2-fluoropyridin-3-yl)-5-(4-fluorophenyl)oxazolidin-2-one (180 mg, 0.507 mmol, 10.99% yield). 1H-NMR (CDCl3, 400 MHz) δ 8.33 (s, 1H), 8.10 (d, J=8.0), 7.42-7.38 (m, 2H), 7.19-7.15 (m, 2H), 5.81 (brs, 1H), 5.36 (d, J=4.0, 1H), 5.01 (d, J=4.0, 1H), LC/Mass spec. (Analytical HPLC method 2): RT=2.17 min. Mass=356.96 (MH)+.
To a 25 mL round bottom flask was added 2-bromo-5-fluoropyridin-4-ylboronic acid (1440 mg, 6.55 mmol), sodium carbonate (1085 mg, 10.23 mmol), and 1-fluoro-4-vinylbenzene (500 mg, 4.09 mmol) in dimethylformamide (8 mL). The solution was stirred at room temperature and the flask was purged with oxygen for 3 min. To the purged flask was quickly added diacetoxypalladium (92 mg, 0.409 mmol) and the reaction flask was again sealed and purged with oxygen for 15 min. The reaction mixture was then stirred at room temperature overnight. The next day the reaction was quenched with water and diluted with ethylacetate (3×). The organic layer was separated, washed with brine, dried over sodium sulfate and evaporated in vacuo. The crude oil was purified by silica gel chromatography eluting with 0% EtOAc/100% hexanes to 25% EtOAc/85% hexanes affording (E)-2-bromo-5-fluoro-4-(4-fluorostyryl)pyridine (100 mg, 0.338 mmol, 8.25% yield) as a white solid. 1H-NMR (CDCl3, 400 MHz) δ 8.45 (s, 1H), 8.25 (m, 1H), 7.58-7.57 (m, 2H), 7.36 (d, J=16.0, 1H), 7.15-7.11 (m, 2H), 7.04 (d, J=16.0, 1H), LC/Mass spec. (Analytical HPLC method 2): RT=2.76 min. Mass=295.98 (MH)+.
To a solution of tert-butyl carbamate (189 mg, 1.612 mmol) in propanol (4 mL) was added sodium hydroxide (54.1 mg, 1.352 mmol) in water (2 mL) followed by tert-butyl hypochlorite (172 mg, 1.586 mmol). After 5 min the solution was cooled to 0° C. and treated with a solution of (DHQD)2PHAL (20.26 mg, 0.026 mmol) in propanol (1 mL). To this solution was added a solution of (E)-2-bromo-5-fluoro-4-(4-fluorostyryl)pyridine (154 mg, 0.520 mmol) in propanol (7 mL). To this solution was added potassium osmate dihydrate (7.66 mg, 0.021 mmol) dissolved in water (3 mL) in one portion. The reaction turned light orange and was allowed to stir at 0° C. overnight. The reaction was complete the next morning after warming to room temperature. The reaction was then quenched with a 10% solution of sodium thiosulfate and stirred for 30 min. The reaction was then extracted with diethylether (3×). The combined organic extracts were combined washed with water, then brine. The organic layer was separated, dried over sodium sulfate and evaporated in vacuo. The crude residue was purified by silica gel chromatography 25% EtOAc/75% Hexanes to 50%/50% EtOAc/Hexanes to afford tert-butyl (1R,2R)-1-(2-bromo-5-fluoropyridin-4-yl)-2-(4-fluorophenyl)-2-hydroxyethylcarbamate (56 mg, 0.130 mmol, 62.7% yield) along with its regioisomer as an inseparable mixture. LC/Mass spec. (Analytical HPLC method 2): RT=2.09 min. Mass=431.05 (MH)+.
To a 25 mL round bottom flask was added tert-butyl (1R,2R)-1-(2-bromo-5-fluoropyridin-4-yl)-2-(4-fluorophenyl)-2-hydroxyethylcarbamate (141 mg, 0.328 mmol) in dichloromethane (4 mL). To this solution was added trifluoroacetic acid (0.253 mL, 3.28 mmol) and the reaction was allowed to stir over night at room temperature. The next day the reaction was checked by LC/MS and was complete. The reaction solvent was evaporated in vacuo and the crude oil was diluted with diethylether and washed with saturated sodium bicarbonate. The organic layer was separated, dried over sodium sulfate and the solvent was then evaporated in vacuo and the crude residue was diluted with dry tetrahydrofuran. The solution was cooled to 0° C. and carbonyldiimidazole (53.3 mg, 0.328 mmol) was added and the reaction was allowed to stir overnight. The reaction was complete by LC/MS. The reaction solvent was then evaporated in vacuo and the crude solid was purified by silica gel chromatography 15% EtOAc/85% Hexanes to 50% EtOAc/50% Hexanes affording (4R,5R)-4-(2-bromo-5-fluoropyridin-4-yl)-5-(4-fluorophenyl)oxazolidin-2-one (20 mg, 0.056 mmol, 42.9% yield) and its regioisomer as an inseparable mixture. LC/Mass spec. (Analytical HPLC method 2): RT=1.79 min. Mass=354.89 (MH)+.
To a 15 mL round bottom flask was added 5-bromo-2-fluoropyridin-3-ylboronic acid (400 mg, 1.820 mmol), SODIUM CARBONATE (386 mg, 3.64 mmol) and 1-(trifluoromethyl)-4-vinylbenzene (407 mg, 2.366 mmol) in dimethylformamide (6 mL). The solution was stirred at room temperature and the flask was purged with oxygen for 3 min. To the purged flask was quickly added palladium(II) acetate (40.9 mg, 0.182 mmol) and the reaction flask was again sealed and purged with oxygen for 15 min. The reaction mixture was then stirred at room temperature overnight and monitored by TLC to determine when the reaction was complete. The next day the reaction was complete by LC/MS. There was no boronic acid left so the reaction was quenched with water and diluted with ethylacetate. The organic layer was separated, washed with brine, dried over sodium sulfate and evaporated in vacuo. The crude oil was puried by silica gel chromatography eluting with 0% EtOAc/100% hexanes to 15% EtOAc/85% hexanes affording (E)-5-bromo-2-fluoro-3-(4-(trifluoromethyl)styryl)pyridine (177 mg, 0.511 mmol, 28.1% yield) as a white solid. 1H-NMR (CDCl3, 400 MHz) δ 8.19 (s, 1H), 8.12 (dd, J=8.0, 4.0, 1H), 7.66 (m, 4H), 7.29 (d, J=16.0, 1H), 7.17 (d, J=16.0, 1H).
To a solution of tert-butyl carbamate (189 mg, 1.612 mmol) in propanol (7 mL) was added sodium hydroxide (54.1 mg, 1.352 mmol) in water (4 mL) followed by tert-butyl hypochlorite (172 mg, 1.586 mmol) (freshly prepared following an org synthesis prep). After 5 min the solution was cooled to 0° C. and treated with a solution of (DHQD)2PHAL (20.26 mg, 0.026 mmol) in propanol (4 mL). To this solution was added a solution of (E)-5-bromo-2-fluoro-3-(4-(trifluoromethyl)styryl)pyridine (180 mg, 0.520 mmol) in propanol (10 mL). To this solution was added potassium osmate dihydrate (7.66 mg, 0.021 mmol) in one portion. The reaction turned light orange and was allowed to stir at 0° C. overnight allowing the reaction to warm up to room temperature. The reaction was quenched with a 10% solution of sodium thiosulfate and stirred for 30 min. The reaction was then extracted with diethylether (3×). The combined organic extracts were combined washed with water, then brine. The organic layer was separated, dried over sodium sulfate and evaporated in vacuo. The crude residue was purified by silica gel chromatography 25% EtOAc/75% Hexanes to 50%/50% EtOAc/Hexanes to afford tert-butyl (1R,2R)-1-(5-bromo-2-fluoropyridin-3-yl)-2-hydroxy-2-(4-(trifluoromethyl)phenyl)ethylcarbamate (250 mg, 0.530 mmol, 99% yield) as an inseparable mixture with its regioisomer. LC/Mass spec. (Analytical HPLC method 2): RT=2.78 min. Mass=503.07 (MNa)+.
To a 25 mL round bottom flask was added tert-butyl (1R,2R)-1-(5-bromo-2-fluoropyridin-3-yl)-2-hydroxy-2-(4-(trifluoromethyl)phenyl)ethylcarbamate (250 mg, 0.53 mmol) in dichloromethane (8 mL). To this solution was added trifluoroacetic acid (1.021 mL, 13.25 mmol) and the reaction was allowed to stir over night at room temperature. The reaction solvent was evaporated in vacuo and the crude oil was diluted with ethylacetate and washed with saturated sodium bicarbonate. The organic layer was separated, dried over sodium sulfate and the solvent was then evaporated in vacuo and the crude residue was diluted with dry tetrahydrofuran. The solution was cooled to 0° C. and carbonyldiimidazole (86 mg, 0.530 mmol) was added and the reaction was allowed to stir overnight. The reaction solvent was then evaporated in vacuo and the crude solid was purified by silica gel chromatography 15% EtOAc/85% Hexanes to 50% EtOAc/50% Hexanes affording (4R,5R)-4-(5-bromo-2-fluoropyridin-3-yl)-5-(4-(trifluoromethyl)phenyl)oxazolidin-2-one (84 mg, 0.207 mmol, 39.1% yield) and its regioisomer as an inseparable mixture. LC/Mass spec. (Analytical HPLC method 2): RT=2.44 min. Mass=406.91 (MH)+.
To a solution of (E)-3-(3-bromophenyl)acrylic acid (7.5 g, 32.4 mmol) in propan-2-ol (50 mL, 832 mmol) was added dropwise H2SO4 (0.431 mL, 8.09 mmol). The reaction was heated to reflux for 18 h then it was concentrated in vacuo providing a brown liquid which was redissolved in 50 mL ethylacetate. 1N NaOH was added dropwise until the aqueous mixture reached pH10. The organic layer was collected and washed with aqueous sodium bicarbonate (sat), brine, dried over magnesium sulfate, filtered and concentrated providing (E)-isopropyl 3-(3-bromophenyl)acrylate (8.4202 g, 29.7 mmol, 92% yield) as a yellow liquid. 1H NMR (500 MHz, DMSO) δ 7.98 (s, 1H), 7.74 (d, J=7.8 Hz, 1H), 7.67-7.55 (m, 2H), 7.37 (t, J=7.9 Hz, 1H), 6.70 (d, J=16.0 Hz, 1H), 5.02 (dt, J=12.5, 6.2 Hz, 1H), 1.26 (d, J=6.3 Hz, 6H). Mass spec.: 270.88 (MH)+.
To a solution of lithium hydroxide monohydrate (0.091 mL, 3.27 mmol) and potassium osmium oxide (VI) (0.049 g, 0.149 mmol) in water (9 mL) was added t-BuOH (18.00 mL), (DHQD)2 PHAL (0.139 g, 0.178 mmol) and the mixture was stirred for 10 min. Water (18.00 mL) was added, and the mixture was immersed in a cooling bath set at 4° C. (E)-isopropyl 3-(3-bromophenyl)acrylate (0.8 g, 2.97 mmol) was added to the reaction mixture. 30 minutes later N-bromoacetamide (0.451 g, 3.27 mmol) was added in one portion and the mixture was vigorously stirred at the same temperature. After 20 h, the reaction mixture was treated with sodium sulfite (1.5 g, 11.90 mmol). After stirring at ambient temperature for 30 min, ethyl acetate (20 mL) was added. The organic layer was separated, and the water layer was extracted with ethyl acetate (3×25 mL). The combined organics were washed with brine (20 mL), and dried over magnesium sulfate. After evaporation of the solvent, the crude was purified by Preparative HPLC Method 10 providing (2S,3R)-isopropyl 3-acetamido-3-(3-bromophenyl)-2-hydroxypropanoate (136.2 mg, 0.396 mmol, 13.31% yield) as a white solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 1.07 (d, J=6.41 Hz, 3H) 1.18 (d, J=6.10 Hz, 3H) 1.86 (s, 3H) 4.29 (dd, J=6.10, 3.97 Hz, 1H) 4.85 (t, J=6.26 Hz, 1H) 5.24 (dd, J=9.31, 4.12 Hz, 1H) 5.69 (d, J=6.10 Hz, 1H) 7.28 (t, J=7.78 Hz, 1H) 7.34 (d, J=7.93 Hz, 1H) 7.44 (dt, J=7.71, 1.49 Hz, 1H) 7.50-7.57 (m, 1H) 8.38 (d, J=9.16 Hz, 1H). Mass spec.: 345.91 (MH)+.
(2S,3R)-isopropyl 3-acetamido-3-(3-bromophenyl)-2-hydroxypropanoate (123 mg, 0.357 mmol) in 10% HCl (12.7 ml) was heated to reflux for four hours at which time the reaction mixture was concentrated providing (2S,3R)-3-amino-3-(3-bromophenyl)-2-hydroxypropanoic acid, HCl (90 mg, 0.273 mmol, 76% yield) as a grey solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 4.34 (d, J=5.49 Hz, 1H) 4.43 (br. s., 1H) 6.67 (br. s., 1H) 7.35-7.42 (m, 1H) 7.54 (d, J=7.63 Hz, 1H) 7.58-7.63 (m, 1H) 7.79 (s, 1H) 8.61 (br. s., 2H) 13.04 (br. s., 1H). Mass spec.: 261.91 (MH)+.
To triphosgene (36.5 mg, 0.123 mmol) and Na2CO3 (65.2 mg, 0.615 mmol) in Water (2.000 mL) at 0° C. was added dropwise a solution of (2S,3R)-3-amino-3-(3-bromophenyl)-2-hydroxypropanoic acid (20 mg, 0.077 mmol) in Water (0.5 mL)/1,4-Dioxane (0.5 mL). After 15 min, the ice bath was removed and stirring was continued for one hour. ethylacetate (1 ml) was added to the reaction mixture and after five minutes the ethylacetate layer was discarded and the aqueous layer was acidified to pH 2 and extracted with ethylacetate (5 mL×3). The combined organics were dried over magnesium sulfate, filtered and concentrated providing (4R,5S)-4-(3-bromophenyl)-2-oxooxazolidine-5-carboxylic acid (14.2 mg, 0.047 mmol, 61.3% yield) as a white solid. Mass spec.: 287.79 (MH)+.
To a solution of (4R,5S)-4-(3-bromophenyl)-2-oxooxazolidine-5-carboxylic acid (20 mg, 0.070 mmol) in tetrahydrofuran (2 mL)/methanol (0.500 mL) was added trimethylsilyldiazomethane (0.063 mL, 0.126 mmol) dropwise at 0° C. After 3 h, the reaction was allowed to warm to ambient temperature and stirred for an additional 15 h, at which time it was concentrated in vacuo to provide (4R,5S)-methyl 4-(3-bromophenyl)-2-oxooxazolidine-5-carboxylate (18.2 mg, 0.058 mmol, 82% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 3.78 (s, 3H) 4.98 (d, J=4.88 Hz, 1H) 5.01-5.04 (m, 1H) 7.37-7.45 (m, 2H) 7.56 (s, 1H) 7.57-7.61 (m, 1H) 8.60 (s, 1H). Mass spec.: 301.77 (MH)+.
This intermediate was prepared using the same procedure as described for the preparation of (+)-(4R,5R)-5-(3-Methoxyphenyl)-4-(3-(phenylethynyl)phenyl)-oxazolidin-2-one.
1H NMR (500 MHz, DMSO-d6) δ ppm 4.85 (br. s., 1H) 4.94-5.02 (m, 1H) 7.37-7.69 (m, 9H) 8.52 (s, 1H) 13.58-13.78 (m, 1H). Mass spec.: 307.91 (MH)+.
To a solution of (4R,5S)-2-oxo-4-(3-(phenylethynyl)phenyl)oxazolidine-5-carboxylic acid (120 mg, 0.390 mmol) in dichloromethane (5 mL) was added thionyl chloride (0.285 mL, 3.90 mmol) and the solution was heated to reflux for 3 h. The reaction mixture was concentrated in vacuo providing (4R,5S)-2-oxo-4-(3-(phenylethynyl)phenyl)oxazolidine-5-carbonyl chloride (127 mg, 0.370 mmol, 95% yield) as a light brown wax.
To (4R,5S)-2-oxo-4-(3-(phenylethynyl)phenyl)oxazolidine-5-carbonyl chloride (120 mg, 0.368 mmol) in tetrahydrofuran (1 mL) was added ammonium hydroxide (3 mL, 23.11 mmol) dropwise. One hour later, the reaction mixture was extracted with ethylacetate (10 mL×3) and the combined organic layer was dried over magnesium sulfate, filtered, and concentrated to obtain (4R,5S)-2-oxo-4-(3-(phenylethynyl)phenyl)oxazolidine-5-carboxamide (114 mg, 0.354 mmol, 96% yield) as a white solid. 1H NMR (500 MHz, DMSO-d6) δ ppm 4.66 (d, J=5.49 Hz, 1H) 4.88 (d, J=5.49 Hz, 1H) 7.37-7.68 (m, 11H) 7.79 (s, 1H). Mass spec.: 307.1 (MH)+.
To a solution of (4R,5S)-2-oxo-4-(3-(phenylethynyl)phenyl)oxazolidine-5-carboxamide (80 mg, 0.261 mmol) in dichloromethane (2 mL) was added phosphorus oxychloride (0.243 mL, 2.61 mmol). The reaction was heated to reflux for 4 h and sodium bicarbonate (sat) was added until pH 7. The reaction mixture was back extracted with dichloromethane (3×5 mL) and the combined organic layers were dried over magnesium sulfate, filtered and concentrated to yield a yellow wax that was purified by Preparative HPLC Method 6 providing (4R,5S)-2-oxo-4-(3-(phenylethynyl)phenyl)oxazolidine-5-carbonitrile (53 mg, 0.178 mmol, 68.3% yield) 1H NMR (500 MHz, DMSO-d6) δ ppm 5.36 (d, J=4.27 Hz, 1H) 5.63 (d, J=4.27 Hz, 1H) 7.39-7.49 (m, 4H) 7.52 (t, J=7.93 Hz, 1H) 7.56-7.64 (m, 4H) 8.76 (br. s., 1H).
A mixture of 2-(bromomethyl)-1,4-difluorobenzene (3 g, 14.49 mmol) and triethyl phosphite (7.72 ml, 43.5 mmol) was heated to 160° C. with stirring for 4 hours, cooled to ambient temperature and concentrated under high vacuum to remove most triethyl phosphite. The resulting residue was purified by column chromatography (20% to 30% EtOAc/Toluene) providing diethyl 2,5-difluorobenzylphosphonate (3.76 g, 13.52 mmol, 93% yield) as colorless oil. 1H NMR (500 MHz, DMSO-d6) δ 7.30-7.10 (m, 3H), 4.05-3.91 (m, 4H), 3.31-3.20 (m, 2H), 1.18 (t, J=7.0 Hz, 6H). MS Anal. Calcd. for [M+H]+ C11H16F2O3P: 265.2. found 265.3.
To a stirred solution of diethyl 2,5-difluorobenzylphosphonate (63.5 g, 240 mmol) and 5-bromonicotinaldehyde (50.7 g, 264 mmol) in tetrahydrofuran (1923 ml) was added potassium tert-butoxide in tetrahydrofuran (312 ml, 312 mmol) at −10° C. After three hours, the reaction mixture was allowed to warm to ambient temperature and stirring was continued for another 16 hours at which time the reaction mixture was diluted with ether (800 mL) and washed with H2O. The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated to provide a yellow wax to which was added 300 mL of hexane and after sonication filtered to provide (E)-3-bromo-5-(2,5-difluorostyryl)pyridine (54 g, 173 mmol, 72.1%) as a white solid. 1H NMR (500 MHz, DMSO-d6) δ 8.78 (d, J=1.8 Hz, 1H), 8.63 (d, J=2.1 Hz, 1H), 8.44 (t, J=2.0 Hz, 1H), 7.67 (ddd, J=9.4, 6.0, 3.2 Hz, 1H), 7.56-7.48 (m, 1H), 7.46-7.40 (m, 1H), 7.34 (td, J=9.6, 4.6 Hz, 1H), 7.24 (tt, J=8.3, 3.6 Hz, 1H). MS Anal. Calcd. for [M+H]+ C13H9BrF2N: 296.0. found 298.1.
A solution of tert-butyl carbamate (4.18 g, 35.0 mmol) in propanol (39 ml) was sequentially treated with sodium hydroxide (1.376 g, 34.4 mmol) in water (72 ml) and tert-butyl hypochlorite (3.88 ml, 34.4 mmol). After 5 min of stirring, the reaction mixture was cooled to 0° C. A solution of (DHQD)2PHAL (0.555 g, 0.677 mmol) in propanol (39 ml), a solution of (E)-3-bromo-5-(2,5-difluorostyryl)pyridine (3.34 g, 11.28 mmol) in propanol (68 ml), and potassium osmate dihydrate (0.166 g, 0.451 mmol) were sequentially added. The reaction mixture was stirred for three additional hours at 0° C., warmed to ambient temperature and after an additional 16 hours the light yellow homogenous solution was quenched with saturated aqueous sodium sulfite (100 mL). The aqueous phase was extracted with ethyl acetate (2×50 mL), the combined organic phases were washed with brine (100 mL), dried over anhydrous magnesium sulfate and concentrated to afford a residue which was purified via column chromatography (25% to 40% EtOAc/Hex) to provide tert-butyl (1R,2R)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)-2-hydroxyethylcarbamate (2.2991 g, 5.09 mmol, 45.1% yield) as an optically enriched mixture of enantiomers. 1H NMR (500 MHz, DMSO-d6) δ 8.56 (d, J=1.8 Hz, 1H), 8.40 (s, 1H), 8.03 (s, 1H), 7.52 (d, J=9.5 Hz, 1H), 7.25 (br. s., 1H), 7.10 (t, J=5.6 Hz, 2H), 5.89 (d, J=4.9 Hz, 1H), 5.03 (t, J=5.0 Hz, 1H), 4.83 (dd, J=8.9, 5.2 Hz, 1H), 1.40-1.34 (m, 9H), MS Anal. Calcd. for [M+H]+ C18H20BrF2N2O3: 429.1. found 431.3.
To a solution of tert-butyl carbamate (83 g, 709 mmol) in 1-propanol (780 mL) was added 0.5 M of aqueous sodium hydroxide (1418 mL, 709 mmol), followed by tert-butyl hypochlorite (77 g, 709 mmol) (internal temperature 28.2° C.). The reaction mixture was stirred at ambient temperature for 10 min. To this reaction mixture was added (DHQD)2PHAL (5.52 g, 7.09 mmol) and 1-propanol (780 mL), followed by (E)-3-bromo-5-(2,5-difluorostyryl)pyridine (70.0 g, 236 mmol) and 1-propanol (780 mL). This white mixture was cooled to 0° C. with a methanol/ice bath. Then potassium osmate dihydrate (2.61 g, 7.09 mmol) was added to this mixture. After 30 min of stirring, the ice bath was removed. The reaction was stirred at room temperature overnight. After 16 h, the reaction mixture was partitioned with water (1 L) and EtOAc (2.4 L). The organic layer was washed with 5% sodium sulfite three times (Note: Each wash was mechanically stirred for 10 min to ensure reduction of osmium. The first two washes were dark; the third wash was clear. The organic layer was washed with brine (3×500 mL), dried (sodium sulfate), filtered, and concentrated to give 136 g of crude tert-butyl((1R,2R)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)-2-hydroxyethyl)carbamate and tert-butyl((1R,2R)-2-(5-bromopyridin-3-yl)-1-(2,5-difluorophenyl)-2-hydroxyethyl)carbamate (ca. 6:1 ratio). LC/MS (ES+) 430.9 (M+H, 100).
To a stirred solution of tert-butyl tert-butyl (1R,2R)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)-2-hydroxyethylcarbamate (2.30 g, 5.09 mmol) in methylene chloride (30 mL) was added HCl in dioxane (30 ml, 120 mmol). The reaction mixture was placed in an oil bath set to 50° C. After three hours, the reaction mixture was concentrated providing (1R,2R)-2-amino-2-(5-bromopyridin-3-yl)-1-(2,5-difluorophenyl)ethanol 2HCl salt (2.10 g, 4.97 mmol, 98% yield) as an optically enriched yellow wax. 1H NMR (500 MHz, DMSO-d6) δ 8.95 (d, J=3.7 Hz, 2H), 8.64 (d, J=2.4 Hz, 1H), 8.45 (d, J=1.5 Hz, 1H), 8.31 (t, J=2.0 Hz, 1H), 7.47-7.09 (m, 3H), 7.04 (td, J=9.2, 4.4 Hz, 1H), 5.29 (d, J=9.2 Hz, 1H), 4.57 (dd, J=9.0, 5.3 Hz, 1H). Anal. Calcd. for [M+H]+ C13H12BrF2N2O: 329.0. found 331.2.
To optically enriched (1R,2R)-2-amino-2-(5-bromopyridin-3-yl)-1-(2,5-difluorophenyl)ethanol, 2 HCl (2.019 g, 4.82 mmol) in tetrahydrofuran (98 ml) was added diisopropylethylamine (2.95 ml, 16.87 mmol) and the resultant solution was stirred for ten minutes at ambient temperature, cooled to 0° C. and carbonyldiimidazole (1.094 g, 6.75 mmol) was added. After an additional three hours at 0° C. the reaction mixture was warmed to ambient temperature and allowed to stir for another 16 hours. 2M NH3 in methanol (5 ml) was added and after ten minutes the suspension was filtered and concentrated to a pink oil which was purified by column chromatography (25% to 40% EtOAc/Hex) providing (4R,5R)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one (1.353 g, 3.62 mmol, 75% yield) as an optically enriched white solid. 1H NMR (500 MHz, DMSO-d6) δ 8.80-8.68 (m, 1H), 8.55 (d, J=2.1 Hz, 2H), 8.16 (t, J=2.1 Hz, 1H), 7.46-7.28 (m, 3H), 5.71-5.58 (m, 1H), 5.02 (d, J=6.7 Hz, 1H). MS Anal. Calcd. for [M+H]+ C14H10BrF2N2O2: 355.0. found 357.2.
Method-2
A mixture of tert-butyl((1R,2R)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)-2-hydroxyethyl)carbamate and tert-butyl((1R,2R)-2-(5-bromopyridin-3-yl)-1-(2,5-difluorophenyl)-2-hydroxyethyl)carbamate (about 6:1 ratio) (101 g, 236 mmol) in tetrahydrofuran (590 mL) was cooled to −7° C. with a methanol/ice bath. To this mixture was added a solution of 1 M potassium tert-butoxide in tetrahydrofuran (590 mL, 590 mmol) via an addition funnel while maintaining the internal temperature <3° C. The reaction mixture was stirred with a cooling bath for 30 min and then allowed to warm up to room temperature. After 20 h, the reaction was deemed complete by LC/MS. The reaction mixture was concentrated to dryness to give crude product. Another identical scale reaction was performed. The crude products of the two batches were combined to work up together. They were treated with ethyl acetate (1.75 L) and water (1.75 L). The layers were separated. The organic layer was washed with brine (1.75 L), dried (sodium sulfate), and evaporated to give 161.5 g of crude product as a brown solid. This was purified by ISCO to give 67.1 g (42% yield). LC/MS (ES+) 355/357 (M+H, 100; Br isotope pattern); 1H NMR (400 MHz, CDCl3) δ 8.75 (d, J=2.2 Hz, 1H), 8.53 (d, J=1.8 Hz, 1H), 7.97 (t, J=2.0 Hz, 1H), 7.29-7.23 (m, 1H), 7.18-7.09 (m, 2H), 6.40 (s, 1H), 5.56 (d, J=5.7 Hz, 1H), 4.84 (d, J=5.5 Hz, 1H); Calcd for C14H9N2BrF2O2: C, 47.34; H, 2.55; N, 7.86; Br, 22.50; F, 10.69. Found: C, 47.29; H, 2.61; N, 7.87; Br, 22.40; F, 10.37. Note: Chiral HPLC of the above sample showed 4.7% of the enantiomer. The (4S,5S) enantiomer can be purged by recrystallization from methanol to give >99.9 ee with 67% recovery.
To a stirred solution of 2-bromo-4-methylpyrimidine (1.5 g, 8.67 mmol) in CCl4 (15 mL) was added NBS (3.39 g, 19.07 mmol) and benzoyl peroxide (0.476 g, 1.907 mmol) then it was heated to 80° C. After 48 hours, the reaction mixture was cooled to ambient temperature and filtered. The black solid was discarded and liquid was concentrated to brown solid which was purified by column chromatography (10% EtOAc/Hex) to obtained a yellow solid of 2-bromo-4-(bromomethyl)pyrimidine (437.6 mg, 1.737 mmol, 20.04% yield). 1H NMR (500 MHz, DMSO-d6) δ 8.74 (d, J=4.9 Hz, 1H), 7.75 (d, J=4.9 Hz, 1H), 4.66 (s, 2H)), Mass spec.: 252.9 (MH)+.
Prepared according to the same procedure as 2-bromo-4-(bromomethyl)pyrimidine, starting with 4-chloro-6-methylpyrimidine. 1H NMR (500 MHz, DMSO-d6) δ 9.07 (s, 1H), 7.91 (d, J=0.9 Hz, 1H), 4.66 (s, 2H), Mass spec.: 208.9 (MH)+.
Prepared according to the same procedure as 2-bromo-4-(bromomethyl)pyrimidine, starting with 4-chloro-2-methylpyrimidine. 1H NMR (500 MHz, DMSO-d6) δ 8.83 (d, J=5.5 Hz, 1H), 7.69 (d, J=5.5 Hz, 1H), 4.68 (s, 2H), Mass spec.: 208.9 (MH)+.
Prepared according to the same procedure as diethyl 2,5-difluorobenzylphosphonate, starting with 2-bromo-4-(bromomethyl)pyrimidine. 1H NMR (500 MHz, DMSO-d6) δ 8.69-8.58 (m, 1H), 7.67-7.44 (m, 1H), 4.14-3.91 (m, 4H), 3.62-3.43 (m, 2H), 1.42-1.09 (m, 6H), Mass spec.: 310.1 (MH)+.
Prepared according to the same procedure as diethyl 2,5-difluorobenzylphosphonate, starting with 4-(bromomethyl)-6-chloropyrimidine. 1H NMR (500 MHz, DMSO-d6) δ 9.00 (s, 1H), 7.68 (dd, J=2.3, 1.1 Hz, 1H), 4.21-3.88 (m, 4H), 3.74-3.45 (m, 2H), 1.20 (t, J=7.0 Hz, 6H), Mass spec.: 265.1 (MH)+.
Prepared according to the same procedure as diethyl 2,5-difluorobenzylphosphonate, starting with 2-(bromomethyl)-4-chloropyrimidine. Analytical HPLC method: Phenomenex LUNA C18, 50×2 3μ, A=90% H2O/10% CH3CN, B=90% CH3CN/10% H2O, Modifier 0.1% TFA, 0.00 min=0% B, 4.0 min=100% B, 5.0 min=100% B, Flow rate=0.8 mL/min. Mass spec.: 265.1 (MH)+.
Prepared according to the same procedure as (E)-3-bromo-5-(2,5-difluorostyryl)pyridine, starting with diethyl (2-bromopyrimidin-4-yl)methylphosphonate. 1H NMR (500 MHz, DMSO-d6) δ 8.70 (d, J=5.2 Hz, 1H), 7.93 (d, J=16.2 Hz, 1H), 7.83 (ddd, J=9.3, 5.8, 3.2 Hz, 1H), 7.72 (d, J=5.2 Hz, 1H), 7.46 (d, J=16.2 Hz, 1H), 7.43-7.30 (m, 2H), Mass spec.: 299.1 (MH)+.
Prepared according to the same procedure as (E)-3-bromo-5-(2,5-difluorostyryl)pyridine, starting with diethyl diethyl (6-chloropyrimidin-4-yl)methylphosphonate. 1H NMR (500 MHz, DMSO-d6) δ 9.01 (s, 1H), 8.01 (d, J=15.9 Hz, 1H), 7.82 (d, J=0.9 Hz, 1H), 7.62 (dd, J=10.4, 1.8 Hz, 1H), 7.59-7.55 (m, 1H), 7.54-7.47 (m, 1H), 7.39 (d, J=16.2 Hz, 1H), 7.26 (td, J=8.5, 2.6 Hz, 1H), Mass spec.: 235.1 (MH)+.
Prepared according to the same procedure as (E)-3-bromo-5-(2,5-difluorostyryl)pyridine, starting with diethyl diethyl (4-chloropyrimidin-2-yl)methylphosphonate. 1H NMR (500 MHz, DMSO-d6) δ 8.80 (d, J=5.2 Hz, 1H), 7.95 (d, J=16.2 Hz, 1H), 7.71 (d, J=10.4 Hz, 1H), 7.62 (d, J=7.6 Hz, 1H), 7.57 (d, J=5.2 Hz, 1H), 7.52-7.44 (m, 1H), 7.36 (d, J=16.2 Hz, 1H), 7.23 (td, J=8.5, 2.7 Hz, 1H), Mass spec.: 235.1 (MH)+.
Prepared according to the same procedure as tert-butyl (1R,2R)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)-2-hydroxyethylcarbamate, starting with (E)-2-bromo-4-(2,5-difluorostyryl)pyrimidine. 1H NMR (500 MHz, DMSO-d6) δ 8.70 (d, J=5.2 Hz, 1H), 7.65 (d, J=5.2 Hz, 1H), 7.45 (d, J=9.8 Hz, 1H), 7.29 (ddd, J=9.0, 5.3, 3.4 Hz, 1H), 7.22-7.10 (m, 2H), 5.82 (d, J=5.2 Hz, 1H), 5.46-5.30 (m, 1H), 4.85 (dd, J=9.8, 3.1 Hz, 1H), 1.29-1.03 (m, 9H), Mass spec.: 432.1 (MH)+.
Prepared according to the same procedure as tert-butyl (1R,2R)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)-2-hydroxyethylcarbamate, starting with (E)-4-chloro-6-(3-fluorostyryl)pyrimidine. 1H NMR (500 MHz, DMSO-d6) δ 9.03 (s, 1H), 7.78 (s, 1H), 7.41-7.31 (m, 1H), 7.27-7.14 (m, 3H), 7.06 (t, J=8.5 Hz, 1H), 5.69 (d, J=5.5 Hz, 1H), 5.15-5.05 (m, 1H), 4.87 (dd, J=9.5, 3.1 Hz, 1H), 1.25 (s, 9H), Mass spec.: 368.2 (MH)+.
Prepared according to the same procedure as tert-butyl (1R,2R)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)-2-hydroxyethylcarbamate, starting with (E)-4-chloro-2-(3-fluorostyryl)pyrimidine. 1H NMR (500 MHz, DMSO-d6) δ 8.78 (d, J=5.5 Hz, 1H), 7.62 (d, J=5.2 Hz, 1H), 7.41-7.27 (m, 1H), 7.24-7.13 (m, 1H), 7.11-6.98 (m, 1H), 6.67 (d, J=9.5 Hz, 1H), 5.65 (d, J=6.4 Hz, 2H), 5.23-5.15 (m, 1H), 4.89 (dd, J=9.5, 3.7 Hz, 1H), 1.29 (s, 9H), Mass pec.: 368.2 (MH)+.
Prepared according to the same procedure as (1R,2R)-2-amino-2-(5-bromopyridin-3-yl)-1-(2,5-difluorophenyl)ethanol, starting with tert-butyl(1R,2R)-1-(2-bromopyrimidin-4-yl)-2-(2,5-difluorophenyl)-2-hydroxyethylcarbamate. Analytical HPLC method: Phenomenex LUNA C18, 50×2 3μ, A=90% H2O/10% CH3CN, B=90% CH3CN/10% H2O, Modifier 0.1% TFA, 0.00 min=0% B, 4.0 min=100% B, 5.0 min=100% B, Flow rate=0.8 mL/min. TR=1.937 min Mass spec.: 286.1 (MH)+.
Prepared according to the same procedure as (1R,2R)-2-amino-2-(5-bromopyridin-3-yl)-1-(2,5-difluorophenyl)ethanol, starting with tert-butyl(1R,2R)-1-(6-chloropyrimidin-4-yl)-2-(3-fluorophenyl)-2-hydroxyethylcarbamate. Analytical HPLC method: Phenomenex LUNA C18, 50×2 3μ, A=90% H2O/10% CH3CN, B=90% CH3CN/10% H2O, Modifier 0.1% TFA, 0.00 min=0% B, 4.0 min=100% B, 5.0 min=100% B, Flow rate=0.8 mL/min., TR=1.460 min, Mass spec.: 268.1 (MH)+.
Prepared according to the same procedure as (1R,2R)-2-amino-2-(5-bromopyridin-3-yl)-1-(2,5-difluorophenyl)ethanol, starting with tert-butyl (1R,2R)-1-(6-chloropyrimidin-4-yl)-2-(3-fluorophenyl)-2-hydroxyethylcarbamate. Analytical HPLC method: Phenomenex LUNA C18, 50×2 3μ, A=90% H2O/10% CH3CN, B=90% CH3CN/10% H2O, Modifier 0.1% TFA, 0.00 min=0% B, 4.0 min=100% B, 5.0 min=100% B, Flow rate=0.8 mL/min., TR=1.823 min, Mass spec.: 268.1
Prepared according to the same procedure as (4R,5R)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one, starting with (1R,2R)-2-amino-2-(2-chloropyrimidin-4-yl)-1-(2,5-difluorophenyl)ethanol 2HCl. 1H NMR (500 MHz, DMSO-d6) δ 8.88 (d, J=4.9 Hz, 1H), 8.69 (s, 1H), 7.68 (d, J=5.2 Hz, 1H), 7.50-7.28 (m, 3H), 5.71 (d, J=5.5 Hz, 1H), 5.04 (d, J=5.5 Hz, 1H), Mass spec.: 312.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one, starting with (1R,2R)-2-amino-2-(6-chloropyrimidin-4-yl)-1-(3-fluorophenyl)ethanol 2HCl. 1H NMR (500 MHz, DMSO-d6) δ 9.13 (s, 1H), 8.55 (s, 1H), 7.86 (s, 1H), 7.52 (td, J=7.9, 6.1 Hz, 1H), 7.42-7.17 (m, 3H), 5.62 (d, J=4.9 Hz, 1H), 4.93 (d, J=5.2 Hz, 1H), Mass spec.: 294.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one, starting with (1R,2R)-2-amino-2-(4-chloropyrimidin-2-yl)-1-(3-fluorophenyl)ethanol 2HCl, Analytical HPLC method: Phenomenex LUNA C18, 50×2 3μ, A=90% H2O/10% CH3CN, B=90% CH3CN/10% H2O, Modifier 0.1% TFA, 0.00 min=0% B, 4.0 min=100% B, 5.0 min=100% B, Flow rate=0.8 mL/min., TR=2.483 min, Mass spec.: 294.1 (MH)+.
To a stirred solution of 5-bromonicotinaldehyde (5 g, 26.9 mmol) in ethanol (Volume: 100 mL) was added sodium borohydride (0.610 g, 16.13 mmol) slowly over five min at ambient temperature. A half hour later, the reaction mixture was placed in an ice bath then slowly added 50 mL saturated ammonium chloride and stirred for 5 min. After that the reaction mixture was concentrated in vacuo to provide a white solid to which was partitioned between water and ether. The ethereal layer was dried over magnesium sulfate, and concentrated to give a clear liquid of (5-bromopyridin-3-yl)methanol (4.8 g, 24.25 mmol, 90% yield). 1H NMR (500 MHz, DMSO-d6) δ 8.59 (d, J=2.1 Hz, 1H), 8.51 (d, J=1.5 Hz, 1H), 8.01-7.93 (m, 1H), 5.46 (t, J=5.6 Hz, 1H), 4.55 (d, J=5.5 Hz, 2H), Mass spec.: 188.0 (MH)+.
To a solution of (5-bromopyridin-3-yl)methanol (1 g, 5.32 mmol) in acetic acid (Volume: 2 mL) was added hydrogen bromide (1.324 mL, 11.70 mmol) and triphenylphosphine (1.726 g, 6.38 mmol) then heat to 90° C. for four days, cooled to ambient temperature. The reaction mixture was wash with ether (20 mL×2) and EtOAc (20 mL×2) then was filtered and concentrated under high vacuum to remove solvent and provide a white solid of 3-bromo-5-((tri-phenylphosphino)methyl)pyridine bromide salt (3.05 g, 4.89 mmol, 92% yield). 1H NMR (500 MHz, DMSO-d6) δ 8.64 (s, 1H), 8.24 (s, 1H), 7.94 (t, J=7.0 Hz, 3H), 7.83-7.70 (m, 12H), 7.46 (d, J=1.5 Hz, 1H), 5.32 (d, J=15.6 Hz, 2H), Mass spec.: 434.2 (MH)+.
To a stirred solution of 3-bromo-5-((tri-phenylphosphino)methyl)pyridine bromide salt (200 mg, 0.337 mmol) in tetrahydrofuran (Volume: 4 mL) was added sodium hydride (90 mg, 0.843 mmol) at 0° C. A half hour later, 2′,5′-difluoroacetophenone (47.0 mL, 0.371 mmol) in tetrahydrofuran (Volume: 1 mL) was added to above solution. Ice bath was removed and heat it to reflux for overnight. Next morning, 10 mL water was added slowly then was extracted by ether (10 mL×3), combined all organic layers, dried over magnesium sulfate, concentrated and obtained a yellow oil which was purified by Preparative HPLC (Preparative HPLC Method 21) and obtained (Z)-3-bromo-5-(2-(2,5-difluorophenyl)prop-1-enyl)pyridine (22 mg, 0.071 mmol, 21.04%). 1H NMR (500 MHz, DMSO-d6) δ 8.45 (d, J=2.1 Hz, 1H), 8.11 (d, J=1.5 Hz, 1H), 7.49 (t, J=2.0 Hz, 1H), 7.36-7.17 (m, 3H), 6.71 (s, 1H), 2.20 (d, J=1.2 Hz, 3H), Mass spec.: 312.1 (MH)+. and (E)-3-bromo-5-(2-(2,5-difluorophenyl)prop-1-enyl)pyridine (18 mg, 0.058 mmol, 17.21%). 1H NMR (500 MHz, DMSO-d6) δ 8.64 (dd, J=6.7, 1.8 Hz, 2H), 8.11 (t, J=1.8 Hz, 1H), 7.38 (ddd, J=9.3, 6.1, 3.2 Hz, 1H), 7.32 (td, J=9.7, 4.7 Hz, 1H), 7.28-7.21 (m, 1H), 6.72 (s, 1H), 2.23 (t, J=1.5 Hz, 3H), Mass spec.: 312.1 (MH)+.
To a stirred solution of (E)-3-bromo-5-(2-(2,5-difluorophenyl)prop-1-enyl)pyridine/(Z)-3-bromo-5-(2-(2,5-difluorophenyl)prop-1-enyl)pyridine (0.7 g, 2.257 mmol), NMO (1.058 g, 9.03 mmol) in acetone (Volume: 30 mL), Water (Volume: 3.33 mL) was added osmium tetroxide (0.354 mL, 0.045 mmol) at ambient temperature. After 18 hours, the reaction mixture was cooled to 0° C., and treated with a solution of sodium thiosulfate (1.3 g) in water (12 mL) and stirred 30 min at ambient temperature, the reaction mixture was poured into water (30 mL) and diluted with ether (30 mL). The ethereal layer was washed with water (20 mL×3), then brine, dried over magnesium sulfate, and concentrated to provide a white solid which was purified via column chromatography (30% to 45% EtOAc/Hex) to provide (1R,2S)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propane-1,2-diol (138.1 mg, 0.401 mmol, 31.1% yield). 1H NMR (500 MHz, DMSO-d6) δ 8.60 (d, J=2.1 Hz, 1H), 8.48 (d, J=1.5 Hz, 1H), 7.95 (t, J=2.0 Hz, 1H), 7.24 (ddd, J=10.1, 6.3, 3.4 Hz, 1H), 7.21-7.09 (m, 2H), 5.71 (d, J=5.2 Hz, 1H), 5.56 (s, 1H), 4.89 (d, J=5.5 Hz, 1H), 1.31 (d, J=1.2 Hz, 3H), Mass spec.: 346.0 (MH)+. and (1R,2R)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propane-1,2-diol (250 mg, 0.726 mmol, 56.3% yield). 1H NMR (500 MHz, DMSO-d6) δ 8.44 (d, J=2.4 Hz, 1H), 8.02 (d, J=1.5 Hz, 1H), 7.75 (t, J=2.0 Hz, 1H), 7.20 (ddd, J=11.1, 9.0, 4.6 Hz, 1H), 7.07 (ddt, J=8.9, 7.4, 3.6 Hz, 1H), 6.93 (ddd, J=10.0, 6.2, 3.4 Hz, 1H), 5.96 (d, J=5.8 Hz, 1H), 5.66 (s, 1H), 4.84 (d, J=5.2 Hz, 1H), 1.63 (d, J=1.5 Hz, 3H), Mass spec.: 346.0 (MH)+.
To a stirred solution of (1R,2S)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propane-1,2-diol/(1R,2R)-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propane-1,2-diol (640 mg, 0.930 mmol) in methylene chloride (12 mL) was added Et3N (0.168 mL, 1.209 mmol) and methanesulfonylchloride (0.152 mL, 1.953 mmol) at −10° C. After 1 hour, the reaction mixture was warmed to ambient temperature and continue stirred for 18 hours. 80 mL ether was added to reaction mixture then washed by water, brine, dried by magnesium sulfate, concentrated to provide 0.81 g off white solid which was dissolved in methanol (70 mL) then added potassium carbonate (643 mg, 4.65 mmol) at once at ambient temperature. After one hour, the reaction mixture was concentrated to provide a yellow solid that was dissolved in 40 mL ether then washed with water, brine, dried by magnesium sulfate to give a yellow liquid that was purified via column chromatography (2% to 5% EtOAc/Hex) to provide 3-bromo-5-((2R,3R)-3-(2,5-difluorophenyl)-3-methyloxiran-2-yl)pyridine (304.6 mg, 0.887 mmol, 95% yield). 1H NMR (500 MHz, DMSO-d6) δ 8.74 (d, J=2.4 Hz, 1H), 8.62 (d, J=1.5 Hz, 1H), 8.10 (t, J=1.8 Hz, 1H), 7.41 (ddd, J=8.9, 5.6, 3.2 Hz, 1H), 7.38-7.33 (m, 1H), 7.32-7.25 (m, 1H), 4.36 (s, 1H), 1.36 (d, J=0.6 Hz, 3H), Mass spec.: 328.0 (MH)+. and 3-bromo-5-((2R,3S)-3-(2,5-difluorophenyl)-3-methyloxiran-2-yl)pyridine (108.4 mg, 0.316 mmol, 34.0% yield). 1H NMR (500 MHz, DMSO-d6) δ 8.50 (d, J=2.1 Hz, 1H), 8.28 (d, J=1.5 Hz, 1H), 7.63 (t, J=2.0 Hz, 1H), 7.30 (ddd, J=8.5, 5.4, 3.2 Hz, 1H), 7.19-7.03 (m, 2H), 4.51 (s, 1H), 1.73 (s, 3H), Mass spec.: 326.0 (MH)+.
Placed 3-bromo-5-((2R,3S)-3-(2,5-difluorophenyl)-3-methyloxiran-2-yl)pyridine (100 mg, 0.307 mmol), methanol (12 mL), water (1.500 mL), ammonium chloride (32.8 mg, 0.613 mmol), and sodium azide (120 mg, 1.840 mmol) in a microware tube and stirred for five minutes then sealed the tube and lowed it to a 110° C. oil bath for 18 hour. The reaction mixture was concentrate to provide a white solid to which was added 25 mL water then extracted it by ether (25 mL×3). Combined all ether layer, dried over magnesium sulfate, concentrated to afford clear wax which was purified via column chromatography (5% to 35% EtOAc/Hex) to provide (1R,2R)-1-azido-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propan-2-ol (96.2 mg, 0.248 mmol, 81% yield). 1H NMR (500 MHz, DMSO-d6) δ 8.73 (d, J=2.1 Hz, 1H), 8.60 (d, J=1.8 Hz, 1H), 8.06 (t, J=1.8 Hz, 1H), 7.40 (ddd, J=9.8, 6.2, 3.2 Hz, 1H), 7.33-7.15 (m, 2H), 6.14 (s, 1H), 5.13 (s, 1H), 1.33 (d, J=0.9 Hz, 3H), Mass spec.: 371.1 (MH)+.
Prepared according to the same procedure as (1R,2R)-1-azido-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propan-2-ol, starting with 3-bromo-5-((2R,3R)-3-(2,5-difluorophenyl)-3-methyloxiran-2-yl)pyridine 1H NMR (400 MHz, DMSO-d6) δ 8.57 (d, J=2.3 Hz, 1H), 8.32 (d, J=1.8 Hz, 1H), 7.86 (t, J=2.0 Hz, 1H), 7.20 (ddd, J=11.0, 9.0, 4.6 Hz, 1H), 7.15-7.02 (m, 2H), 6.38 (s, 1H), 5.08 (s, 1H), 1.72 (d, J=1.3 Hz, 3H). Mass spec.: 371.1 (MH)+.
To a solution of (1R,2S)-1-azido-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propan-2-ol (44 mg, 0.119 mmol) in tetrahydrofuran (2 mL) at 0° C. was added trimethylphosphine (0.179 mL, 0.179 mmol) drop wise. Ice bath was removed once no more nitrogen gas come out. One hour later, water (0.1000 mL) was added and continuously stirred for 18 hours. The reaction mixture was concentrated to afford a yellow oil that was redissolved in 5 mL ether then washed with 10 mL water. The ether layer was dried by magnesium sulfate, filtered, and concentrated to provide a light yellow of (1R,2S)-1-amino-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propan-2-ol (42.2 mg, 0.111 mmol, 93% yield). 1H NMR (500 MHz, DMSO-d6) δ 8.36 (d, J=2.1 Hz, 1H), 8.01 (d, J=1.8 Hz, 1H), 7.73 (t, J=2.0 Hz, 1H), 7.15 (ddd, J=11.1, 8.9, 4.7 Hz, 1H), 7.06-6.98 (m, 1H), 6.90 (ddd, J=9.9, 6.3, 3.4 Hz, 1H), 5.70 (s, 1H), 4.13 (s, 1H), 3.33 (s, 2H), 1.65 (d, J=1.5 Hz, 3H), Mass spec.: 345.1 (MH)+.
Prepared according to the same procedure as (1R,2S)-1-amino-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propan-2-ol, starting with (1R,2R)-1-azido-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propan-2-ol 1H NMR (500 MHz, DMSO-d6) δ 8.57 (d, J=2.1 Hz, 1H), 8.45 (d, J=1.5 Hz, 1H), 8.03 (t, J=1.8 Hz, 1H), 7.38-7.31 (m, 1H), 7.23-7.10 (m, 2H), 5.60 (s, 1H), 4.18 (s, 1H), 1.91 (br. s., 2H), 1.24 (d, J=1.2 Hz, 3H), Mass spec.: 343.1 (MH)+.
Prepared according to the same procedure as ((4R,5R)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one, starting with (1R,2S)-1-amino-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propan-2-ol. 1H NMR (500 MHz, DMSO-d6) δ 8.64 (s, 1H), 8.52-8.46 (m, 1H), 8.29 (s, 1H), 7.66 (s, 1H), 7.19 (ddd, J=9.2, 5.9, 3.2 Hz, 1H), 7.13-7.06 (m, 1H), 7.00 (ddd, J=10.6, 9.2, 4.6 Hz, 1H), 5.15 (d, J=1.8 Hz, 1H), 1.89 (s, 3H), Mass spec.: 371.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one, starting with (1R,2R)-1-amino-1-(5-bromopyridin-3-yl)-2-(2,5-difluorophenyl)propan-2-ol. 1H NMR (500 MHz, DMSO-d6) δ 8.77 (d, J=2.4 Hz, 1H), 8.51 (d, J=1.5 Hz, 1H), 7.95 (t, J=2.0 Hz, 1H), 7.46 (ddd, J=10.9, 9.1, 4.4 Hz, 1H), 7.40-7.33 (m, 1H), 7.25 (ddd, J=9.3, 6.1, 3.2 Hz, 1H), 5.15 (d, J=1.5 Hz, 1H), 1.85 (s, 1H) 1.25 (s, 3H), Mass spec.: 371.1 (MH)+.
A solution of (E)-4-fluorostyrylboronic acid (5 g, 30.1 mmol) and 2,4-dibromopyridine (6.49 g, 27.4 mmol) in tetrahydrofuran (150 mL) was purged with nitrogen for 20 min. To this was added Pd(Ph3P)4 (2.37 g, 2.05 mmol) and a 10% w/w solution of thallium(I) hydroxide (137 g, 62 mmol) in water. The reaction was stirred under nitrogen at room temperature. After 3 h, the gray suspension was diluted with dichloromethane and filtered through celite. The organics were washed with water, dried over magnesium sulfate, and concentrated. The resulting residue was purified by column chromatography (5%→13% EtOAc/Hex) to give 2.65 g (33%). 1H NMR (CDCl3) Shift: 8.43 (d, J=5.2 Hz, 1H), 7.64 (d, J=15.9 Hz, 1H), 7.50-7.59 (m, 3H), 7.34 (dd, J=5.3, 1.7 Hz, 1H), 7.10 (t, J=8.7 Hz, 2H), 7.02 (d, J=16.2 Hz, 1H). 13C NMR (CDCl3) Shift: 163.1, 157.0, 150.4, 133.3, 133.2, 132.5, 129.0, 126.4, 125.3, 116.0. 19F NMR (CDCl3) Shift: −112.69 (bs, 1F). Mass spec.: 278.2 (MH)+.
To a suspension of methyltriphenylphosphonium bromide (26.4 g, 73.9 mmol) in tetrahydrofuran (350 mL) at 0° C. was added nBuLi (2.5M in hexane, 29.6 mL, 73.9 mmol). After addition was complete, the reaction was stirred at 0° C. for 10 min. To this was added 2,5-difluorobenzaldehyde (5.35 mL, 49.3 mmol). The ice bath was removed, and stirring continued for 1 h. The reaction was quenched by addition of saturated ammonium chloride. The reaction was poured into ether, washed with water (3×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (2.5% EtOAc/Hex) gave 2.1 g (30%) as a colorless oil. 1H NMR (CDCl3) Shift: 7.20 (ddd, J=9.2, 5.9, 3.2 Hz, 1H), 7.02 (td, J=9.3, 4.6 Hz, 1H), 6.90-6.97 (m, 1H), 6.86 (dd, J=17.7, 11.3 Hz, 1H), 5.84 (d, J=17.7 Hz, 1H), 5.45 (d, J=11.0 Hz, 1H). 13C NMR (CDCl3) Shift: 158.6, 156.3, 128.6, 126.8, 117.6, 116.8, 115.6, 113.0. 19F NMR (CDCl3) Shift: −120.17-119.46 (m, 1F), −125.20 (d, J=17.3 Hz, 1F).
A suspension of 2-bromo-5-fluoropyridin-4-ylboronic acid (1.569 g, 7.14 mmol) and 1,4-difluoro-2-vinylbenzene (1 g, 7.14 mmol) in dimethylformamide (20 mL) was flushed with a balloon of oxygen. To this was added sodium carbonate (1.51 g, 14.3 mmol) and palladium(II) acetate (0.16 g, 0.71 mmol) as solids in one portion. The flask was flushed with another balloon of oxygen and fitted with a balloon of oxygen. The reaction was warmed to 50° C. After 1 h, the reaction was treated with a second portion of sodium carbonate (0.75 g) and boronic acid (1.6 g). This process was repeated twice more (total boronic acid addition=6.3 g). The reaction was cooled to room temperature, diluted with ether, washed with water (3×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (2.5%→5% EtOAc/Hex) gave 89 mg (4.0%) as a white solid. 1H NMR (CDCl3) Shift: 8.28 (d, J=1.8 Hz, 1H), 7.68 (d, J=5.5 Hz, 1H), 7.49 (d, J=16.5 Hz, 1H), 7.33 (ddd, J=8.9, 5.8, 3.1 Hz, 1H), 7.17 (d, J=16.8 Hz, 1H), 6.98-7.14 (m, 2H). 19F NMR (CDCl3) Shift: −118.54 (d, J=13.0 Hz, 1F), −122.71 (br. s., 1F), −135.71 (br. s., 1F). Mass spec.: 314.0 (MH)+.
To tert-butyl carbamate (206 mg, 1.76 mmol) in propanol (1 mL) was added sodium hydroxide (69.1 mg, 1.73 mmol) in water (1.9 mL) followed by tert-butyl hypochlorite (0.195 mL, 1.73 mmol). After 5 min, the solution was cooled to 0° C. and treated with a solution of (DHQD)2PHAL (22.1 mg, 0.028 mmol) in propanol (0.9 mL). The reaction was diluted with propanol (1.25 mL) and treated with (E)-2-bromo-4-(2,5-difluorostyryl)-5-fluoropyridine (89 mg, 0.28 mmol) as a solid in one portion. To this was added potassium osmate dihydrate (8.4 mg, 0.023 mmol) as a solid in one portion. The reaction was allowed to gradually warm to room temperature in the dewar over 8 h. The reaction was cooled to 0° C. and quenched by addition of sodiumthiosulfate (210 mg) in water (1 mL). The reaction was stirred at room temperature for 30 min. The reaction was extracted with ether (2×). The ethereal was washed with water (2×), then brine, dried over magnesium sulfate, and concentrated to give a solid (quant.). The material was used without purification. Mass spec.: 447.1 (MH)+.
Optically-enriched tert-butyl (1R,2R)-1-(2-bromo-5-fluoropyridin-4-yl)-2-(2,5-difluorophenyl)-2-hydroxyethylcarbamate (253 mg, 0.283 mmol) was dissolved in trifluoroacetic acid (10% in dichloromethane, 10 mL) and stirred at room temperature overnight. In the morning, the reaction was concentrated and loaded onto a strong cation exchange cartridge. The cartridge was flushed with several volumes of methanol which were discarded. The crude aminoalcohol was eluted with 2M ammonia in methanol and concentrated to give 53 mg as a solid. The crude solid was dissolved in tetrahydrofuran (5 mL), cooled to 0° C., and treated with carbonyldiimidazole (45.9 mg, 0.283 mmol). After 5 min, the ice bath was removed, and stirring continued for 1 h. The reaction was quenched by addition of 2M ammonia in methanol. The reaction was concentrated and purified by column chromatography (25%→50% EtOAc/Hex) to give 20 mg (9.5%). Mass spec.: 373.1 (MH)+.
A round bottom flask was charged with 1,4-difluoro-2-vinylbenzene (1 g, 7.14 mmol), 5-bromo-2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (2.69 g, 8.92 mmol), and DMF (27 mL). The resulting mixture was purged with a stream of oxygen for 10 min. To this was added sodium carbonate (1.89 g, 17.8 mmol) and palladium (II) acetate (0.128 g, 0.571 mmol) as a solid in a single portion. The reaction was purged with oxygen for 5 min. The reaction was fitted with a balloon of oxygen and stirred at room temperature overnight. In the morning, the reaction was diluted with ethyl acetate and poured into water. The mixture was treated with excess celite and filtered to remove solids. The organic layer was washed with water (2×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (10% EtOAc/Hex) gave 409 mg (17%). 1H NMR (CDCl3) δ: 8.16-8.22 (m, 1H), 8.13 (dd, J=8.2, 2.4 Hz, 1H), 7.29-7.39 (m, 2H), 7.06-7.20 (m, 2H), 6.97-7.06 (m, 1H). 19F NMR (CDCl3) δ: −74.07 (d, J=8.7 Hz, 1F), −118.78 (d, J=8.7 Hz, 1F), −123.39 (br. s., 1F). Mass spec.: 314.1 (MH)+.
To tert-butyl carbamate (0.462 g, 3.95 mmol) in propanol (6 mL) was added sodium hydroxide (0.155 g, 3.88 mmol) in water (12 mL) followed by tert-butyl hypochlorite (0.438 mL, 3.88 mmol). The solution was cooled to 0° C., and (DHQD)2PHAL (0.060 g, 0.076 mmol) was added in propanol (6 mL), followed by (E)-5-bromo-3-(2,5-difluorostyryl)-2-fluoropyridine (0.4 g, 1.273 mmol) as a solid. The remaining residue was dissolved in propanol (12 mL) and added to the reaction mixture to give a suspension. To this was added potassium osmate dihydrate (0.019 g, 0.051 mmol) as a solid in one portion. The reaction was allowed to gradually warm in the dewar overnight. The reaction was recooled to 0° C., and the reaction quenched by addition of sodium thiosulfate (0.5 g) in water (3 mL). The ice bath was removed, and the reaction stirred at room temperature for 30 min. The reaction was diluted with diethyl ether, washed with water (2×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (25% EtOAc/Hex) gave 0.445 g (78%) as a white foam solid. Mass spec.: 447.1 (MH)+.
To a solution of optically-enriched tert-butyl (1R,2R)-1-(5-bromo-2-fluoropyridin-3-yl)-2-(2,5-difluorophenyl)-2-hydroxyethylcarbamate (380 mg, 0.850 mmol) in dichloromethane (6 mL) at room temperature was added hydrochloric acid (4M in dioxane, 10 mL, 40.0 mmol). The resulting solution was placed in a 45° C. bath. After 20 min, the reaction was concentrated. The resulting viscous oil was dissolved in and reconcentrated from tetrahydrofuran (3×) to give a white solid. The resulting residue was suspended in tetrahydrofuran (15 mL), and treated with diethylisopropylamine (0.297 mL, 1.70 mmol). After stirring briefly, the mixture was cooled to 0° C. and treated with carbonyldiimidazole (207 mg, 1.27 mmol) as a solid in one portion. The ice bath was removed and stirring continued for 1.5 h. The reaction was quenched by addition of 2M ammonia in methanol and concentrated. The material was purified by column chromatography (EtOAc/Hex) to give the product as a mixture of regioisomers. The material was re-purified by chiral prep HPLC (Chiralcel OJ, 30% EtOH/heptane/0.1% DEA) to afford 88 mg (25%). 1H NMR (CDCl3) δ: 8.33 (dd, J=2.3, 1.4 Hz, 1H), 8.11 (dd, J=8.2, 2.1 Hz, 1H), 7.21-7.27 (m, 1H), 7.09-7.17 (m, 2H), 6.48 (br. s., 1H), 5.58 (d, J=5.8 Hz, 1H), 5.04 (d, J=5.5 Hz, 1H). 19F NMR (CDCl3) δ: −74.27 (br. s., 1F), −116.97 (d, J=17.3 Hz, 1F), −123.78-123.41 (m, 1F). Mass spec.: 373.0 (MH)+.
Prepared according to the method used to prepare diethyl 3-fluorobenzylphosphonate starting with 1-(bromomethyl)-2-fluorobenzene. 1H NMR (CDCl3) δ: 7.36 (t, J=7.5 Hz, 1H), 7.19-7.25 (m, 1H), 7.07-7.13 (m, 1H), 7.04 (t, J=9.2 Hz, 1H), 3.99-4.08 (m, 4H), 3.15-3.24 (m, 2H), 1.25 (td, J=7.0, 0.9 Hz, 6H).
To a solution of 2-bromo-5-fluoroisonicotinaldehyde (2 g, 9.80 mmol) and diethyl 2-fluorobenzylphosphonate (2.66 g, 10.78 mmol) in tetrahydrofuran (80 mL) at 0° C., was added potassium tert-butoxide(1M in tetrahydrofuran, 12.75 mL, 12.75 mmol) dropwise over a couple of minutes. When addition was complete, the reaction was allowed to stir at 0° C. for 45 min and quenched by addition of saturated ammonium chloride. The reaction was diluted with ether, washed with water (4×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (8%→15% EtOAc/Hex) gave 450 mg as an oil with solid crystallizing from the mixture. The material was triturated with hexanes (2×) to give a fine white powder. 1H NMR (CDCl3) δ: 8.26 (d, J=1.5 Hz, 1H), 7.69 (d, J=5.5 Hz, 1H), 7.64 (td, J=7.6, 1.5 Hz, 1H), 7.54 (d, J=16.8 Hz, 1H), 7.30-7.41 (m, 1H), 7.17-7.26 (m, 2H), 7.11-7.17 (m, 1H). 13C NMR (CDCl3) δ: 161.0, 156.7, 138.8, 136.6, 135.5, 131.0, 129.3, 127.9, 124.6, 123.7, 119.4, 116.3. 19F NMR (CDCl3) δ: −116.72 (br. s., 1F), −136.08 (br. s., 1F).
To tert-butyl carbamate (150 mg, 1.28 mmol) in n-propanol (1.75 mL) was added sodium hydroxide (49.8 mg, 1.25 mmol) in water (3.5 mL) followed by tert-butyl hypochlorite (0.141 mL, 1.246 mmol). After 5 min, the solution was cooled to 0° C. and treated with a solution of DHQD2(PHAL) (16.57 mg, 0.021 mmol) in n-propanol (1.75 mL). The reaction was diluted with n-propanol (3.5 mL) and treated with (E)-2-bromo-5-fluoro-4-(2-fluorostyryl)pyridine (90 mg, 0.304 mmol) as a solid in one portion. To this was added potassium osmate dihydrate (5.60 mg, 0.015 mmol) as a solid in one portion. The reaction was allowed to gradually warm to room temperature in the dewar overnight. The reaction was cooled to 0° C. and quenched by addition of sodium thiosulfate (150 mg) in water (3 mL). The ice bath was removed and stirring continued for 30 min. The reaction was diluted with ether, washed with water (3×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (25% EtOAc/Hex) gave 93 mg (36%) as a foam solid. Mass spec.: 429.1 (MH)+.
To a solution of optically-enriched tert-butyl (1R,2R)-1-(2-bromo-5-fluoropyridin-4-yl)-2-(2-fluorophenyl)-2-hydroxyethylcarbamate (93 mg, 0.108 mmol) in dichloromethane (2 mL) at room temperature was added hydrogen chloride (4M in dioxane, 2 mL, 8 mmol). The reaction was warmed to 45° C. and held at that temperature for 1 h. The reaction was concentrated. The reaction was concentrated twice more from tetrahydrofuran. The resulting residue was suspended in tetrahydrofuran (2 mL), cooled to 0° C., and treated with diethylisopropylamine (0.038 mL, 0.217 mmol) and carbonyldiimidazole (26.3 mg, 0.162 mmol). After 5 min, the ice bath was removed and stirring continued for 3 h. The reaction was quenched by addition of 2M ammonia in methanol and concentrated. The resulting residue was suspended in dichloromethane, diluted with ethyl acetate, washed with brine, dried over magnesium sulfate, and concentrated. Column chromatography (25%→50% EtOAc/Hex) gave 37.8 mg (49%) as a colorless film. HNMR showed that it was a 1:1 mixture of regioisomers. The mixture was used without separation. Mass spec.: 355.0 (MH)+.
To a solution of 6-bromo-3-fluoropicolinaldehyde (2.147 g, 10.5 mmol) and diethyl benzylphosphonate (2.413 mL, 11.6 mmol) in tetrahydrofuran (80 mL) at 0° C., was added potassium tert-butoxide(1M in tetrahydrofuran, 11.6 mL, 11.6 mmol) dropwise over a couple of minutes. When addition was complete, the reaction was allowed to stir at 0° C. for 45 min and quenched by addition of saturated ammonium chloride. The reaction was diluted with ether, washed with water (4×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (8%→15% EtOAc/Hex) gave 121 mg (4.1%). 1H NMR (CDCl3) δ: 7.86 (d, J=16.2 Hz, 1H), 7.64 (d, J=7.3 Hz, 2H), 7.39-7.47 (m, 2H), 7.22-7.39 (m, 4H). 19F NMR (CDCl3) δ: −130.05 (br. s., 1F). Mass spec.: 278.0 (MH)+.
To tert-butyl carbamate (214 mg, 1.827 mmol) in n-propanol (1.75 mL) was added sodium hydroxide (71.3 mg, 1.784 mmol) in water (3.5 mL) followed by tert-butyl hypochlorite (0.201 mL, 1.78 mmol). After 5 min, the solution was cooled to 0° C. and treated with a solution of DHQD2(PHAL) (23.7 mg, 0.030 mmol) in n-propanol (1.75 mL). The reaction was diluted with n-propanol (3.5 mL), and treated with (E)-6-bromo-3-fluoro-2-styrylpyridine (121 mg, 0.435 mmol) as a solid in one portion. To this was added potassium osmate dihydrate (8.01 mg, 0.022 mmol) as a solid in one portion. The reaction was allowed to gradually warm to room temperature in the dewar overnight. The reaction was cooled to 0° C. and quenched by addition of sodium thiosulfate (150 mg) in water (3 mL). The ice bath was removed and stirring continued for 30 min. The reaction was diluted with ether, washed with water (3×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (25% EtOAc/Hex) gave 208 mg (quant.). Mass spec.: 411.1 (MH)+.
Optically-enriched tert-butyl (1R,2R)-1-(6-bromo-3-fluoropyridin-2-yl)-2-hydroxy-2-phenylethylcarbamate (208 mg, 0.506 mmol) was dissolved in trifluoroacetic acid (25% in dichloromethane, 10 mL). After 2 h at room temperature, the reaction was concentrated. The resulting residue was loaded onto a strong cation exchange cartridge which was flushed with several volumes of methanol and discarded. The product was eluted with 2M ammonia in methanol and concentrated. The resulting residue was suspended in tetrahydrofuran (2 mL), cooled to 0° C., and treated with carbonyldiimidazole (123 mg, 0.759 mmol). After 5 min, the ice bath was removed and stirring continued overnight. The reaction was quenched by addition of 2M ammonia in methanol and concentrated. The resulting residue was purified by column chromatography (25%→50% EtOAc/Hex) to give 96 mg (28%) as a white foam solid. Mass spec.: 337.0 (MH)+.
To a solution of (6-bromopyridin-2-yl)methanol (12.5 g, 66.5 mmol) and triethylamine (12.1 mL, 86 mmol) in dichloromethane (150 mL) at 0° C. was added methanesulfonylchloride (5.44 mL, 69.8 mmol) dropwise. After 1 h at 0° C., the reaction was diluted with ether, quenched by addition of saturated sodium bicarbonate, and stirred for 30 min at 0° C. The layers were separated and the organics washed with water, then brine, dried over magnesium sulfate, and concentrated (quant.). Mass spec.: 266.0 (MH)+.
To a suspension of sodium hydride (5.32 g, 133 mmol) in tetrahydrofuran (250 mL) in a room temperature bath was added diethylphosphite (17.2 mL, 133 mmol) dropwise. After addition was complete, the room temperature bath was removed. After 2 h, the resulting mixture was cooled to 0° C. and treated with a solution of the crude mesylate in tetrahydrofuran (125 mL). After 1 h at 0° C., the ice bath was removed and stirring continued for 2 h. The reaction was poured into ether (1 L), washed with water (3×), then brine, dried over MgSO3, and concentrated. Column chromatography (50% EtOAc/Hex→100% EtOAc) gave 12.58 g (61%) as a faint yellow oil. 1H NMR (CDCl3) δ: 7.49-7.56 (m, 1H), 7.39 (td, J=8.2, 2.3 Hz, 2H), 4.07-4.17 (m, 4H), 3.35-3.46 (m, 2H), 1.31 (t, J=7.0 Hz, 6H). 13C NMR (CDCl3) δ: 154.2, 141.5, 138.9, 126.4, 123.3, 62.5, 36.3, 16.4. Mass spec.: 308.1 (MH)+.
To a solution of diethyl (6-bromopyridin-2-yl)methylphosphonate (320 mg, 1.039 mmol) in tetrahydrofuran (9.4 mL) was added 2-fluorobenzaldehyde (129 mg, 1.04 mmol). The resulting solution was cooled to 0° C., and treated with potassium tert-butoxide (1M in tetrahydrofuran, 1.1 mL, 1.1 mmol). After 15 min at 0° C., the reaction was quenched by addition of saturated ammonium chloride and concentrated. The resulting residue was dissolved in ether, washed with water, then brine, dried over magnesium sulfate, and concentrated to give an oil which solidified upon standing. The solid was triturated with hexane to afford 215 mg (78%). 1H NMR (CDCl3) δ: 7.78 (d, J=16.2 Hz, 1H), 7.64 (td, J=7.6, 1.5 Hz, 1H), 7.50-7.58 (m, 1H), 7.37 (t, J=7.8 Hz, 2H), 7.29-7.34 (m, 1H), 7.15-7.26 (m, 2H), 7.12 (dd, J=10.5, 8.7 Hz, 1H). 13C NMR (CDCl3) δ: 161.1, 157.0, 142.3, 138.9, 130.1, 129.0, 128.4, 127.2, 126.5, 124.4, 124.2, 120.8, 116.1 19F NMR (CDCl3) δ: −116.28 (br. s., 1F). Mass spec.: 278.0 (MH)+.
To tert-butyl carbamate (270 mg, 2.31 mmol) in propanol (3 mL) was added sodium hydroxide (91 mg, 2.27 mmol) in water (6 mL) followed by tert-butyl hypochlorite (0.256 mL, 2.27 mmol). The solution was cooled to 0° C. and (DHQD)2PHAL (34.8 mg, 0.045 mmol) was added in propanol (3 mL) followed by (E)-2-bromo-6-(2-fluorostyryl)pyridine (207 mg, 0.744 mmol) in propanol (6 mL). To this was added potassium osmate dihydrate (10.97 mg, 0.030 mmol) as a solid in one portion. The reaction was allowed to gradually warm to room temperature in the dewar overnight. The reaction was cooled to 0° C. and quenched by addition of sodiumthiosulfate (300 mg) in water (3 mL). The reaction was stirred at room temperature for 30 min. The reaction was diluted with ether, washed with water (2×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (15%→30% EtOAc/Hex) gave 375 mg (quant.). Mass spec.: 411.2 (MH)+.
To a solution of optically-enriched tert-butyl (1R,2R)-1-(6-bromopyridin-2-yl)-2-(2-fluorophenyl)-2-hydroxyethylcarbamate (375 mg, 0.912 mmol) in dichloromethane (4 mL) at room temperature was added hydrogen chloride (4M in dioxane, 3 mL, 12 mmol). After 15 min at room temperature, the reaction was warmed to 45° C. and held at that temperature for 15 min. The reaction was cooled and concentrated. The reaction was concentrated twice more from tetrahydrofuran. The resulting residue was suspended in tetrahydrofuran (10 mL), cooled to 0° C., and treated with diisopropylethylamine (0.319 mL, 1.82 mmol) and carbonyldiimidazole (222 mg, 1.368 mmol). After 5 min, the ice bath was removed and stirring continued for 3 h. The reaction was quenched by addition of 2M ammonia in methanol and concentrated. The resulting residue was suspended in dichloromethane, diluted with ethyl acetate, washed with brine, dried over magnesium sulfate, and concentrated. Column chromatography (25%→50% EtOAc/Hex) gave 75 mg. 1H NMR (CDCl3) δ: 7.60-7.68 (m, 1H), 7.46-7.56 (m, 2H), 7.35-7.45 (m, 2H), 7.24 (td, J=7.7, 1.0 Hz, 1H), 7.12 (ddd, J=10.3, 8.3, 1.0 Hz, 1H), 7.03 (s, 1H), 5.80 (d, J=5.3 Hz, 1H), 4.93 (d, J=5.3 Hz, 1H). 13C NMR (CDCl3) δ: 160.9, 158.9, 158.4, 142.0, 139.2, 130.5, 127.8, 127.2, 125.0, 124.3, 119.6, 115.6, 78.5, 63.1. 19F NMR (CDCl3) δ: −121.48-113.54 (m, 1F). Mass spec.: 337.1 (MH)+.
A solution of 5-bromonicotinaldehyde (15 g, 81 mmol) and ethynylbenzene (9.74 mL, 89 mmol) in triethylamine (150 mL) was purged with nitrogen for 30 min. The reaction was treated with triphenylphosphine (0.656 g, 2.50 mmol), and purged 10 minutes longer. To this was added bis(triphenylphosphine)palladium dichloride (0.147 g, 0.210 mmol) and copper(I) iodide (0.032 g, 0.169 mmol). After purging 10 min longer, the reaction was warmed to a gentle reflux. The reaction was heated at reflux for 24 h. The reaction was cooled to room temperature, diluted with ethyl acetate, poured into water, and the layers were separated. The organics were washed again with water, then brine, dried over magnesium sulfate, and concentrated. Column chromatography (20% EtOAc/Hex) gave 16.05 g (96%) as faint yellow crystalline solid. 1H NMR (CDCl3) δ: 10.16 (s, 1H), 9.01 (dd, J=17.1, 1.8 Hz, 2H), 8.30 (t, J=2.0 Hz, 1H), 7.54-7.66 (m, 2H), 7.38-7.47 (m, 3H). 13C NMR (CDCl3) δ: 190.2, 156.8, 150.3, 138.2, 131.9, 130.9, 129.4, 128.7, 122.0, 121.5, 94.5, 84.7. Mass spec.: 208.0 (MH)+.
To a suspension of 5-(Phenylethynyl)nicotinaldehyde (7.0 g, 33.8 mmol) in ethanol (150 mL), immersed in a room temperature bath to moderate any potential exotherm, was added sodium borohydride (0.639 g, 16.9 mmol) in one portion. After 30 min at room temperature, the reaction was cooled to 0° C. and quenched by the cautious addition of saturated ammonium chloride. The reaction was concentrated and partitioned between water and ether. The aqueous was extracted with ether (2×). The organics were washed with brine, dried over magnesium sulfate, and concentrated to give a faint yellow solid. Material was used without purification. 1H NMR (CDCl3) δ: 8.39-8.81 (m, 2H), 7.88 (s, 1H), 7.51-7.61 (m, 2H), 7.34-7.44 (m, 3H), 4.77 (s, 2H), 3.21 (br. s., 1H). 13C NMR (CDCl3) δ: 151.1, 147.1, 137.3, 131.8, 129.0, 128.6, 122.5, 93.0, 85.9, 62.3. Mass spec.: 210.1 (MH)+.
To a solution of (5-(phenylethynyl)pyridin-3-yl)methanol (7.0 g, 33.5 mmol) and triethylamine (6.06 mL, 43.5 mmol) in dichloromethane (150 mL) at 0° C. was added methanesulfonylchloride (2.74 mL, 35.1 mmol) dropwise. After 30 min at 0° C., the reaction was diluted with ether, quenched by addition of saturated sodium bicarbonate, and stirred for 30 min at 0° C. The layers were separated. The organics were washed with water, then brine, dried over magnesium sulfate, and concentrated to afford the crude mesylate which was used without purification. Mass spec.: 288.1 (MH)+.
To a solution of the crude mesylate (9.6 g, 33.4 mmol) in dimethylformamide (134 mL) at 0° C. was added sodium azide (4.34 g, 66.8 mmol). The reaction was stirred at 0° C. for 1 h. The reaction was diluted with ether, washed with water, then brine, dried over magnesium sulfate, and concentrated to give 7.83 g (90%) as a light yellow oil which was used without purification. 1H NMR (CDCl3) δ: 8.76 (d, J=1.8 Hz, 1H), 8.53 (d, J=2.1 Hz, 1H), 7.83 (t, J=2.1 Hz, 1H), 7.54-7.63 (m, 2H), 7.37-7.45 (m, 3H), 4.44 (s, 2H). 13C NMR (CDCl3) δ: 152.1, 148.0, 138.0, 131.9, 130.9, 129.1, 128.6, 122.4, 120.8, 93.4, 85.5, 51.9. Mass spec.: 235.1 (MH)+.
To a solution of 3-(azidomethyl)-5-(phenylethynyl)pyridine (7.8 g, 33.3 mmol) in tetrahydrofuran (101 mL) at 0° C. was added trimethylphosphine (1M in tetrahydrofuran, 49.9 mL, 49.9 mmol). After evolution of nitrogen had slowed, the ice bath was removed and stirring continued for 1 h. To this was added water (6.0 mL, 333 mmol) and the mixture stirred at room temperature for 2 h. The reaction was concentrated, dissolved in ether, washed with water (5×), then brine, dried over potassium carbonate, filtered, and concentrated to give 5.96 g (77%) as a faint yellow solid which was used without purification. 1H NMR (CDCl3) δ: 8.67 (d, J=1.8 Hz, 1H), 8.52 (d, J=2.1 Hz, 1H), 7.85 (t, J=2.0 Hz, 1H), 7.53-7.61 (m, 2H), 7.35-7.44 (m, 3H), 3.95 (s, 2H), 1.45 (d, J=5.2 Hz, 2H)1H NMR (CDCl3) δ: 8.67 (d, J=1.8 Hz, 1H), 8.52 (d, J=2.1 Hz, 1H), 7.85 (t, J=2.0 Hz, 1H), 7.53-7.61 (m, 2H), 7.35-7.44 (m, 3H), 3.95 (s, 2H), 1.45 (d, J=5.2 Hz, 2H). 13C NMR (CDCl3) δ: 150.8, 147.9, 137.8, 137.4, 131.8, 128.9, 128.6, 122.7, 120.3, 92.7, 86.1, 43.7. Mass spec.: 209.1 (MH)+.
A flask was charged with (5-(phenylethynyl)pyridin-3-yl)methanamine (5.95 g, 28.6 mmol). The oil was concentrated from toluene (2×) to remove any possible moisture. The oil was dissolved in dichloromethane (30 mL) and treated with benzophenone imine (5.03 mL, 30.0 mmol). The reaction was stirred at room temperature for 1 h. The reaction was heated to reflux, applying a gentle stream of nitrogen at the top of the reflux condensor to allow removal of expelled ammonia. After 8 h, the reaction was cooled to room temperature and allowed to stir at room temperature over the weekend. The reaction was concentrated to give the crude product as a viscous oil. The oil was dissolved in toluene to give a total volume of 50 mL (assumed concentration=0.21 g/mL). This intermediate was stored as a solution in toluene and was dispensed as such for subsequent chemistries. Data for the neat, crude title compound is as follows: 1H NMR (CDCl3) δ: 8.68 (d, J=1.8 Hz, 1H), 8.51 (d, J=1.8 Hz, 1H), 7.88 (s, 1H), 7.69-7.77 (m, 2H), 7.36-7.61 (m, 11H), 7.24 (dd, J=7.8, 1.7 Hz, 2H), 4.63 (s, 2H). 13C NMR (CDCl3) δ: 170.2, 150.6, 148.3, 139.4, 137.8, 136.5, 135.8, 131.8, 130.5, 128.9, 128.9, 128.8, 128.7, 128.5, 128.4, 128.3, 127.7, 122.8, 120.2, 92.5, 86.4, 54.7.
To a suspension of 5-bromo-2-fluoronicotinaldehyde (5.00 g, 24.51 mmol) in ethanol (125 mL) immersed in a room temperature bath to moderate any potential exotherm was added sodium borohydride (0.464 g, 12.26 mmol) in one portion. After 30 minutes at room temperature, LC/MS indicated clean, complete conversion to the product. The reaction was cooled to 0 C and quenched by the cautious addition of saturated ammonium chloride solution (effervescence). The reaction was concentrated and partitioned between water and ether. The etheral was washed with water (2×), then brine, dried over anhydrous magnesium sulfate and concentrated to give a yellow oil which solidified upon standing to give 4.66 g (92% yield) of title compound as yellow crystalline solid. 1H-NMR (CDCl3, 500 MHz) δ: 8.21 (s, 1H), 8.08 (ddd, J=8.3, 1.6, 0.8 Hz, 1H), 4.70-4.88 (m, 2H). Mass spec.: 206.0 (MH)+.
Prepared according to the same procedure as diethyl (6-bromopyridin-2-yl)methylphosphonate, starting with (5-Bromo-2-fluoropyridin-3-yl)methanol. 1H-NMR (CDCl3, 500 MHz) δ: 8.18 (d, J=1.2 Hz, 1H), 7.94 (dt, J=8.4, 2.5 Hz, 1H), 4.10-4.16 (m, 4H), 3.10-3.20 (m, 2H), 1.31 (t, J=7.2 Hz, 6H). 13C-NMR (CDCl3, 126 MHz) δ: 147.1, 144.5, 117.0, 116.5, 62.7, 26.9, 25.7, 16.5. Mass spec.: 328.0 (MH)+.
A 250 mL round-bottomed flask equipped with a magnetic stirring bar was charged with 1-(6-bromopyridin-2-yl)ethanone (5.00 g, 25.00 mmol), ammonium chloride (1.538 g, 28.7 mmol), ammonia (3.3 mL, 25.00 mmol), ethanol (7.5 mL), and water (6.3 mL). The resulting suspension was treated with sodium cyanide (1.409 g, 28.7 mmol), and the flask was quickly sealed with a rubber stopper. The mixture was stirred overnight. The reaction was extracted with dichloromethane (3×), the combined organic layer was washed with water to remove the remaining sodium cyanide, dried with anhydrous magnesium sulfate, and concentrated under reduced pressure to afford title compound (quant.) as yellowish sticky oil residue which was used without purification. Mass spec.: 225.9 (MH)+.
A dry 3-neck round-bottom flask (250 mL) was attached via an adaptor and rubber tubing to a funnel submerged in saturated sodium bicarbonate. The flasked was cooled to 0° C. and anhydrous ethanol (127.5 mL) was added. The ethanol was saturated with hydrochloric acid (g) for 10 min. 2-Amino-2-(6-bromopyridin-2-yl)propanenitrile (5.65 g, 25 mmol) in ethanol (13 mL) was added to the reaction mixture and stirred at 65° C. under nitrogen balloon for 24 h. Reaction was cooled to room temperature, concentrated under reduced pressure, and partitioned between water (250 mL) and ethyl acetate (250 mL). The aqueous layer was isolated, saturated sodium bicarbonate was added to adjust solution PH to 8, and the product extracted into ethyl acetate (3×250 mL). The combined organics were dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to afford 4.45 g as dark yellow oil which was used without purification. Mass spec.: 229.0, 273.0 (MH)+.
To a solution of ethyl 2-amino-2-(6-bromopyridin-2-yl)propanoate and ethyl 2-amino-2-(6-chloropyridin-2-yl)propanoate (4.45 g, 16.29 mmol) in tetrahydrofuran (150 mL) at 0° C. was added di-tert-butyl dicarbonate (7.11 g, 32.6 mmol). After stirring at room temperature for an hour, the reaction was heated at reflux overnight. The reaction was cooled to room temperature and concentrated under reduced pressure. Biotage purification (10% EtOAc/Hex) gave 6.2 g as a clear sticky oil. Mass spec.: 351.1, 395.0 (MNa)+.
A solution of ethyl 2-(6-bromopyridin-2-yl)-2-(tert-butoxycarbonylamino)propanate and ethyl 2-(6-chloropyridin-2-yl)-2-(tert-butoxycarbonylamino)propanate (6.00 g, 16.08 mmol) in tetrahydrofuran (150 mL) was cooled to 0° C. To this was added lithium borohydride (2.0M solution in tetrahydrofuran, 16.08 mL, 32.2 mmol). The reaction was allowed to warm to room temperature over 3 h, recooled to 0° C., quenched by addition of methanol, diluted with water (300 mL), and extracted with ethyl acetate (2×300 mL). The organics were combined, washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo to give 5.3 g as clear sticky oil. Mass spec.: 309.1, 353.0 (MNa)+.
To a solution of tert-butyl 2-(6-bromopyridin-2-yl)-1-hydroxypropan-2-ylcarbamate and tert-butyl 2-(6-chloropyridin-2-yl)-1-hydroxypropan-2-ylcarbamate (400 mg, 1.208 mmol) in tetrahydrofuran (10 mL) was added Dess-MartinPeriodinane (307 mg, 0.725 mmol). After 2 h, the reaction was quenched with 1:1 saturated sodium bicarbonate and sodium hydrogen sulfite and extracted into dichloromethane. The organic layer was washed with water, brine, and dried with anhydrous magnesium sulfate, filtered and concentrated. Biotage purification to afford 325 mg as a mixture of the two aldehydes as clear sticky oil.
In a separate flask, isopropylmagnesium chloride (0.664 mL, 1.328 mmol) was added to a solution of 1-bromo-2-fluorobenzene (0.132 mL, 1.208 mmol) in tetrahydrofuran (1.5 mL) at 0° C. The solution was stirred at 0° C. for 1.25 h, then cooled to −78 C. To this was added the above prepared aldehyde in tetrahydrofuran (1.5 mL) dropwise. The reaction was warmed slowly to 0° C. (over 2 h) and quenched by addition of a cold aqueous solution of ammonium chloride. The reaction mixture was extracted with ethyl acetate, and the organics washed with water, then brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. Biotage purification (15% EtOAc/Hex) gave 200 mg (39% yield) as a white foam solid. Mass spec.: 403.1 (MNa)+, 447.1 (MH)+.
To a cold (0° C.) solution of tert-butyl 2-(6-bromopyridin-2-yl)-1-(2-fluorophenyl)-1-hydroxypropan-2-ylcarbamate and tert-butyl 2-(6-chloropyridin-2-yl)-1-(2-fluorophenyl)-1-hydroxypropan-2-ylcarbamate (200 mg, 0.470 mmol) in tetrahydronfuran (4.5 mL) was added a solution of potassium tert-butoxide (1M solution in tetrahydrofuran, 0.564 mL, 0.564 mmol) dropwise. After 5 minutes, the ice bath was removed and stirring continued for 1 h. The reaction was cooled to 0° C., quenched by addition of saturated ammonium chloride, and concentrated. The residue was dissolved in dichloromethane, washed with water, dried over anhydrous magnesium sulfate, and concentrated. Biotage purification (40% EtOAc/Hex) gave 114 mg of title compounds as white foam solid. Mass spec.: 307.1, 351.1 (MH)+.
To a slurry of (4R,5R)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one (1.00 g, 2.82 mmol) in triethylamine (30 mL) was bubbled nitrogen for 20 min at which time ethynyltrimethylsilane (0.557 mL, 3.94 mmol) was added with continued nitrogen bubbling for 5 min before adding bis(triphenylphosphine) palladium (II) chloride (0.148 g, 0.211 mmol), triphenylphosphine (0.133 g, 0.507 mmol), and copper (I) iodide (0.161 g, 0.845 mmol) together in 1 portion. After 5 min additional bubbling of nitrogen, the vessel was capped and placed in a 70° C. bath. After 18 h, the vessel was cooled to ambient temperature, concentrated in vacuo dissolved in ethyl acetate, washed with water and brine, dried over MgSO4, filtered and concentrated in vacuo to a black tar which was dissolved in methanol (30 mL). Potassium carbonate (0.428 g, 3.10 mmol) was added and after 30 min, the reaction was concentrated and dissolved in ethyl acetate, washed with water, brine, dried over MgSO4, filtered and concentrated in vacuo to a black tar which was loaded with dichloormethane onto a 40 g silica gel cartridge. Elution with 5 to 75% EtOAc/Hex over 6 column volumes then 75% EtOAc over 2 column volumes. Fractions containing the main peak were concentrated to (4R,5R)-5-(2,5-difluorophenyl)-4-(5-ethynylpyridin-3-yl)oxazolidin-2-one (766 mg; 91%) as a yellow oil which crystallized upon standing. 1H NMR (500 MHz, CDCl3) δ ppm 8.75 (1H, d, J=1.83 Hz), 8.52 (1H, d, J=2.14 Hz), 7.87 (1H, t, J=1.98 Hz), 7.17-7.24 (1H, m), 6.98-7.15 (2H, m), 5.52 (2H, d, J=5.49 Hz), 4.80 (1H, d, J=5.80 Hz), 3.30 (1H, s). Mass Spectral Anal. Calcd. for [M+H]+ C16H10F2N2O2: 301.07. found 301.01.
To benzyl 2-(5-bromopyridin-3-yl)-1-(tert-butyldimethylsilyloxy)-1-(2,5-difluorophenyl)propan-2-ylcarbamate (80 mg, 0.135 mmol) in tetrahydrofuran (2 mL) was added TBAF (0.176 mL, 0.176 mmol) dropwise over 5 min. After 2 h, the reaction vessel was placed in a heat bath set to 60° C. for an additional 18 h at which time it was diluted with ethyl acetate, washed with water, dried over magnesium sulfate, filtered and concentrated to 79 mg oil which was purified via preparative liquid chromatography (Sunfire C18 OBD 30×100 mm 5 μm, A=95% H2O/5% Acetonitrile, B=95% Acetonitrile/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=10% B, 8.0 min=100% B, 13.0 min=100% B, Flow rate=40 mL/min) providing 11 mg (22%) Cis-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)-4-methyloxazolidin-2-one and 27 mg (54%) trans-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)-4-methyloxazolidin-2-one. Data for cis isomer: 1H NMR (500 MHz, CDCl3) δ ppm 8.44 (1H, d, J=2.14 Hz), 8.29 (1H, d, J=1.83 Hz), 7.59 (1H, t, J=1.98 Hz), 6.85 (2H, td, J=6.33, 1.37 Hz), 6.73-6.81 (1H, m), 6.68 (1H, br. s.), 5.81 (1H, s), 2.03 (3H, s). Mass Spectral Anal. Calcd. for [M+H]+ C15H11BrF2N2O2: 369.0. found 369.0. Data for trans isomer: 1H NMR (500 MHz, CDCl3) δ ppm 8.69 (1H, d, J=2.14 Hz), 8.66 (1H, d, J=1.83 Hz), 8.01 (1H, t, J=1.98 Hz), 7.17-7.30 (1H, m), 7.02-7.15 (2H, m), 6.83 (1H, br. s.), 5.74 (1H, s), 1.40 (3H, s). Mass Spectral Anal. Calcd. for [M+H]+ C15H11BrF2N2O2: 369.0. found 369.0.
To crude 2-(5-bromopyridin-3-yl)-3-(tert-butyldimethylsilyloxy)-3-(2,5-difluorophenyl)-2-methylpropanoic acid (450 mg, 0.925 mmol) in toluene (12 mL) was added benzyl alcohol (0.096 mL, 0.925 mmol), triethylamine (0.258 mL, 1.850 mmol) and diphenyl phosphorazidate (0.200 mL, 0.925 mmol). The mixture was placed in a heat bath set to 60° C. for 18 h, concentrated and purified via preparative liquid chromatography (Sunfire C18 OBD 30×100 mm 5 μm, A=95% H2O/5% Acetonitrile, B=95% Acetonitrile/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=0% B, 8.0 min=100% B, 13.0 min=100% B, Flow rate=40 mL/min) providing 80 mg (15%) benzyl 2-(5-bromopyridin-3-yl)-1-(tert-butyldimethylsilyloxy)-1-(2,5-difluorophenyl)propan-2-ylcarbamate. Mass Spectral Anal. Calcd. for [M+H]+ C28H33BrF2N2O2Si: 591.1. found 590.0.
In a flame dried flask under nitrogen was added diisopropylamine (0.976 mL, 6.85 mmol), tetrahydrofuran (4 mL) and the vessel was cooled to −78° C. n-BuLi (2.74 mL, 6.85 mmol) was added dropwise and after 10 min, the reaction was warmed to −15° C. and held there for 10 min before recooling to −78° C. 2-(5-bromopyridin-3-yl)propanoic acid (750 mg, 3.26 mmol) held in a flame dried flask was dissolved in tetrahydrofuran (4 mL) and added dropwise to the preformed LDA resulting in a kool-aid orange solution. The ice bath was again removed and the reaction was allowed to stir at ambient temperature for 1.5 h, recooled to −78° C. and 2,5-difluorobenzaldehyde (0.779 mL, 7.17 mmol) in 2 mL tetrahydrofuran was added over 10 min. After 1 h, the reaction was quenched with 10% citric acid and the volatiles were removed under vacuum. The residue was extracted with 3 portions ether, washed with brine, dried over MgSO4, filtered and concentrated to 1.31 g red gum which was used immediately in the next step.
Prepared from 5-(bromomethyl)-2-chloropyridine in similar fashion to the preparation of (4R,5R)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one from 3-bromo-5-(bromomethyl)pyridine. 1H NMR (500 MHz, CDCl3) δ ppm 8.19-8.36 (1H, m), 7.72 (1H, dd, J=8.39, 2.59 Hz), 7.42-7.49 (1H, m), 7.32-7.42 (1H, m), 6.94-7.08 (2H, m), 5.56 (1H, s), 5.23 (1H, d, J=7.63 Hz), 4.77 (1H, d, J=7.63 Hz). Mass Spectral Anal. Calcd. for [M+H]+ C14H10ClFN2O2: 293.0. found 293.1.
A suspension of (+)-(4R,5R)-4-(3-bromophenyl)-5-(3-methoxyphenyl)oxazolidin-2-one (2.4 g, 6.89 mmol) in triethylamine (24 mL, 172 mmol) was purged with nitrogen for 1 h (volume dropped by ca. 5 mL). The reaction was treated with triphenylphosphine (0.152 g, 0.579 mmol) and ethynylbenzene (0.776 mL, 7.07 mmol), and purged 10 minutes longer. To this was added PdCl2(PPh3)2 (0.034 g, 0.048 mmol) and copper(I) iodide (7.88 mg, 0.041 mmol). After purging 10 min longer, the reaction was warmed to a vigorous reflux. The reaction was heated at reflux overnight. In the morning, the reaction was cooled to room temperature, diluted with diethyl ether, washed with water (3×), then brine, dried over magnesium sulfate, and concentrated. Column chromatography (25%-->40% EtOAc/Hex) gave 2.2 g (80%) as a colorless foam solid. 1H-NMR (CDCl3, 500 MHz) δ 7.56 (m, 4H), 7.36-7.45 (m, 4H), 7.34 (m, 1H), 7.30 (m, 1H), 6.92-6.98 (m, 1H), 6.85-6.90 (m, 2H), 5.93 (bs, 1H), 5.31 (d, J=7.3, 1H), 4.78 (d, J=7.3, 1H), 3.84 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 160.2, 158.6, 138.92, 138.85, 132.3, 131.8, 130.2, 129.6, 129.4, 128.7, 128.5, 126.4, 124.6, 122.9, 118.1, 115.0, 111.2, 90.6, 88.6, 85.9, 64.6, 55.5. Mass spec.: 370.18 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (−)-(4S,5S)-4-(3-bromophenyl)-5-(3-methoxyphenyl)oxazolidin-2-one and phenylacetylene. 1H-NMR (CDCl3, 500 MHz) δ 7.56 (m, 4H), 7.36-7.45 (m, 4H), 7.34 (m, 1H), 7.30 (m, 1H), 6.92-6.98 (m, 1H), 6.85-6.90 (m, 2H), 5.93 (bs, 1H), 5.31 (d, J=7.3, 1H), 4.78 (d, J=7.3, 1H), 3.84 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 160.2, 158.6, 138.92, 138.85, 132.3, 131.8, 130.2, 129.6, 129.4, 128.7, 128.5, 126.4, 124.6, 122.9, 118.1, 115.0, 111.2, 90.6, 88.6, 85.9, 64.6, 55.5. Mass spec.: 370.14 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (±)-(4R,5S)-4-(3-bromophenyl)-5-(3-methoxyphenyl)oxazolidin-2-one and phenylacetylene. 1H-NMR (CDCl3, 500 MHz) δ 7.53 (m, 2H), 7.37 (m, 3H), 7.31 (m, 1H), 7.24 (m, 1H), 7.09 (dd, J=7.6, 7.6, 1H), 7.06 (dd, J=7.9, 7.9, 1H), 6.88 (bd, J=7.9, 1H), 6.67 (dd, J=8.2, 2.1, 1H), 6.62 (d, J=7.6, 1H), 6.51 (m, 1H), 6.41 (m, 1H), 5.93 (d, J=8.2, 1H), 5.17 (d, J=8.2, 1H), 3.64 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 159.8, 159.5, 136.7, 135.7, 131.7, 131.5, 130.1, 129.2, 128.6, 128.5, 128.4, 127.0, 123.5, 123.0, 118.7, 114.8, 111.3, 90.0, 88.8, 82.2, 61.2, 55.4. Enantiomers were resolved by SFC Prep HPLC (Chiralpak AD-H, 35% MeOH in CO2). Enantiomer 1=first enantiomer to elute from Prep (Example 3): Mass spec.: 370.15 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 4): Mass spec.: 370.11 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (±)-(4R,5R)-4-(6-bromopyridin-2-yl)-5-(3-methoxyphenyl)oxazolidin-2-one and phenylacetylene. 1H-NMR (CDCl3, 500 MHz) δ 7.80 (dd, J=7.9, 7.6, 1H), 7.64 (m, 2H), 7.56 (d, J=7.6, 1H), 7.31-7.47 (m, 5H), 7.04 (m, 2H), 6.94 (m, 1H), 5.85 (bs, 1H), 5.61 (d, J=5.8, 1H), 4.98 (d, J=5.8, 1H), 3.85 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 160.2, 158.8, 158.5, 143.9, 139.7, 137.7, 132.2, 130.2, 129.4, 128.6, 127.3, 122.0, 119.8, 117.9, 114.9, 111.1, 90.3, 88.3, 83.7, 64.9, 55.5. Enantiomers were resolved by SFC Prep HPLC (Chiralpak AD-H, 45% MeOH in CO2). Enantiomer 1=first enantiomer to elute from Prep (Example 5). Enantiomer 2=second enantiomer to elute from Prep (Example 6):
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with optically-enriched (4R,5R)-4-(6-bromopyridin-2-yl)-5-(3-methoxyphenyl)oxazolidin-2-one and 1-ethynyl-4-fluorobenzene. 1H-NMR (CDCl3, 500 MHz) δ 7.79 (dd, J=7.9, 7.6, 1H), 7.61 (m, 2H), 7.54 (d, J=7.6, 1H), 7.36 (m, 2H), 7.10 (m, 2H), 7.04 (m, 2H), 6.94 (m, 1H), 6.40 (bs, 1H), 5.62 (d, J=5.8, 1H), 4.98 (d, J=5.8, 1H), 3.85 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 163.2 (d, J=251), 160.1, 158.9, 143.7, 139.8, 137.7, 134.2 (d, J=7.7), 130.2, 127.2, 120.0, 117.9, 116.0 (d, J=23), 114.8, 111.2, 89.1, 88.1, 83.7, 64.9, 55.5. Mass spec.: 389.17 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with optically-enriched (4R,5R)-4-(6-bromopyridin-2-yl)-5-(3-methoxyphenyl)oxazolidin-2-one and 1-ethynyl-3-fluorobenzene. 1H-NMR (CDCl3, 500 MHz) δ 7.81 (d, J=7.9, 7.6, 1H), 7.57 (dd, J=7.9, 0.6, 1H), 7.30-7.45 (M, 5H), 7.13 (m, 1H), 7.04 (m, 2H), 6.95 (m, 1H), 6.00 (bs, 1H), 5.62 (d, J=6.1, 1H), 4.97 (dd, J=5.8, 0.6, 1H), 3.86 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 162.5 (d, J=248), 160.2, 159.0, 158.6, 143.5, 139.7, 137.8, 130.20 (d, J=8.6), 130.19, 128.1 (d, J=2.9), 127.4, 123.9 (d, J=10), 120.1, 119.0 (d, J=23), 117.9, 116.8 (d, J=21), 114.8, 111.2, 89.0, 88.7 (d, J=3.8), 83.7, 64.9, 55.5.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with optically-enriched (4R,5R)-4-(6-bromopyridin-2-yl)-5-(3-methoxyphenyl)oxazolidin-2-one and 1-ethynyl-2-fluorobenzene. 1H-NMR (CDCl3, 500 MHz) δ 7.81 (dd, J=7.9, 7.6, 1H), 7.63 (ddd, J=7.6, 7.0, 1.2, 1H), 7.60 (d, J=7.6, 1H), 7.41 (m, 2H), 7.36 (dd, J=7.9, 7.9, 1H), 7.18 (m, 2H), 7.05 (m, 2H), 6.94 (m, 1H), 5.89 (bs, 1H), 5.62 (d, J=5.8, 1H), 4.98 (d, J=6.1, 1H), 3.86 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 163.1 (d, J=253), 162.1, 160.2, 158.9, 158.6, 143.6, 139.8, 137.7, 134.0, 131.2 (d, J=7.7), 130.2, 127.4, 124.2 (d, J=3.8), 120.1, 117.9, 115.8 (d, J=21), 114.9, 111.0, 93.1, 83.7, 83.5, 64.9, 55.5.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (±)-(4R,5R)-4-(6-bromopyridin-2-yl)-5-phenyloxazolidin-2-one and phenylacetylene. 1H-NMR (CDCl3, 500 MHz) δ 7.78 (dd, J=7.9, 7.6, 1H), 7.63 (m, 2H), 7.35-7.50 (m, 9H), 6.88 (bs, 1H), 5.66 (d, J=5.8, 1H), 5.01 (d, J=5.8, 1H). 13C-NMR (CDCl3, 126 MHz) 6 159.4, 158.9, 143.8, 138.2, 137.8, 132.2, 129.4, 129.1, 129.0, 128.6, 127.3, 125.9, 122.0, 120.0, 90.4, 88.3, 83.9, 64.9. Enantiomers were resolved by SFC Prep HPLC (Chiralpak AD-H, 45% MeOH in CO2). Enantiomer 1=first enantiomer to elute from Prep (Example 10): Mass spec.: 341.2 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 11): Mass spec.: 341.2 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (±)-(4R,5R)-4-(6-bromopyridin-2-yl)-5-phenyloxazolidin-2-one and 1-ethynyl-3-fluorobenzene. 1H-NMR (CDCl3, 500 MHz) δ 7.79 (dd, J=7.9, 7.6, 1H), 7.55 (d, J=7.6, 1H), 7.35-7.51 (m, 8H), 7.32 (ddd, J=9.2, 2.4, 1.2, 1H), 7.12 (m, 1H), 6.90 (bs, 1H), 5.66 (d, J=5.5, 1H), 4.99 (d, J=5.5, 1H). 13C-NMR (CDCl3, 126 MHz) δ 162.4 (d, J=248), 159.3, 159.1, 143.4, 138.3, 137.8, 130.2 (d, J=8.6), 129.08, 129.05, 128.1 (d, J=2.9), 127.3, 125.9, 123.9 (d, J=9.6), 120.3, 119.0 (d, J=23), 116.7 (d, J=21), 89.0, 88.7 (d, J=2.9), 83.9, 64.9. Enantiomers were resolved by SFC Prep HPLC (Chiralpak AD-H, 45% MeOH in CO2). Enantiomer 1=first enantiomer to elute from Prep (Example 12): Mass spec.: 359.2 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 13): Mass spec.: 359.2 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (±)-(4R,5R)-4-(6-bromopyridin-2-yl)-5-phenyloxazolidin-2-one and 1-ethynyl-2-fluorobenzene. 1H-NMR (CDCl3, 500 MHz) δ 7.79 (dd, J=7.9, 7.6, 1H), 7.61 (ddd, J=7.6, 7.3, 1.6, 1H), 7.57 (dd, J=7.6, 0.6, 1H), 7.35-7.50 (m, 7H), 7.17 (m, 2H), 6.88 (bs, 1H), 5.66 (d, J=5.8, 1H), 5.01 (d, J=5.8, 1H). 13C-NMR (CDCl3, 126 MHz) δ 163.1 (d, J=252), 159.4, 159.0, 143.4, 138.2, 137.9, 134.0, 131.2 (d, J=8.6), 129.1, 129.0, 127.4, 125.9, 124.2 (d, J=3.8), 120.3, 115.8 (d, J=21), 110.8 (d, J=15), 93.0 (d, J=2.9), 83.9, 83.7, 64.9. Enantiomers were resolved by SFC Prep HPLC (Chiralpak AD-H, 45% MeOH in CO2). Enantiomer 1=first enantiomer to elute from Prep (Example 14): Mass spec.: 359.2 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 15): Mass spec.: 359.2 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (±)-(4R,5R)-4-(6-bromopyridin-2-yl)-5-phenyloxazolidin-2-one and 1-ethynyl-4-fluorobenzene. 1H-NMR (CDCl3, 500 MHz) δ 7.78 (dd, J=7.9, 7.6, 1H), 7.61 (m, 2H), 7.53 (d, J=7.6, 1H), 7.36-7.50 (m, 6H), 7.10 (m, 2H), 6.80 (bs, 1H), 5.65 (d, J=5.5, 1H), 4.99 (d, J=5.5, 1H). 13C-NMR (CDCl3, 126 MHz) δ 163.2 (d, J=251), 159.3, 159.0, 143.7, 138.2, 137.8, 134.2 (d, J=8.6), 129.09, 129.05, 127.2, 125.9, 120.0, 118.1 (d, J=3.8), 116.0 (d, J=23), 89.2, 88.1, 83.9, 64.9. Enantiomers were resolved by SFC Prep HPLC (Chiralpak AD-H, 45% MeOH in CO2). Enantiomer 1=first enantiomer to elute from Prep (Example 16): Mass spec.: 360.2 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 17): Mass spec.: 360.2 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (±)-(4R,5R)-4-(4-bromopyridin-2-yl)-5-phenyloxazolidin-2-one and phenylacetylene. 1H-NMR (CDCl3, 500 MHz) δ 8.65 (d, J=5.2, 1H), 7.59 (m, 2H), 7.53 (s, 1H), 7.35-7.50 (m, 9H), 6.89 (bs, 1H), 5.63 (d, J=5.5, 1H), 4.95 (d, J=5.8, 1H). 13C-NMR (CDCl3, 126 MHz) δ 159.1, 157.4, 149.7, 139.8, 133.1, 132.0, 129.4, 129.2, 128.7, 128.5, 126.2, 125.5, 122.8, 121.9, 95.0, 86.3, 85.0, 61.8. Enantiomers were resolved by Prep HPLC (Chiralpak AD, A=heptane, B=ethanol, 10%-->50% over 25 min) Enantiomer 1=first enantiomer to elute from Prep (Example 18): Mass spec.: 341.2 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 19): Mass spec.: 341.2 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (4R,5R)-4-(2-bromopyridin-4-yl)-5-phenyloxazolidin-2-one and phenylacetylene. 1H-NMR (CDCl3, 500 MHz) δ 8.64 (d, J=4.9, 1H), 7.60 (m, 2H), 7.50 (m, 1H), 7.45 (m, 3H), 7.40 (m, 3H), 7.34 (m, 2H), 7.17 (dd, J=5.2, 1.5, 1H), 6.73 (bs, 1H), 5.25 (d, J=7.3, 1H), 4.82 (d, J=7.3, 1H). 13C-NMR (CDCl3, 126 MHz) δ 158.8, 151.0, 148.1, 144.6, 136.7, 132.2, 129.7, 129.4, 129.3, 128.6, 126.2, 124.4, 121.9, 120.2, 90.5, 88.2, 85.4, 63.7. Mass spec.: 341.2 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (4R,5R)-4-(5-bromopyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one and phenylacetylene. 1H-NMR (CDCl3, 500 MHz) δ 8.78 (bs, 1H), 8.42 (bs, 1H), 7.90 (m, 1H), 7.57 (m, 2H), 7.35-7.45 (m, 4H), 7.02-7.17 (m, 3H), 6.83 (bs, 1H), 5.30 (d, J=7.3, 1H), 4.83 (d, J=7.3, 1H). 13C-NMR (CDCl3, 126 MHz) δ 164.2, 162.2, 158.6, 152.9, 146.9, 139.1 (d, J=7.7), 136.4, 133.7 (br), 131.9, 131.1 (d, J=8.6), 129.3, 128.7, 122.1, 121.6 (d, J=2.9), 116.6 (d, J=21), 113.0 (d, J=23), 94.2, 85.2, 84.9, 62.5. Mass spec.: 359.3 (MH)+.
A solution of (4R,5R)-4-(2-bromopyridin-4-yl)-5-phenyloxazolidin-2-one (20 mg, 0.063 mmol) and 2-((trimethylsilyl)ethynyl)pyridine (10.99 mg, 0.063 mmol) in dimethylformamide (300 mL) was purged with nitrogen for 30 min. The reaction was treated with triphenylphosphine (4.93 mg, 0.019 mmol), and purged 10 minutes longer. To this was added PdCl2(PPh3)2 (2.199 mg, 3.13 mmol) and copper(I) iodide (1.193 mg, 6.27 mmol). After purging 10 min longer, the reaction was treated with triethylamine (13.1 mL, 0.094 mmol) and placed in an 85° C. oil bath. To this was added tetrabutylammonium fluoride (1M in tetrahydrofuran, 68.9 mL, 0.069 mmol) dropwise. The reaction was stirred at this temperature for 1 h. The reaction was cooled to room temperature, diluted with ethyl acetate, washed with water, then brine, dried over magnesium sulfate, and concentrated. Column chromatography (50%-->100% EtOAc/Hex) gave 19 mg (89%) as a foam solid. 1H-NMR (CDCl3, 500 MHz) δ 8.68 (d, J=4.6, 1H), 8.60 (d, J=5.2, 1H), 7.73 (ddd, J=7.9, 7.6, 1.6, 1H), 7.59 (d, J=7.6, 1H), 7.38-7.50 (m, 5H), 7.33 (m, 3H), 7.25 (m, 1H), 5.19 (d, J=7.3, 1H), 4.88 (d, J=7.3, 1H). 13C-NMR (CDCl3, 126 MHz) δ 158.8, 151.0, 150.3, 148.6, 143.3, 142.1, 136.7, 136.6, 129.6, 129.3, 127.9, 126.2, 125.1, 123.9, 120.9, 88.5, 87.4, 85.2, 63.6. Mass spec.: 342.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(2-(pyridin-2-ylethynyl)pyridin-4-yl)oxazolidin-2-one, starting with (4R,5R)-4-(2-bromopyridin-4-yl)-5-phenyloxazolidin-2-one and 3-((trimethylsilyl)ethynyl)pyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.82 (bs, 1H), 8.67 (bs, 1H), 7.90 (d, J=7.6, 1H), 7.55 (bs, 1H), 7.30-7.51 (m, 6H), 7.21 (d, J=4.0, 1H), 6.94 (bs, 1H), 5.24 (d, J=7.0, 1H), 4.84 (d, J=7.0, 1H). 13C-NMR (CDCl3, 126 MHz) δ 158.9, 151.1, 148.3, 143.9, 139.0, 136.6, 129.8, 129.4, 126.1, 124.6, 120.8, 91.3, 86.9, 85.3, 63.7. Mass spec.: 342.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(2-(pyridin-2-ylethynyl)pyridin-4-yl)oxazolidin-2-one, starting with (±)-(4R,5R)-4-(6-bromopyridin-2-yl)-5-phenyloxazolidin-2-one and 2-((trimethylsilyl)ethynyl)pyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.69 (d, J=4.3, 1H), 7.70-7.81 (m, 2H), 7.63 (d, J=7.9, 1H), 7.56 (d, J=7.3, 1H), 7.47 (m, 2H), 7.35-7.45 (m, 4H), 7.33 (dd, J=7.6, 4.9, 1.2, 1H), 7.15 (bs, 1H), 5.63 (d, J=5.5, 1H), 4.99 (d, J=5.5, 1H). 13C-NMR (CDCl3, 126 MHz) δ 159.4, 159.2, 150.3, 142.8, 142.4, 138.5, 137.7, 136.5, 129.01, 128.97, 127.9, 127.6, 125.8, 123.8, 120.5, 88.4, 87.7, 83.7, 64.9. Enantiomers were resolved by Prep HPLC (Chiralpak AD, A=heptane, B=ethanol, 30%-->100% over 25 min). Enantiomer 1=first enantiomer to elute from Prep (Example 24): Mass spec.: 342.0 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 25): Mass spec.: 342.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(2-(pyridin-2-ylethynyl)pyridin-4-yl)oxazolidin-2-one, starting with (±)-(4R,5R)-4-(6-bromopyridin-2-yl)-5-phenyloxazolidin-2-one and 3-((trimethylsilyl)ethynyl)pyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.89 (bs, 1H), 8.68 (bs, 1H), 7.91 (d, J=7.9, 1H), 7.79 (dd, J=7.9, 7.6, 1H), 7.56 (d, J=7.6, 1H), 7.30-7.50 (m, 7H), 7.03 (bs, 1H), 5.65 (d, J=5.5, 1H), 4.98 (d, J=5.8, 1H). 13C-NMR (CDCl3, 126 MHz) δ 159.3, 159.2, 152.7, 149.5, 143.1, 139.1, 138.3, 137.8, 129.0, 127.4, 125.9, 120.5, 91.5, 86.4, 83.7, 65.0. Enantiomers were resolved by Prep HPLC (Chiralpak AD, A=heptane, B=ethanol, 35%-->100% over 25 min) Enantiomer 1=first enantiomer to elute from Prep (Example 26): Mass spec.: 342.0 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 27): Mass spec.: 342.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(2-(pyridin-2-ylethynyl)pyridin-4-yl)oxazolidin-2-one, starting with optically-enriched (4R,5R)-4-(5-bromopyridin-3-yl)-5-(3-methoxyphenyl)oxazolidin-2-one and 2-((trimethylsilyl)ethynyl)pyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.87 (d, J=1.8, 1H), 8.69 (m, 1H), 8.51 (d, J=2.1, 1H), 7.96 (dd, J=2.1, 1.8, 1H), 7.77 (ddd, J=7.9, 7.6, 1.8, 1H), 7.60 (m, 1H), 7.35 (m, 2H), 6.98 (dd, J=7.6, 2.0, 1H), 6.89 (m, 1H), 6.86 (d, J=7.6, 1H), 5.50 (bs, 1H), 5.30 (d, J=7.6, 1H), 4.84 (d, J=7.3, 1H), 3.85 (s, 3H). Enantiomers were resolved by SFC Prep HPLC (Chiralpak AD-H, 50% MeOH in CO2). Enantiomer 1=first enantiomer to elute from Prep (Example 28): Mass spec.: 372.0 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 29): Mass spec.: 372.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(2-(pyridin-2-ylethynyl)pyridin-4-yl)oxazolidin-2-one, starting with optically-enriched (4R,5R)-4-(5-bromopyridin-3-yl)-5-(3-methoxyphenyl)oxazolidin-2-one and 2-methyl-4-((trimethylsilyl)ethynyl)thiazole. 1H-NMR (CDCl3, 500 MHz) δ 8.83 (d, J=1.8, 1H), 8.48 (d, J=2.1, 1H), 7.91 (m, 1H), 7.50 (s, 1H), 7.36 (dd, J=7.9, 7.9, 1H), 6.97 (dd, J=8.2, 2.1, 1H), 6.88 (bs, 1H), 6.85 (d, J=7.6, 1H), 5.48 (bs, 1H), 5.29 (d, J=7.6, 1H), 4.83 (d, J=7.6, 1H), 3.85 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 166.4, 160.3, 158.7, 152.7, 147.3, 138.0, 136.6, 135.9, 130.4, 123.9, 118.1, 115.2, 111.3, 87.9, 85.6, 84.8, 62.5, 55.5, 19.3. Enantiomers were resolved by SFC Prep HPLC (Chiralpak AD-H, 50% MeOH in CO2). Enantiomer 1=first enantiomer to elute from Prep (Example 30): Mass spec.: 392.0 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 31): Mass spec.: 392.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(2-(pyridin-2-ylethynyl)pyridin-4-yl)oxazolidin-2-one, starting with optically-enriched (4R,5R)-4-(5-bromopyridin-3-yl)-5-(3-methoxyphenyl)oxazolidin-2-one and trimethyl(phenylethynyl)silane. 1H-NMR (CDCl3, 500 MHz) δ 8.79 (bs, 1H), 8.43 (bs, 1H), 7.90 (s, 1H), 7.57 (m, 2H), 7.40 (m, 3H), 7.34 (dd, J=7.9, 7.9, 1H), 6.96 (dd, J=7.6, 1.8, 1H), 6.86 (m, 2H), 6.60 (bs, 1H), 5.28 (d, J=7.3, 1H), 4.85 (d, J=7.6, 1H), 3.83 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 160.3, 158.8, 152.8, 147.0, 138.1, 136.4, 133.9, 131.9, 130.4, 129.3, 128.6, 122.2, 121.3, 118.1, 115.2, 111.3, 94.1, 85.7, 85.3, 62.5, 55.5. Enantiomers were resolved by SFC Prep HPLC (Chiralpak AD-H, 50% MeOH in CO2). Enantiomer 1=first enantiomer to elute from Prep (Example 32): Mass spec.: 371.1 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 33): Mass spec.: 371.2 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(2-(pyridin-2-ylethynyl)pyridin-4-yl)oxazolidin-2-one, starting with (4R,5R)-4-(5-bromopyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one and 2-((trimethylsilyl)ethynyl)pyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.80 (bs, 1H), 8.66 (d, J=3.7, 1H), 8.49 (bs, 1H), 7.94 (s, 1H), 7.75 (ddd, J=7.9, 7.6, 1.5, 1H), 7.58 (d, J=7.6, 1H), 7.41 (ddd, J=7.9, 7.9, 5.8, 1H), 7.33 (dd, J=7.3, 5.2, 1H), 7.09 (m, 3H), 6.97 (bs, 1H), 5.29 (d, J=7.6, 1H), 4.84 (d, J=7.3, 1H). 13C-NMR (CDCl3, 126 MHz) δ 164.2, 162.2, 158.4, 153.1, 150.3, 147.6, 142.3, 139.1 (d, J=6.7), 136.9, 136.6, 131.1, 131.0, 127.6, 123.8, 121.6 (d, J=2.9), 116.6 (d, J=21), 113.0 (d, J=23), 104.3, 92.8, 84.8, 62.5. Mass spec.: 360.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(2-(pyridin-2-ylethynyl)pyridin-4-yl)oxazolidin-2-one, starting with (4R,5R)-4-(5-bromopyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one and 3-((trimethylsilyl)ethynyl)pyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.10-9.50 (bm, 3H), 7.94 (s, 1H), 7.88 (d, J=7.9, 1H), 7.42 (m, 2H), 7.10 (m, 3H), 6.81 (bs, 1H), 5.31 (d, J=7.3, 1H), 4.85 (d, J=7.3, 1H). 13C-NMR (CDCl3, 126 MHz) δ 164.2, 162.2, 158.4, 152.9, 147.4, 139.1 (d, J=6.7), 138.7, 136.5, 132.1 (d, J=11), 131.13, 131.06, 128.6 (d, J=12), 121.5 (d, J=3.8), 116.7 (d, J=21), 113.0 (d, J=23), 90.8, 88.5, 84.8, 62.5. Mass spec.: 360.0 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (±)-(4R,5R)-4-(2-bromopyridin-4-yl)-5-(3-methoxyphenyl)oxazolidin-2-one and ethynylbenzene. 1H-NMR (CDCl3, 500 MHz) δ 8.67 (d, J=4.9 Hz, 1H), 7.61 (m, 2H), 7.53 (s, 1H), 7.42-7.35 (m, 4H), 7.18 (dd, J=5.2, 1.5 Hz, 1H), 6.98 (m, 1H), 6.89 (m, 2H), 6.06 (s, 1H), 5.24 (d, J=7.0 Hz, 1H), 4.80 (d, J=7.0 Hz, 1H), 3.85 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.3, 158.4, 151.0, 148.0, 144.7, 138.2, 132.2, 130.5, 129.4, 128.6, 124.4, 121.9, 120.2, 118.2, 115.2, 111.4, 90.6, 88.2, 85.2, 63.6, 55.5. Enantiomers were resolved by Prep HPLC (Chiralcel AD, A=heptane, B=ethanol, 35% isocratic over 40 min) Enantiomer 1=first enantiomer to elute from Prep (Example 36): Mass spec.: 371.2 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 37): Mass spec.: 371.2 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (±)-(4R,5R)-4-(5-bromopyridin-3-yl)-5-phenyloxazolidin-2-one and ethynylbenzene. 1H-NMR (CDCl3, 400 MHz) δ 8.79 (d, J=2.1 Hz, 1H), 8.42 (d, J=2.1 Hz, 1H), 7.91 (t, J=1.8 Hz, 1H), 7.58 (m, 2H), 7.45 (m, 3H), 7.41 (m, 3H), 7.34 (m, 2H), 6.24 (s, 1H), 5.33 (d, J=7.3 Hz, 1H), 4.86 (d, J=7.3 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ ppm 160.4, 158.4, 152.9, 147.0, 136.6, 136.3, 133.8, 131.9, 129.5, 129.3, 128.5, 126.0, 122.2, 121.4, 94.1, 85.8, 85.2, 62.5, 42.5. Enantiomers were resolved by Prep HPLC (Chiralpak AD, A=heptane, B=ethanol, 37% isocratic over 40 min) Enantiomer 1=first enantiomer to elute from Prep (Example 38): Mass spec.: 341.1 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 39): Mass spec.: 341.1 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (±)-(4R,5R)-4-(5-bromopyridin-3-yl)-5-(4-fluorophenyl)oxazolidin-2-one and ethynylbenzene. 1H-NMR (CD3OD, 500 MHz) δ 8.74 (s, 1H), 8.46 (s, 1H), 8.05 (m, 1H), 7.61-7.59 (m, 2H), 7.49-7.42 (m, 5H), 7.22 (t, J=8.6 Hz, 2H), 5.47 (d, J=7.6 Hz, 1H), 5.00 (d, J=7.6 Hz, 1H); 13C NMR (100.6 MHz, CD3OD) δ ppm 165.9, 163.5, 160.7, 152.5, 147.6, 138.5, 136.5, 134.4, 134.3, 132.8, 130.3, 129.8, 129.7, 123.4, 117.0, 116.8, 94.7, 86.0, 85.7, 63.4. Enantiomers were resolved by Prep HPLC (Chiralcel OJ, A=heptane, B=ethanol, 75% isocratic over 45 min) Enantiomer 1=first enantiomer to elute from Prep (Example 40): Mass spec.: 359.1 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 41): Mass spec.: 359.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(2-(pyridin-2-ylethynyl)pyridin-4-yl)oxazolidin-2-one, starting with (±)-(4R,5R)-4-(5-bromopyridin-3-yl)-5-(4-fluorophenyl)oxazolidin-2-one and 3-((trimethylsilyl)ethynyl)pyridine. 1H-NMR (CD3OD, 500 MHz) δ 9.08 (d, J=1.5 Hz, 1H), 8.90 (d, J=1.8 Hz, 1H), 8.84 (d, J=5.5 Hz, 1H), 8.62-8.59 (m, 2H), 8.24 (t, J=1.8 Hz, 1H), 7.99 (m, 1H), 7.47 (m, 2H), 7.20 (t, J=8.9 Hz, 2H), 5.46 (d, J=7.3 Hz, 1H), 5.06 (d, J=7.3 Hz, 1H); 13C NMR (126 MHz, CD3OD) δ ppm 164.7, 162.8, 160.0, 159.7, 159.6, 159.3, 159.0, 151.0, 147.0, 146.7, 146.1, 143.9, 139.2, 136.4, 133.3, 128.8, 128.7, 126.7, 122.5, 120.4, 117.0, 116.1, 116.0, 114.7, 110.0, 90.7, 87.5, 84.9, 62.2. Enantiomers were resolved by Prep HPLC (Chiralcel OJ, A=heptane, B=ethanol, 50% isocratic over 35 min) Enantiomer 1=first enantiomer to elute from Prep (Example 42): Mass spec.: 360.4 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 43): Mass spec.: 360.4 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(2-(pyridin-2-ylethynyl)pyridin-4-yl)oxazolidin-2-one, starting with (±)-(4R,5R)-4-(5-bromopyridin-3-yl)-5-(4-fluorophenyl)oxazolidin-2-one and 3-Fluoro-5-(trimethylsilyl)ethynyl)phenyl)pyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.82 (s, 1H), 8.62 (s, 1H), 8.51 (m, 2H), 7.97 (s, 1H), 7.61 (m, 1H), 7.33 (m, 2H), 7.14 (t, J=8.6 Hz, 2H), 5.73 (s, 1H), 5.28 (d, J=7.6 Hz, 1H), 4.89 (d, J=7.3 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ ppm 164.5, 162.5, 159.9, 158.8, 157.9, 151.9, 148.0, 147.9, 146.7, 138.2, 138.0, 137.6, 134.6, 132.0, 128.2, 128.1, 125.9, 125.8, 120.6, 120.5, 116.6, 116.4, 89.3, 89.0, 85.1, 62.5, 62.4. Enantiomers were resolved by Prep HPLC (Chiralcel OJ, A=heptane, B=ethanol, 50% isocratic over 35 min). Enantiomer 1=first enantiomer to elute from Prep (Example 44): Mass spec.: 378.1 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 45): Mass spec.: 378.1 (MH)+.
A solution of (4R,5R)-4-(3-ethnylphenyl-5-(3-methoxyphenyl)oxazolidin-2-one (20 mg, 0.068 mmol) and 3-bromopyridine (13.4 mL, 0.136 mmol) in triethylamine (0.5 mL, 3.07 mmol) was purged with nitrogen for 30 minutes. The reaction was treated with triphenylphosphine (4.83 mg, 0.018 mmol), and purged 10 min longer. To this was added dichlorobis(triphenylphosphine)palladium(II) (1.1 mg, 1.568 mmol) and copper(I) iodide (0.26 mg, 1.364 mmol). After purging 10 min longer, the reaction was heated at 90° C. for 16 h. The reaction was cooled to room temperature, diluted with diethyl ether, washed with water, then brine, dried over anhydrous magnesium sulfate, and concentrated. Biotage purification, eluting with 75% ethyl acetate/hexane, gave 15 mg (55%) as a white foam solid. 1H-NMR (CDCl3, 500 MHz) δ 8.79 (s, 1H), 8.59 (s, 1H), 7.84 (d, J=7.6 Hz, 1H), 7.58 (m, 2H), 7.45 (t, J=7.6 Hz, 1H), 7.34 (m, 3H), 6.95 (m, 1H), 6.88 (m, 2H), 6.01 (s, 1H), 5.30 (d, J=7.3 Hz, 1H), 4.78 (d, J=7.0 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 158.6, 152.4, 148.9, 139.1, 138.8, 138.6, 132.4, 130.3, 129.7, 129.5, 127.0, 123.8, 118.1, 114.9, 111.22, 91.8, 87.1, 85.9, 64.6, 55.5. Mass spec.: 371.08 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 2-bromopyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.79 (d, J=4.9 Hz, 1H), 8.03 (dd, J=7.6, 1.5 Hz, 1H), 7.74 (d, J=7.9 Hz, 1H), 7.67 (d, J=7.6 Hz, 1H), 7.64 (s, 1H), 7.56 (m, 1H), 7.47 (t, J=7.6 Hz, 1H), 7.39 (d, J=7.6 Hz, 1H), 7.34 (t, J=7.9 Hz, 1H), 6.95 (dd, J=8.2, 2.4 Hz, 1H), 6.87 (m, 2H), 6.09 (s, 1H), 5.29 (d, J=7.3 Hz, 1H), 4.81 (d, J=7.3 Hz, 1H), 3.83 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 158.8, 146.8, 140.2, 140.0, 139.2, 138.5, 33.1, 130.3, 129.7, 128.4, 128.2, 124.2, 122.2, 118.1, 115.0, 111.2, 86.0, 64.5, 55.5, 54.4. Mass spec.: 371.08 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 2-bromo-6-methylpyridine. 1H-NMR (CDCl3, 500 MHz) δ 7.60 (m, 3H), 7.43 (t, J=7.6 Hz, 1H), 7.35 (m, 3H), 7.15 (d, J=7.6 Hz, 1H), 6.94 (dd, J=8.2, 2.4 Hz, 1H), 6.86 (m, 2H), 5.96 (s, 1H), 5.28 (d, J=7.3 Hz, 1H), 4.77 (d, J=7.3 Hz, 1H), 3.83 (s, 1H), 2.61 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 159.2, 158.5, 142.39, 139.0, 138.8, 136.6, 132.6, 130.3, 130.2, 129.5, 127.0, 124.6, 123.6, 123.0, 118.1, 115.0, 111.1, 109.7, 89.8, 87.8, 85.9, 64.6, 55.5, 24.7. Mass spec.: 385.12 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromo-5-methylpyridine. 1H-NMR (CDCl3, 400 MHz) δ 8.39 (d, J=1.5 Hz, 1H), 8.30 (d, J=2.8 Hz, 1H), 7.59 (m, 2H), 7.45 (t, J=7.9 Hz, 1H), 7.35 (m, 3H), 6.96 (m, 2H), 5.89 (s, 1H), 5.30 (d, J=7.3 Hz, 1H), 4.79 (d, J=7.3 Hz, 1H), 3.91 (s, 3H), 3.84 (s, 3H). Mass spec.: 401.2 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromo-5-chloropyridine. 1H-NMR (CDCl3, 400 MHz) δ 8.90 (bs, 2H), 7.97 (s, 1H), 7.57 (m, 2H), 7.47 (t, J=7.8 Hz, 1H), 7.35 (m, 2H), 6.96 (m, 1H), 6.88 (m, 2H), 6.38 (bs, 1H), 5.30 (d, J=7.3 Hz, 1H), 4.82 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (100 Hz, CDCl3) δ ppm 159.7, 138.6, 138.0, 132.1, 129.9, 129.4, 129.2, 127.1, 122.5, 117.6, 114.5, 110.9, 85.7, 64.1, 55.0. Mass spec.: 404.98 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 4-bromopyridine hydrochloride. 1H-NMR (CDCl3, 500 MHz) δ 8.89 (bs, 2H), 7.91 (s, 2H), 7.67 (m, 2H), 7.52 (t, J=7.9 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 7.36 (t, J=7.6 Hz, 1H), 6.97 (dd, J=8.2, 2.4 Hz, 1H), 6.88 (m, 2H), 6.26 (s, 1H), 5.30 (d, J=7.0 Hz, 1H), 4.85 (d, J=7.0 Hz, 1H), 3.85 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.3, 158.9, 139.6, 138.5, 133.0, 130.4, 130.3, 129.9, 128.9, 121.8, 118.1, 114.9, 111.5, 86.0, 64.4, 55.5. Mass spec.: 371.06 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 4-bromo-2-methylthiazole. 1H-NMR (CDCl3, 500 MHz) δ 7.59 (d, J=7.6 Hz, 1H), 7.55 (s, 1H), 7.44 (t, J=7.6 Hz, 1H), 7.34 (m, 2H), 6.95 (m, 1H), 6.87 (m, 2H), 6.22 (s, 1H), 5.32 (d, J=7.3 Hz, 1H), 4.81 (d, J=7.3 Hz, 1H), 3.84 (s, 3H), 2.81 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.3, 138.7, 138.4, 132.5, 130.3, 129.8, 129.6, 127.0, 123.5, 118.0, 115.1, 111.2, 89.4, 86.3, 64.7, 55.5. Mass spec.: 391.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromopicolinonitrile. 1H-NMR (CDCl3, 400 MHz) δ 8.68 (dd, J=4.8, 1.5 Hz, 1H), 7.98 (dd, J=8.0, 1.5 Hz, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.61 (s, 1H), 7.56 (m, 1H), 7.48 (t, J=7.8 Hz, 1H), 7.36 (m, 2H), 6.95 (m, 1H), 6.87 (m, 2H), 6.95 (m, 1H), 6.87 (m, 2H), 6.32 (s, 1H), 5.31 (d, J=7.3 Hz, 1H), 4.84 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (100 Hz, CDCl3) δ ppm 159.7, 158.9, 149.1, 139.0, 138.6, 137.9, 35.5, 132.5, 129.9, 129.4, 129.3, 127.5, 125.8, 124.6, 122.2, 117.6, 115.5, 114.6, 110.7, 97.6, 85.7, 83.3, 64.1, 55.0. Mass spec.: 394.04 (MH)−.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 1-bromo-3-methylbenzene. 1H-NMR (CDCl3, 500 MHz) δ 7.57 (d, J=7.6 Hz, 1H), 7.54 (s, 1H), 7.42 (t, J=7.6 Hz, 1H), 7.40 (s, 1H), 7.37-7.33 (m, 2H), 7.29-7.26 (m, 2H), 7.20 (d, J=7.6 Hz, 1H), 6.96 (m, 1H), 6.88 (m, 2H), 5.72 (s, 1H), 5.33 (d, J=7.3 Hz, 1H), 4.78 (d, J=7.3 Hz, 1H), 3.84 (s, 3H), 2.39 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 138.7, 138.2, 132.4, 132.3, 130.3, 129.6, 129.4, 128.8, 128.4, 126.3, 124.7, 122.7, 118.0, 115.0, 111.1, 90.8, 88.2, 86.1, 64.7, 55.5, 21.4. Mass spec.: 384.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromobenzonitrile. 1H-NMR (CDCl3, 500 MHz) δ 7.82 (s, 1H), 7.76 (d, J=7.9 Hz, 1H), 7.65 (d, J=7.6 Hz, 1H), 7.58 (s, 1H), 7.56 (d, J=4.9 Hz, 1H), 7.50 (t, J=7.9 Hz, 1H), 7.45 (t, J=7.9 Hz, 1H), 7.35 (m, 2H), 6.95 (m, 1H), 6.88 (m, 2H), 6.23 (bs, 1H), 5.30 (d, J=7.3 Hz, 1H), 4.81 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 139.1, 138.7, 135.8, 135.0, 132.4, 131.8, 130.3, 129.7, 129.6, 128.9, 127.1, 124.6, 123.6, 118.1, 114.9, 113.1, 111.3, 90.9, 88.0, 86.0, 64.6, 55.5. Mass spec.: 395.2 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 4-bromopicolinonitrile. 1H-NMR (CDCl3, 500 MHz) δ 8.74 (s, 1H), 7.80 (s, 1H), 7.60 (m, 3H), 7.49 (t, J=7.6 Hz, 1H), 7.39 (d, J=7.6 Hz, 1H), 7.35 (t, J=7.6 Hz, 1H), 6.97 (dd, J=8.2, 2.14 Hz, 1H), 6.88 (m, 2H), 6.27 (s, 1H), 5.29 (d, J=7.3 Hz, 1H), 4.83 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.2, 151.2, 139.3, 138.5, 134.3, 132.9, 132.7, 130.34, 130.28, 130.0, 129.8, 128.7, 128.1, 122.5, 118.1, 116.8, 114.9, 111.4, 96.0, 86.0, 85.7, 64.5, 55.5, 50.9. Mass spec.: 396.27 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 4-bromo-2-chloropyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.43 (d, J=5.2 Hz, 1H), 7.59 (m, 2H), 7.48 (m, 2H), 7.38-7.33 (m, 3H), 6.97 (dd, J=8.2, 2.4 Hz, 1H), 6.88 (m, 2H), 5.40 (s, 1H), 5.30 (d, J=7.0 Hz, 1H), 4.79 (d, J=7.3 Hz, 1H), 3.85 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.2, 158.2, 151.9, 149.8, 139.2, 138.6, 133.9, 132.7, 130.3, 130.0, 129.7, 127.7, 126.2, 124.3, 123.0, 118.0, 114.9, 111.3, 94.3, 86.5, 85.9, 64.5, 55.5. Mass spec.: 405.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromo-N,N-dimethylaniline. 1H-NMR (CDCl3, 500 MHz) δ 7.63-7.58 (m, 4H), 7.54 (m, 2H), 7.46 (t, J=7.9 Hz, 1H), 7.38-7.32 (m, 2H), 6.97 (m, 1H), 6.89 (m, 2H), 5.89 (s, 1H), 5.34 (d, J=7.0 Hz, 1H), 4.82 (d, J=7.3 Hz, 1H), 3.85 (s, 3H), 3.25 (s, 6H); 13C NMR (126 MHz, CDCl3) δ ppm 160.3, 159.1, 144.4, 138.9, 138.5, 132.5, 131.6, 130.7, 130.4, 129.7, 129.6, 127.1, 125.5, 123.8, 122.3, 120.0, 118.0, 115.0, 111.3, 90.7, 88.6, 64.6, 55.5, 45.8. Mass spec.: 413.2 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 1-bromo-3-methoxybenzene. 1H-NMR (CDCl3, 500 MHz) δ 7.56 (m, 2H), 7.43 (t, J=7.6 Hz, 1H), 7.34 (t, J=7.9 Hz, 1H), 7.29 (m, 2H), 7.16 (d, J=7.3 Hz, 1H), 7.09 (m, 1H), 6.95 (m, 2H), 6.88 (m, 2H), 5.79 (bs, 1H), 5.32 (d, J=7.0 Hz, 1H), 4.78 (d, J=7.0 Hz, 1H), 3.86 (s, 3H), 3.84 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 159.5, 138.9, 138.8, 132.3, 131.8, 130.3, 129.7, 129.6, 129.4, 128.7, 128.5, 126.5, 126.4, 124.5, 124.3, 123.9, 118.1, 116.5, 115.4, 115.0, 111.2, 90.5, 88.4, 86.0, 64.6, 55.49, 55.45. Mass spec.: 400.25 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 4-bromo-2-methylpyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.82 (d, J=5.8 Hz, 1H), 7.71 (d, J=5.8 Hz, 1H), 7.68 (s, 1H), 7.64 (m, 2H), 7.51 (t, J=7.9 Hz, 1H), 7.43 (d, J=7.9 Hz, 1H), 7.36 (t, J=7.9 Hz, 1H), 6.97 (m, 1H), 6.88 (m, 2H), 6.38 (s, 1H), 5.28 (d, J=7.0 Hz, 1H), 4.84 (d, J=7.3 Hz, 1H), 3.84 (s, 3H), 2.85 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.3, 158.9, 154.3, 142.1, 140.0, 139.7, 138.5, 133.0, 130.4, 130.3, 129.9, 129.0, 128.7, 125.7, 121.7, 118.1, 114.8, 111.5, 100.9, 86.0, 85.8, 64.4, 55.5, 19.9, 15.3. Mass spec.: 385.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 2-bromo-6-methoxypyridine. 1H-NMR (CDCl3, 500 MHz) δ 7.61 (m, 3H), 7.43 (t, J=7.6 Hz, 1H), 7.34 (m, 2H), 6.94 (dd, J=8.9, 2.4 Hz, 1H), 6.87 (m, 2H), 6.13 (s, 1H), 5.30 (d, J=7.3 Hz, 1H), 4.79 (d, J=7.3 Hz, 1H), 4.01 (s, 3H), 3.83 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 159.0, 138.9, 38.7, 132.7, 30.3, 130.1, 129.5, 127.0, 123.8, 118.1, 115.0, 111.2, 87.8, 86.0, 64.6, 55.5, 53.8. Mass spec.: 401.4 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 2-bromo-1H-imidazole. 1H-NMR (CDCl3, 500 MHz) δ 7.73 (bs, 1H), 7.61 (bs, 1H), 7.40 (d, J=7.3 Hz, 1H), 7.23 (m, 2H), 7.18 (s, 2H), 7.10 (m, 1H), 6.91 (m, 1H), 6.74 (m, 2H), 5.08 (d, J=7.3 Hz, 1H), 4.78 (d, J=7.6 Hz, 1H), 3.76 (s, 3H). Mass spec.: 360.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 2-bromopyrazine. 1H-NMR (CDCl3, 500 MHz) δ 8.79 (bs, 2H), 7.64 (d, J=7.6 Hz, 1H), 7.61 (s, 1H), 7.47 (t, J=7.6 Hz, 1H), 7.39 (t, J=7.6 Hz, 1H), 7.34 (t, J=7.9 Hz, 1H), 6.95 (dd, J=8.2, 1.8 Hz, 1H), 6.87 (m, 2H), 6.35 (s, 1H), 5.29 (d, J=7.3 Hz, 1H), 4.82 (d, J=7.3 Hz, 1H), 3.83 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 159.0, 139.2, 138.6, 132.8, 130.3, 130.2, 129.7, 127.7, 122.6, 118.1, 115.0, 111.3, 92.7, 86.0, 64.6, 55.5. Mass spec.: 372.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 2-bromopyrimidine. 1H-NMR (CDCl3, 500 MHz) δ 8.85 (d, J=4.9 Hz, 2H), 7.71 (d, J=7.6 Hz, 1H), 7.65 (s, 1H), 7.49 (t, J=7.6 Hz, 1H), 7.43 (d, J=7.9 Hz, 1H), 7.37-7.33 (m, 2H), 6.96 (dd, J=8.4, 2.4 Hz, 1H), 6.87 (m, 2H), 5.87 (s, 1H), 5.31 (d, J=7.3 Hz, 1H), 4.81 (d, J=7.6 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 158.9, 157.5, 152.6, 138.9, 138.4, 133.3, 130.8, 130.3, 129.7, 127.9, 122.3, 120.2, 118.1, 115.1, 111.2, 88.1, 88.0, 86.1, 64.6, 55.5. Mass spec.: 370.3 (MH)−.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 5-bromopyrimidine. 1H-NMR (CDCl3, 500 MHz) δ 9.26 (bs, 1H), 9.01 (bs, 2H), 7.60 (m, 2H), 7.48 (t, J=7.6 Hz, 1H), 7.36 (m, 2H), 6.97 (m, 1H), 6.88 (m, 2H), 6.21 (s, 1H), 5.31 (d, J=7.3 Hz, 1H), 4.82 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 159.0, 158.7, 156.5, 139.2, 138.6, 132.5, 130.3, 129.8, 129.7, 127.6, 123.0, 118.1, 114.9, 111.4, 95.9, 86.0, 83.2, 64.6, 55.5. Mass spec.: 372.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 2-bromoquinoline. 1H-NMR (CDCl3, 400 MHz) δ 8.49 (d, J=8.5 Hz, 1H), 8.40 (d, J=8.5 Hz, 1H), 7.96 (m, 2H), 7.75 (m, 4H), 7.51 (t, J=7.8 Hz, 1H), 7.42 (d, J=7.8 Hz, 1H), 7.35 (t, J=8.0 Hz, 1H), 6.96 (d, J=8.3 Hz, 1H), 6.90 (m, 2H), 5.75 (s, 1H), 5.32 (d, J=7.3 Hz, 1H), 4.83 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 158.6, 143.6, 140.7, 140.3, 139.3, 138.5, 133.4, 133.1, 130.7, 130.3, 129.8, 129.0, 128.6, 128.0, 127.6, 125.2, 124.4, 122.0, 118.1, 115.1, 111.2, 86.0, 64.5, 55.5. Mass spec.: 421.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromoisoquinoline. 1H-NMR (CDCl3, 500 MHz) δ 9.57 (s, 1H), 8.22 (d, J=8.2 Hz, 1H), 8.15 (s, 1H), 7.98 (m, 2H), 7.83 (m, 1H), 7.67 (m, 2H), 7.45 (t, J=7.9 Hz, 1H), 7.34 (m, 2H), 6.94 (dd, J=8.2, 1.8 Hz, 1H), 6.88 (m, 2H), 6.29 (s, 1H), 5.29 (d, J=7.3 Hz, 1H), 4.82 (d, J=7.3 Hz, 1H), 3.83 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 158.9, 150.3, 139.2, 138.6, 137.2, 134.4, 132.8, 130.7, 130.3, 130.12, 130.08, 129.63, 129.57, 127.9, 127.0, 122.5, 118.1, 115.0, 111.2, 93.8, 86.0, 64.5, 55.5. Mass spec.: 421.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 4-bromothiazole. 1H-NMR (CDCl3, 500 MHz) δ 8.96 (bs, 1H), 7.67 (s, 1H), 7.61 (d, J=7.6 Hz, 1H), 7.56 (s, 1H), 7.44 (t, J=7.6 Hz, 1H), 7.34 (m, 2H), 6.95 (m, 1H), 6.87 (m, 2H), 6.03 (s, 1H), 5.30 (d, J=7.3 Hz, 1H), 4.80 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.2, 158.9, 138.9, 138.6, 132.5, 130.3, 129.9, 129.6, 127.0, 123.5, 118.1, 115.0, 111.2, 89.0, 86.1, 64.6, 55.5. Mass spec.: 377.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 5-bromo-2-fluoropyridine. 1H-NMR (CDCl3, 400 MHz) δ 8.42 (d, J=2.0 Hz, 1H), 7.59 (m, 2H), 7.93 (dd, J=8.3, 2.3 Hz, 1H), 7.56 (m, 2H), 7.44 (t, J=7.8 Hz, 1H), 7.34 (m, 2H), 6.96 (m, 2H), 6.88 (m, 2H), 5.98 (s, 1H), 5.29 (d, J=7.0 Hz, 1H), 4.79 (d, J=7.0 Hz, 1H), 3.84 (s, 3H); 13C NMR (100.6 Hz, CDCl3) δ ppm 163.6, 161.2, 159.8, 158.2, 150.3, 150.2, 143.3, 143.2, 138.7, 138.3, 131.8, 129.8, 129.14, 129.07, 126.6, 123.2, 117.6, 117.5, 114.4, 110.8, 109.4, 109.0, 91.1, 85.5, 85.3, 64.1, 55.0. Mass spec.: 389.02 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 5-bromopicolinonitrile. 1H-NMR (CDCl3, 400 MHz) δ 8.85 (m, 1H), 7.96 (dd, J=8.0, 2.0 Hz, 1H), 7.72 (dd, J=8.0, 0.80 Hz, 1H), 7.62-7.59 (m, 2H), 7.48 (t, J=7.8 Hz, 1H), 7.38-7.33 (m, 2H), 6.97 (m, 1H), 6.89 (m, 2H), 5.93 (s, 1H), 5.31 (d, J=7.3 Hz, 1H)), 4.82 (d, J=7.0 Hz, 1H), 3.84 (s, 3H); 13C NMR (100.6 Hz, CDCl3) δ ppm 159.8, 158.4, 152.8, 138.8, 138.0, 132.1, 131.8, 129.9, 129.4, 129.3, 127.4, 127.3, 123.4, 122.5, 117.6, 116.5, 114.4, 110.9, 95.5, 85.6, 85.2, 64.0, 55.0. Mass spec.: 394.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 5-bromo-2-methoxypyridine. 1H-NMR (CDCl3, 400 MHz) δ 8.44 (bs, 1H), 7.76 (d, J=8.8 Hz, 1H), 7.56 (m, 2H), 7.43 (t, J=7.5 Hz, 1H), 7.35 (t, J=8.3 Hz, 1H), 7.29 (m, 1H), 6.96 (m, 1H), 6.88 (m, 2H), 6.82 (bs, 1H), 6.02 (s, 1H), 5.33 (d, J=7.3 Hz, 1H), 4.80 (d, J=7.3 Hz, 1H), 4.01 (s, 3H), 3.84 (s, 3H); 13C NMR (100.6 Hz, CDCl3) δ ppm 159.8, 158.7, 149.3, 141.3, 138.3, 138.1, 131.8, 129.8, 129.0, 129.03, 129.0, 126.1, 123.9, 117.6, 114.5, 110.8, 89.7, 86.7, 85.7, 64.2, 55.0, 53.8. Mass spec.: 401.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 2-bromo-6-fluoropyridine. 1H-NMR (CDCl3, 500 MHz) δ 7.83 (dd, J=15.6, 7.9 Hz, 1H), 7.63 (d, J=7.6 Hz, 1H), 7.58 (s, 1H), 7.45 (m, 2H), 7.35 (m, 2H), 6.96 (m, 2H), 6.87 (m, 2H), 6.24 (s, 1H), 5.31 (d, J=7.3 Hz, 1H), 4.82 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 159.3, 141.5, 141.0, 138.9, 138.4, 132.8, 130.3, 130.1, 129.6, 127.4, 124.9, 123.1, 118.1, 115.0, 111.3, 110.0, 109.7, 89.5, 88.2, 86.2, 64.7, 55.5. Mass spec.: 389.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 4-bromo-2-fluoropyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.33 (bs, 1H), 7.59 (m, 2H), 7.47 (t, J=7.6 Hz, 1H), 7.38-7.32 (m, 3H), 7.10 (bs, 1H), 6.96 (m, 1H), 6.88 (m, 2H), 6.20 (s, 1H), 5.30 (d, J=7.0 Hz, 1H), 4.82 (d, J=7.0 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.2, 139.2, 138.6, 132.7, 130.3, 129.9, 129.7, 127.7, 122.9, 118.1, 114.9, 111.4, 94.3, 86.6, 86.1, 64.6, 55.5. Mass spec.: 389.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 4-bromopyrimidine. 1H-NMR (CDCl3, 500 MHz) δ 9.27 (d, J=1.2 Hz, 1H), 8.83 (d, J=5.2 Hz, 1H), 7.68 (d, J=7.6 Hz, 1H), 7.64 (s, 1H), 7.57 (dd, J=5.2, 1.2 Hz, 1H), 7.50 (t, J=7.9 Hz, 1H), 7.42 (d, J=7.9 Hz, 1H), 7.35 (t, J=7.9 Hz, 1H), 6.97 (dd, J=8.2, 2.4 Hz, 1H), 6.88 (m, 2H), 6.02 (s, 1H), 5.30 (d, J=7.3 Hz, 1H), 4.82 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.3, 158.9, 158.3, 156.6, 151.0, 139.2, 138.4, 133.2, 130.5, 130.4, 129.8, 128.4, 123.8, 122.1, 118.1, 115.0, 111.3, 94.3, 87.1, 86.1, 64.6, 55.5. Mass spec.: 372.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 6-bromopicolinonitrile. 1H-NMR (CDCl3, 500 MHz) δ 7.89 (t, J=7.9 Hz, 1H), 7.75 (d, J=7.9 Hz, 1H), 7.67 (m, 2H), 7.62 (s, 1H), 7.48 (t, J=7.6 Hz, 1H), 7.39 (d, J=7.6 Hz, 1H), 7.35 (t, J=7.9 Hz, 1H), 6.96 (dd, J=8.6, 2.4 Hz, 1H), 6.87 (m, 2H), 6.16 (s, 1H), 5.30 (d, J=7.0 Hz, 1H), 4.82 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 159.0, 144.8, 139.1, 138.5, 137.6, 134.4, 132.9, 130.3, 129.7, 127.8, 127.5, 122.6, 118.1, 116.6, 115.0, 111.3, 90.7, 87.8, 86.1, 64.6, 55.5. Mass spec.: 394.2 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromoqinoline. 1H-NMR (CDCl3, 500 MHz) δ 9.32 (bs, 1H), 8.72 (s, 1H), 8.42 (d, J=7.0 Hz, 1H), 8.04 (d, J=7.9 Hz, 1H), 7.98 (t, J=7.3 Hz, 1H), 7.83 (t, J=7.9 Hz, 1H), 7.64 (m, 2H), 7.50 (t, J=7.9 Hz, 1H), 7.37 (m, 2H), 6.97 (dd, J=7.9, 2.1 Hz, 1H), 6.90 (m, 2H), 6.02 (s, 1H), 5.33 (d, J=7.0 Hz, 1H), 4.83 (d, J=7.3 Hz, 1H), 3.85 (s, 3H); 13C NMR (126 MHz, CDCl3) δ ppm 160.2, 143.3, 139.2, 138.6, 133.3, 132.6, 130.3, 129.9, 129.8, 129.7, 128.2, 127.7, 122.9, 118.1, 115.0, 111.3, 94.3, 86.1, 64.6, 55.5. Mass spec.: 421.2 (MH)+.
To a solution of (4R,5R)-5-(3-methoxyphenyl)-4-(3-((6-methoxypyridin-2-yl)ethnyl)phenyl)oxazolidin-2-one (11.50 mg, 0.029 mmol) in acetic acid (1 mL) was added sodium iodide (4.30 mg, 0.029 mmol), the reaction was heated at 100° C. for one h. The reaction was concentrated and the residue purified by Prep HPLC TFA-MeOH (Sunfire C18 19×100 mm 5 um, 30-100%, 15 min gradient, 25 mL/min flow rate) to give 7.1 mg (63%). 1H-NMR (CDCl3, 400 MHz) δ 7.65 (s, 1H), 7.58 (d, J=7.5 Hz, 1H), 7.52 (m, 1H), 7.42 (t, J=7.8 Hz, 1H), 7.32 (m, 2H), 6.94 (m, 1H), 6.87 (m, 2H), 6.72 (d, J=8.8 Hz, 1H), 6.65 (d, J=6.8 Hz, 1H), 6.54 (bs, 1H), 4.80 (d, J=7.0 Hz, 1H), 4.80 (d, J=7.0 Hz, 1H), 3.83 (s, 3H); 13C NMR (100.6 MHz, CDCl3) δ ppm 163.9, 159.7, 158.4, 141.6, 139.0, 138.3, 132.0, 129.8, 129.7, 129.03, 128.98, 121.5, 119.9, 117.7, 114.5, 112.7, 110.8, 94.4, 85.3, 82.0, 64.0, 55.0. Mass spec.: 387.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromo-2-methoxypyridine. 1H-NMR (CDCl3, 400 MHz) δ 8.20 (d, J=3.3 Hz, 1H), 7.80 (dd, J=7.5, 1.8 Hz, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.56 (s, 1H), 7.42 (t, J=7.8 Hz, 1H), 7.34 (t, J=8.3 Hz, 1H), 7.29 (d, J=7.8 Hz, 1H), 6.94 (m, 2H), 6.87 (m, 2H), 6.15 (s, 1H), 5.32 (d, J=7.3 Hz, 1H), 4.80 (d, J=7.3 Hz, 1H), 4.08 (s, 3H), 3.83 (s, 3H); 13C NMR (100.6 Hz, CDCl3) δ ppm 163.1, 159.7, 145.9, 141.6, 138.2, 138.1, 132.0, 129.8, 129.2, 129.0, 126.3, 123.9, 117.6, 116.2, 114.5, 110.8, 107.0, 93.4, 85.7, 84.7, 64.2, 55.0, 53.9. Mass spec.: 401.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromo-2-fluoropyridine. 1H-NMR (CDCl3, 400 MHz) δ 8.24 (s, 1H), 7.96 (t, J=7.5 Hz, 1H), 7.61 (d, J=6.5 Hz, 1H), 7.57 (s, 1H), 7.46 (t, J=7.5 Hz, 1H), 7.35 (m, 2H), 7.25 (m, 1H), 6.96 (m, 1H), 6.88 (m, 2H), 6.00 (s, 1H), 5.32 (d, J=7.3 Hz, 1H), 4.81 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (100.6 Hz, CDCl3) δ ppm 159.8, 146.5, 146.4, 143.1, 138.5, 138.1, 132.1, 129.8, 129.3, 129.1, 126.8, 123.0, 117.6, 114.6, 110.8, 94.6, 85.6, 81.6, 81.5, 64.1, 55.0. Mass spec.: 387.07 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 5-bromonicotinonitrile. 1H-NMR (CDCl3, 400 MHz) δ 8.12 (s, 1H), 7.59 (m, 2H), 7.48 (t, J=7.5 Hz, 1H), 7.36 (m, 2H), 6.97 (m, 1H), 6.89 (m, 2H), 6.19 (s, 1H), 5.30 (d, J=7.3 Hz, 1H), 4.82 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (100.6 Hz, CDCl3) δ ppm 159.8, 158.6, 138.8, 138.1, 132.1, 129.9, 129.4, 129.2, 127.3, 122.3, 117.6, 114.4, 111.0, 94.2, 85.6, 64.1, 55.0. Mass spec.: 396.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromo-5-fluoropyridine. 1H-NMR (CDCl3, 500 MHz) δ 7.71 (s, 1H), 7.60 (d, J=7.6 Hz, 1H), 7.57 (s, 1H), 7.47 (t, J=7.6 Hz, 1H), 7.35 (m, 2H), 6.96 (m, 1H), 6.88 (m, 2H), 6.36 (s, 1H), 5.31 (d, J=7.0 Hz, 1H), 4.83 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.2, 159.2, 139.2, 138.5, 132.6, 130.3, 129.9, 129.7, 127.6, 122.9, 118.1, 114.9, 111.4, 86.1, 64.6, 55.5. Mass spec.: 389.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 5-bromo-2-chloropyridine. 1H-NMR (CDCl3, 500 MHz) δ 7.84 (d, J=7.6 Hz, 1H), 7.58 (d, J=7.9 Hz, 1H), 7.56 (s, 1H), 7.46 (t, J=7.6 Hz, 1H), 7.34 (m, 2H), 6.96 (m, 1H), 6.88 (m, 2H), 6.08 (s, 1H), 5.32 (d, J=7.0 Hz, 1H), 4.81 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.2, 159.1, 139.0, 138.5, 132.4, 130.3, 129.7, 129.6, 127.2, 123.5, 118.1, 114.9, 111.3, 93.1, 86.1, 64.6, 55.5. Mass spec.: 404.95 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 5-bromo-2-methylpyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.96 (s, 1H), 8.24 (d, J=8.2 Hz, 1H), 7.60 (m, 3H), 7.47 (t, J=7.9 Hz, 1H), 7.36 (m, 2H), 6.96 (m, 1H), 6.87 (m, 2H), 6.39 (s, 1H), 5.28 (d, J=7.3 Hz, 1H), 4.82 (d, J=7.3 Hz, 1H), 3.84 (s, 3H), 2.86 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.2, 159.2, 153.8, 145.3, 145.1, 139.3, 138.5, 132.6, 130.3, 129.9, 129.7, 128.0, 126.8, 122.4, 118.1, 114.9, 111.4, 95.5, 86.1, 83.3, 64.5, 55.5. Mass spec.: 385.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromo-4-chloropyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.90 (bs, 1H), 8.60 (bs, 1H), 7.63 (m, 3H), 7.49 (t, J=7.6 Hz, 1H), 7.36 (m, 2H), 6.96 (d, J=8.2 Hz, 1H), 6.88 (m, 2H), 5.79 (s, 1H), 5.32 (d, J=7.3 Hz, 1H), 4.82 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.2, 158.6, 151.5, 147.5, 147.0, 139.1, 138.5, 134.5, 132.7, 130.3, 129.9, 129.7, 128.7, 127.7, 123.0, 118.1, 115.0, 111.3, 97.9, 86.0, 83.1, 64.6, 55.5. Mass spec.: 404.9 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromo-2-chloropyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.40 (d, J=4.0 Hz, 1H), 7.90 (d, J=7.6 Hz, 1H), 7.64 (d, J=7.6 Hz, 1H), 7.59 (s, 1H), 7.47 (t, J=7.6 Hz, 1H), 7.35 (m, 2H), 7.30 (m, 1H), 6.96 (d, J=8.6 Hz, 1H), 6.88 (m, 2H), 5.47 (s, 1H), 5.32 (d, J=7.3 Hz, 1H), 4.80 (d, J=7.3 Hz, 1H), 3.84 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.2, 158.3, 148.6, 141.4, 139.0, 138.6, 132.5, 130.3, 129.7, 129.6, 127.3, 123.6, 122.1, 120.3, 118.0, 115.0, 111.2, 95.8, 85.9, 85.3, 64.5, 55.5. Mass spec.: 404.9 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromo-5-methylpyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.82 (bs, 1H), 8.66 (bs, 1H), 8.20 (s, 1H), 7.60 (m, 2H), 7.49 (t, J=7.6 Hz, 1H), 7.37 (m, 2H), 6.97 (dd, J=8.2, 2.1 Hz, 1H), 6.88 (m, 2H), 6.24 (s, 1H), 5.31 (d, J=7.0 Hz, 1H), 4.83 (d, J=7.3 Hz, 1H), 3.84 (s, 3H), 2.59 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.2, 159.2, 139.3, 138.4, 132.7, 130.4, 129.9, 129.8, 128.1, 122.4, 118.1, 114.9, 111.4, 86.1, 64.5, 55.5. Mass spec.: 385.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromo-2-methylpyridine. 1H-NMR (CDCl3, 400 MHz) δ 8.82 (d, J=4.5 Hz, 1H), 8.32 (d, J=8.0 Hz, 1H), 7.70 (t, J=7.0 Hz, 1H), 7.61 (m, 2H), 7.50 (t, J=7.8 Hz, 1H), 7.36 (m, 2H), 6.97 (m, 1H), 6.88 (m, 2H), 6.34 (s, 1H), 5.29 (d, J=7.3 Hz, 1H), 4.84 (d, J=7.3 Hz, 1H), 3.84 (s, 3H), 3.00 (s, 3H); 13C NMR (100.6 Hz, CDCl3) δ ppm 159.8, 158.5, 156.3, 145.1, 141.0, 139.0, 138.0, 132.1, 129.9, 129.3, 127.8, 123.2, 121.8, 117.6, 114.4, 111.0, 98.7, 85.5, 82.5, 64.0, 55.0. Mass spec.: 385.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromo-4-methylpyridine. 1H-NMR (CDCl3, 400 MHz) δ 8.93 (bs, 1H), 8.66 (bs, 1H), 7.70 (s, 1H), 7.61 (m, 2H), 7.49 (t, J=7.8 Hz, 1H), 7.36 (m, 2H), 6.96 (m, 1H), 6.88 (m, 2H), 6.30 (s, 1H), 5.30 (d, J=7.28 Hz, 1H), 4.83 (d, J=7.3 Hz, 1H), 3.84 (s, 3H), 2.77 (s, 3H); 13C NMR (100.6 Hz, CDCl3) δ ppm 159.8, 157.6, 144.5, 140.4, 138.9, 138.0, 132.1, 129.9, 129.3, 127.7, 121.9, 117.6, 114.4, 111.0, 99.2, 85.6, 81.9, 64.1, 55.0. Mass spec.: 385.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 4-bromo-2-methylpyridine. 1H-NMR (CDCl3, 500 MHz) δ 8.23 (d, J=5.5 Hz, 1H), 7.60 (d, J=7.6 Hz, 1H), 7.57 (s, 1H), 7.46 (t, J=7.6 Hz, 1H), 7.35 (m, 2H), 7.04 (m, 1H), 6.95 (m, 1H), 6.92 (s, 1H), 6.88 (m, 2H), 5.93 (s, 1H), 5.31 (d, J=7.3 Hz, 1H), 4.80 (d, J=7.3 Hz, 1H), 4.00 (s, 3H), 3.84 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 164.2, 160.2, 158.8, 146.5, 139.1, 138.6, 134.2, 132.7, 130.3, 129.9, 129.6, 127.4, 123.4, 119.1, 118.0, 115.0, 113.0, 111.3, 92.9, 87.6, 86.0, 64.6, 55.5, 54.2. Mass spec.: 401.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 2-bromobenzonitrile. 1H-NMR (CDCl3, 400 MHz) δ 7.71 (d, J=7.8 Hz, 1H), 7.66 (m, 2H), 7.61 (m, 2H), 7.46 (m, 2H), 7.34 (m, 2H), 6.96 (m, 1H), 6.89 (m, 2H), 5.85 (s, 1H), 5.32 (d, J=7.0 Hz, 1H), 4.80 (d, J=7.0 Hz, 1H), 3.84 (s, 3H); 13C NMR (100.6 Hz, CDCl3) δ ppm 159.8, 138.6, 138.2, 132.4, 132.3, 132.1, 131.9, 129.8, 129.4, 129.1, 128.2, 126.9, 126.4, 122.9, 117.6, 115.1, 114.6, 110.6, 94.5, 86.1, 85.5, 64.1, 55.0. Mass spec.: 392.9 (MH)−.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 1-bromo-2-methoxybenzene. 1H-NMR (CDCl3, 500 MHz) δ 7.59 (m, 2H), 7.53 (dd, J=7.3, 1.5 Hz, 1H), 7.41 (d, J=7.6 Hz, 1H), 7.35 (m, 2H), 7.27 (m, 1H), 6.96 (m, 3H), 6.88 (m, 2H), 5.60 (s, 1H), 5.33 (d, J=7.3 Hz, 1H), 4.77 (d, J=7.3 Hz, 1H), 3.95 (s, 3H), 3.84 (s, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.2, 160.1, 138.8, 138.6, 133.7, 132.4, 130.3, 130.2, 129.7, 129.3, 126.3, 124.9, 120.7, 118.1, 115.0, 112.1, 111.1, 110.8, 92.5, 87.0, 86.0, 64.7, 56.0, 55.5. Mass spec.: 399.97 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 3-bromo-4-fluoropyridine. 1H-NMR (CDCl3, 400 MHz) δ 8.80 (bd, 2H), 7.61 (m, 2H), 7.47 (t, J=7.8 Hz, 1H), 7.35 (m, 3H), 6.96 (m, 1H), 6.88 (m, 2H), 6.12 (s, 1H), 5.29 (d, J=7.3 Hz, 1H), 4.82 (d, J=7.3 Hz, 1H), 4.22 (s, 3H), 3.84 (s, 3H); 13C NMR (100.6 Hz, CDCl3) δ ppm 159.8, 138.8, 138.1, 132.2, 129.9, 129.3, 129.2, 127.7, 117.6, 114.4, 110.9, 85.5, 64.0, 57.5, 55.0. Mass spec.: 401.2 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 5-bromo-N-methylpyrimidine-2-amine 1H-NMR (CDCl3, 500 MHz) δ 9.27 (s, 1H), 8.76 (s, 1H), 8.26 (s, 1H), 7.55 (m, 2H), 7.46 (t, J=7.93 Hz, 1H), 7.35 (m, 2H), 6.97 (m, 1H), 6.88 (m, 2H), 5.47 (s, 1H), 5.31 (d, J=7.32 Hz, 1H), 4.79 (d, J=7.32 Hz, 1H), 3.85 (s, 3H), 3.16 (s, 3H). Mass spec.: 401.0 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-methoxyphenyl)-4-(3-(pyridine-3-ylethynyl)oxazolidin-2-one, starting with 5-bromo-2-ethoxypyrimidine. 1H-NMR (CDCl3, 500 MHz) δ 8.90 (bs, 2H), 7.56 (m, 2H), 7.45 (t, J=7.9 Hz, 1H), 7.34 (m, 2H), 6.95 (m, 1H), 6.88 (m, 2H), 5.95 (s, 1H), 5.32 (d, J=7.3 Hz, 1H), 4.80 (d, J=7.3 Hz, 1H), 4.51 (q, J=6.4 Hz, 2H), 3.84 (s, 3H), 1.49 (t, J=6.7 Hz, 3H); 13C NMR (126 Hz, CDCl3) δ ppm 160.2, 158.9, 139.0, 138.6, 132.3, 130.3, 129.6, 129.57, 127.0, 123.6, 118.1, 114.9, 111.3, 86.1, 64.6, 64.4, 55.5, 14.5. Mass spec.: 416.0 (MH)+.
To diisopropylamine (0.241 mL, 1.693 mmol) in tetrahydrofuran (10 mL) under nitrogen at −78° C. was added n-BuLi (0.677 mL, 1.693 mmol). After 60 min, the colorless solution was warmed to −20° C. and a solution of 2-(3-(phenylethynyl)phenyl)acetic acid (200 mg, 0.847 mmol; Araldi, G. L.; Liao, Y.; Brugger, N. Hydrazide Deriviatives as Prostaglandin Receptor Modulators. WO 2005/012232 A2, 2005) in tetrahydrofuran (5 mL) was added resulting in a red solution which was allowed to stir for 45 min as the cooling bath temperature rose to 5° C. The reaction was recooled to −30° C., benzaldehyde (0.103 mL, 1.016 mmol) was added dropwise resulting in immediate disappearance of the red color and the cooling bath was removed. After 48 h, the reaction mixture was quenched with 1N HCl (20 mL), extracted with ethyl acetate (3×20 mL), washed with brine, dried over MgSO4, filtered and concentrated providing (2S,3R)-3-hydroxy-3-phenyl-2-(3-(phenylethynyl)phenyl)propanoic acid as an amber oil which was used in the next step without further purification or characterization.
To (2S,3R)-3-hydroxy-3-phenyl-2-(3-(phenylethynyl)phenyl)propanoic acid (290 mg, 0.847 mmol) in Toluene (10 mL) was added Hunig'sBase (0.192 mL, 1.101 mmol) followed by diphenyl phosphorazidate (0.183 mL, 0.847 mmol). The reaction mixture was heated to 60° C. for 18 h and an add'l portion of diphenyl phosphorazidate (0.183 mL, 0.847 mmol) was added with continued heating. After 1 h, the reaction was cooled and concentrated to 3 mL volume and applied to 12 g silica gel cartridge which was pre-equilibrated with 5% ethyl acetate/hexanes. Elution with 5 to 40% ethyl acetate/hexanes over 300 mL provided 179 mg racemic trans-5-phenyl-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one which was rechromatographed under identical conditions providing 79 mg racemic trans-5-phenyl-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one as a colorless oil. The enantiomers were separated via chiral preparative HPLC (Preparative HPLC Method 2) in two portions solubilizing in 1:1 CH2Cl2/MeOH providing 36 mg (12%) (4R,5R)-5-phenyl-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one (enantiomer 1; Retention time=8.48 min) and 35 mg (12%) (4S,5S)-5-phenyl-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one (enantiomer 2; Retention time=16.36 min) 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 7.48-7.58 (4H, m), 7.28-7.45 (9H, m), 7.22-7.28 (1H, m), 5.32 (2H, d, J=7.32 Hz), 4.75 (1H, d, J=7.32 Hz). LC/MS (Analytical HPLC Method 1) 1.92 min, Anal. Calcd. for [M+H]+ C23H17NO2: 340.13. found 340.05.
To (S)-tert-butyl 2-hydroxy-1-(3-(phenylethynyl)phenyl)ethylcarbamate (100 mg, 0.296 mmol) in dichloromethane (2 mL) was added sodium bicarbonate (124 mg, 1.482 mmol) followed by Dess-Martin Periodinane (151 mg, 0.356 mmol). After 1 h, the reaction was quenched with 1:1 saturated NaHCO3/Na2SO3 and extracted into ethyl acetate (10 mL). The organic layer was dried with MgSO4, filtered and concentrated to 96 mg (S)-tert-butyl 2-oxo-1-(3-(phenylethynyl)phenyl)ethylcarbamate as an amber oil which was concentrated from toluene under high vacuum and used directly in the next step without further purification. Rf=0.5 (silica gel, 25% ethyl acetate/hexane, UV and phophomolybdic acid).
To (S)-tert-butyl 2-oxo-1-(3-(phenylethynyl)phenyl)ethylcarbamate (95 mg, 0.283 mmol) in tetrahydrofuran (5 mL) at −78° C. was added phenylmagnesium bromide (0.198 mL, 0.595 mmol) dropwise. After half of the phenylmagnesium bromide was added the stir bar stopped spinning due to a gum which formed around it. The ice bath was removed allowing the reaction to warm until the stir bar began to stir again. The addition of Grignard reagent was continued and after 1 h, a fine precipitate was evident. TLC (25% ethyl acetate/hexane; UV and phosphomolybdic acid) showed a single major spot just below starting material (Rf=0.45). After 1.5 h total, the reaction was quenched with 1N HCl (10 mL) and extracted into ethyl acetate (3×10 mL). The combined organics were washed with saturated NaHCO3, brine, dried over MgSO4, filtered and concentrated in vacuo to 126 mg amber oil which was loaded with dichloromethane onto a 12 g silica gel column prepacked with 5% ethyl acetate/hexanes. Elution with 5 to 30% ethyl acetate/hexanes over 250 mL provided 62 mg tert-butyl (1S,2S)-2-hydroxy-2-phenyl-1-(3-(phenylethynyl)phenyl)ethylcarbamate as a colorless oil which was used directly in the next step.
To (S)-tert-butyl 2-hydroxy-2-phenyl-1-(3-(phenylethynyl)phenyl)ethylcarbamate (62 mg, 0.150 mmol) in tetrahydrofuran (3 mL) at −78° C. was added NaH (17.99 mg, 0.450 mmol). After 10 min, the ice bath was removed and the reaction was allowed to stir at ambient temperature for 24 h at which time TLC showed two spots at Rf=0.2 and Rf=0.15 (25% ethyl acetate/hexanes, UV) with the top one as major. The reaction was quenched with 1N HCl (15 mL), extracted into ethyl acetate (3×20 mL), washed with saturated NaHCO3, brine, dried over MgSO4, filtered, and concentrated to 51 mg colorless solid which was dissolved in dichloromethane and applied to a 12 g silica gel cartridge prepacked with 5% ethyl acetate/hexanes. Elution with 5 to 40% ethyl acetate/hexanes over 300 mL provided 29 mg (57%) (4S,5S)-5-phenyl-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one as a colorless oil (top spot) and 5 mg (11%) (4S,5R)-5-phenyl-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one as a colorless solid. Analytical data for (4S,5R)-5-phenyl-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one: 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 7.45-7.57 (2H, m), 7.31-7.41 (3H, m), 7.27 (1H, d, J=7.63 Hz), 7.18 (1H, s), 7.10-7.17 (3H, m), 7.06 (1H, t, J=7.78 Hz), 7.00 (2H, dd, J=7.32, 2.14 Hz), 6.84 (1H, d, J=7.63 Hz), 5.97 (1H, d, J=8.24 Hz), 5.42 (1H, s), 5.18 (1H, d, J=8.24 Hz). LC/MS (Analytical HPLC Method 1) 1.83 min, Anal. Calcd. for [M+H]+ C23H17NO2: 340.13. found 340.13.
The following analogs were prepared using the same procedure as described for the preparation of (4S,5S)-5-phenyl-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one and (4S,5R)-5-phenyl-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one using the appropriate Grignard reagent:
Example | Structure | Analytical Data |
98 |
|
1H NMR (500 MHZ, CHLOROFORM-d) δ ppm 7.46-7.54 (2 H, m), 7.32-7.39 (3 H, m), 7.27 (1 H, d, J = 7.63 Hz), 7.19 (1 H, s), 7.06 (1 H, t, J = 7.78 Hz), 7.01 (1 H, t, J = 7.63 Hz), 6.92 (1 H, d, J = 7.63 Hz), 6.80-6.87 (2 H, m), 6.77 (1 H, d, J = 7.63 Hz), 5.93 (1 H, d, J = 8.24 Hz), 5.47 (1 H, s), 5.16 (1 H, d, J = 8.24 Hz), 2.18 (3 H, s). LC/MS (Analytical HPLC Method 2) 1.83 min, Anal. Calcd. for [M + H]+ C24H19NO2: 353.14; found 354.21. Rf = 0.13 (silica gel, 25% EtOAc/Hex, UV) |
cis-4-(3-(phenylethynyl)phenyl)-5- | ||
m-tolyloxazolidin-2-one | ||
Used tert-butyl 2-hydroxy-1-(3- | ||
(phenylethynyl)phenyl)ethylcarbamate | ||
and m-tolylmagnesium bromide | ||
99 |
|
1H NMR (500 MHZ, CHLOROFORM-d) δ ppm 7.47- 7.61 (4 H, m), 7.33-7.43 (4 H, m), 7.13-7.32 (4 H, m), 7.07 (1 H, d, J = 7.63 Hz), 5.93 (1 H, s), 5.26 (1 H, d, J = 7.02 Hz), 4.76 (1 H, d, J = 7.32 Hz), 2.37 (3 H, s). LC/MS (Analytical HPLC Method 2) 1.98 min, Anal. Calcd. for [M + H]+ C24H19NO2: 354.14; found 354.22. Rf = 0.13 (silica gel, 25% EtOAc/Hex, UV) |
trans-4-(3-(phenylethynyl)phenyl)- | ||
5-m-tolyloxazolidin-2-one | ||
Used tert-butyl 2-hydroxy-1-(3- | ||
(phenylethynyl)phenyl)ethylcarbamate | ||
and m-tolylmagnesium Bromide | ||
100 |
|
1H NMR (500 MHZ, CHLOROFORM-d) δ ppm 7.47- 7.57 (4 H, m), 7.31-7.43 (5 H, m), 7.09-7.19 (2 H, m), 6.96- 7.06 (1 H, m), 5.99 (1 H, s), 5.23 (1 H, d, J = 7.32 Hz), 4.77 (1 H, d, J =7.02 Hz), 2.23-2.29 (6 H, m). LC/MS (Analytical HPLC Method 2) 2.03 min, Anal. Calcd. for [M + H]+ C25H21NO2: 368.16; found 368.26. Rf = 0.20 (silica gel, 25% EtOAc/Hex, UV) |
Trans-5-(3,4-dimethylphenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one | ||
Used (±)-tert-butyl 2-hydroxy-1-(3- | ||
(phenylethynyl)phenyl)ethylcarbamate | ||
and 3,4-dimethylmagnesium | ||
bromide. | ||
101 |
|
separated via Preparative HPLC method 2-retention time 8.1 min |
(4R,5R)-5-(3,4-dimethylphenyl)-4- | ||
(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one | ||
Enantiomer 1 from trans-5-(3,4- | ||
dimethylphenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one | ||
102 |
|
separated via Preparative HPLC method 2-retention time 12.2 min |
(4S,5S)-5-(3,4-dimethylphenyl)-4- | ||
(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one | ||
Enantiomer 2 from trans-5-(3,4- | ||
dimethylphenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one | ||
103 |
|
1H NMR (500 MHZ, CHLOROFORM-d) δ ppm 7.48- 7.58 (4 H, m), 7.32-7.44 (5 H, m), 7.27 (1 H, d, J = 7.93 Hz), 7.08 (1 H, d, J = 3.36 Hz), 7.03 (1 H, dd, J = 4.88, 3.66 Hz), 5.95 (1 H, s), 5.51 (1 H, d, J = 7.63 Hz), 4.95 (1 H, d, J = 7.63 Hz). LC/MS (Analytical HPLC Method 2) 1.83 min, Anal. Calcd. for [M + H]+ C21H15NO2: 346.08; found 368.19. Rf = 0.18 (silica gel, 25% EtOAc/Hex, UV) |
trans-4-(3-(phenylethynyl)phenyl)- | ||
5-(thiophen-2-yl)oxazolidin-2-one | ||
Used (±)-tert-butyl 2-hydroxy-1-(3- | ||
(phenylethynyl)phenyl)ethylcarbamate | ||
and 2-thienylmagnesium bromide | ||
104 |
|
separated via Preparative HPLC method 2-retention time 9.3 min |
(4R,5R)-(3-(phenylethynyl)phenyl)- | ||
5-(thiophen-2-yl)oxazolidin-2-one | ||
Enantiomer 1 from trans-4-(3- | ||
(phenylethynyl)phenyl)-5-(thiophen- | ||
2-yl)oxazolidin-2-one | ||
105 |
|
separated via Preparative HPLC method 2-retention time 15.6 min |
(4S 5S)-(phenylethynyl)phenyl)-5- | ||
(thiophen-2-yl)oxazolidin-2-one | ||
Enantiomer 2 from trans-4-(3- | ||
(phenylethynyl)phenyl)-5-(thiophen- | ||
2-yl)oxazolidin-2-one | ||
106 |
|
1H NMR (500 MHZ, CHLOROFORM-d) δ ppm 7.46- 7.59 (4 H, m), 7.32-7.43 (4 H, m), 7.13-7.25 (5 H, m), 5.72 (1 H, s), 5.27 (1 H, d, J = 7.32 Hz), 4.75 (1 H, d, J = 7.32 Hz), 2.37 (3 H, s). LC/MS (Analytical HPLC Method 2) 1.97 min, Anal. Calcd. for [M + H]+ C24H19NO2: 354.14; found 354.22. Rf = 0.18 (silica gel, 25% EtOAc/Hex, UV) |
(±)-(phenylethynyl)phenyl)-5-p- | ||
tolyloxazolidin-2-one | ||
Used (±)-tert-butyl 2-hydroxy-1-(3- | ||
(phenylethynyl)phenyl)ethylcarbamate | ||
and p-tolylmagnesium bromide | ||
107 |
|
separated via Preparative HPLC method 2-retention time 8.4 min |
(4R,5R)-(phenylethynyl)phenyl)-5- | ||
p-tolyloxazolidin-2-one | ||
Enantiomer 1 from (±)- | ||
(phenylethynyl)phenyl)-5-p- | ||
tolyloxazolidin-2-one | ||
108 |
|
separated via Preparative HPLC method 2-retention time 13.3 min |
(4S,5S)-(phenylethynyl)phenyl)-5- | ||
p-tolyloxazolidin-2-one | ||
Enantiomer 2 from from (±)- | ||
(phenylethynyl)phenyl)-5-p- | ||
tolyloxazolidin-2-one | ||
The following analogs were prepared using the same procedure as described for the preparation of (4R,5R)-5-phenyl-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one and (4S,5S)-5-phenyl-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting from 2-(3-(phenylethynyl)phenyl)acetic acid and the appropriate aldehyde:
Example | Structure | Analytical Data |
109 |
|
HPLC retention time (Analytical HPLC method 3): 10.0 min |
(4R,5R)-5-(2-fluorophenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one | ||
Used 2-fluorobenzaldehyde and | ||
Preparative HPLC method 4, and | ||
then Preparative HPLC method 3 for | ||
purification | ||
110 |
|
1H NMR (500 MHz, CHLOROFORM-d) δ ppm 7.48- 7.61 (5 H, m), 7.31-7.46 (6 H, m), 7.26 (1 H, t, J = 7.63 Hz), 7.11-7.18 (1 H, m), 5.76 (1 H, s), 5.59 (1 H, d, J = 5.49 Hz), 4.84 (1 H, d, J = 5.49 Hz). HPLC retention time (Analytical HPLC method 3): 9.9 min. LC/MS (Analytical HPLC Method 1) 1.90 min, Anal. Calcd. for [M + H]+ C23H16FNO2: 358.12; found 358.07. |
(4S,5S)-5-(2-fluorophenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one | ||
Used 2-fluorobenzaldehyde and | ||
Preparative HPLC method 3 for | ||
purification | ||
111 |
|
1H NMR (500 MHz, CHLOROFORM-d) δ ppm 7.52- 7.62 (4 H, m), 7.32-7.46 (5 H, m), 7.23-7.31 (1 H, m), 6.99- 7.16 (3 H, m), 6.16 (1 H, s), 5.32 (1 H, d, J = 7.02 Hz), 4.75 (1 H, d, J = 7.32 Hz). LC/MS (Analytical HPLC Method 1) 1.91 min, Anal. Calcd. for [M + H]+ C23H16FNO2: 358.12; found 358.03. |
Trans-5-(3-fluorophenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one | ||
Used 3-fluorobenzaldehyde | ||
112 |
|
98.2% ee; HPLC retention time (Analytical HPLC method 3): 10.0 min |
(4R,5R)-5-(2-fluorophenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one | ||
Enantiomer 1 from Trans-5-(3- | ||
fluorophenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one 19 using preparative HPLC | ||
method 2 | ||
113 |
|
97.8% ee; HPLC retention time (Analytical HPLC method 3): 10.0 min |
(4S,5S)-5-(2-fluorophenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one | ||
Enantiomer 2 from Trans-5-(3- | ||
fluorophenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one using preparative HPLC method | ||
2 | ||
114 |
|
1H NMR (500 MHz, CHLOROFORM-d) δ ppm 7.49- 7.60 (4 H, m), 7.21-7.45 (7 H, m), 7.03-7.18 (2 H, m), 6.26 (1 H, s), 5.29 (1 H, d, J = 7.32 Hz), 4.75 (1 H. d, J = 7.63 Hz). LC/MS (Analytical HPLC Method 1) 1.91 min, Anal. Calcd. for [M + H]+ C23H16FNO2: 358.12; found 358.03. HPLC retention time (Analytical HPLC method 3): 10.0 min |
(4R,5R)-5-(4-fluorophenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one | ||
Enantiomer 1 from Trans-5-(4- | ||
fluorophenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one using preparative HPLC method | ||
2 then preparative HPLC method 4 | ||
115 |
|
HPLC retention time (Analytical HPLC method 3): 10.0 min |
(4S,5S)-5-(4-fluorophenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2 | ||
one | ||
Enantiomer 2 from Trans-5-(4- | ||
fluorophenyl)-4-(3- | ||
(phenylethynyl)phenyl)oxazolidin-2- | ||
one using preparative HPLC method | ||
2 | ||
To trans-4-(3-bromophenyl)-5-(pyridin-3-yl)oxazolidin-2-one (46 mg, 0.144 mmol) slurried in triethylamine (3 mL) was added ethynylbenzene (0.021 mL, 0.187 mmol), copper(I) iodide (2.74 mg, 0.014 mmol), and triphenylphosphine (26.5 mg, 0.101 mmol). The reaction mixture was cooled to −78° C. under nitrogen and subjected to three rounds of pump/nitrogen purge. The mixture was then warmed to ambient temperature and (Ph3P)2PdCl2 (10.12 mg, 0.014 mmol) was added. The vessel was fitted with a reflux condensor and placed in an oil bath at 93° C. for 18 h at which time the vessel was removed from the heat and the residue was solubilized in 1:1 dimethylformamide/methanol and purified via preparative HPLC method 4. Pooling and concentration of the fractions containing the peak eluting at 7.37 min provided 14.3 mg trans-4-(3-(phenylethynyl)phenyl)-5-(pyridin-3-yl)oxazolidin-2-one as an indeterminate enantiomeric mixture. 1H NMR (500 MHz, MeOD) δ ppm 8.44 (1H, d, J=7.32 Hz), 8.16 (1H, br. s.), 7.57-7.63 (2H, m), 7.47-7.57 (4H, m), 7.44 (1H, d, J=7.63 Hz), 7.36-7.42 (4H, m), 5.68 (1H, d, J=6.41 Hz), 4.98 (1H, d, J=6.71 Hz). LC/MS (Analytical HPLC Method 6) 1.97 min, Anal. Calcd. for [M+H]+ C22H16N2O2: 341.12. found 341.29. HPLC retention time (Analytical HPLC method 3): 7.30 min. Further purification via preparative SFC method 5 provided 2.2 mg (4%) (4R,5R)-4-(3-(phenylethynyl)phenyl)-5-(pyridin-3-yl)oxazolidin-2-one (5.8 min retention time) as a colorless oil and 2.0 mg (4%) (4S,5S)-4-(3-(phenylethynyl)phenyl)-5-(pyridin-3-yl)oxazolidin-2-one as a colorless oil. HPLC retention time for (4R,5R)-4-(3-(phenylethynyl)phenyl)-5-(pyridin-3-yl)oxazolidin-2-one (Analytical HPLC method 3): 7.12 min. HPLC retention time for (4S,5S)-4-(3-(phenylethynyl)phenyl)-5-(pyridin-3-yl)oxazolidin-2-one (Analytical HPLC method 3): 7.10 min.
The examples in the following table were prepared using the same method for preparation of (+)-(4R,5R)-5-(3-Methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one:
Example | Structure | Analytical Data |
119 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.42 (1H, s), 7.80 (4 H, s), 7.58-7.65 (2 H, m), 7.51 (1 H, t, J = 7.8 Hz), 7.40 (1 H, d, J = 7.9 Hz), 7.36 (1 H, t, J = 7.8 Hz), 6.88-7.03 (3 H, m), 5.33 (1 H, d, J = 7.3 Hz), 4.89 (1 H, d, J = 7.3 Hz), 3.78 (3 H, s). Anal. Calcd. for [M + H]+ C25H19F3NO3: 438.13; found 438.16. |
(4R,5R)-5-(3-methoxyphenyl)-4-(3-((4- | ||
(trifluoromethyl)phenyl)ethynyl)phenyl) | ||
oxazolidin-2-one | ||
120 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.42 (1 H, s), 7.80 (4 H, s), 7.57-7.65 (2 H, m), 7.51 (1 H, t, J = 7.6 Hz), 7.40 (1 H, d, J = 7.9 Hz), 7.36 (1 H, t, J = 7.8 Hz), 6.91-7.03 (3 H, m), 5.33 (1 H, d, J = 7.3 Hz), 4.88 (1 H, d, J = 7.0 Hz), 3.78 (3 H, s). Anal. Calcd. for [M + H]+ C25H19F3NO3: 438.13; found 438.14. |
(4S,5S)-5-(3-methoxyphenyl)-4-(3-((4- | ||
(trifluoromethyl)phenyl)ethynyl)phenyl) | ||
oxazolidin-2-one | ||
121 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.42 (1 H, s), 7.66 (1 H, td, J = 7.6, 1.7 Hz), 7.53- 7.60 (2 H, m), 7.46-7.53 (2 H, m), 7.33-7.42 (3 H, m), 7.28 (1 H, t, J = 7.6 Hz), 6.89- 7.03 (3 H, m), 5.33 (1 H, d, J = 7.3 Hz), 4.89 (1 H, d, J = 7.0 Hz), 3.78 (3 H, s). Anal. Calcd. for [M + H]+ C24H19FNO3: 388.14; found 438.18. |
(4R,5R)-4-(3-((2- | ||
fluorophenyl)ethynyl)phenyl)-5-(3- | ||
methoxyphenyl)oxazolidin-2-one | ||
122 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.42 (1 H, s), 7.66 (1 H, td, J = 7.5, 1.8 Hz), 7.54- 7.61 (2 H, m), 7.46-7.54 (2 H, m), 7.32-7.42 (3 H, m), 7.25-7.31 (1 H, m), 6.92- 7.01 (3 H, m), 5.33 (1 H, d, J = 7.0 Hz), 4.89 (1 H, d, J = 7.3 Hz), 3.78 (3 H, s). Anal. Calcd. for [M + H]+ C24H19FNO3: 388.14; found 388.18. |
(4S,5S)-4-(3-((2- | ||
fluorophenyl)ethynyl)phenyl)-5-(3- | ||
methoxyphenyl)oxazolidin-2-one | ||
123 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.42 (1 H, s), 7.55- 7.63 (2 H, m), 7.50 (1 H, t, J = 7.9 Hz), 7.31-7.43 (5 H, m), 6.88-7.03 (3 H, m), 5.31 (1 H, d, J = 7.0 Hz), 4.88 (1 H, d, J = 7.3 Hz), 3.78 (3 H, s) Anal. Calcd. for [M + H]+ C24H18F2NO3: 406.13; found 406.11. |
(4R,5R)-4-(3-((3,5- | ||
difluorophenyl)ethynyl)phenyl)-5-(3- | ||
methoxyphenyl)oxazolidin-2-one | ||
124 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.42 (1 H, s), 7.56- 7.61 (2 H, m), 7.50 (1 H, t, J = 7.9 Hz), 7.31-7.44 (5 H, m), 6.88-7.02 (3 H, m), 5.31 (1 H, d, J = 7.0 Hz), 4.88 (1 H, d, J = 7.0 Hz), 3.78 (3 H, s). Anal. Calcd. for [M + H]+ C24H18F2NO3: 406.13; found 406.19. |
(4S,5S)-4-(3-((3,5- | ||
difluorophenyl)ethynyl)phenyl)-5-(3- | ||
methoxyphenyl)oxazolidin-2-one | ||
125 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.43 (1 H, s), 7.84 (2 H, t, J = 6.7 Hz), 7.74 (1 H, t, J = 7.6 Hz), 7.64 (1 H, t, J=7.8 Hz), 7.47-7.58 (3 H, m), 7.41 (1 H, d, J = 7.9 Hz), 7.36 (1 H, t, J = 7.8 Hz), 6.88- 7.05 (3 H, m), 5.32 (1 H, d, J = 7.0 Hz), 4.90 (1 H, d, J = 7.0 Hz), 3.78 (3 H, s). Anal. Calcd. for [M + H]+ C25H19F3NO3: 438.13; found 438.17. |
(4R,5R)-5-(3-methoxyphenyl)-4-(3-((2- | ||
(trifluoromethyl)phenyl)ethynyl)phenyl) | ||
oxazolidin-2-one | ||
126 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.43 (1 H, s), 7.84 (2 H, t, J = 6.7 Hz), 7.74 (1 H, t, J = 7.5 Hz), 7.64 (1 H, t, J = 7.6 Hz), 7.48-7.59 (3 H, m), 7.32-7.43 (2 H, m), 6.91- 7.01 (3 H, m), 5.32 (1 H, d, J = 7.0 Hz), 4.90 (1 H, d, J = 7.0 Hz), 3.78 (3 H, s). Anal. Calcd. for [M + H]+ C25H19F3NO3: 438.13; found 438.17. |
(4S,5S)-5-(3-methoxyphenyl)-4-(3-((2- | ||
(trifluoromethyl)phenyl)ethynyl)phenyl) | ||
oxazolidin-2-one | ||
127 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.41 (1 H, s), 7.74 (1 H, td, J = 8.5, 6.6 Hz), 7.53- 7.60 (2 H, m), 7.43-7.52 (2 H, m), 7.31-7.42 (2 H, m), 7.20 (1 H, td, J = 8.4, 2.4 Hz), 6.90-7.01 (3 H, m), 5.32 (1 H, d, J = 7.0 Hz), 4.89 (1 H, d, J = 7.0 Hz), 3.77 (3 H, s). Anal. Calcd. for [M + H]+ C24H18F2NO3: 406.13; found 406.19. |
(4R,5R)-4-(3-((2,4- | ||
difluorophenyl)ethynyl)phenyl)-5-(3- | ||
methoxyphenyl)oxazolidin-2-one | ||
128 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.41 (1 H, s), 7.74 (1 H, td, J = 8.5, 6.7 Hz), 7.52- 7.60 (2 H, m), 7.42-7.53 (2 H, m), 7.32-7.42 (2 H, m), 7.20 (1 H, td, J = 8.3, 2.6 Hz), 6.90-7.02 (3 H, m), 5.32 (1 H, d, J = 7.0 Hz), 4.89 (1 H, d, J = 7.3 Hz), 3.77 (3 H, s). Anal. Calcd. for [M + H]+ C24H18F2NO3: 406.13; found 406.19. |
(4S,5S)-4-(3-((2,4- | ||
difluorophenyl)ethynyl)phenyl)-5-(3- | ||
methoxyphenyl)oxazolidin-2-one | ||
129 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.42 (1 H, s), 7.95 (1 H, s), 7.89 (1 H, d, J = 7.6 Hz), 7.80 (1 H, d, J = 7.9 Hz), 7.69 (1 H, t, J = 7.8 Hz), 7.59- 7.62 (2 H, m), 7.50 (1 H, t, J = 8.1 Hz), 7.32-7.43 (2 H, m), 6.90-7.01 (3 H, m), 5.32 (1 H, d, J = 7.0 Hz), 4.88 (1 H, d, J = 7.0 Hz), 3.78 (3 H, s). Anal. Calcd. for [M + H]+ C25H19F3NO3: 438.13; found 438.17. |
(4R,5R)-5-(3-methoxyphenyl)-4-(3-((3- | ||
(trifluoromethyl)phenyl)ethynyl)phenyl) | ||
oxazolidin-2-one | ||
130 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.42 (1 H, s), 7.95 (1 H, s), 7.89 (1 H, d, J = 7.9 Hz), 7.80 (1 H, d, J = 7.9 Hz), 7.69 (1 H, t, J = 7.9 Hz), 7.57- 7.63 (2 H, m), 7.50 (1 H, t, J = 8.1 Hz), 7.33-7.42 (2 H, m), 6.91-7.01 (3 H, m), 5.32 (1 H, d, J = 7.0 Hz), 4.88 (1 H, d, J = 7.3 Hz), 3.78 (3 H, s). Anal. Calcd. for [M + H]+ C25H19F3NO3: 438.13; found 438.17. |
(4S,5S)-5-(3-methoxyphenyl)-4-(3-((3- | ||
(trifluoromethyl)phenyl)ethynyl)phenyl) | ||
oxazolidin-2-one | ||
131 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.41 (1 H, s), 7.61- 7.68 (2 H, m), 7.52-7.58 (2 H, m), 7.48 (1 H, t, J = 7.6 Hz), 7.36 (2 H, t, J =7.8 Hz), 7.29 (2 H, t, J = 8.9 Hz), 6.91-7.01 (3 H, m), 5.32 (1 H, d, J = 7.0 Hz), 4.87 (1 H, d, J = 7.3 Hz), 3.78 (3 H, s). Anal. Calcd. for [M + H]+ C24H19FNO3: 388.14; found 388.09. |
(4R,5R)-4-(3-((4- | ||
fluorophenyl)ethynyl)phenyl)-5-(3- | ||
methoxyphenyl)oxazolidin-2-one | ||
132 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.40 (1 H, s), 7.61- 7.68 (2 H, m), 7.52-7.58 (2 H, m), 7.48 (1 H, t, J = 7.6 Hz), 7.36 (2 H, t, J = 7.8 Hz), 7.29 (2 H, t, J = 8.9 Hz), 6.91-7.01 (3 H, m), 5.32 (1 H, d, J = 7.0 Hz), 4.87 (1 H, d, J = 7.0 Hz), O 3.78 (3 H, s) Anal. Calcd. for [M + H]+ C24H19FNO3: 388.14; found 388.18. |
(4S,5S)-4-(3-((4- | ||
fluorophenyl)ethynyl)phenyl)-5-(3- | ||
methoxyphenyl)oxazolidin-2-one | ||
133 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.41 (1 H, s), 7.54- 7.60 (2 H, m), 7.41-7.52 (4 H, m), 7.34-7.40 (2 H, m), 7.26-7.33 (1 H, m), 6.91- 7.01 (3 H, m), 5.32 (1 H, d, J = 7.0 Hz), 4.88 (1 H, d, J = 7.0 Hz), 3.78 (3 H, s) Anal. Calcd. for [M + H]+ C24H19FNO3: 388.14; found 388.18. |
(4R,5R)-4-(3-((3- | ||
fluorophenyl)ethynyl)phenyl)-5-(3- | ||
methoxyphenyl)oxazolidin-2-one | ||
134 |
|
1H NMR (500 MHz, DMSO- d6) δ ppm 8.41 (1 H, s), 7.54- 7.60 (2 H, m), 7.33-7.52 (6 H, m), 7.30 (1 H, td, J =8.6, 1.7 Hz), 6.92-7.01 (3 H, m), 5.32 (1 H, d, J = 7.0 Hz), 4.88 (1 H, d, J = 7.0 Hz), 3.75-3.80 (3 H, m) Anal. Calcd. for [M + H]+ C24H19FNO3: 388.14; found 388.11. |
(4S,5S)-4-(3-((3- | ||
fluorophenyl)ethynyl)phenyl)-5-(3- | ||
methoxyphenyl)oxazolidin-2-one | ||
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with optically enriched-(4R,5R)-4-(6-bromopyridin-2-yl)-5-(4-fluorophenyl)oxazolidin-2-one and phenylacetylene. 1H-NMR (CDCl3, 500 MHz) δ 7.78 (dd, J=7.9, 7.6, 1H), 7.63 (m, 2H), 7.54 (d, J=7.6, 1H), 7.47 (dd, J=8.6, 5.5, 2H), 7.42 (m, 4H), 7.13 (dd, J=8.6, 8.6, 2H), 6.81 (bs, 1H), 5.64 (d, J=5.8, 1H), 4.96 (d, J=5.8, 1H). 13C-NMR (CDCl3, 126 MHz) δ 163.1 (d, J=248, 158.9 (d, J=36), 143.9, 137.8, 134.1, 132.2, 129.4, 128.6, 127.8, 127.3, 122.0, 119.8, 116.1, 116.0, 90.3, 88.3, 83.3, 65.0. Enantiomers were resolved by Prep HPLC (Chiralcel OD, A=heptane, B=ethanol, 40% B for 30 min) Enantiomer 1=first enantiomer to elute from Prep (Example 135): Mass spec.: 359.3 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 136): Mass spec.: 359.3 (MH)+.
A solution of (±)-(4R,5R)-4-(5-bromopyridin-3-yl)-4-methyl-5-phenyloxazolidin-2-one (60.0 mg, 0.180 mmol) and ethynylbenzene (19.78 μl, 0.180 mmol) in triethylamine (1129 μl, 8.10 mmol) was purged with nitrogen for 30 minutes. The reaction was treated with triphenylphosphine (12.75 mg, 0.049 mmol), and purged for another 10 minutes. To this was added dichlorobis(triphenylphosphine)palladium(II) (2.91 mg, 4.14 μmol) and copper(I) iodide (0.686 mg, 3.60 μmol). After purging 10 minutes longer, the reaction was sealed and placed in a 90° C. oil bath. The reaction was stirred at this temperature for 16 hours. It was cooled to room temperature, solvent was removed and the residue was taken in ether and ethyl acetate, washed with water, brine, dried over magnesium, filtered and concentrated. Biotage purification (50% EtOAc/Hex) gave title compounds (70 mg, quantitative yield). 1H-NMR (CDCl3, 500 MHz) δ 8.77 (s, 1H), 8.60 (s, 1H), 7.99 (m, 1H), 7.58 (m, 2H), 7.41-7.39 (m, 6H), 7.21 (m, 2H), 6.99 (s, 1H), 5.46 (s, 1H), 1.35 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ 171.3, 158.7, 151.8, 146.3, 138.4, 136.1, 133.3, 131.9, 129.3, 129.2, 128.8, 128.6, 126.2, 122.3, 120.8, 93.8, 88.1, 85.5, 63.3, 60.5, 22.8, 21.2, 14.3. Mass spec.: 355.5 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AS 21×250 mm, 27% B isocratic, flow rate: 15 ml/min, UV 220, 50 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 137). Enantiomer 2=second enantiomer to elute from Prep (Example 138).
To a 15 ml sealable vial was added a 60:40 mixture of (4R,5R)-4-(5-bromo-2-fluoropyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (42 mg, 0.118 mmol) and its regioisomer in triethylamine (2 mL). To this suspension was added 3-ethynylpyridine (14.63 mg, 0.142 mmol), triphenylphosphine (9.31 mg, 0.035 mmol) and copper(I) iodide (0.450 mg, 2.365 μmol). The solution was degassed with nitrogen for 20 min, then bis(triphenylphosphine)palladium(II) chloride (1.660 mg, 2.365 μmol) was quickly added and the vial was sealed, heated to 90° C., and allowed to stir overnight. The next day the suspension had turned homogeneous and the reaction was cooled to room temperature and the solvent was evaporated in vacuo. The crude residue was purified by reverse phase chromatography (Xterra Prep RP18.5 uM 30 mm×100 mm: 0-100% A to B, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA) to isolate a single peak. This single peak was a 60:40 mixture of regioisomers and was subsequently purified by chiral supercritical fluid chromatography Chiralpak AD-H column, 4.6×250 mm, 5 um particle size mobile phase: 35% MeOH in CO2 (w/0.1% diethylamine) column temp: 35 C flow rate: 2 mL/min., affording (4R,5R)-4-(2-fluoro-5-(pyridin-3-ylethynyl)pyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (12 mg, 0.031 mmol, 26.6% yield). 1H-NMR (CD3OD, 400 MHz) δ 8.73 (s, 1H), 8.54 (d, J=4.0, 1H), 8.42 (s, 1H), 8.19 (d, J=8.0, 1H), 8.01 (d, J=8.0, 1H), 7.49-7.44 (m, 2H), 7.25-7.13 (m, 3H), 5.53 (d, J=4.0, 1H), 5.03 (d, J=4.0, 1H), LC/Mass spec. (Analytical HPLC method 2): RT=1.99 min. Mass=378.10 (MH)+.
To a 15 ml sealable vial was added a mixture of (4R,5R)-4-(5-bromo-2-fluoropyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (30 mg, 0.084 mmol) and its regioisomer in triethylamine (2 mL). To this suspension was added 3-ethynyl-5-fluoropyridine (12.28 mg, 0.101 mmol), triphenylphosphine (6.65 mg, 0.025 mmol) and copper(I) iodide (0.322 mg, 1.690 μmol). The solution was degassed with nitrogen for 20 min, then bis(triphenylphosphine)palladium(II) chloride (1.186 mg, 1.690 μmol) was quickly added and the vial was sealed, heated to 90° C., and allowed to stir overnight. The next day the suspension had turned homogeneous and the reaction was cooled to room temperature and the solvent was evaporated in vacuo. The crude residue was purified by silica gel chromotagraphy 1% MeOH/99% CH2Cl2 affording a single peak. This single peak was a 60:40 mixture of regioisomers and was subsequently purified by chiral supercritical fluid chromatography Chiralpak AD-H column, 4.6×250 mm, 5 um particle size mobile phase: 35% MeOH in CO2 (w/0.1% diethylamine) column temp: 35 C flow rate: 2 mL/min., affording (4R,5R)-4-(2-fluoro-5-((5-fluoropyridin-3-yl)ethynyl)pyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (25 mg, 0.062 mmol, 73.4% yield). 1H-NMR (CDCl3, 400 MHz) δ 8.63 (s, 1H), 8.51 (d, J=4.0, 1H), 8.45 (s, 1H), 8.14 (dd, J=8.0, 4.0, 1H), 7.69-7.64 (m, 1H), 7.60-7.54 (m, 1H), 7.50-7.43 (m, 1H), 7.21-7.13 (m, 2H), 6.05 (brs, 1H), 5.39 (d, J=4.0, 1H), 5.04 (d, J=4.0, 1H), LC/Mass spec. (Analytical HPLC method 2): RT=2.01 min. Mass=396.20 (MH)+.
To a 15 ml sealable vial was added (4R,5R)-4-(5-ethynyl-2-fluoropyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (20 mg, 0.067 mmol) in triethylamine (2 mL). To this suspension was added 4-bromo-2-fluoropyridine (15.24 mg, 0.087 mmol), triphenylphosphine (5.24 mg, 0.020 mmol) and copper(I) iodide (0.254 mg, 1.332 μmol). The solution was degassed with nitrogen for 20 min, then bis(triphenylphosphine)palladium(II) chloride (0.935 mg, 1.332 μmol) was quickly added and the vial was sealed, heated to 90° C., and allowed to stir overnight. The next day the suspension had turned homogeneous and the reaction was cooled to room temperature and the solvent was evaporated in vacuo. The crude residue was purified by silica gel chromotagraphy eluting first with 100% CH2Cl2 then 1% MeOH/99% CH2Cl2 affording (4R,5R)-4-(2-fluoro-5-((2-fluoropyridin-4-yl)ethynyl)pyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (9.1 mg, 0.021 mmol, 31.4% yield) as a light yellow solid. 1H-NMR (CDCl3, 400 MHz) δ 8.63 (s, 1H), 8.51 (d, J=4.0, 1H), 8.45 (s, 1H), 8.14 (dd, J=8.0, 4.0, 1H), 7.69-7.64 (m, 1H), 7.60-7.54 (m, 1H), 7.50-7.43 (m, 1H), 7.21-7.13 (m, 2H), 6.05 (brs, 1H), 5.39 (d, J=4.0, 1H), 5.04 (d, J=4.0, 1H), LC/Mass spec. (Analytical HPLC method 2): RT=2.01 min. Mass=396.20 (MH)+.
To a 15 ml sealable vial was added a mixture of (4R,5R)-4-(5-bromo-2-fluoropyridin-3-yl)-5-(4-fluorophenyl)oxazolidin-2-one (270 mg, 0.760 mmol) in triethylamine (15 mL). To this suspension was added 3-ethynylpyridine (94 mg, 0.912 mmol), triphenylphosphine (59.8 mg, 0.228 mmol) and copper(I) iodide (2.90 mg, 0.015 mmol). The solution was degassed with nitrogen for 20 min, then bis(triphenylphosphine)palladium(II) chloride (10.67 mg, 0.015 mmol) was quickly added and the vial was sealed, heated to 90° C., and allowed to stir overnight. The next day the suspension had turned homogeneous and the reaction was cooled to room temperature and the solvent was evaporated in vacuo. The crude residue was purified by silica gel chromotagraphy 2% MeOH/98% CH2Cl2 affording (4R,5R)-4-(2-fluoro-5-(pyridin-3-ylethynyl)pyridin-3-yl)-5-(4-fluorophenyl)oxazolidin-2-one (210 mg, 0.540 mmol, 71.0% yield) 1H-NMR (CDCl3, 400 MHz) δ 8.82 (s, 1H), 8.64 (d, J=4.0, 1H), 8.44 (s, 1H), 8.14 (d, J=8.0, 1H), 7.86, (d, J=8.0, 1H), 7.44-7.40 (m, 2H), 7.38-7.36 (m, 1H), 7.19-7.15 (m, 2H), 5.64 (brs, 1H), 5.38 (d, J=4.0, 1H), 5.05 (d, J=4.0, 1H), LC/Mass spec. (Analytical HPLC method 2): RT=1.78 min. Mass=378.16 (MH)+.
LC/Mass spec. (Analytical HPLC method 2): RT=1.95 min. Mass=395.99 (MH)+.
To a 15 ml sealable vial was added a 60:40 mixture of (4R,5R)-4-(2-bromo-5-fluoropyridin-4-yl)-5-(4-fluorophenyl)oxazolidin-2-one (50 mg, 0.141 mmol) and its regioisomer in triethylamine (3 mL). To this suspension was added 3-ethynyl-5-fluoropyridine (22.17 mg, 0.183 mmol), triphenylphosphine (11.08 mg, 0.042 mmol) and copper(I) iodide (0.536 mg, 2.82 mmol). The solution was degassed with nitrogen for 20 min, then bis(triphenylphosphine)palladium(II) chloride (1.976 mg, 2.82 mmol) was quickly added and the vial was sealed, heated to 90° C., and allowed to stir overnight. The next day the suspension had turned homogeneous and the reaction was cooled to room temperature and the solvent was evaporated in vacuo. The crude residue was purified by reverse phase chromatography to isolate a single peak (4R,5R)-5-(5-fluoro-2-((5-fluoropyridin-3-yl)ethynyl)pyridin-4-yl)-4-(4-fluorophenyl)oxazolidin-2-one (18.4 mg, 0.046 mmol, 49.8% yield). This single peak was still a mixture of the regioisomers. This single peak was a 65:35 mixture of regioisomers and was subsequently purified by chiral supercritical fluid chromatography Chiralpak AD-H column, 4.6×250 mm, 5 um particle size mobile phase: 35% MeOH in CO2 (w/0.1% diethylamine) column temp: 35 C flow rate: 2 mL/min., affording 1H-NMR (CDCl3, 400 MHz) δ 8.67 (s, 1H), 8.54 (s, 1H), 8.51 (d, J=4.0, 1H), 7.79 (d, J=4.0, 1H), 7.64-7.60 (m, 1H), 7.42-7.39 (m, 2H), 7.19-7.15 (m, 2H), 6.00 (brs, 1H), 5.36 (d, J=4.0, 1H), 5.12 (d, J=4.0, 1H), LC/Mass spec. (Analytical HPLC method 2): RT=1.95 min. Mass=395.99 (MH)+.
To a 15 ml sealable vial was added a 60:40 mixture of (4R,5R)-4-(5-bromo-2-fluoropyridin-3-yl)-5-(4-(trifluoromethyl)phenyl)oxazolidin-2-one (84 mg, 0.207 mmol) and its regioisomer in triethylamine (3 mL). To this suspension was added 3-ethynylpyridine (25.7 mg, 0.249 mmol), triphenylphosphine (16.31 mg, 0.062 mmol) and copper(I) iodide (0.790 mg, 4.15 mmol). The solution was degassed with nitrogen for 20 min, then bis(triphenylphosphine)palladium(II) chloride (2.91 mg, 4.15 mmol) was quickly added and the vial was sealed, heated to 90° C., and allowed to stir overnight. The next day the suspension had turned homogeneous and the reaction was cooled to room temperature and the solvent was evaporated in vacuo. The crude residue was purified by reverse phase chromatography (Xterra Prep RP 18.5 uM 30 mm×100 mm: 0-100% A to B, A=90% H2O/10% MeOH, B=90% MeOH/10% H2O, Modifier 0.1% TFA) to isolate a single peak. This single peak was still a mixture of the regioisomers and was further purified by chiral supercritical fluid chromatography: Chiralpak AD-H column, 4.6×250 mm, 5 um particle size mobile phase: 35% MeOH in CO2 (w/0.1% diethylamine) column temp: 35 C flow rate: 2 mL/min., affording (4R,5R)-4-(2-fluoro-5-(pyridin-3-ylethynyl)pyridin-3-yl)-5-(4-(trifluoromethyl)phenyl)oxazolidin-2-one (12 mg, 27% yield). 1H-NMR (CDCl3, 400 MHz) δ 8.80 (s, 1H), 8.62 (d, J=4.0, 1H), 8.45 (s, 1H), 8.13 (d, J=8.0, 1H), 7.86 (d, J=4.0, 1H) 7.77 (d, J=8.0, 2H), 7.57 (d, J=8.0, 2H) 7.37-7.34 (m, 1H), 5.98 (brs, 1H), 5.52 (d, J=4.0, 1H), 4.87 (d, J=4.0, 1H), LC/Mass spec. (Analytical HPLC method 2): RT=2.05 min. Mass=427.98 (MH)+.
LC/Mass spec. (Analytical HPLC method 2): RT=1.91 min. Mass=393.92 (MH)+.
LC/Mass spec. (Analytical HPLC method 2): RT=1.98 min. Mass=396.13 (MH)+.
LC/Mass spec. (Analytical HPLC method 2): RT=1.89 min. Mass=378.23 (MH)+.
LC/Mass spec. (Analytical HPLC method 1): RT=1.71 min. Mass=385.01 (MH)+.
LC/Mass spec. (Analytical HPLC method 1): RT=1.90 min. Mass=433.98 (MH)+.
LC/Mass spec. (Analytical HPLC method 2): RT=1.59 min. Mass=418.17 (MH)+.
LC/Mass spec. (Analytical HPLC method 2): RT=1.16 min. Mass=418.17 (MH)+.
LC/Mass spec. (Analytical HPLC method 2): RT=1. 50 min. Mass=418.17 (MH)+.
LC/Mass spec. (Analytical HPLC method 2): RT=1.66 min. Mass=429.16 (MH)+.
LC/Mass spec. (Analytical HPLC method 3): RT=3.14 min. Mass=418.10 (MH)+.
LC/Mass spec. (Analytical HPLC method 2): RT=1.31 min. Mass=378.16 (MH)+.
LC/Mass spec. (Analytical HPLC method 2): RT=1.53 min. Mass=352.18 (MH)+.
The following analogs were prepared using the same methods for preparation of (+)-(4R,5R)-5-(3-Methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one.
Retention | Analytical | |||
Exam- | Time | HPLC | ||
ple | Structure | Mass | (min) | Method |
158 |
|
406.09 (M − H)− | 2.14 | 8 |
159 |
|
406.13 (M − H)− | 2.15 | 8 |
160 |
|
409.11 (MH)+ | 1.98 | 8 |
161 |
|
409.10 (MH)+ | 1.99 | 8 |
162 |
|
408.97 (MH)+ | 1.93 | 8 |
163 |
|
408.99 (MH)+ | 1.93 | 8 |
164 |
|
409.05 (MH)+ | 1.97 | 8 |
165 |
|
409.00 (MH)+ | 1.96 | 8 |
166 |
|
344.07 (M − H)− | 1.91 | 8 |
167 |
|
344.08 (M − H)− | 1.90 | 8 |
To a solution of (4R,5S)-2-oxo-4-(3-(phenylethynyl)phenyl)oxazolidine-5-carbonitrile (35 mg, 0.121 mmol) in Toluene (2 mL) was added triethylamine hydrochloride (50.6 mg, 0.364 mmol) and sodium azide (23.68 mg, 0.364 mmol) and the reaction was heated to reflux. After 2 days, the reaction was poured into water (1 ml) and extracted with ethylacetate (10 mL×2). The combined organic layers were dried over magnesium sulfate, filtered, and concentrated to an off white solid that was purified by Preparative HPLC method 4 providing (4R,5S)-4-(3-(phenylethynyl)phenyl)-5-(1H-tetrazol-5-yl)oxazolidin-2-one (30 mg, 0.090 mmol, 73.8% yield) 1H NMR (500 MHz, DMSO-d6) δ ppm 5.21-5.55 (m, 2H) 7.10 (br. s., 3H) 7.34 (d, J=7.93 Hz, 1H) 7.39-7.49 (m, 4H) 7.51 (d, J=7.32 Hz, 1H) 7.57 (dd, J=6.41, 3.05 Hz, 2H) 8.27 (s, 1H). Mass spec.: 331.99 (MH)+.
To a solution of (4R,5S)-4-(3-(phenylethynyl)phenyl)-5-(1H-tetrazol-5-yl)oxazolidin-2-one (18.6 mg, 0.056 mmol) in tetrahydrofuran (5 mL) was added potassium carbonate (38.8 mg, 0.281 mmol) and iodomethane (0.035 mL, 0.561 mmol) and the reaction mixture was held at 50° C. for 6 hours. The reaction mixture was concentrated and purified by Preparative HPLC Method 16 providing (4R,5S)-5-(2-methyl-2H-tetrazol-5-yl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one (2.4 mg, 6.60 mmol, 11.76% yield). 1H NMR (500 MHz, DMSO-d6) δ ppm 4.43 (s, 3H) 5.27 (s, 1H) 5.75 (s, 1H) 7.39-7.46 (m, 4H) 7.49 (t, J=7.63 Hz, 1H) 7.55-7.62 (m, 3H) 8.69 (s, 1H). Mass spec.: 344.11 (M−H)−.
The compounds in the following table were prepared by A: Formation of ‘stilbene’, asymmetric aminohydroxylation, formation of oxazolidinone, Sonagashira coupling; B: Sonagashira coupling of (4R,5R)-4-(3-ethynylphenyl)-5-(3-methoxyphenyl)oxazolidin-2-one with an appropriate arylhalide; C: Sonagashira coupling of (4R,5R)-4-(5-ethynylpyridin-3-yl)-5-(4-fluorophenyl)oxazolidin-2-one with an appropriate arylhalide; D: Aldol, TBS protection, Curtius rearrangement/trapping with BnOH, formation of oxazolidinone, Sonagashira Coupling; E: Aldol, Curtius rearrangement/internal trapping to give oxazolidinone, Sonagashira Coupling.
Retention | Analytical | ||||
Mass | Time | HPLC | Synthetic | ||
Example | Structure | Spec. | (min) | Method | Method |
170 |
|
377.04 (MH)+ | 3.56 | 7 | A |
171 |
|
396.1 (MH)+ | 2.54 | 15 | A |
172 |
|
377.1 (MH)+ | 2.9 | 15 | A |
173 |
|
378.1 (MH)+ | 1.91 | 15 | A |
174 |
|
401.96 (MH)+ | 3.28 | 7 | A |
175 |
|
395.95 (MH)+ | 3.18 | 7 | A |
176 |
|
401.96 (MH)+ | 3.26 | 7 | A |
177 |
|
378.01 (MH)+ | 2.3 | 7 | A |
178 |
|
378.01 (MH)+ | 2.98 | 7 | A |
179 |
|
377.05 (MH)+ | 3.53 | 7 | A |
180 |
|
401.95 (MH)+ | 3.25 | 7 | A |
181 |
|
378.01 (MH)+ | 3.02 | 7 | A |
182 |
|
395.97 (MH)+ | 3.18 | 7 | A |
183 |
|
377.95 (MH)+ | 2.93 | 7 | A |
184 |
|
378.04 (MH)+ | 3 | 7 | A |
185 |
|
378.04 (MH)+ | 3.48 | 7 | A |
186 |
|
378.01 (MH)+ | 2.89 | 7 | A |
187 |
|
396 (MH)+ | 3.01 | 7 | A |
188 |
|
402 (MH)+ | 3.19 | 7 | A |
189 |
|
378.06 (MH)+ | 2.9 | 7 | A |
190 |
|
402.2 (MH)+ | 2.78 | 15 | A |
191 |
|
378.2 (MH)+ | 2.04 | 15 | A |
192 |
|
377.3 (MH)+ | 2.92 | 15 | A |
193 |
|
389.0 (MH)+ | 2.36 | 1 | B |
194 |
|
395.0 (MH)+ | 2.27 | 1 | B |
195 |
|
389.0 (MH)+ | 2.33 | 13 | B |
196 |
|
389.0 (MH)+ | 2.33 | 13 | B |
197 |
|
410.0 (MH)+ | 2.34 | 13 | B |
198 |
|
342.1 (MH)+ | 2.05 | 13 | A |
199 |
|
342.1 (MH)+ | 2.05 | 13 | A |
200 |
|
372.0 (MH)+ | 2.01 | 13 | B |
201 |
|
361.0 (MH)+ | 1.68 | 13 | A |
202 |
|
361.0 (MH)+ | 1.68 | 13 | A |
203 |
|
373.2 (MH)+ | 2.08 | 14 | A |
204 |
|
373.2 (MH)+ | 2.08 | 14 | A |
205 |
|
373.1 (MH)+ | 2.08 | 14 | A |
206 |
|
373.1 (MH)+ | 2.08 | 14 | A |
207 |
|
392.1 (MH)+ | 1.93 | 14 | A |
208 |
|
392.1 (MH)+ | 1.93 | 14 | A |
209 |
|
378.2 (MH)+ | 1.84 | 14 | C |
210 |
|
360.1 (MH)+ | 1.69 | 14 | C |
211 |
|
385.1 (MH)+ | 1.81 | 14 | C |
212 |
|
361.2 (MH)+ | 1.7 | 14 | C |
213 |
|
360.2 (MH)+ | 1.42 | 14 | C |
214 |
|
378.2 (MH)+ | 1.9 | 14 | C |
215 |
|
384.2 (MH)+ | 1.9 | 14 | C |
216 |
|
378.1 (MH)+ | 1.84 | 14 | C |
217 |
|
359.3 (MH)+ | 2.09 | 14 | A |
218 |
|
359.3 (MH)+ | 2.1 | 14 | A |
219 |
|
373.3 (MH)+ | 2.07 | 14 | D |
220 |
|
373.3 (MH)+ | 2.08 | 14 | D |
221 |
|
373.3 (MH)+ | 2.23 | 14 | A |
222 |
|
373.3 (MH)+ | 2.23 | 14 | A |
223 |
|
373.5 (MH)+ | 2.13 | 14 | A |
224 |
|
373.5 (MH)+ | 2.13 | 14 | A |
225 |
|
355.5 (MH)+ | 2.07 | 14 | D |
226 |
|
355.5 (MH)+ | 2.07 | 14 | D |
227 |
|
355.1 (MH)+ | 2.22 | 14 | A |
228 |
|
355.1 (MH)+ | 2.17 | 14 | A |
229 |
|
374.1 (MH)+ | 2 | 14 | D |
230 |
|
374.1 (MH)+ | 1.9 | 14 | D |
231 |
|
340.9 (MH)+ | 2.44 | 6 | A |
232 |
|
340.9 (MH)+ | 2.44 | 6 | A |
233 |
|
342.0 (MH)+ | 0.8 | 6 | A |
234 |
|
341.0 (MH)+ | 1.89 | 6 | A |
235 |
|
342.0 (MH)+ | 0.81 | 6 | A |
236 |
|
342.0 (MH)+ | 0.81 | 6 | A |
237 |
|
360.0 (MH)+ | 1.2 | 6 | A |
238 |
|
342.2 (MH)+ | 2.39 | 6 | E |
239 |
|
342.2 (MH)+E | 2.39 | 6 | E |
240 |
|
343.2 (MH)+ | 1.36 | 6 | E |
241 |
|
343.2 (MH)+ | 1.35 | 6 | E |
242 |
|
340.1 (M − H)− | 3.23 | 12 | E |
243 |
|
340.1 (M − H)− | 3.21 | 12 | E |
244 |
|
359.1 (M − H)− | 2.87 | 12 | E |
245 |
|
340.1 (M − H)− | 3.37 | 12 | E |
246 |
|
340.1 (M − H)− | 3.38 | 12 | E |
247 |
|
340.1 (M − H)− | 3 | 12 | E |
248 |
|
341.1 (M − H)− | 2.7 | 12 | E |
249 |
|
341.1 (M − H)− | 2.72 | 12 | E |
250 |
|
341.1 (M − H)− | 2.36 | 12 | E |
251 |
|
341.1 (M − H)− | 2.33 | 12 | E |
252 |
|
360.1 (MH)+ | 1.74 | 10 | A |
253 |
|
361.1 (MH)+ | 1.54 | 10 | A |
254 |
|
342.0 (MH)+ | 3.01 | 11 | A |
255 |
|
367.0 (MH)+ | 2.47 | 12 | A |
256 |
|
378.1 (MH)+ | 2.08 | 2 | A |
257 |
|
385.2 (MH)+ | 2.26 | 2 | A |
258 |
|
360.1 (MH)+ | 1.72 | 2 | A |
259 |
|
359.1 (MH)+ | 2.05 | 1 | A |
260 |
|
416.16 (MH)+ | 6.4 | 9 | B |
261 |
|
412.26 (MH)+ | 5.3 | 9 | B |
262 |
|
404.20 (MH)+ | 6.7 | 9 | B |
263 |
|
404.22 (MH)+ | 6.7 | 9 | B |
264 |
|
395.27 (MH)+ | 5.4 | 9 | B |
265 |
|
385.25 (MH)+ | 5.2 | 9 | B |
266 |
|
428.25 (MH)+ | 5.8 | 9 | B |
267 |
|
428.23 (MH)+ | 5.9 | 9 | B |
268 |
|
454.17 (MH)+ | 6.8 | 9 | B |
269 |
|
454.17 (MH)+ | 6.8 | 9 | B |
To a stirred solution of optically enriched (4R,5R)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one (1.25 g, 3.25 mmol) in triethylamine (70 mL) was added ethynylbenzene (0.592 mL, 5.28 mmol), copper(I) iodide (67 mg, 0.352 mmol), and triphenylphosphine (653 mg, 2.464 mmol). Nitrogen was bubbled through the mixture for 10 minutes before adding dichlorobis(triphenylphosphine)-palladium(II) (202 mg, 0.282 mmol) with continued nitrogen gas bubbling. After an additional 10 minutes the reaction mixture was heated to reflux for 16 hours, cooled to ambient temperature, diluted with EtOAc, washed with water (3×), brine, dried over magnesium sulfate, and concentrated in vacuo. Column chromatography (25%-->40% EtOAc/Hex) provided optically enriched (4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one which was separated by chiral SFC chromatography (Chiralcel OJ-H preparative column, 30×250 mm, 5 μm, Mobile Phase: 40% MeOH (0.1% DEA) in CO2 @ 150 Bar, Temp: 35° C., Flow rate: 70.0 mL/min. for 16 min, UV monitored @ 280 nM. tR=9.23 min) to provide (1.38 g, 2.99 mmol, 85% yield) of pure single enantiomer (4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one. 1H NMR (500 MHz, DMSO-d6) δ ppm 8.77 (d, J=2.21 Hz, 1H) 8.57 (s, 1H) 8.56 (d, J=2.20 Hz, 1H) 8.07 (t, J=2.05 Hz, 1H) 7.58-7.66 (m, 2H) 7.44-7.52 (m, 3H) 7.39-7.45 (m, 1H) 7.28-7.39 (m, 2H) 5.67 (d, J=6.62 Hz, 1H) 5.04 (d, J=6.62 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ ppm 157.28; 157.24 (d, J=240.70 Hz) 155.92 (d, J=245.20 Hz) 151.63; 147.70; 136.78; 135.02; 131.57; 129.43; 128.89; 126.63 (dd, J=14.99, 7.72 Hz) 121.51; 119.47; 117.83 (dd, J=23.60, 9.10 Hz) 117.50 (dd, J=24.50, 8.20 Hz); 114.60 (dd, J=26.34, 4.54 Hz); 92.86; 85.76; 78.12; 59.43; LCMS (ESI) m/z calcd for C22H15F2N2O2: 377.11. found 377.20 [M+H]+; HRMS (ESI) m/z calcd for C22H15F2N2O2: 377.1096. found 377.1096 [M+H]+.
The following analogs were prepared by using the same methods for preparation of (4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one.
Analytical | ||
Example # | Structure | Data |
Example 270 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.94 (d, J = 5.2 Hz, 1H), 8.69 (br. s., 1H), 7.71- 7.66 (m, 2H), 7.62 (d, J = 5.2 Hz, 1H), 7.57-7.47 (m, 3H), 7.43-7.33 (m, 3H), 5.73 (d, J = 5.5 Hz, 1H), 5.03 (d, J = 5.5 Hz, 1H). MS Anal. Calcd. for [M + H]+ C21H14F2N3O2: 378.1; found 378.2. |
racemate | ||
Example 271 |
|
1H NMR (500 MHz, DMSO- d6) δ 9.27 (d, J = 1.2 Hz, 1H), 8.57 (s, 1H), 7.88 (d, J = 0.9 Hz, 1H), 7.73-7.67 (m, 2H), 7.59-7.48 (m, 4H), 7.35-7.30 (m, 2H), 7.27 (td, J = 8.4, 2.1 Hz, 1H), 5.64 (d, J = 5.2 Hz, 1H), 4.93 (d, J = 5.2 Hz, 1H). MS Anal. Calcd. for [M + H]+ C21H15FN3O2: 360.1; found 360.2. |
racemate | ||
Example 272 |
|
1H NMR (500 MHz, DMSO- d6) δ 9.04-8.90 (m, 1H), 8.66-8.53 (m, 1H), 7.77 (d, J = 5.2 Hz, 1H), 7.72-7.69 (m, 2H), 7.56-7.48 (m, 4H), 7.33-7.23 (m, 3H), 5.71 (d, J = 4.6 Hz, 1H), 4.89 (d, J = 4.6 Hz, 1H). MS Anal. Calcd. for [M + H]+ C21H5FN3O2: 360.1; found 360.2. |
racemate | ||
Example 273 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.98 (d, J = 5.2 Hz, 1H), 8.59 (s, 1H), 7.77 (d, J = 5.2 Hz, 1H), 7.73-7.69 (m, 2H), 7.59-7.46 (m, 4H), 7.34-7.23 (m, 3H), 5.71 (d, J = 4.6 Hz, 1H), 4.89 (d, J = 4.6 Hz, 1H). MS Anal. Calcd. for [M + H]+ C21H5FN3O2: 360.1; found 360.3. |
Example 274 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.98 (d, J = 5.2 Hz, 1H), 8.59 (s, 1H), 7.77 (d, J = 4.9 Hz, 1H), 7.73-7.68 (m, 2H), 7.60-7.48 (m, 4H), 7.34-7.23 (m, 3H), 5.71 (d, J = 4.6 Hz, 1H), 4.89 (d, J = 4.6 Hz, 1H). MS Anal. Calcd. for [M + H]+ C21H15FN3O2: 360.1; found 360.3. |
Example 275 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.94 (d, J = 5.2 Hz, 1H), 8.63 (br. s., 1H), 7.72- 7.66 (m, 2H), 7.62 (d, J = 5.2 Hz, 1H), 7.57-7.46 (m, 4H), 7.35-7.24 (m, 3H), 5.63 (d, J = 5.2 Hz, 1H), 4.94 (d, J = 5.2 Hz, 1H). MS Anal. Calcd. for [M + H]+ C21H15FN3O2: 360.1; found 360.2. |
Example 276 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.94 (d, J = 5.2 Hz, 1H), 8.64 (br. s., 1H), 7.72- 7.66 (m, 2H), 7.62 (d, J = 5.2 Hz, 1H), 7.57-7.48 (m, 4H), 7.35-7.25 (m, 3H), 5.63 (d, J = 4.9 Hz, 1H), 4.94 (d, J = 4.9 Hz, 1H). MS Anal. Calcd. for [M + H]+ C21H15FN3O2: 360.1; found 360.2. |
Example 277 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.78 (d, J = 2.1 Hz, 1H), 8.64-8.52 (m, 2H), 8.07 (t, J = 2.0 Hz, 1H), 7.65- 7.60 (m, 2H), 7.58-7.50 (m, 1H), 7.50-7.45 (m, 3H), 7.37-7.30 (m, 2H), 5.73 (d, J = 6.7 Hz, 1H), 5.07 (d, J = 6.4 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H15F2N2O2: 377.1; found 377.3. |
Example 278 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.77 (d, J = 2.1 Hz, 1H), 8.63-8.50 (m, 2H), 8.11 (t, J = 2.0 Hz, 1H), 7.67- 7.53 (m, 3H), 7.51-7.42 (m, 3H), 7.23 (t, J = 8.5 Hz, 2H), 5.69 (d, J = 7.6 Hz, 1H), 5.16 (d, J = 7.6 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H15F2N2O2: 377.1; found 377.2. |
Example 279 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.77 (d, J = 1.8 Hz, 1H), 8.56 (s, 2H), 8.06 (t, J = 2.0 Hz, 1H), 7.74-7.65 (m, 2H), 7.47-7.27 (m, 5H), 5.66 (d, J = 6.7 Hz, 1H), 5.04 (d, J = 7.0 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H14F3N2O2: 395.1; found 395.2. |
Example 280 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.79 (d, J = 1.8 Hz, 1H), 8.60 (d, J = 1.8 Hz, 2H), 8.09 (t, J = 2.0 Hz, 1H), 7.73 (t, J = 1.7 Hz, 1H), 7.63- 7.44 (m, 4H), 7.38-7.28 (m, 2H), 5.72 (d, J = 6.4 Hz, 1H), 5.07 (d, J = 6.4 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H14ClF2N2O2: 411.1; found 411.2. |
Example 281 |
|
11H NMR (500 MHz, DMSO- d6) δ 8.78 (d, J = 1.8 Hz, 1H), 8.59 (d, J = 2.1 Hz, 2H), 8.14 (t, J = 2.0 Hz, 1H), 7.71 (t, J = 1.7 Hz, 1H), 7.64- 7.53 (m, 3H), 7.52-7.46 (m, 1H), 7.23 (t, J = 8.5 Hz, 2H), 5.68 (d, J = 7.3 Hz, 1H), 5.16 (d, J = 7.3 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H14ClF2N2O2: 411.1; found 411.2. |
Example 282 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.79 (d, J = 1.8 Hz, 1H), 8.65-8.52 (m, 2H), 8.09 (t, J = 2.0 Hz, 1H), 7.71 (td, J = 7.5, 1.8 Hz, 1H), 7.58- 7.51 (m, 1H), 7.46-7.26 (m, 5H), 5.68 (d, J = 6.7 Hz, 1H), 5.05 (d, J = 7.0 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H14F3N2O2: 395.1; found 395.1. |
Example 283 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.79 (d, J = 1.8 Hz, 1H), 8.65-8.53 (m, 2H), 8.09 (t, J = 2.0 Hz, 1H), 7.56- 7.46 (m, 3H), 7.45-7.31 (m, 4H), 5.66 (d, J = 6.7 Hz, 1H), 5.04 (d, J = 6.7 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H14F3N2O2: 395.1; found 395.1. |
Example 284 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.79 (d, J = 1.8 Hz, 1H), 8.64-8.56 (m, 2H), 8.08 (t, J = 2.0 Hz, 1H), 7.71 (td, J = 7.5, 1.5 Hz, 1H), 7.58- 7.49 (m, 2H), 7.43-7.28 (m, 4H), 5.74 (d, J = 6.7 Hz, 1H), 5.09 (d, J = 6.4 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H14F3N2O2: 395.1; found 395.1. |
Example 285 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.79 (d, J = 2.1 Hz, 1H), 8.60 (d, J = 2.1 Hz, 2H), 8.09 (t, J = 2.0 Hz, 1H), 7.65- 7.44 (m, 4H), 7.40-7.30 (m, 3H), 5.72 (d, J = 6.4 Hz, 1H), 5.08 (d, J = 6.4 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H14F3N2O2: 395.1; found 395.1. |
Example 286 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.77 (d, J = 1.8 Hz, 1H), 8.66-8.54 (m, 2H), 8.06 (t, J = 2.0 Hz, 1H), 7.76- 7.64 (m, 2H), 7.59-7.47 (m, 1H), 7.40-7.24 (m, 4H), 5.72 (d, J = 6.4 Hz, 1H), 5.07 (d, J = 6.4 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H14F3N2O2: 395.1; found 395.2. |
Example 287 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.80 (d, J = 1.8 Hz, 1H), 8.65-8.53 (m, 2H), 8.08 (t, J = 2.1 Hz, 1H), 7.75 (dd, J = 7.6, 1.8 Hz, 1H), 7.64 (dd, J = 7.9, 0.9 Hz, 1H), 7.57-7.47 (m, 2H), 7.47-7.42 (m, 1H), 7.36- 7.30 (m, 2H), 5.74 (d, J = 6.7 Hz, 1H), 5.09 (d, J = 6.4 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H14ClF2N2O2: 411.1; found 411.2. |
Example 288 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.81 (d, J = 2.1 Hz, 1H), 8.62-8.45 (m, 2H), 7.88 (t, J = 2.0 Hz, 1H), 7.71- 7.60 (m, 2H), 7.53-7.43 (m, 4H), 7.41-7.32 (m, 1H), 7.27 (ddd, J = 9.2, 6.0, 3.1 Hz, 1H), 5.16 (d, J = 1.2 Hz, 1H), 1.26 (s, 3H). MS Anal. Calcd. for [M + H]+ C22H16F2N2O2: 391.1; found 391.2. |
Example 289 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.81 (d, J = 2.1 Hz, 1H), 8.66-8.45 (m, 2H), 7.88 (t, J = 2.0 Hz, 1H), 7.71 7.59 (m, 2H), 7.54-7.42 (m, 4H), 7.40-7.32 (m, 1H), 7.27 (ddd, J = 9.2, 6.0, 3.1 Hz, 1H), 5.16 (d, J = 1.2 Hz, 1H), 1.26 (s, 3H). MS Anal. Calcd. for [M + H]+ C22H16F2N2O2: 391.1; found 391.2. |
Example 290 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.65 (s, 1H), 8.52 (d, J = 1.8 Hz, 1H), 8.30 (s, 1H), 7.65-7.54 (m, 3H), 7.50- 7.41 (m, 3H), 7.20 (ddd, J = 9.2, 5.9, 3.2 Hz, 1H), 7.12-7.06 (m, 1H), 7.01 (td, J = 9.8, 4.6 Hz, 1H), 5.17 (d, J = 1.5 Hz, 1H), 1.90 (s, 3H). MS Anal. Calcd. for [M + H]+ C22H16F2N2O2: 391.1; found 391.2. |
Example 291 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.65 (s, 1H), 8.52 (d, J=1.8 Hz, 1H), 8.30 (s, 1H), 7.65-7.53 (m, 3H), 7.51- 7.37 (m, 3H), 7.20 (ddd, J = 9.2, 5.8, 3.4 Hz, 1H), 7.12-7.06 (m, 1H), 7.01 (td, J = 9.8, 4.6 Hz, 1H), 5.17 (d, J = 1.8 Hz, 1H), 1.90 (s, 3H). MS Anal. Calcd. for [M + H]+ C22H16F2N2O2: 391.1; found 391.2. |
Example 292 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.76 (d, J = 2.1 Hz, 1H), 8.63-8.47 (m, 2H), 8.11 (t, J = 2.0 Hz, 1H), 7.61 (dd, J = 6.6, 2.9 Hz, 2H), 7.52-7.43 (m, 3H), 7.36 (t, J = 9.2 Hz, 2H), 5.64 (d, J = 7.6 Hz, 1H), 5.14 (d, J = 7.6 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H14F3N2O2: 395.1; found 395.3. |
Example 293 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.78 (d, J = 2.1 Hz, 1H), 8.67-8.54 (m, 2H), 8.08 (t, J = 2.0 Hz, 1H), 7.74 7.58 (m, 3H), 7.53-7.39 (m, 3H), 7.35-7.24 (m, 1H), 5.73 (d, J = 6.7 Hz, 1H), 5.08 (d, J = 6.7 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H14F3N2O2: 395.1; found 395.2. |
Example 294 |
|
1H NMR (500 MHz, DMSO- d6) δ 8.78 (d, J = 1.8 Hz, 1H), 8.65-8.50 (m, 2H), 8.06 (s, 1H), 7.62 (dd, J = 6.6, 2.9 Hz, 2H), 7.53- 7.32 (m, 4H), 5.69 (d, J = 6.7 Hz, 1H), 5.08 (d, J = 6.4 Hz, 1H). MS Anal. Calcd. for [M + H]+ C22H14F3N2O2: 395.1; found 395.2. |
Example 295 |
|
1H NMR (500 MHz, DMF) δ 9.38 (d, J = 0.9 Hz, 1H), 9.29 (d, J = 1.5 Hz, 1H), 9.20- 9.05 (m, 3H), 8.65 (s, 1H), 7.79 (t, J = 9.2 Hz, 2H), 6.08 (d, J = 7.3 Hz, 1H), 5.60 (d, J = 7.6 Hz, 1H). MS Anal. Calcd. for [M + H]+ C20H12F3N4O2: 397.1; found 392.2. |
Example 296 |
|
1H NMR (500 MHz, DMF) δ 9.39 (d, J = 1.5 Hz, 1H), 9.30 (d, J = 1.8 Hz, 1H), 9.20- 9.05 (m, 3H), 8.60 (t, J = 1.8 Hz, 1H), 7.95-7.78 (m, 2H), 6.12 (d, J = 6.7 Hz, 1H), 5.53 (d, J = 6.7 Hz, 1H). MS Anal. Calcd. for [M + H]+ C20H12F3N4O2: 397.1; found 397.2. |
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one and (4S,5S)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one, starting with (E)-4-bromo-2-(4-fluorostyryl)pyridine. 1H NMR (CDCl3) δ: 8.64 (d, J=5.2 Hz, 1H), 7.58 (dd, J=7.8, 1.7 Hz, 2H), 7.53 (s, 1H), 7.35-7.49 (m, 6H), 7.13 (t, J=8.5 Hz, 2H), 6.66 (br. s., 1H), 5.59 (d, J=5.8 Hz, 1H), 4.92 (d, J=5.8 Hz, 1H). 13C NMR (CDCl3) δ: 163.1, 159.0, 158.4, 150.3, 134.1, 133.2, 132.1, 129.6, 128.7, 127.8, 125.5, 122.6, 121.8, 116.1, 95.2, 86.4, 83.3, 65.0. Enantiomers were resolved by chiral Prep HPLC (Chiralpak AD, 40% EtOH/Heptane/0.1% DEA). Enantiomer 1=first enantiomer to elute from Prep (Example 297): Mass spec.: 359.3 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 298): Mass spec.: 359.4 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (4R,5R)-4-(5-bromo-2-fluoropyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one and phenylacetylene. 1H NMR (CDCl3) δ: 8.39 (d, J=0.9 Hz, 1H), 8.11 (dd, J=9.0, 2.0 Hz, 1H), 7.56 (dd, J=7.8, 1.7 Hz, 2H), 7.35-7.46 (m, 4H), 7.07-7.22 (m, 3H), 6.77 (s, 1H), 5.37 (d, J=5.2 Hz, 1H), 5.04 (d, J=5.2 Hz, 1H). 19F NMR (CDCl3) δ: −70.65 (d, J=13.0 Hz, 1F), −111.45 (br. s., 1F). 13C NMR (CDCl3) δ: 163.2, 158.8, 159.6, 150.5, 140.8, 139.8, 131.8, 131.0, 129.3, 128.7, 122.0, 121.2, 121.2, 119.8, 116.6, 112.7, 93.8, 84.0, 83.6, 58.0. Mass spec.: 377.2 (MH)+.
To a solution of (4R,5R)-4-(2-fluoro-5-(phenylethynyl)pyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (10 mg, 0.027 mmol) in methanol (0.25 mL) at 0° C. was added a solution of potassium hydroxide (14.9 mg, 0.266 mmol) in methanol (0.25 mL, 6.18 mmol). After 1 h at 0° C., the reaction was allowed to stir at room temperature for 24 h. The reaction was quenched by addition of solid ammonium chloride (30 mg) and concentrated. The resulting residue was dissolved in dichloromethane, diluted with ethyl acetate, washed with brine, dried over magnesium sulfate, and concentrated. The product was purified by Prep HPLC (TFA/MeOH, sunfire column) and concentrated to give 7.7 mg (73%). 1H NMR (CDCl3) δ: 8.38 (d, J=2.1 Hz, 1H), 7.84-7.88 (m, 1H), 7.53-7.58 (m, 2H), 7.43 (td, J=7.9, 5.8 Hz, 1H), 7.36-7.40 (m, 3H), 7.24 (dd, J=7.6, 0.6 Hz, 1H), 7.19 (dt, J=9.4, 2.0 Hz, 1H), 7.09-7.15 (m, 1H), 5.90 (s, 1H), 5.37 (d, J=4.3 Hz, 1H), 4.98 (d, J=4.3 Hz, 1H), 4.00 (s, 3H). 13C NMR (CDCl3) δ: 163.1, 160.1, 158.8, 150.1, 141.1, 137.8, 131.7, 130.7, 128.7, 128.6, 122.7, 121.4, 121.1, 121.1, 116.0, 114.1, 112.8, 91.8, 85.4, 83.1, 58.6, 54.1. Mass spec.: 389.2 (MH)+.
In a 1 mL scint vial, a suspension of optically-enriched (4R,5R)-4-(2-bromo-5-fluoropyridin-4-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one (20 mg, 0.054 mmol), and ethynylbenzene (0.014 mL, 0.129 mmol) in triethyl amine (1.5 mL) was purged with nitrogen for 30 min. Triphenylphosphine (3.7 mg, 0.014 mmol) was added and the suspension stirred for 5 min. To this was added copper (I) iodide (0.408 mg, 2.144 μmol), and bis(triphenylphosphine)palladium(II) chloride (1.8 mg, 2.6 μmol). The vial was purged with nitrogen for an additional 5 min, capped, and immersed in a 90° C. bath for 5 h. The reaction was cooled to room temperature and concentrated. The resulting residue was dissolved in dichloromethane and poured into water. The mixture was diluted with ethyl acetate, washed with water, brine, dried over magnesium sulfate, and concentrated. The material was purified first by reversed phase HPLC (TFA/MeOH/sunfire column) to give an optically enriched mixture of regioisomers. The material was further purified by chiral prep HPLC (Chiralpak AD, A=heptane/0.1% DEA, B=ethanol, 40%→60% over 35 min) to give the title compound (3.4 mg). 1H NMR (CDCl3) δ: 8.52 (d, J=0.9 Hz, 1H), 7.75 (d, J=5.8 Hz, 1H), 7.63 (dd, J=7.3, 2.1 Hz, 2H), 7.38-7.44 (m, 3H), 7.23-7.27 (m, 1H), 7.11-7.17 (m, 2H), 5.79 (br. s., 1H), 5.64 (d, J=5.5 Hz, 1H), 5.08 (d, J=5.5 Hz, 1H). 1H NMR (CDCl3) δ: 8.51 (d, J=0.9 Hz, 1H), 7.73 (d, J=5.5 Hz, 1H), 7.63 (dd, J=7.6, 1.8 Hz, 2H), 7.39-7.46 (m, 3H), 7.23-7.27 (m, 1H), 7.10-7.16 (m, 2H), 5.95 (br. s., 1H), 5.61 (d, J=5.5 Hz, 1H), 5.13 (d, J=5.8 Hz, 1H). Mass spec.: 395.2 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (4R,5R)-4-(5-bromo-2-fluoropyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one and phenylacetylene. 1H NMR (CDCl3) δ: 8.37 (d, J=1.2 Hz, 1H), 8.11 (dd, J=8.9, 2.1 Hz, 1H), 7.56 (dd, J=7.6, 1.8 Hz, 2H), 7.35-7.42 (m, 3H), 7.21-7.26 (m, 1H), 7.07-7.14 (m, 2H), 6.99 (s, 1H), 5.57 (d, J=5.8 Hz, 1H), 5.07 (d, J=5.8 Hz, 1H). 19F NMR (CDCl3) δ: −71.32 (br. s., 1F), −117.12 (br. s., 1F), −123.54 (d, J=8.7 Hz, 1F). Mass spec.: 395.1 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(3-fluorophenyl)-4-(2-methoxy-5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one, starting with ((4R,5R)-5-(2,5-difluorophenyl)-4-(2-fluoro-5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one. 1H NMR (CDCl3) δ: 8.33 (d, J=2.1 Hz, 1H), 7.83 (d, J=1.8 Hz, 1H), 7.50-7.54 (m, 2H), 7.33-7.38 (m, 3H), 7.20-7.25 (m, 1H), 7.03-7.10 (m, 2H), 6.06 (s, 1H), 5.54 (d, J=5.2 Hz, 1H), 4.98 (d, J=5.2 Hz, 1H), 3.88 (s, 3H). 19F NMR (CDCl3) δ: −119.97-115.26 (m, 1F), −123.84 (br. s., 1F). Mass spec.: 407.1 (MH)+.
A suspension of optically-enriched (4R,5R)-4-(2-bromo-5-fluoropyridin-4-yl)-5-(2-fluorophenyl)oxazolidin-2-one (38 mg, 0.107 mmol) in triethylamine (1.1 mL, 8.03 mmol) was degassed by bubbling with nitrogen for 30 min. To this was added ethynylbenzene (15 μl, 0.134 mmol) and triphenylphosphine (3.7 mg, 0.014 mmol). After bubbling 5 min longer, the reaction was treated with copper(I) iodide (0.408 mg, 2.14 μmol) and bis(triphenylphosphine)palladium(II) chloride (1.8 mg, 2.6 μmol), bubbled briefly with nitrogen, sealed, and heated at 90° C. for 5 h. The reaction was concentrated, dissolved in a minimum of dichloromethane, diluted with ethyl acetate, washed with brine, dried over magnesium sulfate, and concentrated. Column chromatography (25%→50% EtOAc/Hex) gave a mixture of the two regioisomers. This material was further purified by chiral prep HPLC (Chiralcel OD, 40% EtOH/heptane/0.1% DEA) to give 9.6 mg (23%). 1H NMR (CDCl3) δ: 8.49 (d, J=1.2 Hz, 1H), 7.76 (d, J=5.8 Hz, 1H), 7.58-7.67 (m, 2H), 7.51 (td, J=7.5, 1.5 Hz, 1H), 7.35-7.48 (m, 4H), 7.23-7.28 (m, 1H), 7.16 (ddd, J=9.8, 8.9, 0.8 Hz, 1H), 6.28 (br. s., 1H), 5.62 (d, J=5.8 Hz, 1H), 5.17 (d, J=5.8 Hz, 1H). 13C NMR (CDCl3) δ: 160.1, 158.4, 156.2, 140.8, 139.2, 135.3, 132.2, 131.4, 129.5, 128.6, 127.5, 125.2, 124.9, 124.5, 121.8, 116.2, 90.2, 87.3, 79.3, 56.6. 19F NMR (CDCl3) δ: −117.69 (d, J=8.7 Hz, 1F), −132.34 (d, J=8.7 Hz, 1F). Mass spec.: 377.2 (MH)+.
A suspension of optically-enriched (4R,5R)-4-(6-bromo-3-fluoropyridin-2-yl)-5-phenyloxazolidin-2-one (96 mg, 0.285 mmol) in triethylamine (3.0 mL, 21.4 mmol) was degassed by bubbling with nitrogen for 30 min. To this was added ethynylbenzene (39 μl, 0.36 mmol) and triphenylphosphine (9.7 mg, 0.037 mmol). After bubbling 5 min longer, the reaction was treated with copper(I) iodide (1.1 mg, 5.7 μmol) and bis(triphenylphosphine)palladium(II) chloride (4.8 mg, 6.8 μmol), bubbled briefly with nitrogen, sealed, and heated at 90° C. for 5 h. The reaction was concentrated, dissolved in a minimum of dichloromethane, diluted with ethyl acetate, washed with brine, dried over magnesium sulfate, and concentrated. Column chromatography (25%→50% EtOAc/Hex) gave the racemate. 1H NMR (CDCl3) δ: 7.58-7.69 (m, 3H), 7.34-7.51 (m, 9H), 5.92 (br. s., 1H), 5.62-5.69 (m, 2H). 13C NMR (CDCl3) δ: 158.2, 157.6, 143.5, 143.4, 139.6, 139.0, 132.2, 129.8, 129.4, 129.0, 128.6, 126.5, 124.5, 121.9, 89.8, 87.5, 80.5, 59.2. 19F NMR (CDCl3) δ: −124.54 (br. s., 1F). Enantiomers were resolved by Prep HPLC (Chiralcel OD, 13% EtOH/Heptane/0.1% DEA). Enantiomer 1=first enantiomer to elute from Prep (Example 305): Mass spec.: 359.2 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 306): Mass spec.: 359.2 (MH)+.
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with optically-enriched (4R,5R)-4-(6-bromopyridin-2-yl)-5-(2-fluorophenyl)oxazolidin-2-one and phenylacetylene. 1H NMR (CDCl3) δ: 7.77 (t, J=7.8 Hz, 1H), 7.61 (dd, J=7.3, 1.8 Hz, 2H), 7.47-7.57 (m, 2H), 7.33-7.46 (m, 5H), 7.20-7.28 (m, 1H), 7.06-7.17 (m, 1H), 6.75 (s, 1H), 5.84 (d, J=5.2 Hz, 1H), 5.00 (d, J=5.2 Hz, 1H). 13C NMR (CDCl3) δ: 160.2, 159.1, 158.8, 143.7, 137.7, 132.2, 130.9, 129.3, 128.5, 127.8, 127.3, 125.6, 124.8, 122.1, 120.1, 116.0, 90.1, 88.4, 79.0, 64.1. 19F NMR (CDCl3) δ: −117.43 (br. s., 1F). Enantiomers were resolved by Prep HPLC (Chiralcel OD, 37% EtOH/Heptane/0.1% DEA). Enantiomer 1=first enantiomer to elute from Prep (Example 307): Mass spec.: 359.3 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 308): Mass spec.: 360.2 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(2-fluorophenyl)-4-(6-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one and (4S,5S)-5-(2-fluorophenyl)-4-(6-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one, starting with diethyl (6-bromopyridin-2-yl)methylphosphonate and 2,4-difluorobenzaldehyde. 1H NMR (CDCl3) δ: 7.79 (t, J=7.8 Hz, 1H), 7.61 (dd, J=7.3, 1.8 Hz, 2H), 7.48-7.57 (m, 2H), 7.37-7.44 (m, 4H), 6.98 (td, J=8.2, 1.8 Hz, 1H), 6.89 (ddd, J=10.5, 8.5, 2.3 Hz, 1H), 6.52 (br. s., 1H), 5.79 (d, J=5.5 Hz, 1H), 4.99 (d, J=5.5 Hz, 1H). 13C NMR (CDCl3) δ: 163.5, 160.4, 158.7, 158.5, 143.8, 137.7, 132.2, 129.4, 129.0, 128.5, 127.4, 122.0, 121.6, 119.9, 112.1, 104.6, 90.2, 88.3, 78.7, 64.0. 19F NMR (CDCl3) δ: −108.67 (d, J=8.7 Hz, 1F), −113.26 (br. s., 1F). Enantiomers were resolved by Prep HPLC (Chiralcel OD, 38% EtOH/Heptane/0.1% DEA). Enantiomer 1=first enantiomer to elute from Prep (Example 309): Mass spec.: 377.2 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 310): Mass spec.: 377.2 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(2-fluorophenyl)-4-(6-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one and (4S,5S)-5-(2-fluorophenyl)-4-(6-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one, starting with diethyl (6-bromopyridin-2-yl)methylphosphonate, 2,4-difluorobenzaldehyde, and 3-fluorophenylacetylene. 1H NMR (CDCl3) δ: 7.82 (t, J=7.8 Hz, 1H), 7.50-7.59 (m, 2H), 7.30-7.46 (m, 4H), 7.09-7.16 (m, 1H), 6.97-7.03 (m, 1H), 6.90 (ddd, J=10.6, 8.6, 2.4 Hz, 1H), 6.16 (s, 1H), 5.79 (d, J=5.5 Hz, 1H), 4.98 (d, J=5.5 Hz, 1H). 19F NMR (CDCl3) δ: −108.57 (t, J=8.7 Hz, 1F), −112.91 (q, J=8.7 Hz, 1F), −113.52-113.23 (m, 1F). Enantiomers were resolved by Prep HPLC (Chiralcel OJ, 30% EtOH/Heptane/0.1% DEA). Enantiomer 1=first enantiomer to elute from Prep (Example 311): Mass spec.: 395.2 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 312): Mass spec.: 395.3 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(2-fluorophenyl)-4-(6-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one and (4S,5S)-5-(2-fluorophenyl)-4-(6-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one, starting with diethyl (6-bromopyridin-2-yl)methylphosphonate and 2,4,6-trifluorobenzaldehyde. 1H NMR (CDCl3) δ: 7.81 (t, J=7.8 Hz, 1H), 7.57-7.65 (m, 2H), 7.54 (d, J=7.9 Hz, 1H), 7.34-7.48 (m, 4H), 6.77 (t, J=8.4 Hz, 2H), 6.69 (br. s., 1H), 5.84 (d, J=6.7 Hz, 1H), 5.21 (d, J=6.7 Hz, 1H). 19F NMR (CDCl3) δ: −104.95 (br. s., 1F), −113.52-109.06 (m, 2F). Enantiomers were resolved by Prep HPLC (Chiralcel OJ, 42% EtOH/Heptane/0.1% DEA). Enantiomer 1=first enantiomer to elute from Prep (Example 313): Mass spec.: 395.2 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 314): Mass spec.: 396.2 (MH)+.
Prepared according to the same procedure as (4R,5R)-5-(2-fluorophenyl)-4-(6-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one and (4S,5S)-5-(2-fluorophenyl)-4-(6-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one, starting with diethyl (6-bromopyridin-2-yl)methylphosphonate and 3,5-difluorobenzaldehyde. 1H NMR (CDCl3) δ: 7.81 (t, J=7.9 Hz, 1H), 7.60-7.68 (m, 2H), 7.56 (d, J=7.9 Hz, 1H), 7.36-7.47 (m, 4H), 7.05-7.13 (m, 2H), 7.03 (s, 1H), 6.84 (tt, J=8.7, 2.3 Hz, 1H), 5.68 (d, J=5.5 Hz, 1H), 4.94 (d, J=5.5 Hz, 1H). 13C NMR (CDCl3) δ: 163.4, 158.8, 158.4, 144.0, 142.4, 137.9, 132.2, 129.4, 128.6, 127.3, 121.9, 119.7, 108.8, 108.8, 104.4, 90.4, 88.2, 82.2, 64.6. 19F NMR (CDCl3) δ: −108.32 (d, J=8.7 Hz, 1F). Enantiomers were resolved by Prep HPLC (Chiralpak AD, 40% EtOH/Heptane/0.1% DEA). Enantiomer 1=first enantiomer to elute from Prep (Example 315): Mass spec.: 377.2 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 316): Mass spec.: 377.2 (MH)+.
A flask was charged with N-(diphenylmethylene)-1-(5-(phenylethynyl)pyridin-3-yl)methanamine (0.21 g/mL in toluene, 1.5 mL, 0.85 mmol) and concentrated. The residue was dissolved in tetrahydrofuran (5.5 mL), and cooled to −78° C. To this was added t-BuLi (1.7M in pentane, 0.60 mL, 1.02 mmol) dropwise. After 20 min, the resulting solution was treated with pyrimidine-4-carbaldehyde (91 mg, 0.85 mmol). After stirring at −78° C. for 10 min, the reaction was allowed to gradually warm to room temperature in the bath The reaction was diluted with ether, quenched by addition of water, and warmed to room temperature with stirring. The layers were separated. The organics were washed with brine and concentrated to give a gummy solid. The crude product was dissolved in methanol (6 mL) and treated with methoxyamine hydrochloride (212 mg, 2.54 mmol). The reaction was stirred at room temperature overnight. The reaction was concentrated, dissolved in methanol, and loaded on a medium cation exchange cartridge (6 g cartridge). The cartridge was flushed with several volumes of methanol which were discarded. The product was eluted with 2M ammonia in methanol and concentrated to afford 277 mg as an orange gum. The crude amino alcohol was dissolved in tetrahydrofuran (5 mL), cooled to 0° C., and treated with carbonyldiimidazole (149 mg, 0.919 mmol). The ice bath was removed and stirring continued overnight. The material was purified by prep HPLC (Sunfire Column, TFA/MeOH) to isolate the two major fractions (F1=first to elute, F2=second to elute). F1(trans): 1H NMR (CDCl3) d: 9.29 (d, J=1.4 Hz, 1H), 8.87 (d, J=5.2 Hz, 1H), 8.78 (d, J=1.7 Hz, 1H), 8.70 (d, J=1.8 Hz, 1H), 8.03 (t, J=1.9 Hz, 1H), 7.63 (dd, J=5.0, 0.5 Hz, 1H), 7.54-7.61 (m, 2H), 7.37-7.43 (m, 3H), 6.50 (br. s., 1H), 5.41 (d, J=5.2 Hz, 1H), 5.23 (d, J=5.2 Hz, 1H). 13C NMR (CDCl3) d: 165.3, 158.9, 158.4, 157.7, 152.6, 146.9, 136.3, 134.7, 131.8, 129.2, 128.6, 122.1, 121.2, 117.6, 94.0, 85.2, 82.8, 58.9. Enantiomers of F1 were resolved by Prep HPLC (Chiralpak AD, 78% EtOH/Heptane/0.1% DEA). Enantiomer 1=first enantiomer to elute from Prep (Example 317): Mass spec.: 343.3 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 318): Mass spec.: 343.3 (MH)+. F2(cis): 1H NMR (CDCl3) d: 9.28 (d, J=1.2 Hz, 1H), 8.86 (d, J=5.2 Hz, 1H), 8.77 (d, J=0.9 Hz, 1H), 8.69 (s, 1H), 8.02 (t, J=1.8 Hz, 1H), 7.62 (d, J=5.0 Hz, 1H), 7.53-7.59 (m, 2H), 7.35-7.43 (m, 3H), 6.79 (br. s., 1H), 5.40 (d, J=5.2 Hz, 1H), 5.22 (d, J=5.2 Hz, 1H). 13C NMR (CDCl3) d: 165.4, 158.9, 158.4, 157.8, 152.5, 146.8, 136.3, 134.8, 131.8, 129.2, 128.6, 122.1, 121.2, 117.6, 93.9, 85.2, 82.8, 58.9. Enantiomers of F2 were resolved by Prep HPLC (Chiralpak AD, 78% EtOH/Heptane/0.1% DEA). Enantiomer 1=first enantiomer to elute from Prep (Example 319): Mass spec.: 343.3 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 320): Mass spec.: 343.3 (MH)+.
Prepared according to the same procedure as (4R,5R)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4R,5S)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4S,5R)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4S,5S)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one using pyridazine-4-carbaldehyde. F1 (trans): 1H NMR (CDCl3) d: 9.33 (dd, J=5.3, 1.1 Hz, 1H), 9.18 (d, J=1.1 Hz, 1H), 8.86 (d, J=1.8 Hz, 1H), 8.53 (d, J=2.1 Hz, 1H), 7.94 (t, J=2.0 Hz, 1H), 7.56-7.61 (m, 2H), 7.52 (dt, J=5.3, 1.2 Hz, 1H), 7.39-7.45 (m, 3H), 5.89 (br. s., 1H), 5.43 (d, J=7.0 Hz, 1H), 4.80 (d, J=7.0 Hz, 1H). 13C NMR (CDCl3) d: 156.7, 153.6, 151.6, 148.3, 146.7, 136.3, 136.3, 132.5, 131.8, 129.4, 128.6, 122.6, 121.8, 121.8, 94.7, 84.7, 81.4, 61.5. Enantiomers of F1 were resolved by Prep HPLC (Chiralpak AD, 78% EtOH/Heptane/0.1% DEA). Enantiomer 1=first enantiomer to elute from Prep (Example 321): Mass spec.: 343.3 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 322): Mass spec.: 343.3 (MH)+. F2: 1H NMR (CDCl3) d: 9.30 (dd, J=5.3, 1.1 Hz, 1H), 9.17 (d, J=0.9 Hz, 1H), 8.84 (d, J=1.8 Hz, 1H), 8.52 (d, J=2.0 Hz, 1H), 7.93 (t, J=2.0 Hz, 1H), 7.54-7.62 (m, 2H), 7.48-7.54 (m, 1H), 7.36-7.45 (m, 3H), 6.47 (br. s., 1H), 5.42 (d, J=7.0 Hz, 1H), 4.82 (d, J=7.0 Hz, 1H). 13C NMR (CDCl3) d: 157.1, 153.4, 151.5, 148.4, 146.7, 136.4, 136.4, 132.7, 131.8, 129.4, 128.6, 122.7, 121.8, 121.7, 94.7, 84.7, 81.4, 61.5. Enantiomers of F2 were resolved by Prep HPLC (Chiralpak AD, 70% EtOH/Heptane/0.1% DEA). Enantiomer 1=first enantiomer to elute from Prep (Example 323): Mass spec.: 343.3 (MH)+. Enantiomer 2=second enantiomer to elute from Prep (Example 324): Mass spec.: 343.3 (MH)+.
Prepared according to the same procedure as (4R,5R)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4R,5S)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4S,5R)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4S,5S)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one using 2,5-dichlorobenzaldehyde. The material was purified by Biotage (35-45% EtOAc/Hex) to isolate the two major fractions (F1=first to elute, F2=second to elute). F1(trans): 1H NMR (CDCl3, 400 MHz) δ: 8.72 (d, J=1.8 Hz, 1H), 8.49 (d, J=2.0 Hz, 1H), 7.94 (t, J=2.0 Hz, 1H), 7.52-7.56 (m, 3H), 7.45 (s, 1H), 7.37 (d, J=1.8 Hz, 1H), 7.36 (d, J=2.0 Hz, 1H), 7.31 (dd, J=3.0, 1.3 Hz, 2H), 5.66 (d, J=4.5 Hz, 1H), 5.01-5.20 (m, 1H), 4.72 (d, J=4.5 Hz, 1H). 13C-NMR (CDCl3, 101 MHz) δ: 158.2, 157.5, 152.2, 146.5, 136.8, 135.9, 134.4, 133.5, 131.4, 130.8, 130.0, 129.9, 129.3, 128.8, 128.1, 126.6, 121.7, 120.8, 93.5, 84.8, 80.8, 60.8. Mass spec.: 409.1 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 21×250 mm, 10 um, 50% B isocratic, flow rate: 15 mL/min, UV 220, 25 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 325). Enantiomer 2=second enantiomer to elute from Prep (Example 326). F2(cis): 1H NMR (CDCl3, 400 MHz) δ: 8.53 (d, J=1.8 Hz, 1H), 8.26 (d, J=2.0 Hz, 1H), 7.56 (td, J=4.6, 2.9 Hz, 3H), 7.37-7.43 (m, 4H), 7.11-7.14 (m, 2H), 6.26 (d, J=8.0 Hz, 1H), 6.09 (br. s., 1H), 5.44 (d, J=8.3 Hz, 1H). 13C-NMR (CDCl3, 101 MHz) δ: 157.5, 152.0, 146.6, 136.2, 133.7, 133.3, 131.4, 131.0, 130.1, 129.7, 128.7, 128.5, 128.1, 126.9, 121.7, 119.9, 101.4, 93.4, 84.5, 78.3, 56.5. Mass spec.: 409.1 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralcel OD 2 1×250 mm, 10 um, 25% B isocratic, flow rate: 15 mL/min, UV 220, 50 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 327). Enantiomer 2=second enantiomer to elute from Prep (Example 328).
Prepared according to the same procedure as (4R,5R)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4R,5S)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4S,5R)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4S,5S)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one using 2,3-dichlorobenzaldehyde. The material was purified by Biotage (35-40% EtOAc/Hex) to isolate the two major fractions (F1=first to elute, F2=second to elute). F1(trans): 1H NMR (CDCl3, 400 MHz) δ: 8.74 (d, J=1.8 Hz, 1H), 8.53 (d, J=2.0 Hz, 1H), 7.95 (t, J=2.0 Hz, 1H), 7.54-7.58 (m, 2H), 7.51 (dd, J=8.0, 1.5 Hz, 1H), 7.43-7.47 (m, 1H), 7.37-7.40 (m, 3H), 7.30-7.36 (m, 1H), 7.06 (s, 1H), 5.73 (d, J=4.0 Hz, 1H), 4.71 (d, J=4.0 Hz, 1H). 13C-NMR (CDCl3, 101 MHz) δ: 170.9, 158.3, 152.2, 146.5, 137.6, 136.0, 134.6, 133.6, 131.4, 130.6, 129.3, 128.8, 128.2, 127.8, 124.4, 121.7, 120.8, 93.6, 84.8, 81.4, 60.6, 60.1. Mass spec.: 409.1 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AS 2 1×250 mm, 10 um, 50% B isocratic, flow rate: 15 mL/min, UV 220, 25 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 329). Enantiomer 2=second enantiomer to elute from Prep (Example 330). F2(cis): 1H NMR (CDCl3, 400 MHz) δ: 8.50 (s, 1H), 8.23 (s, 1H), 7.53-7.57 (m, 3H), 7.39-7.41 (m, 3H), 7.29-7.31 (m, 1H), 7.27 (dd, J=7.9, 0.9 Hz, 1H), 7.08-7.13 (m, 1H), 6.28-6.35 (m, 2H), 5.46 (d, J=8.0 Hz, 1H). 13C-NMR (CDCl3, 101 MHz) δ: 157.8, 151.8, 146.4, 136.2, 134.2, 132.9, 131.5, 131.4, 130.2, 128.8, 128.6, 128.2, 127.8, 127.4, 125.0, 124.4, 121.7, 119.9, 93.3, 89.8, 84.6, 79.0. Mass spec.: 409.1 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralcel OD 21×250 mm, 10 um, 15% B isocratic, flow rate: 60 mL/min, UV 220, 50 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 331). Enantiomer 2=second enantiomer to elute from Prep (Example 332).
Prepared according to the same procedure as (4R,5R)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4R,5S)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4S,5R)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4S,5S)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one using 2-methoxybenzaldehyde. The material was purified by Biotage (60-80% EtOAc/Hex) to isolate the two major fractions (F1=first to elute, F2=second to elute). F1(trans): 1H NMR (CDCl3, 400 MHz) δ: 8.74 (d, J=1.5 Hz, 1H), 8.49 (d, J=2.0 Hz, 1H), 7.94 (t, J=2.0 Hz, 1H), 7.55-7.59 (m, 2H), 7.43 (dd, J=7.5, 1.3 Hz, 1H), 7.35-7.40 (m, 4H), 7.00-7.07 (m, 1H), 6.91-6.96 (m, 2H), 5.57 (d, J=5.0 Hz, 1H), 4.78 (d, J=5.0 Hz, 1H), 3.76 (s, 3H). 13C-NMR (CDCl3, 101 MHz) δ: 159.0, 155.6, 151.7, 146.6, 135.8, 135.5, 131.4, 129.7, 128.7, 128.1, 125.7, 125.6, 121.9, 120.6, 120.5, 110.3, 93.2, 85.1, 81.3, 60.5, 54.8. Mass spec.: 371.2 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AS 21×250 mm, 10 um, 30% B isocratic, flow rate: 15 mL/min, UV 220, 45 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 333). Enantiomer 2=second enantiomer to elute from Prep (Example 334). F2(cis): 1H NMR (CDCl3, 400 MHz) δ: 8.40 (d, J=2.0 Hz, 1H), 8.12 (d, J=2.0 Hz, 1H), 7.49-7.53 (m, 2H), 7.46 (t, J=2.0 Hz, 1H), 7.35-7.38 (m, 3H), 7.27 (dd, J=7.7, 0.6 Hz, 1H), 7.08-7.14 (m, 1H), 6.93 (s, 1H), 6.79-6.87 (m, 1H), 6.58 (d, J=7.8 Hz, 1H), 6.20 (d, J=8.3 Hz, 1H), 5.33 (d, J=8.5 Hz, 1H), 3.70 (s, 3H). 13C-NMR (CDCl3, 101 MHz) δ: 159.1, 154.1, 151.1, 146.9, 136.5, 132.1, 131.3, 129.3, 128.6, 128.1, 125.3, 122.7, 121.9, 120.3, 119.2, 109.2, 92.6, 85.0, 77.7, 60.1, 57.4, 54.6. Mass spec.: 371.2 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AS 21×250 mm, 10 um, 25% B isocratic, flow rate: 15 mL/min, UV 220, 40 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 335). Enantiomer 2=second enantiomer to elute from Prep (Example 336).
Prepared according to the same procedure as (4R,5R)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4R,5S)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4S,5R)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4S,5S)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one using oxazole-2-carbaldehyde. The reaction mixture was purified by silica gel chromatography (25%→55% EtOAc/DCM) to give two fractions, F1 (faster eluting, trans) and F2 (slower eluting, cis). F2(Example 337, racemic): 1H NMR (400 MHz, CD3OD) δ: 8.53 (d, J=2.0 Hz, 1H), 8.35 (d, J=2.3 Hz, 1H), 7.88-7.70 (m, 2H), 7.60-7.48 (m, 2H), 7.46-7.29 (m, 3H), 7.00 (d, J=0.8 Hz, 1H), 6.19 (d, J=9.0 Hz, 1H), 5.61 (d, J=9.0 Hz, 1H); 13C NMR (101 MHz, CD3OD) δ: 159.6, 152.3, 147.6, 141.8, 138.2, 133.5, 132.7, 130.3, 129.7, 128.1, 121.8, 94.4, 85.5, 76.0, 58.2; LC/Mass spec. (Analytical HPLC method 15): RT=2.10 min. Mass=332.2 (MH)+. Enantiomers of F1 were resolved by Prep HPLC (Chiralpak AD, EtOH/Heptane/0.1% DEA). Enantiomer 1=first enantiomer to elute from Prep (Example 338, F1 Ent1). Enantiomer 2=second enantiomer to elute from Prep (Example 339, F1 Ent2). F1 Ent1: 1H NMR (400 MHz, CDCl3) δ: 8.77 (s, 1H), 8.58 (s, 1H), 7.96 (t, J=1.9 Hz, 1H), 7.80 (d, J=0.8 Hz, 1H), 7.60-7.53 (m, 2H), 7.44-7.36 (m, 3H), 7.25 (d, J=0.5 Hz, 1H), 6.54 (s, 1H), 5.60 (d, J=6.8 Hz, 1H), 5.39 (d, J=6.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ: 157.7, 156.9, 152.1, 146.0, 140.8, 136.2, 133.1, 131.4, 128.9, 128.2, 127.6, 121.6, 93.9, 84.5, 57.0, 40.5, 13.8. Mass Spec.: 332.2 (MH)+. F1 Ent2: 1H NMR (400 MHz, CDCl3) δ: 8.77 (s, 1H), 8.59 (br. s., 1H), 7.97 (s, 1H), 7.80 (d, J=0.8 Hz, 1H), 7.65-7.48 (m, 2H), 7.47-7.31 (m, 3H), 7.25 (d, J=0.8 Hz, 1H), 6.45 (s, 1H), 5.60 (d, J=7.0 Hz, 1H), 5.40 (d, J=7.0 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ: 157.7, 156.8, 152.0, 145.9, 140.8, 136.2, 133.2, 131.4, 128.9, 128.2, 127.6, 121.6, 94.0, 84.5, 56.9, 22.3, 13.8. Mass Spec.: 332.2 (MH)+.
Prepared according to the same procedure as (4R,5R)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4R,5S)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4S,5R)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one and (4S,5S)-4-(5-(phenylethynyl)pyridin-3-yl)-5-(pyrimidin-4-yl)oxazolidin-2-one using 1-methyl-1H-pyrazole-5-carbaldehyde. The reaction mixture was purified by silica gel chromatography (0%→50% EtOAc/DCM) to give two fractions, F1 (faster eluting, trans) and F2 (slower eluting, cis). F2(Example 340, racemic): 1H NMR (400 MHz, CD3OD) δ 8.55 (d, J=1.8 Hz, 1H), 8.31 (d, J=2.0 Hz, 1H), 7.69 (t, J=1.9 Hz, 1H), 7.61-7.49 (m, 2H), 7.47-7.35 (m, 3H), 7.29 (d, J=1.8 Hz, 1H), 6.31 (d, J=8.3 Hz, 1H), 6.15 (dd, J=2.0, 0.5 Hz, 1H), 5.53 (d, J=8.3 Hz, 1H), 3.60 (s, 3H). Mass Spec.: 345.3 (MH)+. Enantiomers of F1 were resolved by Prep HPLC (Chiralpak AD, EtOH/Heptane/0.1% DEA). Enantiomer 1=first enantiomer to elute from Prep (Example 341, F1 Ent1). Enantiomer 2=second enantiomer to elute from Prep (Example 342, F1 Ent2). F1 Ent1: 1H NMR (400 MHz, CDCl3) δ 8.78 (d, J=1.5 Hz, 1H), 8.57 (s, 1H), 7.93 (s, 1H), 7.60-7.54 (m, 2H), 7.53 (d, J=1.8 Hz, 1H), 7.44-7.36 (m, 3H), 6.53 (s, 1H), 6.50 (d, J=2.0 Hz, 1H), 5.41 (d, J=7.8 Hz, 1H), 5.20 (d, J=7.8 Hz, 1H), 3.87 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 157.1, 152.2, 145.8, 138.3, 136.1, 135.8, 133.0, 131.4, 129.0, 128.2, 121.5, 121.1, 105.6, 94.2, 84.4, 58.8, 36.9, 29.3. Mass Spec.: 345.3 (MH)+. F1 Ent2: 1H NMR (400 MHz, CDCl3) δ 8.78 (s, 1H), 8.57 (br. s., 1H), 7.93 (s, 1H), 7.59-7.54 (m, 2H), 7.53 (d, J=2.0 Hz, 1H), 7.45-7.36 (m, 3H), 6.50 (d, J=1.8 Hz, 1H), 6.44 (s, 1H), 5.41 (d, J=7.8 Hz, 1H), 5.19 (d, J=7.8 Hz, 1H), 3.88 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 157.0, 152.3, 145.9, 138.3, 136.0, 135.9, 131.4, 129.0, 128.2, 121.5, 105.5, 94.1, 84.4, 58.8, 36.9, 29.3. Mass Spec.: 345.3 (MH)+.
Prepared according to the same procedure as (4S,5S)-4-methyl-5-phenyl-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one and (4R,5R)-4-methyl-5-phenyl-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one, starting with 4-fluorobenzaldehyde, 2-bromo-3-fluoropyridine. 1H-NMR (CDCl3, 500 MHz) δ: 8.85 (s, 1H), 8.70 (s, 1H), 8.50 (m, 1H), 8.03 (m, 1H), 7.55-7.52 (m, 1H), 7.40-7.37 (m, 1H), 7.22-7.20 (m, 2H), 7.14-7.11 (m, 2H), 6.69 (s, 1H), 5.45 (s, 1H), 1.37 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ: 163.3 (d, J=249), 160.4 (d, J=263), 158.2, 152.3, 147.3, 146.2, 138.1, 136.6, 131.7, 128.8, 128.1, 125.2, 123.7, 123.5, 119.5, 116.1, 90.9, 87.4, 86.7, 60.5, 22.7. Mass spec.: 392.1 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AS 21×250 mm, 10 um, 40% B isocratic, flow rate: 15 mL/min, UV 220, 60 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 343). Enantiomer 2=second enantiomer to elute from Prep (Example 344).
Prepared according to the same procedure as (4S,5S)-5-(4-fluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one and (4R,5R)-5-(4-Fluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one, starting with 2-(5-bromopyridin-3-yl)acetic acid and thiophene-2-carbaldehyde. 1H-NMR (CDCl3, 500 MHz) δ: 8.74 (d, J=1.8, 1H), 8.43 (d, J=2.1, 1H), 7.88 (m, 1H), 7.57-7.55 (m, 2H), 7.44 (m, 1H), 7.39-7.38 (m, 2H), 7.14 (bs, 1H), 7.10 (m, 1H), 7.05-7.03 (m, 1H), 5.50 (d, J=7.9, 1H), 5.04 (d, J=7.9, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 158.4, 152.8, 146.8, 138.3, 136.3, 133.4, 132.2, 131.9, 129.3, 128.7, 127.8, 127.5, 122.2, 121.2, 94.0, 85.3, 81.7, 62.7, 60.6. Mass spec.: 347.0 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 21×250 mm, 10 um, 40% B isocratic, flow rate: 15 mL/min, UV 220, min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 345). Enantiomer 2=second enantiomer to elute from Prep (Example 346).
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one and (4S,5S)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one, starting with (4R,5R)-4-(4-bromopyridin-2-yl)-5-(4-fluorophenyl)oxazolidin-2-one, (4S,5S)-4-(4-bromopyridin-2-yl)-5-(4-fluorophenyl)oxazolidin-2-one and 1-chloro-3-ethnylbenzene. 1H-NMR (CDCl3, 500 MHz) δ: 8.67 (d, J=5.2, 1H), 7.57 (m, 1H), 7.53 (s, 1H), 7.48-7.45 (m, 3H), 7.43-7.41 (m, 2H), 7.37-7.34 (m, 1H), 7.16-7.13 (m, 2H), 6.08 (s, 1H), 5.60 (d, J=5.8, 1H), 4.93 (d, J=5.8, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 163.1 (d, J=243), 130.0, 129.9, 158.6, 158.5, 150.4, 134.6, 134.0, 132.7, 131.9, 130.2, 130.0, 129.9, 127.8, 127.7, 125.5, 123.5, 122.5, 116.2, 116.0, 93.5, 87.2, 83.3, 64.9. Mass spec.: 393.0 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 21×250 mm, 10 um, 20% B isocratic, flow rate: 15 mL/min, UV 220, 30 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 347). Enantiomer 2=second enantiomer to elute from Prep (Example 348).
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one and (4S,5S)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one, starting with (4R,5R)-4-(4-bromopyridin-2-yl)-5-(4-fluorophenyl)oxazolidin-2-one, (4S,5S)-4-(4-bromopyridin-2-yl)-5-(4-fluorophenyl)oxazolidin-2-one and 1-chloro-4-ethnylbenzene. 1H-NMR (CDCl3, 500 MHz) δ: 8.66 (d, J=4.3, 1H), 7.52-7.50 (m, 3H), 7.47-7.45 (m, 2H), 7.41-7.38 (m, 3H), 7.16-7.13 (m, 2H), 6.21 (s, 1H), 5.60 (d, J=5.8, 1H), 4.92 (d, J=5.8, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 163.1 (d, J=248.6), 158.7, 158.5, 150.4, 135.9, 134.1, 133.3, 132.9, 129.1, 127.8, 127.7, 125.5, 122.5, 120.3, 116.2, 116.0, 94.0, 87.2, 83.3, 64.9, 50.5, 42.4. Mass spec.: 392.9 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 21×250 mm, 10 um, 17% B isocratic, flow rate: 15 mL/min, UV 220, 35 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 349). Enantiomer 2=second enantiomer to elute from Prep (Example 350).
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one and (4S,5S)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one, starting with (4R,5R)-4-(4-bromopyridin-2-yl)-5-(4-fluorophenyl)oxazolidin-2-one, (4S,5S)-4-(4-bromopyridin-2-yl)-5-(4-fluorophenyl)oxazolidin-2-one and 1-chloro-2-ethynylbenzene. 1H-NMR (CDCl3, 500 MHz) δ: 8.68 (d, J=5.5, 1H), 7.62-7.60 (m, 1H), 7.55 (bs, 1H), 7.50-7.45 (m, 4H), 7.39-7.36 (m, 1H), 7.33-7.30 (m, 1H), 7.16-7.13 9 m, 2H), 6.07 (s, 1H), 5.62 (d, J=5.8, 1H), 4.93 (d, J=5.8, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 163.1 (d, J=248.6), 158.6, 158.4, 150.4, 136.5, 134.0, 133.7, 132.8, 130.7, 129.7, 127.8, 127.7, 126.8, 125.6, 122.6, 121.9, 116.2, 116.0, 91.7, 83.3, 64.9, 42.2. Mass spec.: 392.9 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 21×250 mm, 10 um, 45% B isocratic, flow rate: 15 mL/min, UV 220, 35 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 351). Enantiomer 2=second enantiomer to elute from Prep (Example 352).
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one and (4S,5S)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one, starting with (4R,5R)-4-(4-bromopyridin-2-yl)-5-(4-fluorophenyl)oxazolidin-2-one, (4S,5S)-4-(4-bromopyridin-2-yl)-5-(4-fluorophenyl)oxazolidin-2-one and 1-ethynyl-2-fluorobenzene. 1H NMR (CDCl3, 500 MHz) δ: 8.62-8.71 (m, 1H), 7.51-7.61 (m, 2H), 7.38-7.50 (m, 4H), 7.09-7.23 (m, 4H), 6.27 (s, 1H), 5.61 (d, J=5.8 Hz, 1H), 4.92 (d, J=5.8 Hz, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 163.1 (d, J=247.6), 163.0 (d, J=253.4), 158.7, 158.4, 150.4, 134.0, 133.8, 132.8, 131.5, 127.8, 127.7, 125.6, 124.4, 122.6, 116.2, 116.0, 115.8, 110.7, 91.1, 88.5, 83.3, 64.9. Mass spec.: 377.0 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 21×250 mm, 10 um, 12% B isocratic, flow rate: 15 mL/min, UV 220, 45 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 353). Enantiomer 2=second enantiomer to elute from Prep (Example 354).
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one and (4S,5S)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one, starting with (4R,5R)-4-(4-bromopyridin-2-yl)-5-(4-fluorophenyl)oxazolidin-2-one, (4S,5S)-4-(4-bromopyridin-2-yl)-5-(4-fluorophenyl)oxazolidin-2-one and 1-ethynyl-3-fluorobenzene. 1H NMR (CDCl3, 500 MHz) δ: 8.67 (d, J=4.9 Hz, 1H), 7.53 (s, 1H), 7.44-7.49 (m, 2H), 7.40-7.43 (m, 1H), 7.36-7.40 (m, 2H), 7.26-7.28 (m, 1H), 7.12-7.17 (m, 3H), 6.21 (s, 1H), 5.60 (d, J=5.8 Hz, 1H), 4.93 (d, J=5.8 Hz, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 163.1 (d, J=247.6), 162.5 (d, J=247.6), 158.7, 158.5, 150.4, 134.0, 132.7, 130.4, 130.3, 128.0, 127.8, 125.5, 123.7, 122.6, 119.0, 118.8, 117.1, 116.2, 93.7, 87.0, 83.3, 64.9. Mass spec.: 377.0 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 21×250 mm, 10 um, 10% B isocratic, flow rate: 15 mL/min, UV 220, 55 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 355). Enantiomer 2=second enantiomer to elute from Prep (Example 356).
Prepared according to the same procedure as (4R,5R)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one and (4S,5S)-5-phenyl-4-(4-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one, starting with (4R,5R)-4-(4-bromopyridin-2-yl)-5-(4-fluorophenyl)oxazolidin-2-one, (4S,5S)-4-(4-bromopyridin-2-yl)-5-(4-fluorophenyl)oxazolidin-2-one and 1-ethynyl-4-fluorobenzene. 1H NMR (CDCl3, 500 MHz) δ: 8.65 (d, J=4.9 Hz, 1H), 7.55-7.60 (m, 2H), 7.52 (s, 1H), 7.44-7.49 (m, 2H), 7.40 (dd, J=5.0, 1.4 Hz, 1H), 7.08-7.17 (m, 4H), 6.27 (s, 1H), 5.59 (d, J=5.8 Hz, 1H), 4.92 (d, J=5.8 Hz, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 163.3 (d, J=252.4), 163.1 (d, J=248.6), 158.7, 158.5, 150.3, 134.2, 134.1, 134.0, 133.0, 127.8, 127.7, 125.4, 122.5, 118.0, 117.9, 116.2, 116.0, 94.2, 86.1, 83.3, 65.0. Mass spec.: 377.0 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 21×250 mm, 10 um, 12% B isocratic, flow rate: 15 mL/min, UV 220, 55 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 357). Enantiomer 2=second enantiomer to elute from Prep (Example 358).
Prepared according to the same procedure as (4R,5R)-5-(3-fluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one, starting with diethyl-4-chlorobenzylphosphonate. 1H NMR (CDCl3, 500 MHz) δ: 8.80 (s, 1H), 8.42 (s, 1H), 7.89 (t, J=2.1 Hz, 1H), 7.55-7.63 (m, 2H), 7.38-7.46 (m, 5H), 7.27 (d, J=8.5 Hz, 2H), 6.18 (s, 1H), 5.30 (d, J=7.3 Hz, 1H), 4.80 (d, J=7.6 Hz, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 158.3, 153.1, 146.9, 136.3, 135.7, 134.9, 133.4, 131.9, 129.6, 129.3, 128.7, 127.4, 122.1, 121.5, 94.3, 85.1, 62.6. Mass spec.: 374.8 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 2 1×250 mm, 10 um, 25% B isocratic, flow rate: 15 mL/min, UV 220, 75 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 359). Enantiomer 2=second enantiomer to elute from Prep (Example 360).
Prepared according to the same procedure as (4R,5R)-5-(3-fluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one, starting with 1-(bromomethyl)-3-chlorobenzene. 1H NMR (CDCl3, 500 MHz) δ: 8.81 (br. s., 1H), 8.43 (br. s., 1H), 7.91 (t, J=2.0 Hz, 1H), 7.54-7.64 (m, 2H), 7.36-7.47 (m, 6H), 7.13-7.21 (m, 1H), 6.39 (s, 1H), 5.30 (d, J=7.3 Hz, 1H), 4.83 (d, J=7.3 Hz, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 158.3, 153.1, 146.9, 138.6, 136.3, 135.4, 133.5, 131.9, 130.6, 129.9, 129.3, 128.7, 126.1, 124.1, 122.1, 121.5, 94.2, 85.1, 84.9, 62.4, 53.6. Mass spec.: 374.8 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 21×250 mm, 10 um, 25% B isocratic, flow rate: 15 mL/min, UV 220, 60 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 361). Enantiomer 2=second enantiomer to elute from Prep (Example 362).
Prepared according to the same procedure as (4R,5R)-5-(3-fluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one, starting with 1-(bromomethyl)-2-chlorobenzene. 1H NMR (CDCl3, 500 MHz) δ: 8.79 (d, J=1.5 Hz, 1H), 8.55 (d, J=2.1 Hz, 1H), 7.98 (t, J=2.1 Hz, 1H), 7.56-7.62 (m, 3H), 7.36-7.48 (m, 6H), 6.08 (br. s., 1H), 5.77 (d, J=4.6 Hz, 1H), 4.78 (d, J=4.6 Hz, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 158.5, 152.9, 147.1, 136.3, 135.4, 134.8, 131.9, 131.7, 130.5, 130.3, 129.2, 128.6, 127.7, 127.0, 122.2, 121.3, 94.0, 85.3, 82.1, 61.2. Mass spec.: 374.8 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 21×250 mm, 10 um, 25% B isocratic, flow rate: 15 mL/min, UV 220, 55 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 363). Enantiomer 2=second enantiomer to elute from Prep (Example 364).
Prepared according to the same procedure as (4R,5R)-5-(3-fluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one, starting with 4-(bromomethyl)benzonitrile. 1H NMR (CDCl3, 500 MHz) δ: 8.80 (d, J=1.8 Hz, 1H), 8.44 (d, J=2.1 Hz, 1H), 7.90 (t, J=2.0 Hz, 1H), 7.75 (d, J=8.5 Hz, 2H), 7.53-7.63 (m, 2H), 7.35-7.48 (m, 5H), 5.39 (d, J=7.3 Hz, 1H), 4.77 (d, J=7.3 Hz, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 158.1, 153.2, 146.8, 141.7, 136.4, 133.3, 133.2, 131.9, 129.4, 128.7, 126.4, 122.0, 121.6, 118.1, 113.6, 94.5, 85.0, 84.5, 62.4, 43.8, 15.0. Mass spec.: 365.9 (MH)+. The sample was further purified by SFC Prep HPLC (Chiralpak AS-H, 20% MeOH in CO2).
Prepared according to the same procedure as (4R,5R)-5-(3-fluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one, starting with diethyl (6-bromopyridin-2-yl)methylphosphonate and nicotinaldehyde. 1H NMR (CDCl3, 500 MHz) δ: 8.78 (d, J=2.1 Hz, 1H), 8.67 (dd, J=4.9, 1.5 Hz, 1H), 7.92 (dt, J=7.9, 1.7 Hz, 1H), 7.78-7.84 (m, 1H), 7.62-7.67 (m, 2H), 7.58 (d, J=7.6 Hz, 1H), 7.51 (d, J=7.9 Hz, 1H), 7.38-7.45 (m, 4H), 5.84 (br. s., 1H), 5.47 (d, J=5.2 Hz, 1H), 5.35 (d, J=5.5 Hz, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 157.9, 157.1, 150.5, 148.6, 143.7, 137.6, 134.2, 132.2, 129.4, 128.6, 127.5, 124.2, 122.0, 120.0, 90.2, 88.3, 84.5, 77.7, 59.4. Mass spec.: 342.2 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 21×250 mm, 10 um, 55% B isocratic, flow rate: 15 mL/min, UV 220, 30 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 366). Enantiomer 2=second enantiomer to elute from Prep (Example 367).
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-Methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (4R,5R)-4-(6-bromopyridin-2-yl)-5-(3-fluorophenyl)oxazolidin-2-one, (4S,5S)-4-(6-bromopyridin-2-yl)-5-(3-fluorophenyl)oxazolidin-2-one and 2-bromopyrazine. 1H NMR (CDCl3, 500 MHz) δ: 8.89 (d, J=1.5 Hz, 1H), 8.64-8.70 (m, 1H), 8.60 (d, J=2.7 Hz, 1H), 7.87 (t, J=7.8 Hz, 1H), 7.68 (d, J=7.6 Hz, 1H), 7.44-7.52 (m, 3H), 7.15 (t, J=8.5 Hz, 2H), 5.96 (br. s., 1H), 5.62 (d, J=5.8 Hz, 1H), 4.96 (d, J=5.5 Hz, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 163.2 (d, J=248.6), 159.1, 158.4, 148.3, 144.8, 143.9, 142.5, 139.4, 138.0, 133.9, 128.0, 127.8, 120.8, 116.2, 116.1, 91.0, 85.8, 83.3, 77.7, 64.9, 58.6. Mass spec.: 361.1 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 2 1×250 mm, 10 um, 50% B isocratic, flow rate: 15 mL/min, UV 254, 30 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 368). Enantiomer 2=second enantiomer to elute from Prep (Example 369).
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-Methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (4R,5R)-4-(6-bromopyridin-2-yl)-5-(3-fluorophenyl)oxazolidin-2-one, (4S,5S)-4-(6-bromopyridin-2-yl)-5-(3-fluorophenyl)oxazolidin-2-one and 2-bromo-3-fluoropyridine. 1H NMR (CDCl3, 500 MHz) δ: 8.52 (dt, J=4.7, 1.3 Hz, 1H), 7.83 (t, J=7.8 Hz, 1H), 7.60-7.68 (m, 1H), 7.36-7.57 (m, 5H), 7.08-7.18 (m, 2H), 6.54 (br. s., 1H), 5.63 (d, J=5.5 Hz, 1H), 4.97 (d, J=5.5 Hz, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 164.1 (d, J=247.6), 160.6 (d, J=264), 159.2, 158.7, 146.2, 142.6, 137.9, 134.1, 131.6, 127.8, 127.7, 125.2, 123.6, 123.5, 120.5, 116.1, 116.0, 93.2, 83.2, 82.6, 64.8, 58.6. Mass spec.: 378.1 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 21×250 mm, 10 um, 40% B isocratic, flow rate: 15 mL/min, UV 220, 40 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 370). Enantiomer 2=second enantiomer to elute from Prep (Example 371).
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-Methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with (4R,5R)-4-(6-bromopyridin-2-yl)-5-(3-fluorophenyl)oxazolidin-2-one, (4S,5S)-4-(6-bromopyridin-2-yl)-5-(3-fluorophenyl)oxazolidin-2-one and 4-bromo-2-fluoropyridine. 1H NMR (CDCl3, 500 MHz) δ: 8.29 (d, J=5.2 Hz, 1H), 7.87 (t, J=7.8 Hz, 1H), 7.61 (d, J=7.6 Hz, 1H), 7.43-7.51 (m, 3H), 7.38 (d, J=5.2 Hz, 1H), 7.09-7.21 (m, 3H), 6.24 (s, 1H), 5.61 (d, J=5.5 Hz, 1H), 4.96 (d, J=5.8 Hz, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 163.7 (d, J=239), 163.2 (d, J=248.6), 148.2, 148.1, 142.5, 138.1, 135.1, 133.9, 127.8, 123.8, 120.9, 116.3, 116.1, 112.3, 112.0, 93.0, 85.7, 83.3, 64.9, 58.6, 53.6. Mass spec.: 378.1 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralcel OD 21×250 mm, 10 um, 15% B isocratic, flow rate: 15 mL/min, UV 220, 50 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 372). Enantiomer 2=second enantiomer to elute from Prep (Example 373).
Prepared according to the same procedure as (4S,5S)-4-(6-(phenylethynyl)pyridin-2-yl)-5-(pyridin-3-yl)oxazolidin-2-one and (4R,5R)-4-(6-(phenylethynyl)pyridin-2-yl)-5-(pyridin-3-yl)oxazolidin-2-one, starting with diethyl (5-bromo-2-fluoropyridin-3-yl)methylphosphonate and 2-fluorobenzaldehyde. 1H NMR (CDCl3, 500 MHz) δ: 8.35 (d, J=1.5 Hz, 1H), 8.12 (dd, J=8.9, 2.1 Hz, 1H), 7.45-7.61 (m, 3H), 7.34-7.44 (m, 4H), 7.19-7.27 (m, 1H), 7.08-7.16 (m, 1H), 5.59 (d, J=5.8 Hz, 1H), 5.09 (d, J=5.8 Hz, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 160.1 (d, J=247.6), 159.8 (d, J=243.8), 159.1, 150.4, 150.3, 141.1, 131.8, 131.3, 129.2, 128.6, 127.6, 124.9, 124.7, 122.1, 121.5, 121.3, 119.5, 116.2, 116.0, 93.5, 84.2, 79.6, 57.5. Mass spec.: 377.1 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralpak AD 2 1×250 mm, 10 um, 45% B isocratic, flow rate: 15 mL/min, UV 220, 40 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 374). Enantiomer 2=second enantiomer to elute from Prep (Example 375).
Prepared according to the same procedure as (+)-(4R,5R)-5-(3-methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one, starting with a mixture of 4-(6-bromopyridin-2-yl)-5-(2-fluorophenyl)-4-methyloxazolidin-2-one and 4-(6-chloropyridin-2-yl)-5-(2-fluorophenyl)-4-methyloxazolidin-2-one. The material was purified by prep HPLC (Phenomenex Luna Column, TFA/MeOH) to isolate the two major fractions (F1=first to elute, F2=second to elute). F1(cis): 1H NMR (CDCl3, 500 MHz) δ: 7.57-7.64 (m, 2H), 7.36-7.44 (m, 4H), 7.23 (d, J=7.3 Hz, 1H), 7.10-7.17 (m, 1H), 6.90-7.02 (m, 3H), 6.84-6.89 (m, 1H), 6.43 (s, 1H), 5.96 (s, 1H), 2.04 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ: 159.8 (d, J=247.6), 159.4, 159.1, 142.5, 136.3, 132.2, 130.3, 129.2, 128.5, 127.7, 126.0, 124.0, 122.6, 122.2, 119.6, 115.1, 114.9, 89.6, 88.4, 82.5, 66.4, 60.6, 27.1. Mass spec.: 373.2 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralcel OD 21×250 mm, 10 um, 13% B isocratic, flow rate: 15 mL/min, UV 220, 60 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 376). Enantiomer 2=second enantiomer to elute from Prep (Example 377). F2(trans): 1H NMR (CDCl3, 500 MHz) δ: 7.80 (t, J=7.8 Hz, 1H), 7.63-7.69 (m, 2H), 7.50-7.60 (m, 3H), 7.38-7.45 (m, 4H), 7.29-7.32 (m, 1H), 7.11-7.18 (m, 1H), 6.17-6.26 (m, 2H), 1.34 (s, 3H). 13C-NMR (CDCl3, 126 MHz) δ: 161.0 (d, J=246.7), 159.1, 158.5, 143.0, 137.5, 132.2, 130.7, 129.3, 128.5, 128.1, 126.6, 124.7, 123.3, 122.2, 118.5, 115.7, 115.4, 89.7, 88.9, 81.2, 65.2, 53.5, 14.2. Mass spec.: 373.2 (MH)+. Enantiomers were resolved by Prep HPLC (Chiralcel OJ 21×250 mm, 10 um, 15% B isocratic, flow rate: 15 mL/min, UV 220, 50 min run, solvent A: 0.1% diethylamine/heptane, solvent B: ethanol). Enantiomer 1=first enantiomer to elute from Prep (Example 378). Enantiomer 2=second enantiomer to elute from Prep (Example 379).
(4R,5R)-5-(3-Methoxyphenyl)-4-(3-(phenylethynyl)phenyl)oxazolidin-2-one in dichloromethane (3 mL) was cooled to −78° C. under nitrogen, boron tribromide (0.406 mL, 0.406 mmol) was added slowly. The reaction mixture was stirred at −78° C. for one hour and then allowed to warm to room temperature overnight. The reaction was quenched by addition of a 2% sodium carbonate solution and extracted with dichloromethane. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. Biotage purification eluting with 40% ethyl acetate in hexane gave 37 mg (71.5% yield). 1H NMR (CDCl3, 500 MHz) δ: 7.58 (s, 1H), 7.48-7.54 (m, 3H), 7.44 (s, 1H), 7.31-7.39 (m, 4H), 7.18 (dt, J=7.7, 3.9 Hz, 2H), 7.00 (s, 1H), 6.88 (dd, J=8.0, 1.7 Hz, 1H), 6.64 (d, J=7.6 Hz, 1H), 6.41 (s, 1H), 5.20 (d, J=7.3 Hz, 1H), 4.73 (d, J=7.3 Hz, 1H). 13C-NMR (CDCl3, 126 MHz) δ: 171.5, 159.6, 157.1, 138.7, 138.5, 132.1, 131.7, 130.2, 129.4, 129.3, 128.6, 128.4, 126.3, 124.3, 122.8, 118.0, 116.7, 112.3, 90.4, 88.7, 86.1, 64.5, 60.6. Mass spec.: 356.2 (MH)+.
To a mixture of (4R,5R)-4-(5-bromopyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one (33 mg, 0.093 mmol) in triethylamine (Volume: 1 mL) was bubbled nitrogen for 20 min followed by the addition of 1-ethynyl-4-methylbenzene (13 mg; 0.112 mmol) bis(triphenylphosphine)palladium (II) chloride (4.89 mg, 6.97 μmol), triphenylphosphine (4.39 mg, 0.017 mmol), and copper (I) iodide (5.31 mg, 0.028 mmol). After 5 min bubbling nitrogen, the vessel was capped and placed in a 70° C. bath. After 18 h, the reaction was allowed to cool to ambient temperature, concentrated and dissolved in 0.25 mL dimethylformamide/0.5 mL methanol and purified via preparative liquid chromatography (Sunfire C18 OBD 30×100 mm 5 μm, A=95% H2O/5% Acetonitrile, B=95% Acetonitrile/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=20% B, 8.0 min=100% B, 13.0 min=100% B, Flow rate=40 mL/min) providing (4R,5R)-5-(2,5-difluorophenyl)-4-(5-(p-tolylethynyl)pyridin-3-yl)oxazolidin-2-one (25 mg; 67%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ ppm 8.81 (1H, br. s.), 8.54 (1H, br. s.), 7.90 (1H, br. s.), 7.34-7.55 (3H, m), 7.20-7.32 (1H, m), 7.17 (1H, d, J=7.93 Hz), 6.93-7.13 (2H, m), 6.46 (1H, br. s.), 5.53 (1H, d, J=5.19 Hz), 4.82 (1H, d, J=4.88 Hz), 2.38 (3H, s). Mass Spectral Anal. Calcd. for [M+H]+ C23H16F2N2O2: 391.12. found 391.08. Chiral HPLC retention time (Chiralpak AS-H analytical column, 4.6×250 mm, 5 μm, Mobile Phase: A=100% Heptane with 0.1% Diethylamine, B=100% Ethanol, Flow rate: 1.0 mL/min, 30% A Isocratic): 3.57 min.
The following examples were prepared using a modification of the procedure describing the preparation of (4R,5R)-5-(2,5-difluorophenyl)-4-(5-(p-tolylethynyl)pyridin-3-yl)oxazolidin-2-one employing the appropriately substituted commercially available aryl acetylene:
Number | Structure | Analytical Data |
Example 382 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.80 (1 H, br. s.), 8.53 (1 H, br. s.), 7.89 (1 H, br. s.), 7.49 (2 H, d, J = 8.85 Hz), 7.15-7.34 (1 H, m), 7.00-7.15 (2 H, m), 6.89 (2 H, d, J = 8.55 Hz), 6.25 (1 H, br. s.), 5.54 (1 H, d, J = 4.88 Hz), 4.82 (1 H, d, J = 4.27 Hz), 3.84 (3 H, s). Mass Spectral Anal. Calcd. for [M + H]+ C23H16F2N2O3: 407.11; found 407.00. Chiral HPLC retention time (Chiralpak |
AS-H analytical column, 4.6 × | ||
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-((4-methoxyphenyl) | 250 mm, 51 μm, Mobile Phase: A = | |
ethynyl)pyridin-3-yl)oxazolidin-2-one | 100% Heptane with 0.1% | |
Diethylamine, B = 100% | ||
Ethanol, Flow rate. 1 0 mL/min, | ||
30% A Isocratic): 5.09 min. | ||
Example 383 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.78 (1 H, s), 8.52 (1 H, s), 7.91 (1 H, s), 7.66 (1 H, d, J = 1.83 Hz), 7.41-7.53 (2 H, m), 7.35-7.43 (1 H, m), 7.32 (1 H, t, J = 7.32 Hz), 7.03-7.16 (1 H, m), 5.66 (1 H, br. s.), 5.55 (1 H, d, J = 5.49 Hz), 4.81 (1 H, d, J = 5.19 Hz), Mass Spectral Anal. Calcd. for [M + H]+ C22H12Cl2F2N2O2: 445.02; found 445.10. |
(4R,5R)-4-(5-((3,4- | ||
dichlorophenyl)ethynyl)pyridin-3-y1)-5-(2,5- | ||
difluorophenyl)oxazolidin-2-one | ||
Example 384 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.84 (1 H, br. s.), 8.55 (1 H, br. s.), 7.91 (1 H, br. s.), 7.45- 7.54 (2 H, m), 7.41 (2 H, d, J = 8.55 Hz), 7.20-7.28 (1 H, m), 7.03-7.15 (2 H, m), 5.58- 5.70 (1 H, m), 5.56 (1 H, d, J = 5.49 Hz), 4.82 (1 H, d, J = 5.19 Hz), 1.33 (9 H, s), Mass Spectral Anal. Calcd. for [M + H]+ C26H22F2N2O2: 433.16; found 433.2. Chiral HPLC retention time (Chiralpak AS-H analytical column, 4.6 × 100 mm, 51. μm, Mobile Phase: A = |
100% Heptane with 0.1% | ||
(4R,5R)-4-(5-((4-tert- | Diethylamine, B = 100% | |
butylphenyl)ethynyl)pyridin-3-y1)-5-(2,5- | Ethanol, Flow rate. 1 0 mL/min, | |
difluorophenyl)oxazolidin-2-one | 50% A Isocratic): 2.20 min | |
Example 385 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.79 (1 H, br. s.), 8.52 (1 H, br. s.), 7.91 (1 H, s), 7.56 (1 H, t, J = 1.53 Hz), 7.42-7.48 (1 H, m), 7.35-7.41 (1 H, m), 7.29-7.35 (1 H, m), 7.20-7.29 (1 H, m), 7.06-7.15 (2 H, m), 5.56 (1 H, d, J = 5.49 Hz), 5.36 (1 H, s), 4.82 (1 H, d, J = 5.49 Hz), Mass Spectral Anal. Calcd. for [M + H]+ C22H13ClF2N2O2: 411.06; found 411.20. Chiral HPLC retention time (Chiralpak AS-H analytical column, 4.6 × 100 mm, 51 μm, Mobile Phase: A = |
100% Heptane with 0.1% | ||
(4R,5R)-4-(5-((3-chlorophenyl)ethynyl)pyridin-3- | Diethylamine, B = 100% | |
yl)-5-(2,5-difluorophenyl)oxazolidin-2-one | Ethanol, Flow rate. 1 0 mL/min, | |
40% A Isocratic): 3.05 min | ||
Example 386 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.81 (1 H, d, J = 1.83 Hz), 8.53 (1 H, d, J = 1.83 Hz), 7.94 (1 H, t, J = 2.14 Hz), 7.84 (1 H, s), 7.74 (1 H, d, J = 7.63 Hz), 7.65 (1 H, d, J = 7.63 Hz), 7.46- 7.59 (1 H, m), 7.16-7.34 (1 H, m), 7.03-7.18 (2 H, m), 5.56 (1 H, d, J = 5.49 Hz), 5.37 (1 H, s), 4.82 (1 H, d, J = 5.49 Hz), Mass Spectral Anal. Calcd. for [M + H]+ C23H13F5N2O2: 445.09; found 445.20. Chiral HPLC retention time (Chiralpak AS-H analytical column, 4.6 × |
100 mm, 5 μm, Mobile Phase: A = | ||
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-((3- | 100% Heptane with 0.1% | |
(trifluoromethyl)phenyl)ethynyl) | Diethylamine, B = 100% | |
pyridin-3-yl)oxazolidin-2-one | Ethanol, Flow rate. 1.0 mL/min, | |
40% A Isocratic): 2.40 min | ||
Example 387 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.77 (1 H, br. s.), 8.51 (1 H, br. s.), 7.93 (1 H, s), 7.30- 7.45 (2 H, m), 7.15-7.30 (3 H, m), 6.98-7.15 (2 H, m), 6.61 (1 H, s), 5.54 (1 H, d, J = 5.49 Hz), 4.84 (1 H, d, J = 5.49 Hz), 2.36 (3 H, s), Mass Spectral Anal. Calcd. for [M + H]+ C23H16F2N2O2: 391.12; found 391.20 |
(4R,5R)-5-(2,5-difluorophenyl)-4- | ||
(5-(m-tolylethynyl)pyridin-3-yl)oxazolidin-2-one | ||
Example 388 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.85 (1 H, br. s.), 8.31- 8.70 (1 H, br. s.), 7.92 (1 H, br. s.), 7.48 (2 H, d, J = 8.24 Hz), 7.36 (2 H, d, J = 8.55 Hz), 7.18- 7.30 (1 H, m), 6.97-7.16 (2 H, m), 6.27 (1 H, br. s.), 5.55 (1 H, d, J = 4.88 Hz), 4.84 (1 H, d, J = 4.27 Hz). Mass Spectral Anal. Calcd. for [M + H]+ C22H13ClF2N2O2: 411.1; found 411.0 |
(4R,5R)-4-(5-((4-chlorophenyl)ethynyl)pyridin-3- | ||
y1)-5-(2,5-difluorophenyl)oxazolidin-2-one | ||
To a slurry of (4R,5R)-5-(2,5-difluorophenyl)-4-(5-ethynylpyridin-3-yl)oxazolidin-2-one (50 mg, 0.167 mmol) in Triethylamine (Volume: 2 mL) was bubbled nitrogen for 20 min at which time 1-bromo-3,5-dichlorobenzene (49 mg, 0.22 mmol) was added with continued nitrogen bubbling for 5 min before adding bis(triphenylphosphine) palladium (II) chloride (8.8 mg, 0.012 mmol), triphenylphosphine (7.9 mg, 0.030 mmol), and copper (I) iodide (9.5 mg, 0.050 mmol) together in 1 portion. After 5 min additional nitrogen bubbling, the vessel was capped and placed in a 70° C. bath. After 18 h, the reaction was cooled, concentrated and diluted with methanol and purified via preparative liquid chromatography (Sunfire C18 OBD 30×100 mm 5 μm, A=95% H2O/5% Acetonitrile, B=95% Acetonitrile/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=20% B, 8.0 min=100% B, 13.0 min=100% B, Flow rate=40 mL/min) providing (4R,5R)-4-(5-((3,5-dichlorophenyl)ethynyl)pyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one (24 mg; 32%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ ppm 8.78 (1H, d, J=1.83 Hz), 8.54 (1H, d, J=1.83 Hz), 7.79-7.97 (1H, m), 7.45 (2H, d, J=1.83 Hz), 7.39 (1H, t, J=1.83 Hz), 7.18-7.32 (2H, m), 7.00-7.18 (1H, m), 5.55 (1H, d, J=5.49 Hz), 5.40 (1H, s), 4.82 (1H, d, J=5.49 Hz), Mass Spectral Anal. Calcd. for [M+H]+ C22H12Cl2F2N2O2: 445.02. found 445.10.
The following examples were prepared using a modification of the procedure describing the preparation of (4R,5R)-4-(5-((3,5-dichlorophenyl)ethynyl)pyridin-3-yl)-5-(2,5-difluorophenyl)oxazolidin-2-one employing the appropriately substituted commercially available aryl halide:
Example 390 |
|
LC/MS (Phenomenex Luna C18 30 × 2 mm 31 μm, A = 90% H2O/10% Acetonitrile, B = 90% Acetonitrile/10% H2O, Modifier 0.1% TFA, 0.00 min = 0% B, 2.0 min = 100% B, 3.0 min = 100% B, Flow rate = 1 mL/min) 1.68 min, Anal. Calcd. for [M + H]+ C23H16F2N2O2: 391.12; found 391.20 |
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-(o- | ||
tolylethynyl)pyridin-3-yl)oxazolidin-2-one | ||
Example 391 |
|
LC/MS (Phenomenex Luna C18 30 × 2 mm 3 μm, A = 90% H2O/10% Acetonitrile, B = 90% Acetonitrile/10% H2O, Modifier 0.1% TFA, 0.00 min = 0% B, 2.0 min = 100% B, 3.0 min = 100% B, Flow rate = 1 mL/min) 1.56 min, Anal. Calcd. for [M + H]+ C23H13F2N3O2: 402.1; found 402.2 |
4-((5-((4R,5R)-5-(2,5-difluorophenyl)-2-oxooxazolidin- | ||
4-yl)pyridin-3-yl)ethynyl)benzonitrile | ||
Example 392 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.85 (2 H, br. s.), 8.23 (1 H, br. s.), 7.60 (1 H, d, J = 7.32 Hz), 7.47 (1 H, d, J = 7.93 Hz), 7.36 (1 H, t, J = 7.63 Hz), 7.19- 7.33 (2 H, m), 6.99- 7.19 (2 H, m), 6.74 (1 H, br. s.), 5.60 (1 H, d, J = 1.22 Hz), 5.00 (1 H, br. s. Mass Spectral Anal. Calcd. for |
[M + H]+ | ||
(4R,5R)-4-(5-((2-chlorophenyl)ethynyl)pyridin-3- | C22H13ClF2N2O2: | |
yl)-5-(2,5-difluorophenyl)oxazolidin-2-one | 411.1; found 411.2 | |
Example 393 |
|
1H NMR (500 MHz, CDCl3) δ ppm 9.28 (1 H, s), 9.25 (1 H, d, J = 5.19 Hz), 8.85 (1 H, d, J= 1.83 Hz), 8.61 (1 H, d, J = 2.14 Hz), 7.99 (1 H, t, J = 1.98 Hz), 7.58 (1 H, dd, J = 5.34, 2.29 Hz), 7.21-7.30 (1 H, m), 7.04-7.16 (2 H, m), 5.83 (1 H, s), 5.56 (1 H, d, J = 5.49 Hz), 4.85 (1 H, d, J = 5.19 |
Hz). Mass Spectral | ||
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-(pyridazin-4- | Anal. Calcd. for | |
ylethynyl)pyridin-3-yl)oxazolidin-2-one | [M + H]+ C20H12F2N4O2: | |
379.1; found 379.2 | ||
Example 394 |
|
LC/MS (Phenomenex Luna C18 30 × 2 mm 3 μm, A = 90% H2O/10% Acetonitrile, B = 90% Acetonitrile/10% H2O, Modifier 0.1% TFA, 0.00 min = 0% B, 2.0 min = 100% B, 3.0 min = 100% B, Flow rate = 1 mL/min) 1.40 min, Anal. Calcd. for [M + H]+ C20H12F2N4O2: 379.1; found 379.2 |
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-(pyrimidin-4- | ||
ylethynyl)pyridin-3-yl)oxazolidin-2-one | ||
Example 395 |
|
1H NMR (500 MHz, CDCl3) δ ppm 9.19 (1 H, s), 8.90 (2 H, s), 8.82 (1 H, d, J = 2.14 Hz), 8.57 (1 H, d, J = 2.14 Hz), 7.96 (1 H, t, J = 2.14 Hz), 7.18-7.33 (1 H, m), 7.03-7.16 (2 H, m), 6.15 (1 H, s), 5.55 (1 H, d, J = 5.49 Hz), 4.85 (1 H, d, J = 5.49 Hz), Mass Spectral Anal. Calcd. |
for [M + H]+ | ||
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-(pyrimidin-5- | C20H12F2N4O2: 379.1; | |
ylethynyl)pyridin-3-yl)oxazolidin-2-one | found 379.2 | |
Example 396 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.87 (1 H, d, J = 1.83 Hz), 8.81 (1 H, d, J = 1.22 Hz), 8.60-8.65 (1 H, m), 8.59 (1 H, d, J = 2.14 Hz), 8.56 (1 H, d, J = 2.44 Hz), 8.00 (1 H, t, J = 1.98 Hz), 7.19- 7.30 (1 H, m), 7.02- 7.17 (2 H, m), 5.99 (1 H, s), 5.55 (1 H, d, J = 5.80 Hz), 4.84 (1 H, |
d, J = 5.80 Hz), Mass | ||
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-(pyrazin-2- | Spectral Anal. Calcd. | |
ylethynyl)pyridin-3-yl)oxazolidin-2-one | for [M + H]+ | |
C20H12F2N4O2: 379.1; | ||
found 379.2 | ||
(4R,5R)-4-(5-ethynylpyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (50 mg, 0.177 mmol; prepared in analogous fashion to the preparation of (4R,5R)-5-(2,5-difluorophenyl)-4-(5-ethynylpyridin-3-yl)oxazolidin-2-one starting from 3-fluorobenzaldehyde in place of 2,5-difluorobenzaldehyde), 2-bromopyrazine (31.0 mg, 0.195 mmol), bis(triphenylphosphine) palladium (II) chloride (6.22 mg, 8.86 mmol), triphenylphosphine (9.29 mg, 0.035 mmol), and copper (I) iodide (1.687 mg, 8.86 mmol) were combined in a microwave vial. Dimethylformamide (0.250 mL) and diisopropylethylamine (0.75 mL) were added resulting in a biphasic mixture. Nitrogen was bubbled through the vessel for 10 min, the vessel was capped and the reaction was run at 120° C. for 25 min on a Biotage microwave reactor. The diisopropylethylamine removed in vacuo, the remaining solution was diluted with methanol and the solution was purified via preparative liquid chromatography (Sunfire C18 19×100 mm 5 nm, A=95% H2O/5% Acetonitrile, B=95% Acetonitrile/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=20% B, 8.0 min=100% B, 13.0 min=100% B, Flow rate=25 mL/min) providing (4R,5R)-5-(3-fluorophenyl)-4-(5-(pyrazin-2-ylethynyl)pyridin-3-yl)oxazolidin-2-one (31 mg; 48%) as an amber foam. 1H NMR (500 MHz, CDCl3) δ ppm 8.89 (1H, br. s.), 8.81 (1H, s), 8.63 (1H, d, J=1.53 Hz), 8.57 (1H, d, J=2.44 Hz), 8.52 (1H, br. s.), 7.97 (1H, s), 7.41 (1H, td, J=7.93, 5.49 Hz), 6.94-7.19 (3H, m), 5.61 (1H, br. s.), 5.30 (1H, d, J=7.32 Hz), 4.81 (1H, d, J=7.32 Hz), Mass Spectral Anal. Calcd. for [M+H]+ C20H13FN4O2: 361.1. found 361.2.
The following examples were prepared using a modification of the procedure describing the preparation of (4R,5R)-5-(3-fluorophenyl)-4-(5-(pyrazin-2-ylethynyl)pyridin-3-yl)oxazolidin-2-one. employing the appropriately substituted commercially available aryl halide:
Example 398 |
|
1H NMR (500 MHz, CDCl3) δ ppm 9.21 (1 H, s), 8.91 (2 H, s), 8.84 (1 H, br. s.), 8.50 (1 H, br. s.), 7.94 (1 H, s), 7.35-7.48 (1 H, m), 7.09-7.21 (1 H, m), 6.99-7.09 (2 H, m), 5.70 (1 H, s), 5.30 (1 H, d, J = 7.02 Hz), 4.81 (1 H, d, J = 7.02 Hz), Mass Spectral Anal. Calcd. |
for [M + H]+ | ||
(4R,5R)-5-(3-fluorophenyl)-4-(5- | C20H13FN4O2: 361.1; | |
(pyrimidin-5-ylethynyl)pyridin-3- | found 361.2 | |
yl)oxazolidin-2-one | ||
Example 399 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.83 (1 H, d, J = 1.83 Hz), 8.43 (1 H, d, J = 2.14 Hz), 7.92 (1 H, t, J = 1.98 Hz), 7.59 (1 H, dd, J = 7.32, 1.83 Hz), 7.47 (1 H, d, J = 7.93 Hz), 7.40 (1 H, td, J = 7.93, 5.80 Hz), 7.29-7.37 (2 H, m), 6.97-7.18 (3 H, m), 5.37 (1 H, s), 5.32 |
(1 H, d, J = 7.32 Hz), | ||
(4R,5R)-4-(5-((2-chlorophenyl)ethynyl) | 4.79 (1 H, d, J = 7.32 | |
pyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one | Hz). Mass Spectral | |
Anal. Calcd. for [M + H]+ | ||
C22H14ClFN2O2: | ||
393.1; found 393.2 | ||
Example 400 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.79 (1 H, d, J = 1.83 Hz), 8.43 (1 H, d, J = 2.14 Hz), 7.90 (1 H, t, J = 2.1Hz), 7.30- 7.49 (3 H, m), 7.19- 7.30 (1 H, m), 6.85- 7.19 (4 H, m), 5.58 (1 H, br. s.), 5.31 (1 H, d, J = 7.32 Hz), 4.79 (1 H, d, J = 7.32 Hz). Mass Spectral Anal. Calcd. for [M + H]+ C22H14F2N2O2: |
377.1; found 377.2 | ||
(4R,5R)-5-(3-fluorophenyl)-4-(5-((3-fluorophenyl) | ||
ethynyl)pyridin-3-yl)oxazolidin-2-one | ||
Example 401 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.78 (1 H, d, J = 1.22 Hz), 8.40 (1 H, d, J = 1.83 Hz), 7.88 (1 H, t, J = 1.98 Hz), 7.32- 7.51 (3 H, m), 7.16- 7.32 (2 H, m), 6.84- 7.16 (3 H, m), 5.42- 5.65 (1 H, m), 5.31 (1 H, d, J = 7.32 Hz), 4.78 (1 H, d, J = 7.32 Hz), 2.37 (3 H, s). Mass Spectral Anal. Calcd. for [M + H]+ |
C23H17FN2O2: 373.1; | ||
(4R,5R)-5-(3-fluorophenyl)-4-(5-(m- | found 373.3 | |
tolylethynyl)pyridin-3-yl)oxazolidin-2-one | ||
Example 402 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.81 (1 H, d, J = 1.83 Hz), 8.45 (1 H, d, J = 2.14 Hz), 7.91 (1 H, t, J = 1.98 Hz), 7.83 (1 H, s), 7.73 (1 H, d, J = 7.63 Hz), 7.65 (1 H, d, J = 7.93 Hz), 7.52 (1 H, t, J = 7.78 Hz), 7.41 (1 H, td, J = 7.93, 5.80 Hz), 6.94-7.18 (3 H, m), 5.71 (1 H, s), 5.31 (1 H, d, J = 7.32 Hz), |
4.80 (1 H, d, J = 7.32 | ||
(4R,5R)-5-(3-fluorophenyl)-4-(5((3-(trifluoromethyl) | Hz). Mass Spectral | |
phenyl)ethynyl)pyridin-3-yl)oxazolidin-2-one | Anal. Calcd. for | |
[M + H]+ | ||
C23H14F4N2O2: | ||
427.1; found 427.2 | ||
Example 403 |
|
1H NMR (500 MHz, CDCl3) δ ppm 8.78 (1 H, d, J = 1.83 Hz), 8.43 (1 H, d, J = 2.14 Hz), 7.89 (1 H, t, J = 1.98 Hz), 7.55 (1 H, s), 7.28-7.50 (4 H, m), 6.93-7.19 (3 H, m), 5.93 (1 H, br. s.), 5.30 (1 H, d, J = 7.32 Hz), 4.79 (1 H, d, J = 7.32 Hz). Mass Spectral Anal. Calcd. for [M + H]+ C22H14ClFN2O2: |
393.1; found 393.2 | ||
(4R,5R)-4-(5-((3- | ||
chlorophenyl)ethynyl)pyridin-3-y1)-5- | ||
(3-fluorophenyl)oxazolidin-2-one | ||
To a slurry of (4R,5R)-4-(5-bromopyridin-3-yl)-5-(2-fluorophenyl)oxazolidin-2-one (100 mg, 0.297 mmol; prepared in analogous fashion to the preparation of (4R,5R)-5-(2,5-difluorophenyl)-4-(5-ethynylpyridin-3-yl)oxazolidin-2-one starting from 2-fluorobenzaldehyde in place of 2,5-difluorobenzaldehyde) in triethylamine (Volume: 5 mL) was bubbled nitrogen for 20 min. Ethynylbenzene (0.049 mL, 0.445 mmol) was added and nitrogen bubbling was continued for 5 min before adding bis(triphenylphosphine) palladium (II) chloride (15.61 mg, 0.022 mmol), triphenylphosphine (14.00 mg, 0.053 mmol), and copper (I) iodide (4.24 mg, 0.022 mmol) in 1 portion. After 5 min of additional nitrogen bubbling, the vessel was placed in a 70° C. bath under nitrogen for 18 h at which time it was cooled and concentrated. The residue was dissolved in methanol and purified via preparative liquid chromatography (Sunfire C18 OBD 30×100 mm 5 μm, A=95% H2O/5% Acetonitrile, B=95% Acetonitrile/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=20% B, 8.0 min=100% B, 13.0 min=100% B, Flow rate=40 mL/min) and then by chiral HPLC (Chiralpak AD 21×250 10 μm, A=Heptane with 0.1% diethylamine, B=Ethanol, Isocratic 50% A, Flow Rate=15 mL/min providing (4R,5R)-5-(2-fluorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one (61 mg; 57%). 1H NMR (500 MHz, CDCl3) δ ppm 8.78 (1H, d, J=1.83 Hz), 8.48 (1H, d, J=1.83 Hz), 7.92 (1H, t, J=1.98 Hz), 7.56 (2H, dd, J=6.71, 2.75 Hz), 7.46-7.53 (1H, m), 7.34-7.46 (4H, m), 7.20-7.31 (1H, m), 7.06-7.20 (1H, m), 5.58 (1H, d, J=5.80 Hz), 5.44 (1H, br. s.), 4.86 (1H, d, J=5.80 Hz). Mass Spectral Anal. Calcd. for [M+H]+ C22H15FN2O2: 359.1. found 359.1.
To a slurry of 4-(5-bromopyridin-3-yl)-5-(2-fluorophenyl)-4-methyloxazolidin-2-one (9 mg, 0.026 mmol) in triethylamine (0.5 mL) was bubbled nitrogen for 20 min. Ethynylbenzene (4.22 μl, 0.038 mmol) was added with continued nitrogen bubbling for an additional 5 min before adding bis(triphenylphosphine) palladium (II) chloride (1.349 mg, 1.922 μmol), triphenylphosphine (1.210 mg, 4.61 μmol), and copper (I) iodide (1.464 mg, 7.69 μmol) together in 1 portion. After 5 min bubbling nitrogen, the vessel was placed in a 70° C. bath. After 18 h the reaction was concentrated, dissolved in 50% dimethylformamide/methanol and purified via preparative liquid chromatography (Sunfire C18 19×100 mm 5 μm, A=95% H2O/5% Acetonitrile, B=95% Acetonitrile/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=10% B, 10.0 min=100% B, 15.0 min=100% B, Flow rate=25 mL/min) providing racemic 5-(2,5-difluorophenyl)-4-methyl-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one (2.2 mg; 22%) as a colorless oil. 1H NMR (500 MHz, CDCl3) δ ppm 8.51 (1H, br. s.), 8.26 (1H, br. s.), 7.61 (1H, s), 7.48-7.57 (2H, m), 7.32-7.43 (3H, m), 6.71-6.92 (3H, m), 5.84 (1H, s), 5.65 (1H, s), 2.05 (3H, s). Mass Spectral Anal. Calcd. for [M+H]+ C23H16F2N2O2: 391.1. found 391.2.
To a slurry of racemic 4-(5-bromopyridin-3-yl)-5-(2-fluorophenyl)-4-methyloxazolidin-2-one (22 mg, 0.063 mmol) in triethylamine (0.5 mL) was bubbled nitrogen for 20 min. Ethynylbenzene (10.3 μl, 0.094 mmol) was added with continued nitrogen bubbling for an additional 5 min before adding bis(triphenylphosphine) palladium (II) chloride (3.30 mg, 4.70 μmol), triphenylphosphine (2.96 mg, 0.011 mmol), and copper (I) iodide (3.58 mg, 0.019 mmol) together in 1 portion. After 5 min bubbling nitrogen, the vessel was placed in a 70° C. bath. After 18 h the reaction was concentrated, dissolved in 50% dimethylformamide/methanol and purified via preparative liquid chromatography (Sunfire C18 19×100 mm 5 μm, A=95% H2O/5% Acetonitrile, B=95% Acetonitrile/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=10% B, 10.0 min=100% B, 15.0 min=100% B, Flow rate=25 mL/min) providing racemic trans-5-(2,5-difluorophenyl)-4-methyl-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one. 1H NMR (500 MHz, CDCl3) δ ppm 8.82 (2H, br. s.), 7.99 (1H, s), 7.48-7.63 (2H, m), 7.32-7.46 (3H, m), 7.19-7.32 (1H, m), 7.00-7.14 (2H, m), 6.64 (1H, br. s.), 5.77 (1H, s), 1.42 (3H, s). Mass Spectral Anal. Calcd. for [M+H]+ C23H16F2N2O2: 391.1. found 391.2. The two enantiomers were separated via chiral preparative liquid chromatography (Chiralpak AS 21×250 10 μm, A=0.1% Diethylamine/Heptane, B=Ethanol, Isocratic 20% B for 40 min, Flow Rate=15 mL/min) providing 7.5 mg (30%) peak 1 ((4S,5S)-5-(2,5-difluorophenyl)-4-methyl-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one; Example 406) and 7.7 mg (31%) peak 2 ((4R,5R)-5-(2,5-difluorophenyl)-4-methyl-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one; Example 407).
(4R,5R)-4-(6-chloropyridin-3-yl)-5-(3-fluorophenyl)oxazolidin-2-one (52 mg; 0.18 mmol), ethynylbenzene (20.0 mg, 0.19 mmol), bis(triphenylphosphine) palladium (II) chloride (6.2 mg, 8.88 μmol), triphenylphosphine (9.3 mg, 0.036 mmol), and copper (I) iodide (1.6 mg, 8.88 μmol) were combined in a microwave vial. dimethylformamide (0.5 mL) and diisopropylethylamine (1.5 mL) were added resulting in a biphasic mixture. Nitrogen was bubbled through the vessel for 10 min, the vessel was capped and the reaction was run at 120° C. for 25 min on a Biotage microwave reactor. The diisopropylethylamine removed in vacuo, the remaining solution was diluted with methanol and the solution was purified via preparative liquid chromatography (Sunfire C18 OBD 30×100 mm 5 μm, A=95% H2O/5% Acetonitrile, B=95% Acetonitrile/5% H2O, Modifier 10 mM Ammonium Acetate, 0.00 min=20% B, 10.0 min=100% B, 15.0 min=100% B, Flow rate=40 mL/min) providing 31 mg (48%) (4R,5R)-5-(3-fluorophenyl)-4-(6-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one. 1H NMR (500 MHz, CDCl3) δ ppm 8.49 (1H, d, J=2.14 Hz), 7.75 (1H, dd, J=8.24, 2.44 Hz), 7.56-7.66 (3H, m), 7.32-7.46 (4H, m), 7.11 (1H, td, J=8.39, 2.44 Hz), 6.98-7.09 (2H, m), 5.34 (1H, s), 5.28 (1H, d, J=7.63 Hz), 4.79 (1H, d, J=7.32 Hz). Mass Spectral Anal. Calcd. for [M+H]+ C22H15FN2O2: 359.1. found 359.3.
Prepared from (4R,5R)-4-(5-bromopyridin-2-yl)-5-(3-fluorophenyl)oxazolidin-2-one using the same procedure as that used to prepare (4R,5R)-5-(3-fluorophenyl)-4-(6-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one from 5-bromo-2-(bromomethyl)pyridine. The two enantiomers were purified via chiral preparative liquid chromatography (Chiralpak AS 21×250 10 μm, A=0.1% Diethylamine/Heptane, B=Ethanol, Isocratic 45% B for 15 min, Flow Rate=15 mL/min) providing 8.5 mg (15%) (4S,5S)-5-(3-fluorophenyl)-4-(5-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one and 6.2 mg (11%) (4R,5R)-5-(3-fluorophenyl)-4-(5-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one. 1H NMR (500 MHz, CDCl3) δ ppm 8.79 (1H, d, J=1.53 Hz), 7.90 (1H, dd, J=8.09, 1.98 Hz), 7.51-7.62 (2H, m), 7.32-7.45 (5H, m), 7.14-7.24 (2H, m), 7.08 (1H, td, J=8.32, 1.98 Hz), 5.77 (1H, s), 5.57 (1H, d, J=5.80 Hz), 4.90 (1H, d, J=5.19 Hz). Chiral LC for (4S,5S)-5-(3-fluorophenyl)-4-(5-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one; example 409 (Chiralpak OJ-H analytical column, 4.6×100 mm, 5 μm, Mobile Phase: A=100% Heptane with 0.1% Diethylamine, B=100% Ethanol, Flow rate: 2.0 mL/min, 40% A Isocratic) 4.57 min. Chiral LC for (4R,5R)-5-(3-fluorophenyl)-4-(5-(phenylethynyl)pyridin-2-yl)oxazolidin-2-one; example 410 (Chiralpak OJ-H analytical column, 4.6×100 mm, 5 μm, Mobile Phase: A=100% Heptane with 0.1% Diethylamine, B=100% Ethanol, Flow rate: 2.0 mL/min, 40% A Isocratic) 9.94 min.
It will be evident to one skilled in the art that the present disclosure is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Claims (16)
1. A compound of formula I
where;
R1 is hydrogen or alkyl;
R2 is hydrogen or alkyl;
R3 is
Ar1 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, or pyridazinyl, and is substituted with 1 R3 substituent and with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;
Ar2 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, furanyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, or benzimidazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, and phenyl; and
Ar3 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, oxazolyl, thiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, or pyrrolopyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino;
or a pharmaceutically acceptable salt thereof.
2. A compound of claim 1 where R1 is hydrogen or alkyl; R2 is hydrogen or alkyl; R3 is
Ar1 is phenyl, pyridinyl, or pyrimidinyl and is substituted with 1 R3 substituent and with 0-1 halo or alkoxy substituents; Ar2 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, pyrazolyl, oxazolyl, oxadiazolyl, or tetrazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, hydroxy, alkoxy, and phenyl; and Ar3 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, thiazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, or pyrrolopyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino; or a pharmaceutically acceptable salt thereof.
3. A compound of claim 2 where R1 is hydrogen or alkyl; R2 is hydrogen or alkyl; R3 is
Ar1 is phenyl, pyridinyl, halopyridinyl, alkoxypyridinyl, or pyrimidinyl; Ar2 is phenyl, cyanophenyl, halophenyl, dihalophenyl, (haloalkyl)phenyl, alkylphenyl, dealkylphenyl, hydroxyphenyl, alkoxyphenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, (alkyl)pyrazolyl, oxazolyl, (alkyl)oxadiazolyl, (phenyl)oxadiazolyl, or tetrazolyl; and Ar3 is phenyl, cyanophenyl, halophenyl, dihalophenyl, alkylphenyl, (haloalkyl)phenyl, alkoxyphenyl, (haloalkoxy)phenyl, (alkylthio)phenyl, (amino)phenyl, alkylaminophenyl, dialkylaminophenyl, alkoxycarbonylphenyl, alkylcarbonylphenyl, pyridinyl, cyanopyridinyl, halopyridinyl, alkylpyridinyl, cycloalkylpyridinyl, alkoxypyridinyl, pyrazinyl, pyrimidinyl, alkoxypyrimidinyl, aminopyrimidinyl, alkylaminopyrimidinyl, dialkylaminopyrimidinyl, pyridazinyl, isoquinolinyl, quinoxalinyl, imidazolyl, thiazolyl, or alkylthiazolyl or a pharmaceutically acceptable salt thereof.
4. A compound of claim 3 where R1 is hydrogen or methyl; R2 is hydrogen or methyl; R3 is
Ar1 is phenyl, pyridinyl, fluoropyridinyl, methoxypyridinyl, or pyrimidinyl and is substituted with 1 R3 substituent; Ar2 is phenyl, cyanophenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, trifluoromethylphenyl, methylphenyl, dimethylphenyl, hydroxyphenyl, methoxyphenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, (methyl)pyrazolyl, oxazolyl, (methyl)oxadiazolyl, (phenyl)oxadiazolyl, or tetrazolyl; and Ar3 is phenyl, cyanophenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methylphenyl, t-butylphenyl, trifluoromethylphenyl, methoxyphenyl, trifluoromethoxyphenyl, methylthiophenyl, (amino)phenyl, dimethylaminophenyl, methoxycarbonylphenyl, methylcarbonylphenyl, pyridinyl, cyanopyridinyl, chloropyridinyl, fluoropyridinyl, methylpyridinyl, cyclopropylpyridinyl, methoxypyridinyl, pyrazinyl, pyrimidinyl, ethoxypyrimidinyl, methylaminopyrimidinyl, pyridazinyl, isoquinolinyl, quinoxalinyl, imidazolyl, thiazolyl, or methylthiazolyl; or a pharmaceutically acceptable salt thereof.
5. A compound of claim 4 where R1 is hydrogen; R2 is hydrogen; Ar1 is phenyl, pyridinyl, halopyridinyl, alkoxypyridinyl, or pyrimidinyl substituted in the meta position with R3.
6. A compound of claim 5 where; Ar2 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, (uranyl, thienyl, pyrazolyl, isoxazolyl, isothiazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, or benzimidazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, and phenyl; Ar3 is phenyl or pyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino; or a pharmaceutically acceptable salt thereof.
7. A compound of claim 6 where Ar2 is phenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, pyrazolyl, oxazolyl, oxadiazolyl, or tetrazolyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, hydroxy, alkoxy, and phenyl; Ar3 is phenyl or pyridinyl, and is substituted with 0-3 substituents selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, hydroxy, alkoxy, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, amino, alkylamino, and dialkylamino; or a pharmaceutically acceptable salt thereof.
8. A compound of claim 7 where; A2 is phenyl, cyanophenyl, halophenyl, dihalophenyl, (haloalkyl)phenyl, alkylphenyl, dialkylphenyl, hydroxyphenyl, alkoxyphenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, (alkyl)pyrazolyl, oxazolyl, (alkyl)oxadiazolyl, (phenyl)oxadiazolyl, or tetrazolyl; Ar3 is phenyl, cyanophenyl, halophenyl, dihalophenyl, dihalophenyl, alkylphenyl, (haloalkyl)phenyl, alkoxyphenyl, (haloalkoxy)phenyl, (alkylthio)phenyl, (amino)phenyl, alkylaminophenyl, dialkylaminophenyl, alkoxycarbonylphenyl, alkylcarbonylphenyl, pyridinyl, cyanopyridinyl, halopyridinyl, alkylpyridinyl, cycloalkylpyridinyl, alkoxypyridinyl; or a pharmaceutically acceptable salt thereof.
9. A compound of claim 8 where Ar2 is phenyl, cyanophenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, trifluoromethylphenyl, methylphenyl, dimethylphenyl, hydroxyphenyl, methoxyphenyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, (methyl)pyrazolyl, oxazolyl, (methyl)oxadiazolyl, (phenyl)oxadiazolyl, or tetrazolyl; Ar3 is phenyl, cyanophenyl, chlorophenyl, dichlorophenyl, fluorophenyl, difluorophenyl, methylphenyl, t-butylphenyl, trifluoromethylphenyl, methoxyphenyl, trifluoromethoxyphenyl, methylthiophenyl, (amino)phenyl, dimethylaminophenyl, methoxycarbonylphenyl, methylcarbonylphenyl, pyridinyl, cyanopyridinyl, chloropyridinyl, fluoropyridinyl, methylpyridinyl, cyclopropylpyridinyl, methoxypyridinyl, thiazolyl, or methylthiazolyl; or a pharmaceutically acceptable salt thereof.
11. A compound of claim 1 selected from the group consisting of
(4R,5R)-5-phenyl-4-(6-(phenylethynyl)-2-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-phenyl-4-(2-(phenylethynyl)-4-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-phenyl-4-(2-(3-pyridinylethynyl)-4-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-methoxyphenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-4-(5-(3-pyridinylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-methoxyphenyl)-4-(2-(phenylethynyl)-4-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-phenyl-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(5-(3-pyridinylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(5-((5-fluoro-3-pyridinyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-methoxyphenyl)-4-(3-(2-pyridinylethynyl)phenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-methoxyphenyl)-4-(3-(4-pyridinylethynyl)phenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-methoxy phenyl)-4-(3-((6-methoxy-2-pyridinyl)ethynyl)phenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-methoxyphenyl)-4-(3-(1,3-thiazol-4-ylethynyl)phenyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(3-((6-fluoro-3-pyridinyl)ethynyl)phenyl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(3-((2-fluoro-4-pyridinyl)ethynyl)phenyl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one;
5-((3-((4R,5R)-5-(3-methoxyphenyl)-2-oxo-1,3-oxazolidin-4-yl)phenyl)ethynyl)nicotinonitrile;
(4R,5R)-4-(3-((5-fluoro-3-pyridinyl)ethynyl)phenyl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-phenyl-4-(3-(phenylethynyl)phenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3,4-dimethylphenyl)-4-(3-(phenylethynyl)phenyl)-1,3-oxazolidin-2-one;
(4R,5S)-4-(3-(phenylethynyl)phenyl)-5-(2-thienyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-methylphenyl)-4-(3-(phenylethynyl)phenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2-fluorophenyl)-4-(3-(phenylethynyl)phenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-4-(3-(phenylethynyl)phenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(3-(phenylethynyl)phenyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(3-(phenylethynyl)phenyl)-5-(3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(3-((2-fluorophenyl)ethynyl)phenyl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(3-((3-fluorophenyl)ethynyl)phenyl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(6-(phenylethynyl)-2-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-methyl-5-phenyl-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-4-(2-fluoro-5-(3-pyridinylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(2-fluoro-5-((5-fluoro-3-pyridinyl)ethynyl)-3-pyridinyl)-5-(3-fluorophenyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(2-fluoro-5-((2-fluoro-4-pyridinyl)ethynyl)-3-pyridinyl)-5-(3-fluorophenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(2-fluoro-5-(3-pyridinylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(2-fluoro-5-((5-fluoro-3-pyridinyl)ethynyl)-3-pyridinyl)-5-(4-fluorophenyl)-1,3 oxazolidin-2-one;
(4R,5R)-4-(5-fluoro-2-((5-fluoro-3-pyridinyl)ethynyl)-4-pyridinyl)-5-(4-fluorophenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-chlorophenyl)-4-(2-fluoro-5-(3-pyridinylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(2-fluoro-5-((6-fluoro-2-pyridinyl)ethynyl)-3-pyridinyl)-5-(4-fluorophenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3,5-difluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3,4-difluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3,4-difluorophenyl)-4-(5-(3-pyridinylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3,4-difluorophenyl)-4-(5-((5-fluoro-3-pyridinyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
3-((5-((4R,5R)-5-(3,4-difluorophenyl)-2-oxo-1,3-oxazolidin-4-yl)-3-pyridinyl)ethynyl)benzonitrile;
(4R,5R)-5-(2,4-difluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,4-difluorophenyl)-4-(5-((5-fluoro-3-pyridinyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,4-difluorophenyl)-4-(5-pyridinylethynyl)-3-pyridinyl)-1-oxazolidin-2-one;
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-((5-fluoro-3-pyridinyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(3-((4-fluoro-2-pyridinyl)ethynyl)phenyl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(3-((3-fluoro-2-pyridinyl)ethynyl)phenyl)-5-(3-methoxyphenyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(5-(phenylethynyl)-3-pyridinyl)-5-(3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-5-methyl-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5S)-5-(4-fluorophenyl)-5-methyl-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(5-((5-fluoro-3-pyridinyl)ethynyl)-3-pyridinyl)-5-methyl-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(5-((3-fluoro-2-pyridinyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(5-(2-pyrazinylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(5-(4-pyridinylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(5-((2-fluoro-4-pyridinyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
3-((5-((4R,5R)-5-(4-fluorophenyl)-2-oxo-1,3-oxazolidin-4-yl)-3-pyridinyl)ethynyl)benzonitrile;
(4R,5R)-5-(4-fluorophenyl)-4-(5-((6-fluoro-2-pyridinyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-4-(6-(phenylethynyl)-2-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-methyl-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-5-methyl-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5S)-4-methyl-5-phenyl-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-methyl-5-phenyl-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(5-((3-fluoro-2-pyridinyl)ethynyl)-3-pyridinyl)-4-methyl-5-phenyl-1,3-oxazolidin-2-one;
(4R,5S)-4-(3-(phenylethynyl)phenyl)-5-(2-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-pyridinyl)-4-(3-(2-pyridinylethynyl)phenyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(3-(phenylethynyl)phenyl)-5-(4-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5S)-4-(3-(phenylethynyl)phenyl)-5-(4-pyrimidinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-4-(5-((5-fluoro-3-pyridinyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-4-(2-(3-pyridinylethynyl)-4-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-4-(2-(phenylethynyl)-4-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-4-(2-(phenylethynyl)-4-pyrimidinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,3-difluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-((4-fluorophenyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-((2-fluorophenyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,3-difluorophenyl)-4-(5((2-fluorophenyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,3-difluorophenyl)-4-(5-((4-fluorophenyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(5-(phenylethynyl)-3-pyridinyl)-5-(2,4,6-trifluorophenyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(5-(phenylethynyl)-3-pyridinyl)-5-(2,3,4-trifluorophenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(4-(phenylethynyl)-2-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-4-(2-fluoro-5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-4-(2-methoxy-5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-fluoro-2-(phenylethynyl)-4-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,5-difluorophenyl)-4-(2-fluoro-5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2-fluorophenyl)-4-(5-fluoro-2-(phenylethynyl)-4-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,4-difluorophenyl)-4-(6-(phenylethynyl)-2-pyridinyl-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,4-difluorophenyl)-4-(6-((3-fluorophenyl)ethynyl)-2-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(5-(phenylethynyl)-3-pyridinyl)-5-(4-pyrimidinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,3-dichlorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4S,5R)-5-(1-methyl-1H-pyrazol-5-yl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(5-((3-fluoro-2-pyridinyl)ethynyl)-3-pyridinyl)-4-methyl-1,3-oxazolidin-2-one;
(4R,5S)-4-(5-(phenylethynyl)-3-pyridinyl)-5-(2-thienyl-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(4-((2-fluorophenyl)ethynyl)-2-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(4-((3-fluorophenyl)ethynyl)-2-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(4-((4-fluorophenyl)ethynyl)-2-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-chlorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-chlorophenyl-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5S)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
4-((4R,5R)-2-oxo-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-5-yl)benzonitrile;
(4R,5R)-5-(4-fluorophenyl)-4-(6-((3-fluoro-2-pyridinyl)ethynyl)-2-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(4-fluorophenyl)-4-(6-((2-fluoro-4-pyridinyl)ethynyl)-2-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(2-fluoro-5-(phenylethynyl)pyridin-3-yl)-5-(2-fluorophenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2,5-difluorophenyl)-4-(5-(2-pyrazinylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(5-((2-chlorophenyl)ethynyl)-3-pyridinyl)-5-(3-fluorophenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-4-(5-((3-fluorophenyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(3-fluorophenyl)-4-(5-((3-methylphenyl)ethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
(4R,5R)-4-(5-((3-chlorophenyl)ethynyl)-3-pyridinyl)-5-(3-fluorophenyl)-1,3-oxazolidin-2-one;
(4R,5R)-5-(2-fluorophenyl)-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one; and
5R)-5-(2,5-difluorophenyl)-4-methyl-4-(5-(phenylethynyl)-3-pyridinyl)-1,3-oxazolidin-2-one;
or a pharmaceutically acceptable salt thereof.
13. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
14. A method for the treatment of schizophrenia which comprises administering to a patient a therapeutically affective amount of a compound of claim 1 .
16. A composition comprising the compound of claim 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/481,947 USRE49735E1 (en) | 2010-11-11 | 2021-09-22 | Oxazolidinones as modulators of MGLUR5 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41254110P | 2010-11-11 | 2010-11-11 | |
US13/287,487 US8691821B2 (en) | 2010-11-11 | 2011-11-02 | Oxazolidinones as modulators of mGluR5 |
US17/481,947 USRE49735E1 (en) | 2010-11-11 | 2021-09-22 | Oxazolidinones as modulators of MGLUR5 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/287,487 Reissue US8691821B2 (en) | 2010-11-11 | 2011-11-02 | Oxazolidinones as modulators of mGluR5 |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE49735E1 true USRE49735E1 (en) | 2023-11-28 |
Family
ID=44999936
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/287,487 Ceased US8691821B2 (en) | 2010-11-11 | 2011-11-02 | Oxazolidinones as modulators of mGluR5 |
US17/481,947 Active 2031-11-16 USRE49735E1 (en) | 2010-11-11 | 2021-09-22 | Oxazolidinones as modulators of MGLUR5 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/287,487 Ceased US8691821B2 (en) | 2010-11-11 | 2011-11-02 | Oxazolidinones as modulators of mGluR5 |
Country Status (6)
Country | Link |
---|---|
US (2) | US8691821B2 (en) |
EP (1) | EP2638022B1 (en) |
AR (1) | AR083861A1 (en) |
TW (1) | TW201300369A (en) |
UY (1) | UY33722A (en) |
WO (1) | WO2012064603A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103159738B (en) * | 2011-12-19 | 2016-09-07 | 上海泓博智源医药股份有限公司 | The heteroaryl aroma compounds of alkynyl bridging and application thereof |
US9790203B2 (en) * | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
BR112015014579A2 (en) | 2012-12-19 | 2017-07-11 | Basf Se | compounds of formula i, use of a compound of formula i, method for combating harmful fungi and seeds. |
EP3055306A1 (en) * | 2013-10-07 | 2016-08-17 | Bristol-Myers Squibb Company | Oxazolidinones as modulators of mglur5 |
PE20180358A1 (en) | 2015-06-03 | 2018-02-21 | Hoffmann La Roche | ETHINYL DERIVATIVES |
WO2023183428A1 (en) * | 2022-03-22 | 2023-09-28 | Allyx Therapeutics, Inc. | Mglur5 modulating compounds, compositions, and methods of use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005094822A1 (en) | 2004-03-22 | 2005-10-13 | Eli Lilly And Company | Pyridyl derivatives and their use as mglu5 receptor antagonists |
WO2011051201A1 (en) | 2009-10-27 | 2011-05-05 | F. Hoffmann-La Roche Ag | Positive allosteric modulators (pam) |
US9688669B2 (en) * | 2013-10-07 | 2017-06-27 | Bristol-Myers Squibb Company | Oxazolidinones as modulators of mGluR5 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7465755B2 (en) | 2003-07-18 | 2008-12-16 | Laboratoires Serono Sa | Hydrazide derivatives as prostaglandin receptors modulators |
WO2009094265A1 (en) * | 2008-01-24 | 2009-07-30 | Merck & Co., Inc. | 3,5-substituted-1,3-oxazolidin-2-one derivatives |
-
2011
- 2011-11-02 US US13/287,487 patent/US8691821B2/en not_active Ceased
- 2011-11-04 WO PCT/US2011/059339 patent/WO2012064603A1/en active Application Filing
- 2011-11-04 EP EP11785233.5A patent/EP2638022B1/en not_active Not-in-force
- 2011-11-11 UY UY0001033722A patent/UY33722A/en unknown
- 2011-11-11 AR ARP110104237A patent/AR083861A1/en not_active Application Discontinuation
- 2011-11-11 TW TW100141327A patent/TW201300369A/en unknown
-
2021
- 2021-09-22 US US17/481,947 patent/USRE49735E1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005094822A1 (en) | 2004-03-22 | 2005-10-13 | Eli Lilly And Company | Pyridyl derivatives and their use as mglu5 receptor antagonists |
WO2011051201A1 (en) | 2009-10-27 | 2011-05-05 | F. Hoffmann-La Roche Ag | Positive allosteric modulators (pam) |
US9688669B2 (en) * | 2013-10-07 | 2017-06-27 | Bristol-Myers Squibb Company | Oxazolidinones as modulators of mGluR5 |
Non-Patent Citations (1)
Title |
---|
Lee et al. (Acta Neurobiol Exp 2004, 64: 89-98). * |
Also Published As
Publication number | Publication date |
---|---|
US8691821B2 (en) | 2014-04-08 |
TW201300369A (en) | 2013-01-01 |
EP2638022A1 (en) | 2013-09-18 |
WO2012064603A1 (en) | 2012-05-18 |
UY33722A (en) | 2012-05-31 |
US20120283264A1 (en) | 2012-11-08 |
AR083861A1 (en) | 2013-03-27 |
EP2638022B1 (en) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE49735E1 (en) | Oxazolidinones as modulators of MGLUR5 | |
US20140315881A1 (en) | Compounds and methods | |
US9346798B2 (en) | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors | |
US8901156B2 (en) | Compounds and methods | |
US10221170B2 (en) | Difluoropyrrolidines as orexin receptor modulators | |
KR102203552B1 (en) | Allosteric modulator of nicotinic acid acetylcholine receptor | |
US7915270B2 (en) | Oxazole ketones as modulators of fatty acid amide hydrolase | |
US10377753B2 (en) | Substituted 4-azaindoles and their use as GluN2B receptor modulators | |
US8569292B2 (en) | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | |
US8598202B2 (en) | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase | |
US20200347021A1 (en) | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof | |
JP2016505055A (en) | Fluoro- [1,3] oxazine as a BACE1 inhibitor | |
US11530210B2 (en) | Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators | |
US9988400B2 (en) | Thiazolopyrimidinones and methods of use thereof | |
US10611730B2 (en) | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | |
US20140256740A1 (en) | Compounds and methods | |
JP2006500362A (en) | Substituted pyrrolopyridines | |
JP5840793B2 (en) | Ethynyl derivatives as MGLUR5 allosteric modulators | |
US8722670B2 (en) | Selective NR2B antagonists | |
US20160159814A1 (en) | Glycine transporter inhibitor | |
TW201718589A (en) | Ethynyl derivatives | |
JP2013541569A (en) | Dihydrooxazol-2-amine derivative | |
US9688669B2 (en) | Oxazolidinones as modulators of mGluR5 | |
US20220274984A1 (en) | Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |